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ABSTRACT OF THE DISSERTATION  
NAVIGATING HEALTH SOURCES ON THE INTERNET: A MIXED-METHODS 
EXAMINATION OF ONLINE CONSUMER REVIEWS AND EXPERT TEXT ON 
PSYCHOTROPIC DRUGS  
by 
Shannon Hughes 
Florida International University, 2010 
Miami, Florida 
Professor David Cohen, Major Professor 
Purpose: The Internet has provided an unprecedented opportunity for psychotropic 
medication consumers, a traditionally silenced group in clinical trial research, to have 
voice by contributing to the construction of drug knowledge in an immediate, direct 
manner. Currently, there are no systematic appraisals of the potential of online consumer 
drug reviews to contribute to drug knowledge. The purpose of this research was to 
explore the content of drug information on various websites representing themselves as 
consumer- and expert-constructed, and as a practical consideration, to examine how each 
source may help and hinder treatment decision-making. 
Methodology: A mixed-methods research strategy utilizing a grounded theory approach 
was used to analyze drug information on 5 exemplar websites (3 consumer- and 2 expert-
constructed) for 2 popularly prescribed psychotropic drugs (escitalopram and quetiapine).  
A stratified simple random sample was used to select 1,080 consumer reviews from the 
websites (N=7,114) through February 2009. Text was coded using QDA Miner 3.2 
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software by Provalis Research. A combination of frequency tables, descriptive excerpts 
from text, and chi-square tests for association were used throughout analyses.  
Findings: The most frequently mentioned effects by consumers taking either drug were 
related to psychological/behavioral symptoms and sleep. Consumers reported many of 
the same effects as found on expert health sites, but provided more descriptive language 
and situational examples. Expert labels of less serious on certain effects were not 
congruent with the sometimes tremendous burden described by consumers. Consumers 
mentioned more than double the themes mentioned in expert text, and demonstrated a 
diversity and range of discourses around those themes.   
Conclusions: Drug effects from each source were complete relative to the information 
provided in the other, but each also offered distinct advantages. Expert health sites 
provided concise summaries of medications’ effects, while consumer reviews had the 
added advantage of concrete descriptions and greater context. In short, consumer reviews 
better prepared potential consumers for what it’s like to take psychotropic drugs. Both 
sources of information benefit clinicians and consumers in making informed treatment-
related decisions. Social work practitioners are encouraged to thoughtfully utilize online 
consumer drug reviews as a legitimate additional source for assisting clients in learning 
about treatment options. 
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Chapter 1: Statement of Problem 
The central issue examined in the proposed research concerns the construction of 
expertise in the age of the Internet. To address the central issue, this study focuses on an 
area – psychotropic drugs prescribed and used as medicines – to examine evolving 
relations of power in the production and dissemination of knowledge in today’s 
prescription drug market.  
Expert knowledge of psychotropic drugs is that which is produced using 
procedures of science, and represents the official account of drugs’ uses and effects. The 
forthcoming review of literature will show, however, that this scientifically-derived 
expert knowledge has become highly contested. The blurring lines between 
pharmaceutical industry marketing and scientific activities, and the near monopoly of the 
industry over production and dissemination of expert/scientific knowledge of 
psychotropic drugs has resulted, at a minimum, in well-documented publication biases 
and considerable uncertainty about drug efficacy and safety (Huston & Moher, 1996; 
Ioannidis & Lau, 2001; Melander, Ahlqvist-Rastad, Meijer, & Beermann, 2003; Perlis et 
al., 2005; E. Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008). Also, to reach a 
“valid” understanding of drugs’ effects, researchers have persistently muted the direct 
voice and speech of the patient in favor of a presumably more objective (biomedical, 
scientific, statistical) discourse (Jacobs & Cohen, 1999). 
In parallel, the Internet allows researchers, clinicians, and consumers to review 
drug experiences and information from thousands of consumers without professional 
mediation, and presumably without pharmaceutical industry supervision over content. 
The Internet thus makes more apparent multiple and sometimes contradictory claims to 
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knowledge. How these less scientific ways of knowing about psychotropic drugs made 
accessible through the web contribute to or dilute the expert/scientific knowledge base, or 
how they constitute their own knowledge base, remains virtually unexplored. 
Moreover, “democratizing” the production of knowledge and consumers’ 
broadened acceptance of what constitutes legitimate, trustworthy, or credible information 
results in a trans-disciplinary debate about the appropriate role of experts and non-experts 
in policy, media, science, and culture, as well as the true nature of what is being 
applauded as “democratization” (Dahlberg & Siapera, 2007; David, 2007; Keen, 2007; 
Siegel, 2008). Applied to the construction of knowledge about psychotropic drugs, the 
fundamental pragmatic concern of this debate is whether expert knowledge on 
psychotropic drugs is sufficient for building a knowledge base and helpful to those who 
believe they need expertise to come to an understanding or decision about a drug issue, or 
whether expertise is a shroud that actually limits or distorts the knowledge base and 
disadvantages those seeking expertise because of conflicts of interest and other biases. 
Has the Internet rendered expertise in the area of psychotropic drugs obsolete? 
Following from this, the main question of the research was: Does the accumulated 
consumer or layperson knowledge that the Internet allows dissolve the traditional 
boundary between expert/scientific and consumer/lay knowledge? The research 
specifically sought to examine the content, in terms of drug effects and themes, of drug 
information on consumer-constructed and expert-constructed web sources. A grounded 
theory approach as part of a mixed-methods research strategy was used to analyze the 
content of five websites containing drug information for two popularly prescribed 
psychotropic drugs from different drug classes. As a practical consideration, how does 
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each source help and hinder treatment decision-making for clinicians and for actual and 
potential consumers? 
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Chapter 2: Literature Review 
Definitions and Concepts 
Psychotropic drugs. 
Psychotropic drugs of relevance in the present analysis are those drugs available 
by prescription, consumed as medicine, and intended to alter the behavior, mood, 
thinking, and/or feeling of the individual ingesting the drug. Psychotropic drugs can be 
analyzed on numerous levels, such as for their effects on biological processes or their 
personal, social, cultural, political, and economic meaning and symbolism, and each level 
of meaning or understanding interacts with drug effects (Cohen, McCubbin, Collin, & 
Perodeau, 2001). In the marketplace, a psychotropic drug may be considered an 
“experience good,” meaning a good whose value or quality cannot be known until the 
good has been personally experienced (Azoulay, 2002). In Foucauldian analysis, 
psychotropic drugs may be considered technologies of the body that carry disciplinary 
messages of transformation and self-surveillance to the consumer (Clarke, Mamo, 
Fishman, Shim, & Fosket, 2003). The proposed research does not reduce psychotropic 
drugs to a single defining quality or use, but rather acknowledges that many ways of 
understanding drug use or effects may be equally valid.  
That being said, there are some pharmacological basics that may elucidate the 
nature of drug knowledge. First, a basic tenet of pharmacokinetics is that the blood or 
plasma concentration of drugs is related to drugs’ effects, but for most psychotropic 
drugs, no clear or simple relationship has been found (Brunton, Lazo, & Parker, 2006). In 
trials of antidepressants, for example, “such a high proportion of patients respond to 
placebo that it is difficult to determine the plasma level associated with efficacy” (p. 
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128). Second, at the population level, therapeutic dose ranges for all drugs will overlap 
with toxic dose ranges. This is also true at the individual level for antipsychotic drugs, 
which are typically selected based on the likely tolerability of adverse effects.  
Complicating all of this, a single individual may not always respond the same way to the 
same drug given at different times. Third, psychotropic drugs primarily act initially on 
the transport of specific neurotransmitters, but cause a cascade of secondary effects and 
adaptive processes that still elude researchers.  
In sum, much is still not known physiologically about how, why, or for whom 
psychotropic drugs “work.”  Drugs have multiple effects, which are unpredictable for 
individuals and too complicated for current scientific processes to tease apart. However, 
even if there did exist a “perfect” knowledge of the physiology of drug action, it would 
be an incomplete knowledge because drugs’ effects are as much social phenomena as 
they are biological (Cohen et al., 2001). 
Knowledge. 
 Methods and procedures of science are widely accepted as producing – or at least of 
providing the optimum means of progressing towards – what may be called “true” 
knowledge characterized by objectivity and neutrality. It is arguable, however, that 
knowledge produced by scientific methods (henceforth, scientific knowledge) is 
incomplete, limited, and not free from bias due to cultural and political influences.  The 
alternative, critical hypothesis that informs the proposed research posits that knowledge 
takes various forms, may be dispersed in an incomplete and often contradictory manner 
among individuals, and cannot be concentrated, organized, integrated, or “knowable” by 
any one or elite group of individuals (Foucault, 1980; Hayek, 1945). Central to the 
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research is the best utilization of dispersed knowledges, a position which may 
consequentially suspend oppositions between scientific and non-scientific knowledge, or 
objective and subjective ways of knowing.   
 This paper also adopts Michel Foucault’s concept of knowledge as inextricably and 
inevitably linked to power (power/knowledge) (Foucault, 1980). According to Foucault, 
power is dispersed, exercised from innumerable points, and refers to relations rather than 
a possession or privilege of a dominant class. Power may be repressive, but is more often 
productive by, for example, producing knowledge and discourses which are exercised at 
the level of everyday life in activities like self-surveillance and self-discipline. Foucault 
describes: 
there is no power relation without the correlative constitution of a field of 
knowledge, nor any knowledge that does not presuppose and constitute at 
the same time power relations… It is not the activity of the subject of 
knowledge that produces a corpus of knowledge, useful or resistant to 
power, but power-knowledge, the processes and struggles that traverse it 
and of which it is made up, that determines the forms and possible 
domains of knowledge. (Rabinow, 1984, p. 175)  
The effectiveness of the positive, productive characteristics of power rests on the 
installation of a field of empirical truth, or what Foucault terms a politics or regime of 
truth (Foucault, 1980). The politics of truth encompasses: the types of discourse a society 
accepts and makes function as true, the mechanisms used to distinguish true from false 
statements, the procedures accorded value for acquiring truth, and the status afforded to 
those authorized to say what counts as true. The analysis of power/knowledge, then, is 
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not concerned with discerning true from false statements, but rather stresses the historical 
conditions of possibility for what counts as truth. In the current politics of truth, the 
procedures and practitioners of science hold great currency. As a result, seemingly 
natural objects (like disease or schizophrenia) are best understood only in relation to the 
science or expertise that posits them, as “the very discourse that is supposed to discover 
the reality of the thing’s being, the truth of disease itself..., has always already actively 
contributed to the constitution of the object” (Rawlinson, 1987, p. 377). If scientific-
medical knowledge appears neutral in medical discourse (i.e., what is said by those 
speaking as medical experts), it is because the knowledge offered is constructed as 
external to power (Peterson & Bunton, 1997). Thus, while it is mostly inaccurate to 
construe medical experts as figures of domination who possess power that could be given 
to someone else, it is accurate to say that they are important links in a set of power 
relations capable of producing knowledge.  
Expertise and the role of experts in society. 
 Political rule in liberal societies has greatly depended on experts and the authority of 
truth to govern populations (Rose, 1993). Experts are authorized to construct knowledge 
around an identified object, and political rule is exercised in light of the knowledge of 
that which is to be governed. The expert knowledge is not typically a new knowledge or 
expertise over an object where no knowledge or expertise had existed before, but rather 
often represents a reorganized, reformatted, and concentrated form of a local, dispersed, 
or subjugated knowledge (Mitchell, 2002). Thus, experts are those who can speak and 
enact truth, and serve as the means of circulation of this reorganized and concentrated 
knowledge. 
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In advanced liberal societies, such as presently in the U.S. according to many 
social scientists, experts are increasingly distanced from overt political rule through a 
shift in location of experts and expert knowledges to the market governed partly by 
consumer demand (Rose, 1993). Advanced liberal rule depends on the self-government 
of individuals “whereby each individual binds themselves to expert advice as a matter of 
their own freedom… what starts off as a norm to be implanted into citizens can be 
repossessed as a demand which citizens can make of authorities” (p. 296). As opposed to 
the use of coercive or repressive techniques based on expert knowledge of a human 
subject or population, advanced liberal societies seek to govern through regulated spheres 
of autonomy in which an individual’s relation to oneself is constituted and shaped by a 
proliferation of discourses and technologies.  
 Expertise in areas of medicine, law, science and similar professions has traditionally 
emerged in society through the institutionalization of a field of knowledge, setting up of 
professional bodies, training and accreditation, and other techniques for regulating and 
managing the respective knowledge and activities (Abbott, 1988). This expert 
knowledge, though, is a contested knowledge in that there are always parallel 
disagreements and struggles both within expert circles and from the outside margins 
(such as that of the ill person or psychiatric patient) (Foucault, 1980). Constituting the 
outside margins are the local, particular, subjugated knowledges which have been 
“disqualified as inadequate to their task or insufficiently elaborated; naïve knowledges, 
located low down on the hierarchy, beneath the required level of cognition or 
scientificity” (p. 82). According to norms of science (and the current politics of truth) 
such knowledge may be considered either a flawed form of knowledge or something 
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other than knowledge altogether. Social studies of health and illness have often used the 
term “lay beliefs”  in reference to local, particular experiences, perspectives, meanings, 
and ways of managing health and the body, and have only recently accorded these the 
status of “lay knowledge” (Popay & Williams, 1996). Alternatively construed, that which 
may be or become subjugated knowledge often involves an expertise (local and 
particular) too widely dispersed to provide a means for political power or corporate 
profits (Mitchell, 2002). This knowledge contains the “historical knowledge of struggles” 
and helps to reveal the contestations, multiple claims, local variations, and sometimes 
violence in the politics of truth (Foucault, 1980, p. 83). For the present analysis, to 
operationally define or label what knowledge is would entail “settling on paper issues 
that are not settled in reality, where they are the stake of ongoing social struggles” 
(Bourdieu, 1988, p. 778). Reference throughout this paper is therefore simply made to 
scientific knowledge and consumer knowledge – the former referring to that which is 
accepted as true using procedures of science (often called “knowledge” or “fact”), and the 
latter referring to that which holds less significance in determining what is accepted as 
true (often called “belief” or “opinion”).  
Evolving market conditions. 
 The individual and collective health of bodies in the U.S. is a political and economic 
issue because health, reproduction, and disease are central to economic processes and 
therefore subject to political control. Evolving market conditions, including 
medicalization, consumerism, direct-to-consumer advertising of prescription drugs, and 
the user-generated Internet, continually alter and transform power relations surrounding 
access to and demand for knowledge, and power over its production. 
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 Medicalization refers to the increasing number of life and bodily experiences that are 
placed within medical jurisdiction and subject to technical solutions (Conrad, 2007). 
Consumerism refers to the increased responsibility citizens carry to choose health goods 
and services through the marketplace (Gabe & Calnan, 2000). Unique to the health 
domain, this form of consumerism involves an end user who does not necessarily 
“choose” the good since this decision may be mediated by the doctor, and who does not 
usually directly purchase the good because of health insurance and third-party payments 
(Busfield, 2006; Lakoff, 2004). Nevertheless, health in modern America is promoted and 
perceived as a commodity under which everyday lifestyle choices are subsumed, and 
health care is increasingly subject to consumer market forces (Conrad, 2005; Lewis, 
2006). This consumerist trend, however, is less likely to apply to certain populations, 
such as children receiving Medicaid benefits or adults institutionalized in long-term care 
facilities. In this paper, the term “consumer” is meant to apply to a participative adult 
population. The commodification of health and increased responsibility put on consumers 
to “take control” of their care and treatment, for example by gaining medical knowledge, 
combines with medicalization to extend self-care and self-discipline into more and more 
corners of individuals’ daily lives (i.e, through self-surveillance, risk assessment, 
consumption of appropriate goods/services for treatment/prevention of various problems) 
(Clarke et al., 2003).  
Direct-to-consumer advertising (DTCA) of drugs available only by prescription 
has helped fuel both consumerism and medicalization by motivating individuals to 
proactively seek a drug, as well as more generally expanding the range of human 
distresses presumed amenable to drug treatment (Davis, 2006; McCurdy, 2003). As 
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testimony to the former, one estimate found that nearly 8.5 million Americans each year 
request and receive a drug that they heard about or saw in an advertisement (McCurdy, 
2003). Between half and three-quarters of consumer requests for a specific or general 
drug for depression were complied with by physicians according to one randomized 
controlled trial (Kravitz et al., 2005). DTCA is intended to blur the boundaries between 
mild and severe distress and to suggest that all degrees of suffering – or even a lifestyle 
wish that causes no apparent suffering – are  amenable to drug treatment (Davis, 2006; 
Gilbert, Walley, & New, 2000). The life one wants, that is, to be thinner, happier, more 
productive, more confident, better liked, and better rested, is promoted as a doctor visit 
away. This brand of “cosmetic psychopharmacology” has been particularly successful for 
easily self-diagnosed problems such as for weight, baldness, and erectile dysfunction, as 
well as for shyness and other behavioral, performance or personality difficulties 
(Applbaum, 2006; Avorn, 2005; Conrad & Leiter, 2004; Lexchin, 2006).    
Pharmaceutical companies may also use DTCA to market a disease to build 
awareness of an underutilized psychiatric diagnosis and subsequently sell the drug to treat 
the disease (Conrad, 2005).  “Mood stabilizer” drugs, for example, had scantly been 
discussed until after 1995 when the anti-convulsant drug, Depakote, was approved by the 
FDA for treating mania (Healy, 2006a). The campaign for Bipolar Disorder and mood 
stabilizers involved DTC television and magazine advertisements, popular media 
coverage such as a 2002 Time magazine cover story titled Young and Bipolar, new 
medical journals devoted to the disease, drug company-funded online patient groups, 
Internet sites, and scientific and medical conferences. Pediatric Bipolar Disorder, an 
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extremely rare diagnosis 10 years ago, has today an estimated prevalence among youth 
reaching up to 1 million (Smarty & Findling, 2007).  
Direct-to-consumer advertising, as part of the overall phenomena of 
medicalization and consumerism, has served to transform relationships between product 
and consumer, and consumers and themselves. Paradoxically, the shift of the site of 
responsibility for screening and managing health from the doctor’s office to the home of 
the consumer increases while it transforms and disperses the processes of medicalization 
(Clarke et al., 2003). The ongoing maintenance of health has become an individual goal, 
while the realm of what is considered “health” expands to include nearly any lifestyle 
choice, and consumer demand for health knowledge and technologies increases. 
The Internet. 
 The Internet has created conditions for access to knowledge from multiple sources with 
sometimes contradictory messages, and carries the potential to alter power relations 
involving the production of what is deemed legitimate health (including psychotropic 
drug) knowledge. According to a Harris Interactive Poll, 110 million Americans use the 
Internet at least sometimes to seek health information (Taylor & Leitman, 2002). This 
figure represents 80% of all adults online and 53% of all adults in the population. A 2008 
survey reported the Internet to be the most widely used resource by adults for finding 
health information, though doctors were the most trusted source for information (Elkin, 
2008). Thirty-four percent of online health searchers reported visiting Wikipedia, 
message boards, and discussion forums, mostly to find or exchange information about a 
specific disease, condition, or treatment. Use of user-generated online content is 
particularly prominent among consumers age 18 to 34 and those with at least some 
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college education. A group of about 10 million Internet users regularly post health 
information online, and nearly 9 million users visit personal blogs for health information 
("Today in eHealth news: Heard on the street," 2007, January 4). With a full 23% of 
Americans without access to the Internet, it is accurate to assert that only a sub-set of 
adults use and contribute to the user-generated Internet, suggesting that its role and 
effects in health knowledge production and dissemination have only begun to develop. 
Still, media commentators insist that the cutting edge of today’s evolving market is that 
“the rise of consumerism across American society today has positioned the consumer as 
king and the Internet as queen in the realm of healthcare communications” (O'Neill, 
2007, p. 13). 
The openness of the Internet highlights the always existing tension between 
expertise and democracy, and appears to swing the pendulum towards the extension of 
democratic participation (in the sense that the system is open to non-experts) while 
shrinking the perceived need or value of, and possibly attempting to redefine, expertise. 
Public participation in areas of science, medicine, and technology, especially as they 
intersect with morals and ethics, may be offered as a solution to the “problem of 
legitimacy,” or crisis of confidence, in these fields (Collins & Evans, 2007). The growing 
use and participation on the Internet has helped create a parallel “problem of extension,” 
referring to the problem of identifying the point at which public involvement should be 
curtailed in order to maintain the presumably necessary boundary between expert and lay 
knowledge.  
Some social commentators take the position that the abundance and variety of 
health information available through the Internet makes it ever more necessary to rely on 
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expert-provided disciplined analysis and understanding to decipher truth from non-truth 
(Collins & Pinch, 2005; S. Turner, 2001). The Internet is described as a chaotic mess of 
anonymous, uninformed, and unaccountable amateur opinions and claims that crowd 
thoughtful analysis by trained, qualified, and accountable experts (Keen, 2007; Siegel, 
2008). This perspective assumes the traditional criterion of qualifications or credentials 
for judging expertise (Collins & Evans, 2007). Too much “democratization” of 
knowledge to an unqualified lay public may have serious adverse social consequences as 
highly valued concepts of truth, reliability, and accountability become obscure or empty.  
An alternative view of the Internet’s potential effects posits that the Internet is 
“democratizing” only as much as it allows marginalized discourses – those that only 
weakly influence the public sphere – “to develop their own deliberative spaces…; to link 
up with other excluded voices…; and subsequently to contest those meanings and 
practices dominating mainstream public spheres” (Dahlberg & Siapera, 2007, p. 134). 
Monetary requirements to ensure search engine optimization and extensive hyperlinked 
networks make it more likely that dominant and institutionalized discourses are codified 
“as so-called quality and thus trusted” (Dahlberg, 2005, p. 166). Rather than a fear of 
expert knowledge being drowned in a sea of ill-considered lay opinions, then, this 
perspective emphasizes that expert knowledge continues to dominate discourse on the 
Internet through the same corporate and professional influences that permeate off-line 
realms of knowledge production and dissemination. Thus, “democratization” of 
marginalized and counter discourses may need to be strategically fostered, rather than 
limited or regulated, on the Internet.  
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Expert Drug Knowledge in the Off-Line World 
Expert (scientific/medical) drug knowledge. 
 Discourse serves to constitute the subjects to whom and of whom it speaks, as well as to 
create conditions for what is possible and acceptable to say or claim as true (Rabinow, 
1984). In line with this function, a scientific biomedical discourse has shaped the 
definition and treatment of a range of human maladies and distresses over the last 50 
years (Dixon-Woods, 2001; Gabe, Kelleher, & Williams, 1994). This discourse has 
thrived in tandem with cultural expectations and health policies that promote an ideal of a 
healthy and productive citizen (Gardner, 2003), as well as professional and regulatory 
demands that prescribed drugs be disease-targeted and tested for efficacy with specific 
scientific methodologies (Lakoff, 2004). For psychiatry, in particular, “the financial 
muscle of the pharmaceutical industry has helped to favor a predominantly biological 
view of psychiatric disorder,” which has driven psychiatric treatment and the research 
agenda (Moncrieff & Thomas, 2002, p. 216).  
 Expert knowledge about psychotropic drugs is primarily produced using procedures of 
science, exemplified by the randomized controlled clinical trial. The resulting knowledge 
is officially disseminated through the FDA-approved drug label and funneled to 
practicing clinicians through publication of trial results in medical journals, the 
Physician’s Desk Reference (PDR), pharmaceutical representatives and medical 
education venues.  However, significant conflicts of interest posed by pharmaceutical 
industry activity in both science and marketing threaten the integrity of the “expert” 
evidence base (Cohen, 2005; Healy, 2006b; Woosley, 1994). Pharmaceutical companies 
do not only manufacture the promoted drug, but, it will be shown, also produce and 
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disseminate the information to be used by clinicians and consumers to make treatment 
decisions. This problem is not new or unknown to researchers – and perhaps also to 
clinicians and consumers – as researchers on many occasions have suggested the 
“manipulation of medical knowledge by the pharmaceutical industry…is endemic in 
psychiatry” (Moncrieff & Thomas, 2002, p. 216).  
Procedures of science in the making of drug knowledge. 
Scientific procedures and regulatory demands for drug approval have combined to 
make certain requirements, termed in phases of drug testing, for producing valid 
knowledge about a drug. Phase III trials are intended to provide the most definitive 
efficacy data and additional safety data once the drug completes pre-clinical through 
Phase II testing. These efficacy trials take the form of short-term (usually 3-8 weeks), 
double-blind, randomized, controlled studies (RCT), which are presumed – assuming 
homogeneity of patients and their proper randomization – to generate causal links 
between treatment and outcome. The RCT format has trumped other methodologies as 
the “gold standard” for ascertaining a treatment’s efficacy (Cohen, 2005; Oates, 2006). In 
psychopharmacology, however, the procedures of the RCT may be misapprehended and 
misapplied in several ways.  
First, as opposed to other areas of medicine in which objective pathologies of the 
body are amenable to technological intervention and monitoring, psychiatry and 
psychopharmacology have no standard other than the behaviors listed in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) to identify what is being treated. The 
creation of diagnostic categories in the DSM can be likened to an opinion poll among 
experts, as the authors of the text clearly suggest: “Before DSM-IV, diagnostic manuals 
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were generally constructed by expert consensus” (American Psychiatric  Association, 
1998, p. 1).  Revisions to the current manual were mandated by the DSM-IV task force to 
be “data based,” which paradoxically institutionalized the consensus-derived categories 
of previous editions while allowing the text to now be promoted as empirically informed 
(Kutchins & Kirk, 1997). DSM authors further state that the manual’s categorical 
distinctions between disorders cannot be supported logically (American Psychiatric 
Association, 1994), thus begging the question of what exactly is being treated in a 
psychopharmacological RCT (Cohen & Jacobs, 2007)? 
Correlatively, the determination of a psychiatric diagnosis and drug treatment 
effectiveness is unique because they are each based on the person’s subjective complaints 
and feelings, as well as the doctor’s observation of the person’s behavior as in accordance 
or not with what the person expresses (Freund & McGuire, 1999). However, the RCT 
format effectively mutes the participant’s voice in favor of the investigator’s voice 
through the use of investigator-rated measurements, narrowly defined outcomes which 
are of medical/professional interest, limited or no opportunities for unstructured or 
spontaneous speech by the participant, and limited interaction between the participant and 
investigator (Jacobs & Cohen, 1999). Conventional symptom-based checklists and 
laboratory tests for biological effects (i.e., heart rate, blood pressure, plasma 
concentration) that are widely used in trials for medical products are only minimally 
relevant to psychopharmacology. 
Finally, RCT criteria to ensure internal validity and rigorous testing appear to be 
misapplied or misapprehended in psychopharmacology trials. For example, placebos 
have demonstrated considerable efficacy – often equivalent or superior to the treatment 
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drug – in psychopharmacology (Kirsch, Moore, Scoboria, & Nicholls, 2002), yet this 
response receives little serious discussion in the literature with most researchers viewing 
it as a methodological problem that “complicates clinical trials of efficacy” (Oates, 2006, 
p. 118). The placebo response is further obscured in drug trials through the frequent use 
of inert placebos and abrupt drug discontinuations (Cohen & Jacobs, 2007).  The double-
blind is used in RCT procedures to minimize the bias of expectation and suggestion, 
though rarely do studies report methods for ensuring or testing maintenance of the blind. 
Use of inert placebos may further contribute to penetration of the blind in 
psychopharmacology trials in which active drugs nearly always have noticeable adverse 
effects. Third, RCT procedures for assessing adverse effects are underdeveloped and 
receive little attention compared to methods for measuring and reporting efficacy 
outcomes (Cohen, Hughes, & Jacobs, in press; Greenhill et al., 2003). The most 
frequently used methods for collecting information on adverse effects involve “open-
ended questioning” and “unsolicited reports” of the patient, which undoubtedly 
underestimate the frequency of many events and may mask the severity of others. Other 
methodological limitations of the RCT as used in psychopharmacology include: 
inattention to implications of widespread polypharmacy on drug efficacy and effects, 
discontinuation designs that may be confounded by drug withdrawal effects, failure to 
adequately recognize drug withdrawal effects, lack of post-treatment follow-ups of the 
previous drug experience, insufficient consideration of non-surrogate measures such as 
social and functional outcomes, and a general neglect of the psychoactive nature of 
psychotropic drugs (Charlton, 2001; Cohen & Jacobs, 2007; Lagomasino, Dwight-
Johnson, & Simpson, 2005; Moncrieff, 2001). All of the above outlined factors combined 
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provide legitimate grounds for contesting the validity of the primary means of production 
of expert drug knowledge. 
Nevertheless, the information derived from pre-clinical through Phase III research 
is negotiated between the FDA and sponsoring pharmaceutical company and serves as the 
basis for the drug product label (Murphy & Roberts, 2006). According to FDA 
representatives, the drug label is “the closest one can get to the truth regarding the 
scientific information known about a drug” (p. 36), and represents the “formal, 
government-approved definition of a drug’s benefits and risks” (Avorn, 2006, p. 2409). 
However, litigation has revealed negotiations between the FDA and a pharmaceutical 
company spanning 5 years “over changing the drug’s label to include adverse event data 
that had been submitted to the agency but not made fully available to the public” 
(Kesselheim & Avorn, 2007, p. 310). The FDA has consistently supported the argument 
that a pharmaceutical company should not be expected to provide adverse event 
information other than that required to be printed in the drug label. Except for these few 
cases in which documents are revealed as part of litigation, it remains largely unknown 
what information in the drug label remains absent, minimized or reconfigured as a result 
of the negotiation process.  
Information about a drug’s full effects, which remains incomplete upon initial 
drug approval, is theorized to eventually emerge through long-term use in the general 
population. Phase IV post-marketing trials are deemed necessary to examine a drug’s 
long-term effectiveness, rare and distal adverse effects, withdrawal effects, cost-
effectiveness, the impact of a drug on quality of life, and other important clinical 
outcomes (Corrigan, 2002). However, as of 2006, at least 71% of post-marketing studies 
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that drug companies committed to conducting when their product was approved by the 
FDA remain uncompleted or never started (Avorn, 2007).  Post-marketing surveillance 
systems, such as the FDA’s MedWatch, are under-utilized, tedious to complete, and 
subject to many of the same inadequacies in data collection identified above with clinical 
trial research (Kessler, 1993; Medawar & Herxheimer, 2003). Information that is 
theorized to emerge from wide-spread drug use is not reliably collected nor promptly 
added to the drug’s officially recognized profile (the drug label) (Avorn, 2006; 
Kesselheim & Avorn, 2007).   
Pharmaceutical company influence in scientific drug knowledge production. 
An issue that magnifies methodological deficiencies of psychopharmacology 
trials and lack of regulatory enforcement by the FDA is the fact that the pharmaceutical 
industry supports 70% of all costs of clinical trial research in the United States, and 
contributes over half of the budget for the Center for Drug Evaluation and Research 
through user fees (Avorn, 2007). Frequently, large Phase III RCTs occur in the context of 
multi-site, often multi-country trials conducted by contract research organizations 
(CROs) that are hired by the sponsoring pharmaceutical company (Relman & Angell, 
2002). Medical education and communication companies (MECCs) are hired to 
“ghostwrite” and strategically plan the resulting publications, while the pharmaceutical 
company’s marketing department coordinates the process from beginning to end (Healy, 
2004; Sismondo, 2007). This entails deciding which studies to pursue and for what 
indication, who a publication should be authored by, and what journal it should appear in.  
Accordingly, the sponsorship of drug trials is inextricably linked to their design 
and outcomes. Out of 42 published articles of head-to-head comparisons of newer 
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antipsychotic drugs, 33 (78.6%) were funded by a pharmaceutical company and 90% 
reported outcomes in favor of the sponsoring company’s drug (Heres et al., 2006). In 
different comparisons of the same drugs, this resulted in contradictory findings as “it 
appears that whichever company sponsors the trial produces the better antipsychotic” (p. 
189). Two additional reviews of drug studies found odds ratios of 4.05 and 3.6, 
respectively, for a positive recommendation resulting from pharmaceutical industry-
funded compared to non-industry-funded publications (Bekelman, Mphil, & Gross, 2003; 
Lexchin, Bero, Djulbegovic, & Clark, 2003). A recent analysis comparing outcomes of 
published clinical trials and FDA reviews of the same data for 12 antidepressant drugs 
discovered that 94% of the former showed positive outcomes, whereas only 51% of trial 
outcomes were positive according to the FDA analysis (E. Turner et al., 2008). These and 
other well-documented publication biases leave considerable doubt about the credibility 
of the major “scientific” source for drug information (Ioannidis & Lau, 2001; Melander et 
al., 2003; Papanikolaou, Churchill, Wahlbeck, & Ioannidis, 2004; Perlis et al., 2005). In 
an essay titled “Medical journals are an extension of the marketing arm of pharmaceutical 
companies,” a former British Medical Journal editor suggested a remedy to this far-
reaching problem: medical journals should stop publishing clinical trials (Smith, 2005).  
In sum, FDA approval of a drug, which results from pre-clinical through Phase III 
testing, provides a “cognitive closure” in which clinicians and consumers accept the 
given “scientific” facts about the drug (Busfield, 2006). The drug testing and approval 
process may be ineffectual, though, because the pharmaceutical company makes the facts 
and selects the data to present.  
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Limitations to scientific testing in psychopharmacology and the peculiar complexity of 
the industrial-regulatory process are not often noted once the official “badge of 
effectiveness and safety” is issued by the regulatory agency (p. 305). 
Dissemination and credentialed practice of scientific drug knowledge. 
In the offline world, scientific drug knowledge is typically disseminated to 
credentialed medical practitioners through published peer-reviewed journals (discussed in 
the previous section), pharmaceutical representatives or “detailers,” medical education 
venues, and medical texts, particularly the Physicians Desk Reference (PDR). 
Pharmaceutical companies are intimately involved with each of the above activities and 
products, with the effect of increasing the grey area between marketing and science. 
Pharmaceutical representatives, or “detailers.” 
 Marketing expenditures in the pharmaceutical industry have grown from $11.4 billion 
in 1996 to $29.9 billion in 2005, according to industry reporting and surveys (Donahue, 
Cevasco, & Rosenthal, 2007). A recent independent source estimates a more realistic 
figure to be $57.5 billion (Gagnon & Lexchin, 2008).  Physician and hospital detailing by 
pharmaceutical representatives is the largest expense, making up approximately 65% of 
marketing expenditures of top-selling psychotropic drugs. The job of the detailer is to 
provide “details” to the psychiatrist about the products they represent, and up to 90% of 
doctors report meeting with detailers (Lexchin, 1993) with an average frequency of 4 
times per month (Wazana, 2000). At the same time, while many doctors indicate they 
place little value on detailers as a source of accurate and objective drug information, 
studies demonstrate strong evidence that detailing effectively influences doctors to 
prescribe the promoted drug. The significance of the detailer, however, is not only that 
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such promotional practices are effective, but also that they represent an “extension of a 
hierarchically structured marketing apparatus – based on rationalized principles of 
management and market analysis – into social spaces previously thought to be occupied 
only by doctors and patients” (p. 285). Detailers track the effectiveness of their 
educational-promotional efforts by purchasing marketing maps that provide information 
on individual doctor’s prescribing habits (Greene, 2004). Marketing maps may, for 
example, enable a detailer to target “stubborn” doctors with a different strategy, or to 
invite doctors prescribing in high volume to speak at a professional symposium.  
Pharmaceutical detailing represents one of the most targeted and well-funded 
promotional efforts aimed directly at individual clinicians who, under this scenario, may 
be considered another type of medical/health consumer.  
Opinion leaders and medical-educational venues. 
 As an “experience good,” the adoption of a new drug by psychiatrists is largely 
dependent on word-of-mouth and learning (Azoulay, 2002). This highlights the need for 
pharmaceutical companies to engage “opinion leaders” and to sponsor continuing 
medical education, professional symposiums, and scientific conferences. Opinion leaders 
are prominent experts in the field who receive honoraria and fees to speak at scientific or 
medical conferences, and to contribute to textbooks and journal articles (Relman & 
Angell, 2002). Unlike pharmaceutical advertisements under FDA regulation, opinion 
leaders are able to diffuse to their colleagues the unapproved or novel uses of a drug. 
Pharmaceutical companies further provide the most support, in the form of funding and 
organization, of the above mentioned educational and professional events (Relman & 
Angell, 2002). Some researchers have found bias in favor of the sponsoring company’s 
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drug in continuing medical education curricula, even when institutional CME guidelines 
were in place (Wazana, 2000). Additionally, psychiatrists often receive industry-funded 
meals, free samples, all-expenses-paid travel to attend pharmaceutical-sponsored 
educational events, and other gifts. Data from Vermont and Minnesota, two states that 
now require disclosure of drug company payments to doctors, indicate that psychiatrists 
earn more from pharmaceutical companies than any other medical specialty (Harris, 
2007, June 27). Moreover, “psychiatrists who took the most money from makers of 
antipsychotic drugs tended to prescribe the drugs to children the most often” (para. 8). 
While doctors report that they are not influenced by pharmaceutical “education” and gift-
giving, the evidence consistently indicates increased prescribing of sponsored drugs by 
doctors who attend such events or accept pharmaceutical gifts (Lexchin, 1993; Wazana, 
2000).  
Credentialed medical experts’ practice of scientific drug knowledge.  
Clinicians and psychiatrists, as licensed intermediaries between the drug and the 
end consumer, are provided access to scientifically produced drug knowledge through the 
above outlined channels (Lakoff, 2004). The knowledge actually utilized by these 
practitioners is typically more pragmatic than that produced by scientific methods, and 
reflects only the portion of scientific/medical knowledge that is relevant to the conditions 
likely to be encountered in routine clinical practice (Freund & McGuire, 1999). This 
“recipe knowledge” may include such scientifically given facts as the recommended 
treatment for a condition or age group, side effects, and contraindications. Psychiatrists 
and clinicians may also rely on less “scientific” sources, such as popular media, the 
Internet, discussion with colleagues, and clinical experience (Phillips, Kanter, 
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Bednarczyk, & Tastad, 1991; Relman & Angell, 2002; Woosley, 1994; Wyatt, 1991). 
Patient requests may further impact practice with evidence demonstrating, for example, 
high physician compliance with specific or general drug requests (53% and 76%, 
respectively) to treat major depression (Kravitz et al., 2005). Of course, a variety of other 
factors may also help shape actual clinical practice, such as the need or desire of the 
clinician to satisfy the demands or anxieties of a patient, to quell an overwhelming 
workload, or to quickly terminate a difficult or time-consuming consultation (Weiss & 
Fitzpatrick, 1997). 
Popular media and the Internet. 
 The lay press may serve as a “filtering mechanism” for doctors and scientists to identify 
important findings from the vast amount of information found in medical journals 
(Phillips et al., 1991). However, on a daily basis health and medical reporters are 
“inundated with press kits, announcements, faxes…from drug companies and the public 
relations firms that represent them” ("Miracle drugs or media drugs?," 1992, March, p. 
142). Popular media articles are commonly written with input from a pharmaceutical 
company’s marketing firm as part of the public relations campaign to promote the drug 
(Healy, 2006b). Even media coverage of articles appearing in peer-reviewed journals 
have been found to frequently exaggerate findings, neglect harms, and fail to adequately 
identify study limitations or author conflicts of interest (Moynihan et al., 2000; Woloshin 
& Schwartz, 2002).  
 While much of the research literature focuses on the Internet as a tool for consumers, 
psychiatrists and clinicians may also use the Internet to research clinical information, 
read articles from medical journals, and communicate with colleagues (Trickett, 2007, 
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May 28). A 2002  survey of U.S. physicians found that most (70%) report using three or 
fewer websites to regularly find medical information, with WebMD consistently topping 
the list of online sources (Von Knoop, Lovich, Silverstein, & Tutty, 2003). Nearly all 
physicians (96%) reported that information they found online impacted their knowledge 
of available treatments, including drugs. A slightly smaller majority (73%) reported that 
the information impacted their prescription decisions.  
Clinical experience. 
In addition to official scientific drug knowledge funneled to clinicians through the 
previously discussed channels, clinical experience may be a primary source of knowledge 
utilized to make decisions about psychiatric diagnosis, and the appropriateness and 
effectiveness of a treatment (Charlin, Tardif, & Boshuizen, 2000; Wyatt, 1991). This is 
especially so in selecting psychotropic drugs because the “difficulty in applying valid and 
sensitive measures of therapeutic effect” requires selection based on the individual’s 
likely tolerability of adverse effects or knowledge of a previously favorable response to 
the drug (Brunton et al., 2006, p. 429). As already mentioned, the speech and expressions 
of the psychiatric patient are uniquely important in psychopharmacology, and are equally 
so in clinical practice with psychotropic drugs. Though because medical training and 
professional ideologies may effectively restrict problem-solving to the specialized tools 
of the profession (Nordin, 2000), it is likely that the clinician interprets the impact and 
meaning of drug effects differently than the individual experiencing it first-hand 
(McCubbin & Cohen, 1996). For example, the psychiatrist may primarily seek 
congruence of the patient’s story with prevailing diagnostic systems such as the DSM 
(Tucker, 1998), and some recognized scientific facts about the drug. Through taking the 
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patient’s treatment or “medication history,” the clinician embarks on an interpretive 
process of meaning-making that may or may not remotely reflect the true nature and 
impact of the drug as experienced by the user (Cohen, 2003). This is partially empirically 
demonstrated by studies finding poor correlation between clinician-rated and patient-
rated psychopathology measures (Lasalvia, Ruggeri, & Santolini, 2002). Clinician-rated 
psychopathology is also poorly correlated, while patient-rated psychopathology is 
moderately to highly correlated, with subjective quality of life. 
Additionally, several studies have revealed insufficiencies in the process of 
relating expert drug knowledge to actual or potential drug users within the clinical 
consultation. In multiple surveys, tardive dyskinesia, a common serious adverse effect of 
certain antipsychotic drugs, was simply unmentioned by psychiatrists as a risk to patients. 
In a survey of patients taking antipsychotic medications, over half (59%) reported that 
other treatment options had not been presented and 46% indicated that they had not 
received any information about potential adverse effects of the prescribed treatment 
(Gray, Rofail, Allen, & Newey, 2005). In a survey of 223 patients receiving medications 
for a diagnosis of bipolar disorder, between 60% and 70% of respondents reported 
dissatisfaction with receiving too little information from their clinicians about adverse 
effects, what to do in case of experiencing an adverse effect, and whether the medication 
would affect sexual functioning (Bowskill, Clatworthy, Parham, Rank, & Horne, 2007). 
After interviews with 51 patients starting antidepressant drug treatment, the most 
commonly reported unmet information need concerned adverse effects, followed by the 
role of treatment in recovery, expected length of treatment, and the risk of physical and 
psychological dependency on the drug (Garfield, Francis, & Smith, 2004). Such 
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omissions by psychiatrists and clinicians, whether intentional or not, violate the principle 
of informed consent and serve to undermine the credibility and reliability of clinical 
expertise. 
 Due to the distorting effects on scientific drug knowledge of extensive 
pharmaceutical company involvement in the production of drug fact-making and 
subsequent dissemination to practicing experts, it may be justifiably argued that clinicians 
are unequipped and unable to provide a “balanced” risk-benefit appraisal to drug 
consumers. Further, the esteemed status of the credentialed medical expert may be 
threatened if the specialized knowledge that distinguishes expert from non-expert loses 
credibility and relevance. Despite professional ethics and licensing requirements intended 
to instill trust and proclaim competence, many psychiatrists may themselves have only 
limited understanding of drugs’ full effects.  
Consumer Drug Knowledge in the Off-line World 
 In trying to come to a “valid” understanding of drugs’ effects, the voice and speech of 
the patient has traditionally been muted or neglected in favor of a presumably more 
objective biomedical discourse (Hyden, 1997; Jacobs & Cohen, 1999). With this, the 
depth and complexity of an individual’s suffering and treatment are reduced or eliminated 
(Miller & Crabtree, 2005). While it may be legitimately argued that the patient’s “voice” 
is irrelevant to a scientific understanding of disease (defined in Western models as 
pathological alterations at cellular or molecular levels), the role of the patient’s voice in 
psychiatric medicine might be profoundly different because there exist no accompanying 
physical signs or symptoms to aid a psychiatric diagnosis and treatment plan (except for 
substance-induced conditions and conditions, such as dementias, consequent to various 
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physical diseases). Absent both strict disease determinations in psychiatry and patients’ 
voices in psychiatric drug research, it is important to explore what power this biomedical 
discourse and professionally-mediated treatment reflect. 
The drug consumer may consider information from a variety of sources to 
interpret and label symptoms and make treatment decisions. Common sources for the 
consumer include their doctor or psychiatrist, advice from non-medical helping 
professionals or non-professionals in their social network, scientific/medical texts such as 
the PDR or the drug label, DTC advertising and popular media, Internet sites and 
discussion forums, personal and shared experiences, and personal beliefs about health, 
disease healing and medicine (Harmon, 2005; S. Williams & Calnan, 1996). Consumers 
typically seek information that is congruent with the everyday experience of their 
problem (Kivits, 2004), which may or may not include strictly biomedical interpretations 
and categorizations.  This carries potential for dissonance between the consumer’s 
explanation and perceived needs, and psychiatric/medical explanations and cures.  
A consumer’s reliance on a clinician or psychiatrist for drug information may be 
caricatured on a continuum ranging from rejection of the value and/or validity of expert 
knowledge, to autonomy in gathering and digesting expert knowledge, to complete 
dependence on the expert for relaying knowledge and making associated treatment 
decisions (Fox & Ward, 2006). Autonomous consumers generally accept medical 
explanations for their suffering and may carefully research treatment options prior to the 
medical encounter in order to offer their clinician specific treatment suggestions. Some 
may even lie about their symptoms to ensure they receive their desired drug (Harmon, 
2005). Others may experiment with increasing or decreasing their already prescribed dose 
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or trying different medications borrowed from a friend. Particularly among drug 
consumers under age 40, the popular media have reported, “there’s this increasingly 
widespread attitude that ‘we are our own best pharmacist’” (para. 22) and that a medical 
degree “is useful, but not essential, and certainly not sufficient” (para. 6). As an aside, it 
may be hypothesized that consumers in the autonomous and perhaps rejection range 
would be more likely to contribute to consumer-generated online health and prescription 
drug sites than dependent consumers. 
 Personal and shared experience. 
 Any “expertise” or special knowledge a patient may be granted by professionals is 
rooted in experience (Caron-Flinterman, Broerse, & Bunders, 2005). Consumers have 
first-hand knowledge of the impact of illness on their body and social life, and the 
benefits and pitfalls of tried treatments. The consumer is the only one who can decide the 
usefulness of the treatment for their life circumstances (Kazdin, 1999; Nordin, 2000). The 
notion of efficacy – a statistically significant superiority of the drug over placebo of 
paramount importance in psychopharmacology – is minimally relevant to clinical 
significance and the total drug experience.  
Personal experience and the insight gained from others with similar experiences is 
often perceived and utilized by consumers as a relevant, useful, and trustworthy source 
for gaining knowledge and making treatment decisions (S. Williams & Calnan, 1996). A 
recent survey found that experiencing an adverse effect, but not contact with a clinician, 
receipt of a medical diagnosis or admission to a hospital, was significantly related to 
increased awareness of a prescribed drug’s adverse effects (Papanikolaou & Ioannidis, 
2003). Similarly, consumers may be warned, for example, about severe withdrawal 
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effects of certain antidepressants from an experienced friend, but not from their 
prescribing physician who may be unaware of such an effect as it is often not part of the 
drug’s official profile (Cohen, 2007). Inasmuch as drug effects are unpredictable for any 
one individual, the experience of others may serve as a trusted and “objective” – in terms 
of the direct testing of an “experience good” without apparent conflict of interest – source 
of information.  
Some social scientists have strongly recommended viewing scientific and lay 
knowledges as necessary complements, suggesting that they are equal in value and 
contribution to the overall knowledge of a domain, though different in their content and 
epistemology (Goodare & Lockwood, 1999; Popay & Williams, 1996). Accordingly, 
either one or both may be wrong on occasion.  This paper is further concerned with 
power relations and the politics of truth – that is, how scientific knowledge about drugs is 
legitimated (through associations of it as objective, reliable, and valid) while consumer 
knowledge is more often de-legitimated or made inferior (through associations of it as 
subjective, idiosyncratic, and naïve). This dynamic surrounding the production of drug 
knowledge is partly due to the construction of “medication” as an expert domain, and 
persists despite possible distortions in the objectivity, reliability, and validity of 
scientifically produced knowledge largely due to pharmaceutical companies’ far-reaching 
involvement. The user-generated Internet introduces a new component to conventional 
power relations in drug knowledge production and dissemination. 
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Expert and Consumer Knowledge in the Online World 
The dynamics of knowledge on the web.  
 The original Internet was dubbed “the information superhighway” – a name which no 
longer seems suitable to describe its current dynamics and uses. Today’s Internet – 
variously called the programmable web, the user-generated web, or Web 2.0 – is about 
participation, collaboration, and communication (Tapscott & Williams, 2006). The 
difference reflects more than just a shift in popular use of a technology, but rather 
suggests a greater cultural impact and a different way of thinking about knowledge. 
Dynamics of the user-generated Internet of interest for this paper include the evolving 
roles and expectations of consumers in the online realm, the potential of the Web to 
anticipate later acknowledged realities, and the competition for online space and 
attention. 
The development of the user-generated web consisted of a bottom-up 
transformation of traditional practices in multiple market sectors (Tapscott & Williams, 
2006). The assumption of a passive consumer who quietly accepted a finished good 
(including information) or service was challenged by self-organized online consumer 
communities in media, journalism, software development, and other areas that fulfilled 
unmet needs in a grassroots way. By 2006, “the programmable Web eclipsed the static 
Web every time: Wikipedia beat Britannica; Blogger beat CNN; Epinions beat Consumer 
Reports…and craigslist beat Monster” (p. 38-39). These leaders among consumers have 
arguably ignited a shift in the relations of power to become something more like 
“prosumers” who participate in the creation or production of the good or service they are 
consuming (p. 125). Consumers more broadly appear to carry expectations for formerly 
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static websites to provide opportunities to participate, collaborate, or interact with the site 
and/or with other users. Inevitably, such openness leads to multiple claims to knowledge 
and uncertainty as to claims’ credibility and authenticity in an inherently non-transparent 
realm (credibility on the Internet is discussed in detail in following sections). Despite 
difficulties, the potential of Web 2.0 is ballooning as companies and research institutes in 
all sectors are grappling with innovative business, marketing, and research models to 
accommodate this cultural shift ("Let data speak to data," 2005; Tapscott & Williams, 
2006).  
As a result of increasing consumer participation and interaction online, the Web 
may carry the potential to anticipate what only later is officially acknowledged as a 
reality (Rogers, 2003). In the case of psychotropic drugs, an actual or potential consumer 
on the Internet can find the official medical/professional/industry accounts of a drug’s 
uses and effects, as well as unofficial accounts from consumers and “fringe” groups that 
may “enrich and complicate more official accounts” (p. 196). Insofar as the Web is a 
grassroots technology used by individuals to (often spontaneously) self-organize and 
“have a voice”, the Web may be the “first to know” of novel or underground drug uses 
and professionally unrecognized desirable or adverse drug effects (p. 196).  This is 
certainly the case with “brain shivers” – an adverse effect associated with antidepressant 
use and withdrawal, which was recognized by clinicians and researchers only after online 
discussion of the phenomena among consumers became too overwhelming to dismiss 
(Christmas, 2005).  Clinical trial reports indicated some incidence of “dizziness,” 
“vertigo,” and “sensory disturbances” upon drug “discontinuation,” but the experience of 
consumers was congruent with difficult-to-describe electrical shocks to the head and 
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often a feeling of severe drunkenness – even after missing just one dose of certain 
antidepressants. The discrepancy, not only in terminology, but in depth of understanding 
resulted in individual doctors and pharmacovigilance centers dismissing, minimizing, or 
misclassifying consumers’ complaints (Medawar, Herxheimer, Bell, & Jofre, 2002). 
Brain shivers continued to be defined and described so differently by experts and 
consumers that the phenomenon recognized by one appeared foreign to the other. Further, 
the medical community seemed reluctant to take seriously the “anecdotal” reports of 
consumers, despite the rapid growth of websites dedicated to discussing the issue. In this 
case, the Web was the “first to know” of brain shivers and could be described as 
anticipating a later acknowledged reality, as the medical community did eventually 
recognize this effect to be a “new” drug problem even without an understanding of its 
causal mechanisms. Of course, there are numerous examples in the off-line world of 
patients recognizing iatrogenic effects of an intervention before professionals and having 
their recognition contested or discounted (Popay & Williams, 1996; S. Williams & 
Calnan, 1996). The web as potentially anticipatory adds a new component to this existing 
power relation. 
Finally, with unlimited virtual space on the Internet and the ease of publishing 
one’s views online, the most valuable resource in the online realm may be attention 
(Dahlberg, 2005). Millions of web pages make it less likely that any one page will be 
noticed by an audience of considerable size. Search engines do not frequently reveal their 
algorithms for returning search term results, so it is not possible to definitively outline all 
of the most important elements in the determination of online attention. To tip the scales 
in one’s favor may require maintaining an extensive network of inbound hyperlinks, 
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reproduction of one’s content on other sites, and costly pay-per-click advertising. Sites 
can also purchase such items as “prime time” and “sole supplier” status on search engines 
to minimize the chances that a competitor site will garner similar attention.  
In the health domain, some medical researchers, practitioners, and regulatory 
authorities as high up as the World Health Organization are advocating for regulation of 
health websites using quality ratings and seals of approval (Eysenbach, Powell, Kuss, & 
Sa, 2002; Fox, 2010). Such actions would presumably protect consumers from wrong or 
potentially dangerous information and, simultaneously, assert what gets counted as 
legitimate health information (Brown, 2002). These efforts have not been in vain as an 
unknown number of search engines “already exclude or marginalize health websites that 
don’t meet recommended medical grading system requirements” (Lewis, 2006, p. 528), 
which may include consumer-led sites and other “unconventional” health resources.  
However, the negotiation of space and attention is continually challenged by the 
Internet’s openness. For example, the rise in consumer complaint forums has been met by 
companies “attempting to defend themselves by setting up anti-domains” before 
consumers have an opportunity to register them (Harrison-Walker, 2001, p. 398). Days 
prior to launching the site Priceline.com, the company purchased the domain Priceline-
sucks.com and a variety of other spin-off names. The hugely popular video site YouTube 
allows individuals to post video clips which are searchable by other users using keywords 
attached to the video. A recent high-profile video featured a five minute segment from a 
former sales representative for Eli Lilly’s antipsychotic drug Zyprexa, “who reveals what 
Lilly officials told him to say about the drug’s side effects” (Thomaselli, 2007, p. 4). 
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Pharmaceutical companies are in return posting positive and entertaining videos about 
their products on the site. Wikipedia is another prime example of the battle over virtual 
space (and knowledge in Wikipedia’s case). A detailed look at Wikipedia follows in the 
Limitations section. 
It is clear that the negotiation of space and attention on the Web is not as 
straightforward or transparent as one might easily believe, and certainly is not a 
haphazard or spontaneous occurrence. The above strategies to guarantee attention require 
extensive monetary or networking resources, favoring those corporations and 
organizations with pre-existing resources in the off-line world (Dahlberg, 2005). Quality 
ratings for health websites serve to reinforce traditional power relations in the production 
and dissemination of the respective knowledge.  These dynamics reveal some of the 
inequalities in what is promoted as an inherently democratic medium supposedly 
governed by the free choice of users.  The user-generated web is a contested terrain with 
competition for attention and claims to knowledge. The actual and potential altering of 
power relations around knowledge production has caused heated debate among 
researchers and social commentators about the evolving role of expertise in the age of the 
Internet.    
Credibility on the Internet. 
Users of the Internet may come across a variety of information on any particular 
health topic, and thus are no longer limited to receiving a pre-filtered presentation from a 
traditional gatekeeper such as a trusted doctor (Eysenbach, 2008). However, sources of 
information across all domains are non-transparent in the online realm. It is difficult to 
know what conflicts of interest and scientific or financial stakes are involved in the 
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construction of expert sites, just as it is difficult to gauge the presence of unauthentic 
accounts contributed by persons with vested interests in consumer sites (Clarke et al., 
2003). In parallel, an identity as an expert can be as easily misrepresented as an identity 
as a consumer. What this amounts to for Internet users is a shift in the importance of 
source credibility to a greater reliance on message credibility (Eysenbach, 2008). Rather 
than relying on any particular claim or assertion based on expertise, Internet users appear 
more often to cross-check bits and pieces of information across sites with less concern for 
whether the author is speaking from credentials or experience (David, 2007; Eysenbach, 
2008; Sillence, Briggs, Harris, & Fishwick, 2007).  
This dynamic of the Internet causes some medical authorities to disapprovingly 
judge the Internet to be “an unruly, unregulated space marked by plurality of claims to 
knowledge and authority” (Lewis, 2006, p. 528). This perception has led to concern 
among many medical researchers and practitioners about the “quality” of information 
found online (Eysenbach et al., 2002; Ferguson, 2002). However, what may be needed is 
a new model for judging the credibility of these anonymous, distributed, co-constructed 
web sources that are becoming so popular and familiar among Internet users. One such is 
the “field-dependent model” in which credibility depends on the user accepting the 
principles and practices specific to the field or context within which the site operates 
(Warnick, 2007). For example, an independent media (Indymedia) site based on 
principles of open peer publishing, constructing alternative accounts, and the 
impossibility of objective reporting will not be judged credible using the same standards 
of mainstream journalism which is based on a very different set of principles. The field-
dependent model explains that users “must look to his or her own assessments, based on 
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what is said on the site, in its comments, its external links, and on other sites” in order to 
decide whether the content may be viewed as credible (Warnick, 2007, p. 62). Under this 
model and suitable to many medical domains in which criteria for providing “complete” 
and “accurate” information are necessarily problematic, credibility is a subjective concept 
arrived at with consideration of the user’s prior experience, knowledge, and needs 
(Eysenbach, 2008). Consumer-constructed sites are not generally meant to provide 
scientific health information to readers, but rather exist for a variety of other purposes 
that may be judged “credible” in their own respective contexts. This model gives agency 
to Internet users and allows for different standards to be applied to the variety of web 
sources existing in multiple contexts. Of course, regulatory concerns regarding health 
content appear unjustified in the absence of equally vigorous attempts within the medical 
community to ensure the unbiased flow and content of “official” health information.  
More broadly emerging is a re-evaluation of ways of producing what is judged to 
be legitimate knowledge in online communities. The emergent and community models 
illustrate how knowledge is differently produced within online groups. In the emergent 
model of a user-generated site, thousands of individual users each contribute a small part 
(like a review of a product) and out of this emerges a coherent body of work (Wales, 
2005). Credibility on these sites is established through reputation mechanisms, such as 
the ranking system on Slashdot or the complex system of user reviews on Amazon. In 
Slashdot’s ranking system of technology news stories, users gain reputation and influence 
by their invested participation in the community and their ability to meet the information 
needs of other users (David, 2007).  
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 The community model is characterized by a dedicated group of volunteers who work 
together to create and maintain the site’s content (Wales, 2005). As in any organization or 
community, users get to know one another as part of their continued interactions and the 
collaborative process is thought to ensure the site’s quality and credibility. The non-
profit, volunteer-led encyclopedic website Wikipedia is the most notorious example of 
the community model. A core group of about 524 users (0.7% of all Wikipedia users) do 
about half of the site’s editing. Any Internet user may create or contribute to an entry 
anonymously or as a registered user, though only 18-21% of all edits are anonymous. The 
English-version Wikipedia has over 1 million entries and had reached top 50 website 
status by 2005, receiving more traffic than the New York Times (Tapscott & Williams, 
2006). The strengths of Wikipedia include its constant growth in the addition of new 
entries on obscure and niche topics, and its rapid and in-depth coverage of recent events. 
Wikipedia’s openness also makes it vulnerable to inaccuracies, vandalism, and “edit 
wars” in which disagreeing users change one another’s edits. However, despite the 
inevitability of errors in any encyclopedia, an obscenity randomly inserted in a Wikipedia 
article is removed in an average of 1.7 minutes. Disagreements and inaccuracies may be 
particularly a problem for entries in philosophy, politics, and culture, but for science 
topics Wikipedia has recently been found to be about as accurate as The Encyclopedia 
Britannica (Carnevale, 2006). In a study of exposure of user-generated sites in popular 
search engine returns for health-related searches, Wikipedia appeared on the first page of 
Google and Yahoo in 63% of searches, making it the most frequently cited user-
generated resource ("Diving deeper into online health search," 2007).  
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Thus, “Wikipedia, like the larger open system of the Internet, is charting new territory in 
which widespread use is not contingent on widespread trust, at least on the terms 
established by earlier expert systems” (David, 2007, p. 185). 
The credibility of the user-generated web and of individual contributions within 
specific websites is an unresolved and evolving issue. Despite their lack of credibility in 
certain quarters, user-generated sites are highly trafficked and carry validity for their 
constituents and users. Revisions to concepts of truth, credibility, legitimacy, and 
expertise brought on by the Internet are at the heart of discussion and debate among 
Internet researchers in a variety of fields (David, 2007; Keen, 2007; Warnick, 2007). As a 
beginning attempt to add to this discussion in the area of psychotropic drugs, the present 
research sought to compare the information found on expert and consumer online 
sources. This is to distinguish the aim of the research from one that seeks mainly to 
determine the truth value of specific claims. 
Consumer drug knowledge and the Internet. 
Consumers may use the Internet to supplement, verify, translate, or replace 
information from other sources (Eng & Beauchamp, 2005). The almost unlimited 
information available on the Internet creates the opportunity to find personalized and 
individualized information, as consumers can keep searching until they find information 
that resonates with their experience and beliefs.  A 2002 survey of 10,000 U.S. patients 
found that most patients (75%) report visiting 2 to 5 websites regularly to find health 
information (Von Knoop et al., 2003). Similar to results from physician respondents, 
patients consistently report WebMD as a top online source. WebMD is constructed and 
monitored by medical professionals and contains health information presented as 
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scientifically legitimated. It is intended for an audience of other experts and the lay 
public. It is unknown whether the reported popularity of WebMD is due to its relevance 
to and fulfillment of information needs, or to its success in negotiating online space 
through search engine placement and advertisements.  
Second, consumers may use the Internet to share their experiences, give advice 
and recommendations, or act as a resource linking individuals to other relevant sources 
(Hardey, 2002). This use of the Internet transforms consumers into producers of health 
information (Hardey, 2001). Personal web pages describing illness, for example, may be 
considered “a new genre” of the illness narrative, in which the story is unmediated by a 
health professional or researcher, receives guaranteed instant publication to a global 
audience, and is dynamic in nature in that the story can be continually updated (p. 395). 
Information-, advice-, and resource-sharing are similarly accomplished in online 
community groups, discussion forums, and chat rooms, with a range of discourses 
potentially represented (Fox & Ward, 2006). In a consumer-led discussion forum called 
CrazyBoards, “fluency in the language of psychopharmacology is taken for granted. 
Dozens of drugs are referred to in passing by both brand name and generic, and no one is 
reticent about suggesting medications and dosage levels” (Harmon, 2005) (para. 37). In 
this case, users approximate the “autonomous” consumer discussed previously, as the 
doctor appears necessary primarily to purchase the desired drug rather than for 
information-gathering and decision-making.  
 Finally, the frontier of Internet uses by consumers may include creation of a consumer 
research community in which consumers across the country offer ongoing data about 
their symptoms and treatments in order to create a large database comparable to, and 
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more timely, accessible, and relevant than, data from clinical trial research. One website, 
PatientsLikeMe.com, has been exploring this frontier since March 2006 with consumer 
research communities for Lou Gehrig’s disease, multiple sclerosis, HIV, and, as of early 
2008, mood disorders (Goetz, 2008, March 23). Participants on the site can provide 
information as often as they wish on their symptoms, symptom severity, treatments, and 
dosages, and the website’s software automatically converts the information into charts 
and graphs for ongoing monitoring. These quantitative measures are supplemented with 
discussion forums that provide participants opportunity for elaboration. Further, by filling 
out a personal profile, the site instantly matches up a newcomer with other participants 
who share similar symptom and/or treatment profiles. The creator of the site, the brother 
of a person who died from Lou Gehrig’s disease, envisions that it “might complement 
large-scale and long-term clinical research by conducting observational research ‘on the 
fly’” (para. 52) and supports this by adding that data “are present not just in laboratories 
or universities or proverbial halls of science but in everyday life” (para. 54). Such 
research came to fruit in November 2007 when a small group of the Lou Gehrig’s disease 
community chose to seek lithium treatment from their doctors on the basis of an 
unpublished study in Italy that showed promising results. Each member of the group uses 
the site to share and track treatment effects with the intent to expeditiously verify or cast 
doubt on the scientific research results. With this and future possible drug “trials,” the 
creators and users of the site perceive the site’s potential to transform health research: 
 
most health-care data is inaccessible due to privacy regulations or 
proprietary tactics… When you and thousands like you share your data, 
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you open up the health-care system… We believe that the Internet can 
democratize patient data and accelerate research like never before. (para. 
33)  
PatientsLikeMe.com has received attention in the New York Times and numerous 
health blogs as a potential disrupter to the health care industry and medical research 
(Goetz, 2008, March 23; Schonfeld & Morrison, 2007). They also published a paper 
about Lou Gehrig’s disease in the European Journal of Neurology and received their first 
scientific award for a poster presentation in 2007 at the British Neuropsychiatry 
Association (Wicks, 2008; D. Williams, 2007). When proactive consumers take it upon 
themselves to create and disseminate the knowledge they feel a need for and even form 
their own drug trials, it may arguably represent a contestation of consumer exclusion 
from conventional processes of knowledge production.    
Expert drug knowledge and the Internet. 
Just as there has been an explosion in consumer-constructed health websites, there 
has been an equal explosion of expert-constructed sites. These include international and 
governmental health authorities, healthcare hospitals, academic institutions and insurers, 
medical research organizations and databases, professional associations, pharmaceutical 
companies, non-profit organizations formed around a particular psychiatric diagnosis, 
individual and group medical expert web pages, and many more (Parr, 2002). Such expert 
sources typically aim to interpret and/or disseminate scientifically legitimated medical 
knowledge about psychiatric diagnosis and treatment. The Internet, in contrast to all other 
mediums, provides a means to accomplish this in a highly accessible and up-to-date 
manner. At the same time, the dynamic linking of web pages means that the producers of 
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messages have decreased power over the placement, timing, and context within which 
their message is presented (Weare & Lin, 2000). Thus, the Internet “is arguably 
facilitative of a different kind of knowledge base about health and illness (it is not just a 
new and different medium, but helps to alter the nature of the knowledge accumulated)” 
(p. 78). While interesting to note, it is beyond the scope of this review and of the 
proposed research to explore how medical knowledge may actually be transformed by 
this new method of transmission.  
Pharmaceutical companies, like companies in all sectors, are finding innovative 
ways to communicate with consumers online and maintain a strong market presence.  
Direct-to-consumer prescription drug websites have been found in multiple analyses to 
present incomplete and limited drug information, especially concerning drug risks and 
harms (Davis, Cross, & Crowley, 2007; Hicks, Wogalter, & Vigilante, 2005; Macias & 
Lewis, 2003). Using a sample of 44 drugs, Davis and colleagues (2007) compared risk 
statements on the manufacturers’ websites to statements on the FDA label. Websites 
promoting drugs with only 1 adverse effect occurring at a rate greater than 10% generally 
reported this effect (90.9%). Only 15.3% of websites promoting drugs with 4 or more 
adverse effects occurring at this rate reported all of these effects. The greater the number 
of adverse effects, the less likely the consumer would learn of them on the 
manufacturer’s website. This finding is particularly notable given the unlimited virtual 
space available to present comprehensive information. Hicks and colleagues (2005) 
examined the structure of 20 randomly selected drug manufacturer websites to determine 
the relative accessibility of information pertaining to benefits and risks. Risk information 
was found to be located deeper into the website structure and more difficult to access 
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than information about benefits as measured by the amount of scrolling and number of 
clicks required for viewing.   
However, DTC websites are only the tip of the iceberg in online communication. 
Pharmaceutical companies looking for new opportunities to influence consumer behavior 
are keenly aware of the power of consumer forums to build trust and offer support 
(O'Neill, 2007). A DTCA strategy termed “patient-centric marketing” recognizes that 
“the most effective method for true health engagement includes online patient 
communities” (p. 13). This involves recruiting “brand advocates” to build an “online 
community of like-minded consumers” who can create content that is “clear, jargon-free, 
and provided by the ‘citizen’ for the emotional and personal credibility” (p. 16). It is not 
known whether a “consumer” site sponsored by a pharmaceutical company or a 
pharmaceutical representative visiting a genuine consumer site would acknowledge the 
sponsorship or presence.  
Another innovation draws on the influence of “respected physicians” to suggest 
specific health websites to their patients (Von Knoop et al., 2003). A pharmaceutical 
company may offer “prepackaged content for physicians’ personal websites,” which 
ensures that “doctors and patients alike find consistent messages…about the 
appropriateness of a particular treatment option” and that “information about a 
company’s product is perceived [by the patient] as objective and credible” (p. 32). 
Finally, similar to pharmaceutical company financial sponsorship of medical journals and 
medical educational venues, one study found that 58% of the top 50 websites retrieved 
from Google and Yahoo searches of the term “schizophrenia” were funded by drug 
companies (Read, 2008). Most frequently, these were pharmaceutical company sites, sites 
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that represented or served families of persons with schizophrenia, commercial sites with 
product for sale, and non-governmental organizations. Pharmaceutical company funded 
sites were significantly more likely to espouse a biomedical cause of schizophrenia and 
focus on psychotropic drug treatment.  
The participation, collaboration, and interaction that characterize the user-
generated web are obviously equally applicable to consumers and corporate stakeholders. 
The Internet allows any individual with online access to produce or consume information 
without a professional intermediary, though, in many instances it appears that the 
immense resources and allies of pharmaceutical companies still tip the scales in their 
favor. 
Previous Forms of Internet Research 
An unknown number of websites allow consumers to rank and review consumer 
products and services, such as digital cameras, software, airlines, and now prescription 
drugs. Research on consumer review sites and online community groups related to mental 
health issues and drug use is limited in number and scope. Many qualitative studies into 
discussion groups for depression describe benefits of community group participation, 
such as social support and coping, or describe help-seeking behaviors in the online 
context (Powell, McCarthy, & Eysenbach, 2003). Content analysis has been used by 
some researchers to examine the completeness or balance of drug information found on 
pharmaceutical company websites (Davis et al., 2007; Macias & Lewis, 2003; Waack, 
Ernst, & Graber, 2004). Several other studies have used content analysis, grounded 
theory approaches, or a mix of the two to describe characteristics and themes of 
patient/consumer discussion groups. In one such mixed approach, the researchers created 
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codes for their pre-identified conceptual concerns in an electronic support group for 
persons with fibromyalgia, and created additional codes for emerging themes identified 
during readings (Barker, 2008). In fibromyalgia (Barker, 2008) and multiple sclerosis 
(Parr, 2002) online patient forums, researchers concluded the groups at various times 
(and sometimes simultaneously) contested and subverted expert medical knowledge, as 
well as reinforced and expanded the scope of expert medical knowledge. At least two 
additional studies have used solely a grounded theory approach to compare themes in 
online discussion board and narrative content between males and females with breast or 
prostate cancer (Gooden & Winefield, 2007) and posthemorrhagic stroke (Stone, 2007). 
These studies were interested in differential informational and supportive needs for men 
and women, and the potentially supportive role of the online group, after diagnosis and 
treatment.  
Few studies have attempted to explore consumer sites for their potential 
contribution to the overall knowledge of a topic, such as psychotropic drugs. One study 
retrospectively analyzed 1 year of discussion on an online forum for individuals with 
Parkinson’s disease for information pertaining to adverse effects of prescribed drugs 
(Schroder, Zollner, & Schaefer, 2007). Using a structured classification system for 
adverse drug effects to analyze the data, the researchers identified 153 adverse drug 
reactions on the forum, including a high rate of dermatological problems consistently 
described by participants as being “severe and stressful” (p. 1163). In the case of one 
antiparkinsonian drug, the incidence of skin problems in clinical trials was 0.8% 
compared to a 23% rate of mention in discussion forum entries. In contrast, 
cardiovascular adverse events, which were identified in clinical trials as a primary risk, 
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were rarely discussed in the forum. It thus appeared that consumers online were more 
likely to discuss effects with the most burden or most obvious manifestation.  
Finally, there are a dearth of studies that go beyond the boundaries of 
conventional methodologies to explore power and discourse in the online realm. Moore 
and Clarke (2001) used a critical interpretive approach to compare the conventions and 
heterogeneity of medical and popular online representations (visual and textual) of 
human genitalia. Their analysis included biomedical images for medical students, images 
found in popular newsgroups about human sexuality, and pornography. It appeared that 
traditional patterns of anatomical representation abound online, offering a narrow, 
technical, and singular view of genital anatomies. Pornographic sites provided the most 
diversity in representing various body types and ages, though in this genre each variation 
was fetishized for a consumerist purpose.  
Rogers and colleagues are pioneers in mapping debate and discourse on the 
Internet, as they have done for issues of climate change (Rogers & Marres, 2000) and 
genetically modified foods (Rogers & Zelman, 2002). They accomplish this through 
mapping hyperlinks to determine the relevant players in an issue debate and to describe 
the concentrations and patterns of hyperlinks within and between various types of sites 
(i.e., .com, .org., .gov). They further identify and trace the recurrence of key phrases 
across sites in an issue debate. In the case of the climate change debate, the presence of a 
statement by the United Nations appeared to have particularly shaped the debate. Actors 
in the debate used the officially recognized, scientifically-backed statement to affirm, 
reinforce, contest, or otherwise position their own stance.  
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In studying the web as an anticipatory medium, Rogers (2004) gave the drug 
Viagra a “more honest identity” by capturing and exposing the range of uses, 
experiences, and arguments about the drug from a variety of actors (p. 24). He used 
groups of Internet “surfer-experts” to answer a basic question: “What is Viagra, and 
whom is it for?” (Rogers, 2003, p. 198). The surfer-experts were instructed to compile 
lists of Viagra uses found in accounts of the drug from any source, and were given free 
reign to search the Internet using their personally preferred methods. Lists were 
compared among the surfers resulting in the conclusion that Viagra “has become a 
lifestyle drug for men in their 30s and 40s, to be obtained from virtual doctors, having 
had referrals from ‘death by Viagra’ search engine queries or from banner ads on porn or 
racy sites” (p. 204). The exploration of unofficial online accounts of the drug led the 
researchers to further conclude that “Viagra leads a richer, more youthful and 
experimental life than it is granted by doctors, the medical industry and by the 
manufacturer – all of whom retain Viagra as a prescription drug for a patient with a 
medical ailment” (p. 209).  
The present research built on the distinct aims and methods of earlier projects by 
describing the content and themes of expert and consumer sites starting from a critical 
conceptual approach and using grounded theory methods within a mixed-methods 
research strategy. 
 
 
Grounded Theory  
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 Grounded theory was originally developed by Glaser and Strauss (1967) for the purpose 
of generating theory grounded in empirical data, as opposed to testing hypotheses based 
on abstract theorizing. Theory generation is accomplished by using a number of analytic 
tools. The most popular are coding, memo-writing, theoretical sampling, and the constant 
comparative method. The grounded theory research process is an iterative process of 
collecting and analyzing data, with the expectation that codes and concepts derived 
remain provisional as the research progresses. This method most closely resembles an 
inductive process, but arguably requires both inductive and deductive inquiry (Berg, 
2000). The researcher is formulating hypotheses about appropriate concepts and 
connections between them, while continuing to test these hypotheses (using the constant 
comparative method, for example) and generate new ones with additional data collection 
and analysis.   
Since its origin, the above basic grounded theory guidelines have been used as 
part of a variety of research strategies and for multiple aims other than building theory 
(Corbin & Strauss, 2008). A number of methodologists recognize that grounded theory 
guidelines are best viewed as a set of principles and practices for conducting qualitative 
data analysis, rather than a set of methodological rules or requirements (Charmaz, 2006). 
Its original developers, Glaser and Strauss, too, eventually disagreed on the appropriate 
methods for conducting grounded theory research and continued developing the method 
independently of one another (Denscombe, 2007). Glaser believed the researcher should 
maintain a distance from the data and allow meaning to emerge by a neutral examination 
of manifest content. Strauss adopted a more interpretive approach claiming that the role 
of the researcher was to find meaning in the data, which usually required looking beyond 
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superficialities. More recently, several scholars have provided constructionist and 
postmodern adaptations of grounded theory (Charmaz, 2006; Clarke, 2005). The present 
research drew from elements of recent versions of grounded theory, including the work of 
Corbin and Strauss (2008), Charmaz (2006), and Clarke (2005).  
In their most recent edition of Basics of Qualitative Research, Corbin and Strauss 
(2008) describe grounded theory as a general approach to research that is appropriate not 
only for theory development as originally formulated, but also for superficial description 
or in-depth analysis. In-depth analysis “is more likely to generate new knowledge and 
deeper understandings because it tends to go beyond what everyone already knows” (p. 
51). The present research aimed for an in-depth analysis, which included a presentation 
of reported medication effects and generated themes/categories. In keeping with the 
social constructionist framework, categories/themes were not assumed to emerge from 
the material, as “rather than discovering order within the data, we create an explication, 
organization, and presentation of the data” (Charmaz, 2006, p. 140).  
Summary 
Pharmaceutical industry influence over the production and dissemination of 
scientific drug knowledge on which clinicians, other professionals, and consumers may 
rely is ubiquitous and inescapable. The effect of such influence is the extensive blurring 
of marketing and science, and an emerging critical questioning of the validity and 
integrity of the “scientific” evidence base for psychotropic drugs. In parallel, the Internet 
has provided an opportunity to review drug information from thousands of consumers 
without professional mediation. Most research positions expert health or drug knowledge 
as the standard, authoritative source to which other forms and sources of knowledge are 
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compared for their accuracy, completeness, validity, and so on. It is unknown how 
consumer-constructed and expert-constructed web sources for psychotropic drugs may 
compare if neither form of knowledge was a priori privileged as a standard.  
Conceptual Approach 
 The central issue of the proposed research concerns the construction of expertise in the 
age of the Internet. The research asks: Has the Internet rendered expertise in the area of 
psychotropic drugs obsolete?   The validity, credibility, and integrity of scientific/medical 
knowledge in the area of psychotropic drugs have become highly contested in recent 
years, as extensively explored in the review of literature. The Internet is 1) an evolving 
communication medium, 2) a network of computers and people, 3) a socially constructed 
virtual reality, and 4) a potentially transforming component to traditional power relations 
in knowledge production and dissemination (Markham, 2004). The push-and-pull 
dynamics of traditional and presently evolving power relations, illustrated in Figure 2.1, 
leads to an unspecified situation for the production and dissemination of psychotropic 
drug knowledge in the Internet age.  
Social constructionist (Berger & Luckmann, 1967) and critical perspectives 
(Foucault, 1980) frame this investigation into the production of psychotropic drug 
knowledge on the Internet. This research takes the position that there is no pre-constituted 
objective social world waiting for specific procedures to unveil and articulate. Working 
from Foucault’s concept of power/knowledge, “truth” is not so much discovered as it is 
produced according to historically situated conditions that make up the politics of truth – 
that is, who is authorized to speak, what objects are worthy of inquiry, and the techniques 
and procedures for acquiring truth and enabling one to distinguish between true and false 
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statements (Rawlinson, 1987). However, to say that truth is constructed, or that drug 
effects are constructed, may be a misnomer as it implies a falsely clear distinction 
between the “objective” existence of the physical object, and its “constructed” existence 
of representations and meanings (Mitchell, 2002). It may be more precise to say these 
things are “made,” or according to Foucault “produced,” out of processes that are at the 
same time material and cultural, and as much real as abstract. Teasing apart the “real” 
object, for example the physical drug, from its personal, social, cultural, political, and 
economic meanings and uses is arguably a fruitless task because all of these elements 
interact to produce what a person experiences as or what scientists make to be 
“psychotropic drug.”  
This perspective also has a number of implications for the online textual material 
used for analysis in this research. “Text” here specifies any written language, images, 
symbols, or other that “means something to someone, it is produced by someone to have 
meanings for someone else” (Krippendorff, 2004) (p. 19). First, a text’s message or 
meaning is not something objective to be found or identified by the researcher, but rather 
is subject to an interpretation process according to the context developed by the 
researcher (Krippendorff, 2004). Researchers working within different disciplines, such 
as economics, psychology, or political science, will interpret the same text from different 
perspectives and within different contexts. None of the resulting analyses would be more 
“right” than the other, just as none would represent “the” message or meaning inscribed 
in the text.  
Second, a social constructionist perspective rejects the traditional sender-receiver 
model of communication in favor of the consideration of intertextuality, meaning that 
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text is always related to larger discourses and is often understood in reference to 
presumed knowledge of other texts (Titscher, Meyer, Wodak, & Vetter, 2000). For 
example, a text may explicitly or implicitly articulate a position on the role of patients in 
healthcare decision-making within a biomedical, political, or consumer activist discourse. 
As humans are “routinely both producing and awash in seas of discourses,” so are texts, 
as products of human thought and action, embedded in these discourses (Clarke, 2005, p. 
145). One text may be connected with multiple and various, sometimes conflicting, 
discourses. Also, ascribing meaning to a text often depends on the reader’s presumed 
knowledge of other texts, which may include general everyday knowledge or experience, 
publicized current events, or an understanding of humor or satire, among others 
(Warnick, 2007). Consequentially, “Because of intertextuality, there can in principle be 
no objective beginning and no clear end, since every discourse is bound up with many 
others and can only be understood on the basis of others” (Titscher et al., 2000, p. 26).  
Third, text content speaks to something other than itself. For example, words and 
images may inform, evoke a feeling, encourage action or behavioral change, and much 
more. This implies that the researcher must look beyond the physicality of the text to 
consider how the text is used and what and how it encourages. At the same time, meaning 
making on the Internet “is an emergent process that commences when the user first 
encounters the site and then develops his or her understanding based on signs, pathways, 
forms of expression, and representations encountered on the site” (Warnick, 2007, p. 
104). Moreover, users can create entirely different texts in their use of hyperlinks so that 
one user’s individuated pathway is nearly non-replicable. The fragmented and 
hyperlinked nature of the Internet gives the creator of an online text little control over the 
55 
 
context within which the text will be discovered or how the text may be interpreted in 
light of that context. Yet, authors of online text may still be deliberate and strategic in the 
use of hyperlinks to position the site within an issue network (the entire network of linked 
organizations and sites around a particular issue, such as climate change or childhood 
autism) (Rogers & Zelman, 2002). To hyperlink to another organization makes the 
players and positions of the linked organization relevant to the overall discussion or 
debate, and “In this way, the act of not linking, non-reciprocal linking, or un-linking 
similarly reveals a politics of association” (italics in original; p. 3). In sum, different 
readers will navigate to and from the same site differently, making it difficult or 
impossible to represent a “typical” user reading of either expert- or consumer-constructed 
drug accounts.  
Finally, discourse in the proposed research is defined as “communication of any 
kind around/about/on a particular socially or culturally recognizable theme,” which may 
entail analysis of language, images, symbols, and nonhuman objects (Allan, 2006, p. 
148). According to Foucault, discourse creates “conditions of existence” for what is 
possible and not possible to say, just as power/knowledge creates “conditions of 
possibility” for what is acceptable and not acceptable to say as true (Peterson & Bunton, 
1997). Individuals’ language to describe personal problems, health, illness, or treatment, 
then, is enabled and constrained by culturally available explanations proliferated through 
discourse. Discourse also partly constitutes the object it describes through the use of 
discursive strategies (Rabinow, 1984). For example, a discursive strategy utilized in 
biomedical discourse may be to construct a subject – “patients” – on an axis of 
disempowered/empowered with an increase in empowerment contingent on gaining 
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certain medical knowledge.  The typically taken-for-granted functions and strategies of 
discourse must be continually considered and assessed in research comparatively 
analyzing consumer and expert descriptions of a treatment, or else the researcher carries 
the risk of again reinforcing traditional power relations and norms of popular discourse.  
Research Questions 
The main question of the proposed research is: Does the accumulated consumer or 
layperson knowledge that the Internet allows dissolve the traditional boundary between 
expert and consumer/lay knowledge?  
The research specifically sought to examine the content of drug information in 
consumer-constructed and expert-constructed web sources. This was accomplished by 
using a grounded theory approach resting on critical and constructivist frameworks to 
analyze the content of five websites containing drug information for two popularly 
prescribed psychotropic drugs from different drug classes. Also, as a practical 
consideration, the research asked, how does each source help and hinder treatment 
decision-making – both for clinicians and for actual and potential consumers? 
 
57 
 
Figure 2.1 Traditional and Evolving Dynamics in the Production of Psychotropic Drug 
Knowledge
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Chapter 3: Methodology 
Research Strategy 
A grounded theory approach was used as part of a mixed-methods research 
strategy for an in-depth textual analysis. The grounded theory approach was defined in a 
broad sense: “a research strategy that involves working with the concepts and categories 
of the research subjects” (Dyson & Brown, 2006, p. 190). A primary competing research 
strategy for textual materials is content analysis, in which analysis is guided by pre-
structured expectations. Specific to textual analyses of drug effects, researchers utilizing 
a content analytic approach might use a hierarchical classification system used in medical 
research, such as the MEDRA dictionary or a drug-specific effects checklist, to guide 
coding. However, these classification systems are typically designed for coding adverse 
drug effects, and therefore already reflect a particular perspective related to drug use. 
That is, the dominant medical perspective that classifies psychotropic drug effects into 
main/therapeutic effects and side/adverse effects is built into these classification systems. 
As discussed earlier, however, there is reason to believe that users do not experience 
effects this way and that the main effect/adverse effect division is often arbitrary and 
changeable (Moncrieff & Cohen, 2009).  
A significant component of the present research, and the fundamental point of 
departure between the present research and previous work in this area, was the 
consideration of power related to knowledge. Most previous analyses of consumer 
treatment accounts have included only thematic analyses or have imposed medical 
classification systems or standards on the data prior to analysis. For this research, it was 
presumed that consumer perspectives and experiences were best represented by 
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maintaining the concepts and categories that consumers provided, rather than classifying 
them into some form of a dominant medical framework of drug effects. The grounded 
theory approach was selected for the present research because it helped extinguish some 
imbalances of power (if they exist) related to the construction of labels and categories by 
not privileging either source (expert or consumer) as a standard for quality or accuracy.  
The grounded theory approach is arguably one of the more interpretive qualitative 
research methods, as there is little pre-established structure to guide coding. It is difficult 
for other researchers to replicate a grounded theory study, which may be the major 
problem and limitation of this approach. The present study attempted to address this 
limitation through a couple of modifications. While still interpretive and flexible in terms 
of not applying an outside pre-determined template of codes and meaning on the data, the 
codebook was “fixed” at certain points in the process to calculate inter-coder agreement 
indices. Many codebook revisions were decided by agreement between two coders, rather 
than by the interpretation of a single coder. In these ways, the coding process was 
“standardized” more than would be expected in a strictly qualitative, grounded theory 
study. Further, most analyses included some combination of frequency tables, chi-square 
tests for independence of categories, and descriptive excerpts from the text.  
In sum, this research followed a unique mixed-methods strategy based on a 
grounded theory approach to analyzing text. The influence of power on information was a 
central component of this research, and was best considered using a grounded theory 
approach. Other, more structured research strategies to analyze this textual data may have 
produced a different set of results, particularly in terms of the naming of drug effects and 
in their ultimate classification. For example, this study ended with no clear division 
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between many conventionally considered therapeutic and adverse effects, a result which 
likely would not have been possible had the researcher started with a classification 
system structured to record “adverse drug effects.” The major leverage this grounded 
theory approach offered over other strategies, then, was a critical analysis (in terms of 
examining an issue from outside the mainstream or dominant framework) of data that 
well represented (in terms of groundedness) drug experiences.  
The Sample 
Website typologies and inclusion criteria. 
Five exemplar websites were sampled for in-depth analysis according to their 
status as expert-constructed (two sites) or consumer-constructed (three sites) sources with 
the goal of representing typologies. Representing a variety of websites (as opposed to, for 
example, a greater variety of drugs) was important to this study because it related to 
practical concerns of consumers who may question how drug information is similar or 
different across sites. Table 3.1 summarizes these typologies. Expert-constructed 
websites were categorized as professional health and consumer-centric, and one site 
representing each category was selected for analysis. Professional health sites are created 
and monitored by professionals in the medical or health field, typically involving medical 
journalists who gather and write content, and medical doctors who serve as consultants 
and oversee content. Content on professional health sites is promoted as reflecting 
recognized standards of scientific and medical excellence. For the purposes of the present 
research, then, the key criterion marking a website as “professional health” is the 
oversight of content by a team of medical doctors. Professional health sites are intended 
for both lay and professional audiences, and may include a component for discussion 
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among the site’s users. Consumer-centric sites are similar in all ways except for the latter. 
As opposed to having an added component for user interaction, consumer-centric sites 
attempt to infuse principles of Web 2.0 by specifically designing the site to maximize 
participation and interaction of users. 
Table 3.1  
Description of Website Typologies 
 Typology 
 
Description of Typology Selected Site 
Professional 
health 
 
 created and monitored by medical or 
health professionals 
 reflect recognized standards of 
scientific/medical excellence 
 intended for both lay and professional 
audiences 
 may include a component for discussion 
among the site’s users 
 
www.webmd.com 
Ex
pe
rt
-c
on
st
ru
ct
ed
 
Consumer-
centric 
 created and monitored by medical or 
health professionals 
 reflect recognized standards of 
scientific/medical excellence 
 intended for both lay and professional 
audiences 
 specifically designed  to maximize 
participation and interaction of users 
 
www.revolutionhealth.com
Rigid structure,  
narrowly 
defined function 
 pre-defined fields for user input 
 limited ability for extended conversation 
www.askapatient.com 
Loose structure,  
defined but fluid 
function 
 
 no or few pre-defined fields for user input 
 conversation is structured around 
medication classes/brands 
 
www.crazymeds.us 
C
on
su
m
er
-c
on
st
ru
ct
ed
 
No structure, 
vaguely defined 
function 
 no pre-defined fields for user input 
 users construct structure and function by 
adding conversations/threads 
www.theicarusproject.net 
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Inclusion criteria for expert-constructed websites were: 1) the site was operated 
by a non-governmental group or organization, and 2) there was no evidence that the 
selected websites were owned by the same company or that they share professional 
contributors. The latter criterion was stipulated because many popular news and health 
sites exist as networks in which medical and other professionals who write or oversee 
content do so for the entire network of sites. Analyzing two expert-constructed sites that 
were designed by the same team of professionals would have been redundant in this 
research. Criteria for the selected websites were verified by examining pages within the 
“about us” (or similar) section. If the site was owned, for example, by a private or public 
corporation, then criterion 1 was met. For criterion 2, the staff, editorial team, expert 
reviewers, and management boards as listed on each website was examined by the 
principal investigator. 
In contrast, consumer-constructed sites pertaining to psychotropic drugs are more 
heterogeneous in terms of the structure and function of the site – from 1) rigid structure 
and a narrowly defined function, to 2) loose structure and a defined, but fluid function, to 
3) no structure and vaguely defined functions. An exemplar consumer-constructed site 
was selected to reflect each point along the continuum of structure and function. Multiple 
and varied discourses surrounding drug treatment were anticipated to naturally appear on 
this continuum due to the lack of a unitary “voice” among consumer discourses.  
Inclusion criteria for consumer-constructed websites were: 1) the site content was 
viewable without requiring registration or membership conditioned on moderator 
approval, and 2) the site had a minimum of 200 contributions to an identifiable section or 
discussion about psychotropic drugs. The latter criterion was included because a 
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preliminary search for consumer sites on the Internet revealed many sites with as few as 
three contributions to a discussion, which would not have furthered the aims of this 
research. Requiring a minimum of 200 contributions narrowed the consumer-constructed 
sample to those most likely to enrich the analysis. This also introduced a selectivity bias 
that favored larger websites. Larger website size may reflect greater fulfillment of the 
needs of site users, greater resources or marketing ability to garner attention, or 
something more random, such as being mentioned by a popular media outlet. Thus, small 
websites with few contributors were excluded from selection in this study. 
Description and limitations of search strategies. 
This research used a combination of search engine and collector site searches, and 
field immersion to sample websites that best represented the outlined typologies. Given 
the range of website typologies under consideration, it was difficult to apply a standard 
search and selection criteria for all 5 sites. Expert sites typically appear at the top of most 
search engine results, but may be better selected for the purposes of this research 
according to their “quality” rank by highly regarded collector sites. Consumer sites may 
appear in the first few pages of search engine results (after the first few pages, search 
returns become barely related to the search terms), but may be equally or more likely to 
be retrieved on collector sites, as well as from time and experience within a field or 
community. Table 3.1 lists the exemplar site selected for each typology in the proposed 
research, and Appendix A provides visual snapshots of each website’s homepage and 
Lexapro page.  
A considerable difficulty with sampling websites on the Internet is the 
unknowable population of websites to sample from (Weare & Lin, 2000). One popular 
64 
 
strategy among researchers is to use search engines, such as Google and Yahoo. 
Depending on the study aim, the researcher may randomly select from search returns, 
choose all returned sites consecutively up to a certain number, or screen sites according 
to certain inclusion/exclusion criteria. Search engine sampling is an arguably valid 
strategy because it replicates what most Internet users may retrieve and view. However, 
some major disadvantages to this method limited its usefulness for the present research. 
First, as the Internet continues to grow, the proportion of sites indexed in the major 
search engines decreases. It is unlikely that any combination of search engines would 
retrieve even half of pertinent websites. Second, as mentioned in the review of literature, 
search engine results for health information may be biased towards sites earning medical 
seals of approval for content quality (Dahlberg, 2005; Fox, 2010). Consumer-constructed 
health sites are typically not considered for such accolades and are, therefore, less likely 
to be located in the top search engine returns. Currently, major search engines like 
Google are specifically designing health search algorithms to return government health 
and medical institution websites at the top of returns, while “everything else is pushed 
down and out” (Fox, 2010, para. 6). Beyond open initiatives such as this, however, each 
search engine has unreported rules for site indexing and search retrieval, making it 
difficult to determine what is missing and why.  
 A second frequently used strategy is to base sampling on “collector sites” (Weare & 
Lin, 2000). This method relies on an individual or organization with a specialized interest 
to collect and list links to relevant websites. The major advantage of this technique is its 
ability to locate obscure and special interest sites that are not retrieved by search engines, 
possibly for some of the reasons cited in the previous paragraph. The disadvantage of this 
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technique is the existence of unknown biases resulting from non-standardized collection 
methods by the lists’ authors.  
 The present study used a combination of the above strategies for selecting the 5 
websites. While every attempt was made to provide clear and transparent criteria for the 
selection of websites, the specific selection process for each site was unique to its 
grouping (expert or consumer) and typology (see discussion of selection below). It is 
unknown whether this particular set of 5 websites would be replicated by other 
researchers using a similar selection method. However, with the dynamic nature and 
enormity of the Internet, it is unclear that any one sample would be duplicated even with 
a more highly consistent or systematic approach.    
Selection of expert-constructed website sample. 
The “professional health” type of expert-constructed site was selected based on its 
status as a highly-trafficked, long-established, and trusted source for the official account 
on illness and treatment. It was retrieved from a list of the top 20 health information 
websites compiled by HealthRatings.org, a joint project of Consumer Reports WebWatch 
and the Health Information Institute. The project ranked health information sites 
according to highest site traffic and then rated each of the 20 most popular sites according 
to 10 quality indicators. These included disclosure of ownership information, advertising 
and sponsorships, ease of use and accessibility, currency, privacy, coverage and content, 
authors and interests, references and resources, editorial policies, and health information. 
The site ranking highest in popularity and meeting all inclusion criteria was 
WebMD.com. This site scored an overall rating of “very good” and a rating of 
“excellent” for health information. Launched over 10 years ago, this site has a long-
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established reputation among professional health sites and has received numerous awards 
and recognitions from media and health fields. The site content is developed by staff 
writers and journalists with contributors from Medicinenet.com and reviewers from an 
Independent Medical Review Board. Health content covers a wide range of illnesses and 
conditions, treatments, strategies for healthy living, good nutrition, proper fitness, better 
parenting, mental health, and even pet health.   
 The second type of expert-constructed sites, “consumer-centric,” represents a 
newer strand of health website that have not yet been organized or ranked in this same 
way. One of the first consumer-centric health site ventures was launched by an AOL co-
founder in April 2007, though beta versions of the site were being tested well before the 
official launch ("AOL co-founder to launch revolutionhealth.com," 2007). This site, 
revolutionhealth.com, already has hundreds or thousands of registered users associated 
with any one psychotropic drug. The 2007 eHealthcare Leadership Awards named this 
site as “Best Overall Internet Health Site” for its excellence in providing strong health 
content, interactive opportunities, and good web design and navigation ("2007 web 
awards winners," 2008).  Revolutionhealth.com exemplifies the current movement of 
expert-constructed health sites towards consumer-centric and Web 2.0 principles. The site 
boasts having “125 online tools aimed at helping individuals take control of their well-
being” (“About revolution health,” para. 3). Health content is pulled from a network of 
partners, including clinics, other health news sources, and health publishers. Similar to 
WebMD, content on RevolutionHealth covers a wide range of illnesses, treatments, and 
healthy living tips and tools. Of note, both expert-constructed websites allow space for 
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user-generated content, including posting of consumer ratings and reviews (see Figures 
A8 and A11).  
 Selection of consumer-constructed website sample.   
 Search engines, a collector site, and insight gained from field immersion were used to 
find consumer-constructed websites pertaining to psychotropic drugs and to select a 
sample that best represented a range of structures and functions. First, in February 2008 
Google and Yahoo search engines were searched for one drug using the following 
keywords and Boolean operators: “(consumer OR patient) (discussion OR rating OR 
review OR support) Lexapro”. This search in Google returned 130,000 hits, and in Yahoo 
returned 2,000,000 hits. The first 50 hits from each search engine were reviewed. Only 1 
site, AskAPatient.com, returned in Google and no site returned in Yahoo met the 
inclusion criteria of unrestricted viewing of content and a minimum of 200 consumer 
contributions. AskAPatient.com was returned in Google twice, as the second and forty-
fifth hit. Excluded returns from Google and Yahoo combined were: 27 links to expert-
constructed health information that may have included a community forum component, 
21 links to consumer-constructed websites that did not contain the minimum number of 
contributions for the drugs under study, 16 links to online pharmacies, 7 links to 
pharmaceutical company websites, 5 portal sites with advertisements, 5 government 
websites, 5 broken links, and 12 links to miscellaneous sites including commercial 
product sites, academic institutions, health insurance, and attorney solicitations. 
AskAPatient.com well represents a consumer-constructed site with rigid structure 
and a narrowly defined function. The site has a set number of pre-defined fields for drug 
consumers to input comments, with the apparent function of sharing basic demographic 
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information, “side effects” of medications, and a brief comment about a specific drug 
(see Figure A2). Other than consumer ratings and reviews, content on this site is scarce 
and includes only links to websites providing additional drug information and an opinion 
poll on a topic of the week.  
 The second website was selected upon reviewing a collector site called 
PsychCentral.com, a directory of online mental health resources created and maintained 
by professionals in psychology. The site has been indexing online mental health support 
groups for 16 years and currently receives over 650,000 visits per month. The 94 listings 
indexed within the site’s page for “Resources” for “Medication,” and 74 listings indexed 
within the subcategory “Support Groups” for “Mental Health” were searched. One 
website, CrazyMeds.us, on the medication resources page, and two websites, 
CrazyMeds.us and CrazyBoards.org, on the support groups for mental health page met 
the inclusion criteria. Both well represented the intermediate position of loose structure 
and fluidly defined function, though CrazyMeds.us was structured specifically around 
medication issues rather than general mental health issues. CrazyMeds.us was also listed 
as receiving a top rating on a scale from zero (“the worst”) to 10 (“the best”) based on 
2,323 consumer votes. CrazyBoards.org received a top rating based on 416 consumer 
votes. CrazyMeds.us was selected for the proposed analysis because its function was 
more closely targeted to the purpose of this research and it appeared to receive higher site 
traffic based on the number of votes. Discussions on the CrazyMeds.us forum are loosely 
structured according to class and brand name of psychiatric drugs, with an apparent 
function of allowing users to discuss sometimes complicated medication issues. The 
creator of the website (a non-medically trained consumer) also writes a main information 
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page for each drug that users are encouraged to visit prior to posting questions in the 
forum. Users of the CrazyMeds forum generally have a more sophisticated understanding 
of drug issues than might the typical consumer. 
  Excluded websites under the “medication resources” listings on PsychCentral.com 
were: 60 listings that linked to consumer reviews of specific drugs on PsychCentral.com 
(none of the 4 drugs under study had the minimum contributions on PsychCentral.com to 
be included in the analysis), 22 expert-constructed websites presenting information on 
specific adverse effects of drugs, 5 websites offering medication purchase assistance 
programs, 3 websites that did not have a minimum 200 contributions for the drugs under 
study, 2 forums for physician health programs, and 1 medical news site. Excluded 
websites under the support groups for mental health listings were: 36 websites and 
forums relating to general mental health issues and/or services not pertaining to the drugs 
under study, 20 newsgroups or mailing lists, 9 closed or private forums requiring a 
moderated membership, 4 websites that did not have a minimum 200 contributions for 
the drugs under study, 2 websites moderated by medical professionals, and 1 broken link.  
 The site best representing the unstructured, multi-functioning typology was selected 
based on the researcher’s immersion in online health sites, mental health communities, 
and health blogs. TheIcarusProject.net is an online community of current and former 
psychiatric patients that stands out from other mental health communities for its relatively 
advanced website that includes multiple opportunities for online participation and 
interaction. Content on the site is largely user/community-generated, including user 
blogs, articles, art, as well as links to relevant news, publications, and volunteer 
opportunities. Pertinent to this research, the site contains a discussion forum with an 
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unstructured “psychiatric medications” thread in which users can post or discuss any 
issue related to any psychotropic drug (see Figure A6). The function of the forum is not 
pre-structured, rather the users of the forum construct its function by determining what 
drugs and topics are discussed. This site meets all other inclusion criteria for consumer-
constructed sites.  
Data Collection 
Selected psychotropic drugs. 
Specific psychotropic drugs were used as the point of entry for all sites. If a site 
was not structured according to specific drugs, then text pertaining to “psychotropic 
drugs” served as the subject of analysis. Text regarding two psychotropic drugs from 
different drug classes was analyzed for each group: 1) an antidepressant, escitalopram 
(Lexapro), and 2) an antipsychotic, quetiapine (Seroquel), These drugs were chosen 
because they each appeared on the top 10 drug products of 2006 based on number of 
prescriptions or retail dollars.  Escitalopram was approved by the FDA in 2002 and had 
approximately 30 million prescriptions dispensed in 2006 in the United States ("Top 10 
products by  U.S. dispensed prescriptions," 2007). Quetiapine was approved by the FDA 
in 1997 and was ranked as the ninth best-selling drug in 2006 with $3 billion in U.S. 
retail sales ("Top 10 products by U.S. sales," 2007).  
Units of analysis. 
 Existing online text pertaining to the drugs under study for each group served as the 
source of data. The recording unit of analysis was individual web pages within each site’s 
root domain that contained information about the drugs under study, or “psychotropic 
drugs” more generally (for 1 website, see below). Each individual consumer review on 
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WebMD, RevolutionHealth, and AskAPatient represented a single case for the analysis. 
Similarly, each individual discussion forum poster on CrazyMeds and TheIcarusProject 
represented a single case. For example, if AnonymousUser35 posted a total of 10 
comments about Lexapro throughout several different discussion threads on CrazyMeds, 
those comments were collected so that all comments by AnonymousUser35 would 
represent only a single case.  Expert drug information copied from expert-constructed 
websites also counted as one case each, creating a sample size of 4 for expert-constructed 
material (2 sites x 2 drugs = 4 cases).  
Data collection procedures. 
Relevant text was copied from each website and pasted into either a Microsoft 
Word 2007 document or Microsoft Excel 2007 spreadsheet. All consumer reviews and 
discussion posts available on each website through the end of February 2009 were 
manually cut and pasted into the spreadsheet. In addition to consumer reviews and posts 
on consumer-constructed sites, the two expert-constructed sites selected for this study 
also allowed consumers to post individual drug reviews. Therefore, consumer 
reviews/posts from all 5 websites were represented in this research.  
In some cases, consumers posted additional information, including their gender, 
age, and length of time taking the drug. When provided, these data were copied as 
additional columns (variables) in the spreadsheet along with the date the comment was 
posted and whether the consumer posted an email address or user name.  
On expert-constructed sites, the relevant webpage for each drug was located using 
the website’s internal search engine. All text pertaining to each drug, excluding 
advertisements and sidebar hyperlinks, was copied and pasted into a Word document. 
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Consumer reviews for Lexapro and Seroquel were copied and pasted into the Excel 
spreadsheet.  
All consumer reviews for the two drugs on AskAPatient and discussion threads on 
CrazyMeds were copied and pasted into the spreadsheet. TheIcarusProject discussion 
forum was loosely centered on “psychotropic medications,” rather than containing an 
identifiable section specific to the drugs under study. Therefore, any discussion threads 
related to Lexapro or Seroquel as well as general topics involving psychotropic 
medications were copied and pasted into the spreadsheet. Once discussion threads from 
CrazyMeds and TheIcarusProject were copied, each unique poster was identified. Then, 
discussion posts were manually regrouped according to posters’ user names so that all 
comments by a single user were grouped together as a single case. 
To ensure proper use in the data analysis software program, all cases (consumer 
reviews) had to be formatted identically in the spreadsheet. To accomplish this, 
standardized columns were created and missing cells were filled in with “not given” for 
text variables and “999” for numeric variables. The variables gender, age, and length of 
time on the drug were transformed into categorical variables. Whether the user posted an 
email or user ID was a nominal (yes/no) variable. If provided, the actual email address or 
user ID was copied into the spreadsheet to assist with data cleaning, and was deleted prior 
to data analysis.  Multiple comments using the same email/user ID were searched for as 
part of data cleaning and, when present, merged into a single comment to count as one 
case. Finally, the data was purged of duplicate entries.  
 
Sampling procedures. 
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 The data collection procedures resulted in a sampling frame of 7,418 consumer 
reviews/cases (see Table 3.2) and 4 expert cases. Overall, there were more consumer 
cases for Lexapro (62.5%) than Seroquel (31.9%), and more consumer cases came from 
expert-constructed sites (62.3%) than consumer-constructed sites (37.7%). Sampling 
from consumer cases occurred three times during this research, each by using the random 
numbers generator tool in Microsoft Excel. First, 85 cases from the sampling frame were 
randomly chosen for preliminary codebook development (see following section). Second, 
a coding sample of 1,080 cases was randomly chosen from the sampling frame and, 
finally, 216 cases from the coding sample were randomly selected for a coding agreement 
analysis. All 4 expert cases were coded for the analysis. 
 The coding sample of 1,080 consumer cases (14.6% of the sampling frame) was 
selected using a stratified simple random sample of 120 cases per drug per website (120 
cases x 4 websites x 2 drugs, plus 120 cases x 1 website). Due to the larger percentage of 
consumer cases found on expert-constructed sites, this sampling strategy had the effect of 
oversampling cases from consumer-constructed sites and under-sampling those from 
expert-constructed sites. This was deemed appropriate because the primary focus of this 
research involved a comparison between expert- and consumer-constructed websites, and 
an analysis of consumer reviews found on expert-constructed sites was not part of the 
original research proposal.  Table 3.3 shows the probability of selection for any single 
case within each stratum.  
 
Table 3.2  
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Sampling Frame for Consumer Reviews (through February 2009) 
 
Table 3.3  
Probability of Selection in a Stratified Simple Random Sample of 120 Cases per Drug                
per Website 
 Lexapro 
(n/N) 
Seroquel
(n/N) 
“Psychotropic Drugs”
(n/N) 
AskAPatient 11% 15.2% -- 
CrazyMeds 45% 52.9% -- 
TheIcarusProject -- -- 28.6% 
WebMD 8.6% 16.6% -- 
RevolutionHealth 6.4% 19.2% -- 
 
 
 
 Lexapro Seroquel “Psychotropic  
Drugs” 
Total (%) 
 
AskAPatient 1,093 791 
 
-- 1,884 (25.4%)
CrazyMeds 266 227 
 
-- 493 (6.6%)
TheIcarusProject -- -- 
 
420 420 (5.7%)
WebMD 1,402 722 
 
-- 2,124 (28.6%)
RevolutionHealth 1,873 624 
 
-- 2,497 (33.7%)
Total (%) 4,634 (62.5%) 2,364 (31.9%) 
 
420 (5.7%) 7,418 
75 
 
Software. 
 Data coding and analysis was performed using QDA Miner version 3.2 released by 
Provalis Research in 2009. QDA Miner is a mixed methods data analysis software 
package ideal for content analysis, grounded theory, and other textual analyses. Unlike 
other qualitative data analysis programs, however, QDA Miner allows flexibility on the 
level that a case is assigned. For the present research, this meant that each consumer 
review could be imported from Microsoft Excel as a single case with a set of variables 
attached to it (i.e., age, gender, etc.). Expert cases were imported into QDA Miner from 
Microsoft Word. Appendix B provides 3 screenshots of coded cases in QDA Miner.  
Data Analysis 
Codebook development. 
 An initial codebook was developed by coding 85 randomly selected cases from the 
sampling frame. This was a means to begin working with the data in preparation for the 
full coding sample. The end product of this phase was not a final or fixed codebook, but 
rather a substantial preliminary codebook that continued to evolve during subsequent 
stages of the coding process. In keeping with the grounded theory approach, no checklist 
or organizational frame was relied on to pre-structure the data. All codes were developed 
based on the drug effects and themes that the researcher observed in the data. However, 
the list of codes was eventually grouped in a logical way in a collaborative discussion 
between the researcher and a second coder (see subsequent section) in order to ease the 
coding process and facilitate a more organized analysis. Similar drug effects were 
grouped into a category of effects, which was determined by logic (i.e., like goes with 
like) as well as basic understanding of body systems (i.e., what belongs to 
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musculoskeletal versus gastrointestinal systems). For example, the codes “weight gain,” 
“weight loss,” “appetite increase,” and “appetite decrease” were grouped into a category 
called “Weight and Appetite Effects.”  Codes such as “constipation,” “diarrhea,” 
“nausea,” and “urinary problems” were grouped into a category called “Gastrointestinal 
and Urinary Effects.” Similarly, drug themes sharing a fundamental concept were also 
grouped into a category. For example, each code reflecting a strategy used to counteract 
medications’ side effects was grouped into a category called “Dealing with Side 
Effects/Finding Optimum Effectiveness.” The product of preliminary codebook 
development (i.e., the initial version of the codebook) can be found in Appendix C. The 
most recent version of the codebook can be found in Appendix D. Finally, more detailed 
descriptions of each code in the most recent codebook can be found in Appendix E. 
Coding agreement analysis. 
To increase reliability and credibility of findings, a coding agreement analysis 
was conducted for two independent coders on 20% of the coding sample. The second 
coder was professionally known to the lead investigator, but had not previously worked 
within or studied issues related to mental health or psychopharmacology. The second 
coder received a Masters degree in Applied Social Research in 2002 and, on this basis, 
was judged qualified to understand and assist in coding. This coder was first briefed on 
the purpose of the project and then trained in the use of the software by practice coding 
the 85 cases from the initial development of the codebook using the preliminary 
codebook developed by the lead investigator. An additional 20 cases from the sampling 
frame were then randomly chosen for a practice coding agreement analysis using the 
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preliminary codebook. Acceptable agreement was reached (Scott’s Pi = 0.77) on these 20 
cases, and disagreements were resolved by discussion.  
Once the training and practice coding for the second coder was completed, a 20% 
coding agreement sample (216 cases) was randomly selected from the coding sample of 
1,080 cases.  Inter-coder agreement was calculated in QDA Miner for each category of 
codes (i.e., weight gain, weight loss, appetite change were all in the category “Weight 
and Appetite Effects”) on the level of code occurrence within a case using Scott’s pi. 
Scott’s pi is a statistical measure for inter-rater agreement of nominal level variables that 
takes into account chance agreements that occur from guessing (Krippendorff, 2004). It 
was calculated as: 
 
 While there is no firmly established rule for interpreting inter-coder agreement indices, 
0.70 is often an appropriate minimum level of agreement, particularly for more 
conservative statistics such as Scott’s pi. A Scott’s pi index of at least 0.70 was pre-
specified in this project to indicate an acceptable level of inter-coder agreement.  
However, this being a grounded theory approach to examining the data, it was 
expected that the codebook would continue to evolve as additional cases were reviewed. 
It was important that the coding agreement analysis reflected the evolving, rather than 
static, nature of the codebook. For this reason, the agreement coding was completed in 
two phases. Both coders coded the first 100 cases of the agreement sample and a Scott’s 
Pi was calculated. The two coders together reviewed each disagreement and came to a 
mutual decision about its resolution. After discussion of individual coding decisions, the 
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coders discussed and agreed upon revisions to the codebook (i.e., collapsing or splitting 
codes). Then, the same process was performed with the remaining 116 cases of the 
agreement sample. No changes could be made to the codebook while coding agreement 
was in process because both coders were required to use identical codebooks. The 
remaining cases in the coding sample (n=864) were coded by the lead investigator.  
Grounded theory coding.  
Coding in grounded theory refers to “naming segments of data with a label that 
simultaneously categorizes, summarizes, and accounts for each piece of data” (Charmaz, 
2006, p. 43). Data was analyzed line-by-line for reported drug effects and 
themes/concepts in an iterative process of initial and focused coding. These were not 
distinct phases with a strict temporal sequence. The research began with initial coding but 
moved back-and-forth between initial and focused coding as the research progressed. In-
vivo codes, as opposed to researcher-derived codes, were used as frequently as possible 
when determining a code name. This meant that code names reflected as much as 
possible the language and terms of the research subjects. For example, rather than create 
a code called “drowsiness” or “somnolence,” which reflects the standard terminology in 
drug literature, this study borrowed descriptive terms found in consumer comments, such 
as “extreme sleepiness,” to serve as code names.  
 Initial coding stuck very close to the data and was intended to capture and 
condense meanings. Reported drug effects for Lexapro or Seroquel were coded only on 
the level of initial coding. Effects were coded literally and with as little interpretation as 
possible by the researcher. For example, statements such as “I was always sleepy” or 
“could’ve slept 23 hours a day” would have been coded as “excessive sleeping/tired” 
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within the category “Sleep Effects.” The constant comparative method of comparing data 
to data was used to ensure consistency in categorizing drug effects. For instance, effects 
such as “foggy head,” “dopey” and “slowed thinking” were coded together, as were 
effects such as “fatigued,” “tired,” and “lethargic.” Consistency and reliability were 
enhanced, then, by continually comparing new instances of an effect or variations of an 
effect to already coded effects.  
Focused coding was intended to condense, synthesize, and explain larger 
segments of data using the most frequent and/or significant codes from the initial coding 
phase (Charmaz, 2006). Focused coding was more conceptual and served to develop the 
properties and dimensions of themes/concepts (Corbin & Strauss, 2008). As part of this 
process, the constant comparative method was again used to compare data to data, data to 
codes, and codes to other codes. As additional data were coded, the description and range 
of each theme became more defined. Themes that began to overlap were merged 
together, whereas as a single theme with considerable range or variation may have been 
divided. For example, originally separate themes of “riding out the storm” and “waiting” 
were later merged into one theme because the central concept of “time” was present and 
overlapping in both.  
Memo-writing, a conventional grounded theory technique, served as an additional 
window into the processes of coding. Memos are simply notes begun at the initial coding 
phase and intended to provide the researcher a means to track coding decisions and 
evolving ideas about data, codes, and concepts. They also serve as a methodological log 
for maintaining transparency and reflexivity in the research process (Corbin & Strauss, 
2008). In this research, memos were used at various times to 1) define and describe codes 
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or themes, 2) make comparisons between data and data, data and codes, codes and codes, 
3) bring raw data into the memo, 4) explain coding decisions, and 5) identify gaps in the 
analysis (Charmaz, 2006). For example, one gap in the analysis related to how best to 
describe consumers’ categorization of drug effects. Memos attached to specific cases 
documented the tentativeness of codes such as “less severe,” “severe,” “best effect,” or 
“worst effect.” Other memos described the range and dimension of a theme. The code 
“my doctor was wrong” originally reflected consumer comments about being 
misinformed by their doctor, but as additional data were coded, broadened to include 
consumer comments about feeling uninformed after visiting their doctor, or of having a 
disagreement with their doctor. Memos were used to make note of these developments 
and refinements. All memos written during the coding process, along with the date, case 
number, and code are provided in Appendix F.  
Statistical analysis. 
 Sample characteristics, reported drug effects, and themes were summarized in 
frequency tables.  For some comparisons, such as of gender, age, and length of time on 
the drug across each website, empty cells prevented a statistical analysis. When cell 
frequencies were appropriately robust, chi-square was used in QDA Miner to test the null 
hypothesis that the categorical variables were independent. When possible, categories 
were collapsed to increase cell frequencies to 5 or higher, such as for age and length of 
time taking the drug. Comparisons using the chi-square test were made for: 1) gender, 
age, and time taken by drug, 2) commonly reported effects by website on which the 
comment was posted, 3) commonly reported effects by website classification as expert- 
or consumer-constructed, 4) categories of drug effects by variables of gender, age, and 
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time taken, 5) themes by website classification, 6) commonly reported effects and effect 
categories by time period the comment was posted, and 7) drug effect categories and 
themes by anonymity of the user.  
For numbers 3 and 5 above, chi-square was used to test the null hypothesis that 
there was no association between a reported drug effect or theme and the website the 
effect or theme originated from. For these analyses, websites were grouped according to 
their status as expert-constructed (RevolutionHealth and WebMD) or consumer-
constructed (AskaPatient, CrazyMeds, and IcarusProject) in order to minimize empty 
cells and small cell frequencies.  
All significance tests were two-tailed with p-values set at <0.05, unless otherwise 
stated. In some instances and as stated in the findings, a correction was made for multiple 
comparisons by dividing the alpha level of 0.05 by k number of comparisons.  
Usability of consumer sites according to “typical” web use. 
 An important and practical aspect of this research related to the “usability” of consumer 
sites for the typical Internet user. It is difficult to duplicate or estimate a “typical” web 
search for any given topic because of the near infinite possible pathways to navigate the 
Internet. One survey reported that 41% of respondents visited 2 or 3 websites when 
seeking health information online, and another 20% visited 4 or 5 websites (Fox, 2006). 
Consumer-generated media, such as discussion forums and message boards, have become 
increasingly important as 34% of online health seekers reported using these resources to 
gather information that weighed in on their health-related decision (Elkin, 2008). It is 
also reasonable to assume that a “typical” online health seeker would review only a 
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handful of consumers’ posts on consumer review or discussion sites, rather than sifting 
through the full set of reviews as done in the present research. 
As an attempt to preliminarily speak to the usability of consumer sites for 
consumers and professionals needing to make health-related decisions, the most recent 20 
consumer posts from each website were extracted to examine how well they represented 
the full dataset of consumer reviews/posts. This analysis was limited to the 4 websites 
that reported drug effects: AskaPatient, CrazyMeds, RevolutionHealth, and WebMD 
(n=960). For Crazymeds, the 20 users with the most recent posts were extracted for each 
drug. It was reasoned that if these 80 recent posts reported drug effects in a similar 
proportion to the full dataset (and depending on how the full dataset compared to expert 
text), then consumer reviews may be preliminarily accepted in terms of their 
representativeness as an additional source of information during “typical” web use. If 
there were significant differences in proportions of reported effects between recent posts 
and the full dataset, then consumers and professionals may be “harmed” by accessing 
incomplete information from consumer reviews during a “typical” web search. Either 
conclusion is preliminary as additional strategies are needed to fully understand and 
examine the usability issues of online consumer reviews.     
Preliminary data checking. 
In May 2008 as a preliminary exploration prior to data collection, nine Web 2.0 
researchers, bloggers, and webmasters were contacted with inquiries as to the state-of-
the-art for identifying or preventing unauthentic accounts on sites for consumer reviews 
or discussion. Five responses were received. 
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Computer science graduate student and developer of the Wikiscanner software, 
Virgil Griffith, suggested auditing Wikipedia edits of pharmaceutical companies as a way 
to gauge their presence in one of the most popular user-generated communities on the 
Internet. Wikiscanner is a free online tool used to search anonymous user edits from 
Wikipedia’s log of IP addresses. Between February 2002 and August 2007, there were 
over 34.5 million anonymous edits to Wikipedia entries, making up about 21% of all 
Wikipedia edits during that period (Griffith, n.d.). Griffith purchased a database of over 
2.6 million Internet Protocol (IP) addresses owned by organizations and found that 
187,529 different organizations (7% of the database) contributed at least 1 anonymous 
Wikipedia edit. Dozens of high profile edits were immediately publicized, such as from 
the Federal Bureau of Investigations (FBI), Central Intelligence Agency (CIA), Walmart, 
Exxon, Diebold, and several others (Hafner, 2007). Also publicized and of relevance to 
this research topic, a person with access to the pharmaceutical company AstraZeneca’s 
network deleted a sentence about the risk of suicidal thinking and behavior associated 
with the drug Seroquel (quetiapine). By 2005 Wikipedia was a top 50 website, making it 
likely that pharmaceutical companies may have had an interest in shaping relevant 
content on the site. Prior to the launch of Wikiscanner, it was also assumed that 
anonymous edits would remain “anonymous” in the traditional sense of “unidentified.” 
Thus, a review of edits from pharmaceutical company networks provided a unique 
opportunity to gauge the activity of these organizations in popular user-generated media.  
As another preliminary exploration prior to data collection, Wikiscanner was used 
to search Astra-Zeneca, Eli Lilly, and GlaxoSmithKline for Wikipedia edits.  
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Any edited entries related generally or specifically to medications or pharmaceutical 
companies were identified and copied into a Microsoft Word document. 
Data checking of the research sample. 
Consumer reviews from the present research sample were checked in an attempt 
to uncover possible bias that may have resulted from unauthentic consumer accounts. The 
first strategy addressed the hypothesis that pharmaceutical representatives may not be 
interested in a consumer website until it had gained some popularity among users. If a 
bias existed, it may appear in more recent comments. A check of the data compared early 
and recent comments for an imbalance of overly favorable comments in recent entries. 
Consumer reviews and discussion posts were divided into an early period (2002-2005) 
and a recent period (2006-2009) and compared across drug effect categories. The analysis 
of the 20 most recent posts from each website (above section) was also used to contribute 
to this portion of data checking.  
The second strategy addressed the hypothesis that pharmaceutical representatives 
may prefer to contribute comments anonymously, if that option was given. A check of the 
data compared drug effects reported by anonymous users to user-registered/identifiable 
comments for an imbalance of positive reported effects in the anonymous group. 
CrazyMeds was excluded from this check because all users on the discussion forum had 
an identifiable user name. A chi-square test was used to test for an association between 
anonymity of the user and reported drug effects. The analysis proceeded with all data 
included regardless of possible bias found using these strategies. It was pre-specified that 
a finding of bias was to be used to add nuance to conclusions relating to the analytic 
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situation – that of expertise in the age of the Internet. Such a bias was anticipated to be an 
important dynamic playing into those already identified in Figure 2.1.    
A final check was to look for what appeared to be “scripted” comments taken 
from the drug manufacturer’s website or downloadable medication guide. QDA Miner 
software was used to search the sampling frame (7,418 cases) for 14 common phrases 
found on the manufacturer’s drug website and medication guide for each of the two drugs 
being examined. The search was broadened to key words, such as “maintain* treatment,” 
after a search of full sentences and phrases returned no results. For example, the above 
key words were pulled from the following sentence on Lexapro.com, “In patients who 
have already responded to treatment with Lexapro for their depression, maintaining 
treatment with Lexapro was shown to prevent the depression from returning.” Retrieved 
entries from the 14 key words/phrases were individually scrutinized. This strategy 
stemmed from the comment of one consumer discussion forum owner cited previously: 
“They'll (pharmaceutical representatives) defend their meds if something hasn't been 
100% proven, using studies that were funded by their companies or just pulling stuff out 
of the PI sheets.  Sometimes it's as if they copied a paragraph or two from the company's 
website and pasted it into a post.” In instances where a comment duplicated or nearly 
duplicated information found on the manufacturer’s website or patient information sheet, 
the comment was excluded from analysis. Comments that appeared similar to, but did not 
duplicate these sources were included in the analysis. A count of the frequency of such 
instances was kept and used to again nuance the final conclusions.  
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Chapter 4: Findings 
Sample Characteristics 
 The coding sample consisted of 1,080 consumer reviews and discussion posts from 5 
websites, and 4 expert cases from 2 websites. Most consumers on AskaPatient and 
WebMD reported their gender, age, and length of time on the drug (Tables 4.1, 4.3, and 
4.5). The majority of consumers on the remaining 3 websites did not report gender or age, 
and at least half did not report length of time on the drug.  
Gender. 
On average and considering that 42.7% of the sample did not report gender, most 
consumers reported themselves as female (41.4%). The remaining 15.9% reported 
themselves as male. A chi-square test of gender by drug taken (Table 4.2) showed no 
association between these two variables (chi-square=1.426, df=2, p=0.49).  
Age. 
Similarly, 53.5% of consumers across websites did not report their age. 
Approximately 33% of consumers reported an age between 25 and 54 years old, with a 
slight majority (13.4%) of those consumers reporting to be in the younger 25-34 bracket. 
Another 8.5% of consumers reported an age less than 24 years, and just less than 5% 
reported an age over 55 years. A chi-square test of age by drug taken (Table 4.4) did 
show an association between the two variables (chi-square=14.355, df=6, p=0.026). 
Consumers in the younger age groups of 7-18 and 25-34 reported slightly higher use of 
Seroquel, whereas a higher percentage of consumers aged 19-24 and 35-44 were taking 
Lexapro.  
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Length of time on drug. 
Approximately 35% of the sample did not report the length of time taking 
Lexapro or Seroquel, but 37% reported taking the drug for less than 6 months (Table 4.5). 
Another 18% reported taking the drug between 1 and 5 years, and less than 2.5% reported 
taking it for more than 5 years. A chi-square test (Table 4.6) of this variable by drug 
taken did show an association (chi-square=20.423, df=6, p=0.002). Consumers taking the 
drug for less than 6 months were more often using Lexapro, while consumers taking the 
drug for 2 years or more were more often using Seroquel.   
Year posted. 
Consumer reviews were posted as early as 2002 on RevolutionHealth, 2003 on 
AskaPatient, CrazyMeds, and IcarusProject, and 2007 on WebMD (Table 4.7). More than 
68% of consumer reviews were posted from 2006-2008.  Approximately 24% of reviews 
were posted in or before 2005, and nearly two-thirds of those came from 
RevolutionHealth. Table 4.8 shows there were also more reviews for Lexapro than 
Seroquel in 2002-2003 (Lexapro received FDA approval in 2002), and more reviews for 
Seroquel in 2004-2005 (Seroquel received FDA approval for a second indication in 
2004).  
User ID/email. 
More than half (55.7%) of consumers did provide a user ID or email address with 
their review or post (Table 4.9), however, this number reflected the fact that all users on 
CrazyMeds and IcarusProject have a unique user ID for posting and for receiving private 
messages from other users. Table 4.10 shows a slightly higher proportion of consumers 
using Seroquel provided a user ID or email address.  
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Table 4.1 
Number of Consumers Reporting Gender across All Websites 
 Askapatient 
(N=240) 
CrazyMeds 
(N=240) 
IcarusProject
(N=120) 
RevHealth 
(N=240) 
WebMD 
(N=240) 
Total 
(%) 
Female 158 64 25 22 179 448 
(41.4%) 
Male 81 27 4 10 50 172 
(15.9%) 
Not 
Given  
1 (0.4%) 149 
(62.1%) 
91 (75.8%) 208 
(86.7%) 
11 
(4.6%) 
462 
(42.7%) 
 
Table 4.2 
Number of Consumers Reporting Gender According to Drug Takena 
 Lexapro (%) 
(N=480) 
Seroquel (%) 
(N=480) 
Female 216 (45.0%) 207 (43.1%) 
Male 77 (16.0%) 91 (19.0%) 
Not Given  187 (39.0%) 182 (37.9%) 
aChi-square=1.426, df=2, p=0.49 
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Table 4.3 
Number of Consumers Reporting Age across All Websites 
Age Askapatient 
(N=240) 
CrazyMeds 
(N=240) 
IcarusProject
(N=120) 
RevHealth
(N=240) 
WebMD 
(N=240) 
Total (%) 
7-12 2 1  1 1 5 (0.5%) 
13-18 13 2 1 1 4 21 (1.9%) 
19-24 41 1 2  22 66 (6.1%) 
25-34 75 2 5 3 60 145 
(13.4%) 
35-44 52 6  2 50 110 
(10.2%) 
45-54 41 4 2 4 53 104 
(9.6%) 
55-64 11 1  1 32 45 (4.2%) 
65-74 1 1   3 5 (0.5%) 
75+ 1    1 2 (0.2%) 
not 
given  
3 (1.3%) 224 
(92.6%) 
110 (91.7%) 228 (95%) 14 
(5.8%) 
579 
(53.5%) 
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Table 4.4 
Number of Consumers Reporting Age According to Drug Takena 
Age Lexapro (%) 
(N=480) 
Seroquel (%) 
(N=480) 
7-18 b 7 (1.5%) 18 (3.8%) 
19-24 38 (7.9%) 26 (5.4%) 
25-34 64 (13.3%) 76 (15.8%) 
35-44 67 (14.0%) 43 (9.0%) 
45-54 46 (10.0%) 56 (11.7%) 
55+ b 26 (4.4%) 26 (5.0%) 
not given  232 (48.3%) 235 (49.0%) 
aChi-square=14.355, df=6, p=0.026 
bCategories were collapsed for this analysis. 
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Table 4.5 
Number of Consumers Reporting Length of Time on the Drug across All Websites 
Time 
Taken 
Askapatient 
(N=240) 
CrazyMeds 
(N=240) 
IcarusProject 
(N=120) 
RevHealth 
(N=240) 
WebMD 
(N=240) 
Total 
(%) 
<1 mth 67 23 3 43 51 187 
(17.3%) 
1-6 
mths 
72 38 2 42 59 213 
(19.7%) 
6 mths - 
1 yr 
29 16 1 11 28 85 
(7.9%) 
1-2 yrs 29 21  6 27 83 
(7.7%) 
2-5 yrs 34 20 2 8 46 110 
(10.2%) 
5-10 yrs 7 4  2 11 24 
(2.2%) 
10 yrs+ 1    1 2 (0.2%) 
not 
given  
1       
(0.4%) 
120 
(49.6%) 
112   
(93.3%) 
128 
(53.3%) 
17 
(7.1%) 
378  
(34.9%) 
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Table 4.6 
Number of Consumers Reporting Length of Time on the Drug according to Drug Takena 
Time Taken Lexapro (%) 
 
(N=480) 
Seroquel (%) 
 
(N=480) 
 
<1 mth 106 (22.1%) 78 (16.2%) 
1-6 mths 122 (25.4%) 89 (18.5%) 
6 mths - 1 yr 42 (8.6%) 42 (8.6%) 
1-2 yrs 43 (9.0%) 40 (8.3%) 
2-5 yrs 46 (9.6%) 62 (12.9%) 
5 yrs+ b 9 (1.9%) 17 (3.5%) 
not given  112 (23.3%) 152 (31.7%) 
aChi-square=20.423, df=6, p=0.002 
bThe categories 5-10yrs and 10yrs+ were collapsed for this analysis. 
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Table 4.7 
Number of Consumer Posts According to Year Posted across all Websites 
Year 
Posted 
Askapatient 
(N=240) 
CrazyMeds
(N=240) 
IcarusProject
(N=120) 
RevHealth
(N=240) 
WebMD 
(N=240) 
Total 
(%) 
2002    19  19 (1.8%) 
2003 2 1 7 36  46 (4.3%) 
2004 15 1 23 48  87 (8.0%) 
2005 26  23 57  106 
(9.8%) 
2006 47  26 68  141 
(13.0%) 
2007 81 88 26 6 52 253 
(23.4%) 
2008 52 127 15 3 148 347 
(32.1%) 
2009a 17 25  3 40 85 (7.9%) 
aData in this row represents January and February 2009. 
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Table 4.8 
Number of Consumer Posts for Each Drug According to Year Posted  
Year Posted Lexapro (%) 
 
(N=480) 
Seroquel (%)
 
(N=480) 
 
2002 17 (3.5%) 2 (0.4%) 
2003 25 (5.2%) 13 (2.7%) 
2004 22 (4.6%) 41 (8.5%) 
2005 31 (6.5%) 52 (10.8%) 
2006 57 (11.9%) 58 (12.1%) 
2007 117 (24.4%) 110 (22.9%) 
2008 163 (34.0%) 167 (34.8%) 
2009a 48 (10.0%) 37 (7.7%) 
aData in this row represents January and February 2009. 
 
Table 4.9 
Number of Consumers Who Provided a User ID or Email Address across All Websites 
 Askapatient 
(N=240) 
CrazyMeds
(N=240) 
IcarusProject
(N=120) 
RevHealth 
(N=240) 
WebMD 
(N=240) 
Total 
(%) 
(YES) 
ID/email 
was given 
60 240 120 33 150 603 
(55.7%) 
(No) ID/ 
email was 
not given 
180   207 90 477 
(44.1%) 
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Table 4.10 
Number of Consumers Who Provided a User ID or Email Address According to Drug 
Taken 
Lexapro (%)
 
(N=480) 
Seroquel (%)
 
(N=480) 
 
(YES) ID/email was given 226 (47.1%) 257 (53.5%) 
(No) ID/email was not given 254 (52.9%) 223 (46.5%) 
 
Inter-Coder Agreement Analysis 
 Two coders coded a random sample of 216 cases in two phases (n=100 in phase 1, 
n=116 in phase 2). Table 4.11 shows the results of the inter-coder agreement analysis. 
Acceptable overall agreement was found in both phases (Scott’s Pi=0.756 in phase 1, 
Scott’s Pi=0.751 in phase 2). In general, agreement was higher for drug effects than for 
themes and concepts. After each phase of agreement analysis, the two coders discussed 
and resolved disagreements (see Appendix G). Many of the coding disagreements were 
traced to a lack of clarity or understanding by the second coder.  For example, upon 
reviewing the codes of both coders, it became clear that the second coder was unsure 
when to appropriately apply codes within the category “Evidence of Causality” because 
of a misunderstanding about the purpose of those codes. The second coder also had 
difficulty applying codes for “Discontinuing/Missed Doses” due to a lack of knowledge 
of what “discontinuing” meant. In other cases, such as for “Other Drug Issues” and 
“Support and Advice,” the second coder applied these codes more liberally than the 
principal investigator, despite the provided descriptions of the concepts each of these 
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codes encompassed. Finally on a few occasions, such as for “Other Effects” of the drugs, 
and as part of the process of grounded theory coding, the principal investigator began 
applying codes to text segments that broadened the scope of the code. For example, the 
code “no/limited side effects” which falls under the “Other Effects” category, was 
initially defined to only include comments that clearly stated there were no side effects of 
the drug. During coding, however, the principal investigator observed many comments 
that seemed to define drug effects according to the absence (rather than the presence) of a 
specific effect (i.e., “I’ve experienced no weight gain on this drug”). These comments 
were coded by the principal investigator as “no/limited side effects,” and often left 
uncoded by the second coder.  
 The remaining coding and analysis proceeded as planned because the overall inter-
coder agreement statistic was above the minimally acceptable level of 0.70, and because 
most coding disagreements were related to 1) a lack of clarity or understanding of 
terminology and/or code definitions by the second coder, and 2) the evolving nature of 
the grounded theory coding method in which codes continued to expand and collapse 
throughout the process. The coders agreed that there did not appear to be unfounded leaps 
from data to codes. Revisions to the codebook to clarify codes and ease the coding 
process were made after each phase of the agreement analysis based upon the two coders’ 
discussions.  
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Table 4.11  
Inter-coder Agreement Analysis 
 Scott’s Pi, part 
1 
(N=100) 
Scott’s Pi, part 
2 
(N=116) 
Drug Effects   
Appetite and Weight Effects 1 0.82 
Gatrointestinal and Urinary Effects 0.851 1 
Head/Face Effects 0.889 0.683 
Lab Tests and Chronic Conditions 1 0.884 
Mental or Mood Effects 0.889 0.809 
Musculoskeletal and Neurological Effects 0.826 0.811 
Nose/Throat/Chest Effects 0.591 0.81 
Other Effects 0.632 0.361 
Sexual Effects 0.852 1 
Skin Effects 0.949 0.653 
Sleep Effects 0.928 0.913 
Themes/Concepts   
Assessing the Overall Experience 0.476 0.628 
Citations and Links 1 0.633 
Classification of Effects 0.202 0.644 
Contraindications -0.005 0.791 
Dealing with Side Effects/Finding Optimum 
Effectiveness 
0.668 0.723 
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 Scott’s Pi, part 
1 
(N=100) 
Scott’s Pi, part 
2 
(N=116) 
Discontinuing/Missed Doses 1 0.598 
Evidence of Causality 0.333 0.504 
Finances / The System 0.918 0.948 
Friends and Family 0.556 0.646 
My Diagnosis/Reason for Use 0.74 0.69 
My Doctor 0.645 0.741 
Other Drug Issues 0.904 0.563 
Other Drugs and Drug Combinations 0.485 0.822 
Pharmaceutical Companies/FDA 0.398 0.597 
Support and Advice 0.936 0.56 
Theories of Drug Action 0.668 0.741 
TOTAL 0.756 0.751 
 
Drug Effects According to Consumers 
 Overview of drug effect categories. 
 The most recent codebook in Appendix D shows 11 categories of drug effects. Effects 
were grouped broadly in order to facilitate robust analyses. The categories that resulted 
were not based on a standardized medical dictionary, and the meaning of the specific 
groupings should not be exaggerated in the final conclusions. In most cases where 
categories were used for analysis, individual effects were further examined to determine 
where differences lay.  
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Appetite and weight effects were grouped in their own category, paralleling what 
might be called metabolic effects in a standardized dictionary. These effects appeared 
frequently enough in the data to warrant their own category, rather than be grouped with, 
for example, gastrointestinal effects.  Similarly, sexual effects, which could have 
alternatively been grouped under genito-urinary effects, and sleep effects recurred 
frequently enough to merit autonomous categories. At the same time, there were few 
instances of other genito-urinary effects (i.e., involving urination and menstruation), so 
these were combined with gastrointestinal effects (i.e., nausea/vomiting, constipation, 
etc.) to create a single category called gastrointestinal and urinary effects.  
 Head/face effects involved physical effects of those body parts, such as headache and 
jaw clenching. Codes under nose/throat/chest effects and skin effects were similarly 
grouped. Again, these were grouped broadly, rather than broken down into smaller 
categories of respiratory effects, sensory effects, and so on. Mental or mood effects 
included all non-physical, psychological and behavioral drug effects. 
 Musculoskeletal and neurological effects were grouped into 1 category because of slight 
overlap in these effects, such as for tingling sensations and numbness which could be 
reasonably classified under either body system. Also, there were too few effects within 
either category alone to stand on its own.  
 The category “lab tests and chronic conditions,” referred to effects that show up only on 
laboratory tests, such as high blood sugar or cholesterol, and that may cause chronic 
disease conditions, such as diabetes. These were grouped together, rather than distributed 
across various body systems, because previous research in this area found that consumers 
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online less frequently mentioned these types of effects specifically as compared to 
information provided in expert sources. 
 Finally, “other effects” included codes that were infrequently mentioned and could not 
be otherwise classified. 
Lexapro. 
 Table 4.12 shows the percentage of consumers mentioning an effect grouped by the 
category of effects. For example, the category “sexual effects” included codes for lost sex 
drive, trouble with orgasm, and other sexual effects.. “Mental or mood effects” was the 
most commonly reported category of effects with almost 62% of consumers mentioning 
them.  
Table 4.13 lists all effects of Lexapro mentioned by at least 3% of consumers. The 
top 4 most mentioned effects were related to symptoms and sleep. Approximately 30% of 
consumers reported improvement in symptoms, such as anxiety, depression, or mania, as 
an effect of Lexapro. Another 15.8% reported new or worsening symptoms as an effect of 
Lexapro, including new or worsened panic attacks, depression, or mania. Sleep changes 
ranging from excessive sleepiness to insomnia were mentioned by about 24% and 13% of 
consumers, respectively. All other effects mentioned could be considered “side effects.” 
 Figure 4.1 and Table 4.14 show the 9 most reported effects for Lexapro across 4 
websites, measured by code occurrence in a case (posts from IcarusProject were not 
included in analyses of drug effects). Figure 4.1 visually displays the lack of consistency 
of consumer reporting across these websites. With p-values set at 0.001 for multiple 
comparisons, statistically significant chi-square coefficients were reached for half of 
these effects, indicating that there was an association between symptom improvement, 
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extreme sleepiness, nausea/vomiting, and lost sex drive, and the website the post 
originated. Compared to the other 3 websites, WebMD showed a relatively low number 
of consumers mentioning what are usually considered “side effects” of the drug, 
including sleep changes, new or worsened symptoms, brain fog/zombie, weight gain, and 
nausea/vomiting. Across all 9 top reported effects, consumers on AskaPatient reported 
these effects in high numbers, whereas consumers on CrazyMeds reported a 
comparatively low number of drug effects. RevolutionHealth had the highest percentage 
of consumers mentioning symptom improvement compared to the other 3 websites, and 
the lowest percentage of consumers mentioning weight gain. For the remaining listed 
effects, consumers on RevolutionHealth provided varied reports.  
 In Table 4.15, Lexapro effects mentioned by at least 3% of consumers are compared 
across consumer-constructed websites (AskaPatient and CrazyMeds) and expert-
constructed websites (RevolutionHealth and WebMD). Only 1 of the 28 effects listed 
reached statistically significant p-values at the 0.001 level (dreams vivid/nightmares), 
indicating that for a majority of effects there was no association between the effect and 
the classification of the website as consumer- or expert-constructed. More consumers 
posting on expert-constructed websites reported Lexapro improved their symptoms 
(p=.037), while more consumers on consumer-constructed websites reported the drug 
worsened or induced new symptoms (p=.034). All effects that would be popularly labeled 
as side effects or adverse effects were each mentioned more by consumers on consumer-
constructed rather than expert-constructed websites, with the exception of loss of 
appetite. 
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Table 4.12  
Top 5 Effect Categories Mentioned by Consumers for Lexapro 
Category of effects % of consumers mentioning the effect 
Mental or mood effects 61.7% 
Sleep effects 36.0% 
Appetite and weight effects 22.5% 
Sexual effects 20.2% 
Gastrointestinal and urinary effects 16.7% 
 
Table 4.13  
Effects of Lexapro Mentioned by at Least 3% of Consumers  
Drug effect % of consumers mentioning the effect 
(N=480) 
Symptoms reduced / improved 30.4% 
Extreme sleepiness / tired 23.8% 
Symptoms new / worsened 15.8% 
Trouble sleeping / insomnia 13.3% 
Emotionally stable / calm / "normal" 13.1% 
Weight gain 13.1% 
Nausea / sick stomach / vomiting 12.1% 
Numb / detached / lack of energy or 
interest 11.3% 
Brain fog / zombie 10.8% 
Lost sex drive/low libido 10.6% 
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Drug effect % of consumers mentioning the effect 
(N=480) 
Trouble achieving orgasm 8.5% 
Headache increased 7.1% 
Jaw clenching / grinding 6.9% 
Energy increased / euphoria / mania 6.9% 
“Sweating like a pig” 6.5% 
Dreams vivid / nightmares 6.3% 
Abnormal movements 5.6% 
Agitated / restless 5.4% 
Loss of appetite 4.8% 
Weight loss 4.8% 
Other misc effects 4.6% 
Dizzy / lightheaded / faint 4.6% 
Diarrhea / gas 4.6% 
Dry mouth / sore throat 4.4% 
Increase appetite / cravings 4.2% 
Ability to do things in absence of 
symptoms 4.0% 
Yawning 3.1% 
Other sexual effects 3.1% 
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Figure 4.1 Most Popularly Mentioned Lexapro Effects by Consumers across Websites 
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Table 4.14  
Number of Consumers on each Website Mentioning the Most Popularly Reported Effects 
of Lexaproa 
 AskaPatient
N=120 
CrazyMeds
N=120 
RevHealth
N=120 
WebMD 
N=120 
Chi-
square 
p-
value 
Symptoms 
improved 45 18 50 33 24.543 0.000
Extreme 
sleepiness/tired 41 22 35 16 18.735 0.000
Symptoms new/ 
worsened 31 15 19 11 14.396 0.002
Brain fog/zombie 27 8 13 4 -- -- 
Trouble sleeping 
/insomnia 26 7 19 12 15.236 0.002
Weight gain 26 16 9 12 12.301 0.006
Nausea/sick 
stomach/ vomiting 22 6 24 6 23.123 0.000
Lost sex 
drive/libido 24 5 10 12 17.497 0.001
Emotionally 
stable/calm/ 
"normal" 23 6 18 16 11.467 0.009
ap-value set at 0.001 for k=35 comparisons in Tables 4.14 and 4.15 
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Table 4.15  
Lexapro Effects Mentioned by >3% of Consumers according to Website Classificationa  
Drug effect Consumer-
constructed 
(N=220) 
Expert-
constructed 
(N=220) 
Chi-square p-value 
Symptoms reduced / 
improved 
62 83 4.358 0.037 
Extreme sleepiness / 
tired 
62 51 1.400 0.237 
Symptoms new / 
worsened 
47 30 4.470 0.034 
Trouble sleeping / 
insomnia 
32 31 0.018 0.892 
Emotionally stable / 
calm / "normal" 
29 34 0.457 0.499 
Weight gain 41 21 7.409 0.006 
Nausea / sick 
stomach / vomiting 
27 30 0.179 0.672 
Numb / detached / 
lack of energy or 
interest 
31 22 1.718 0.19 
Brain fog / zombie 34 17 6.340 0.012 
Lost sex drive/low 
libido 
28 22 0.804 0.37 
Trouble achieving 
orgasm 
24 16 1.745 0.186 
Headache increased 20 13 1.594 0.207 
Jaw clenching / 
grinding 
23 9 6.653 0.01 
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Drug effect Consumer-
constructed 
(N=220) 
Expert-
constructed 
(N=220) 
Chi-square p-value 
Energy increased / 
euphoria / mania 
17 15 0.134 0.714 
“Sweating like a pig” 19 11 2.276 0.131 
Dreams vivid / 
nightmares 
25 5 14.222 0.000 
Abnormal 
movements 17 
10 1.923 0.166 
Agitated / restless 19 7 5.856 0.016 
Loss of appetite 9 14 1.142 0.285 
Weight loss 13 10 0.411 0.521 
Other misc effects 12 9 0.448 0.503 
Dizzy / lightheaded / 
faint 
12 10 0.191 0.662 
Diarrhea / gas 14 8 1.715 0.19 
Dry mouth / sore 
throat 10 
10 0.000 1.00 
Increase appetite / 
cravings 
12 8 0.835 0.361 
Ability to do things 
in absence of 
symptoms 
6 13 2.685 0.101 
Yawning 12 3 -- -- 
Other sexual effects 8 6 0.294 0.587 
ap-value set at 0.001 for k=35 comparisons in Tables 4.14 and 4.15 
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Seroquel. 
Table 4.16 shows the percentage of consumers mentioning an effect of Seroquel 
grouped by the category of effect (also see Appendix D). Sleep effects were mentioned 
by over 60% of consumers, followed by nearly 52% of consumers mentioning mental or 
mood effects.  
Table 4.17 lists all effects of Seroquel mentioned by at least 3% of consumers. 
The top 2 effects were related to sleep, including the drug helps sleep or causes too much 
sleep and tiredness. About a quarter of consumers mentioned an improvement in 
symptoms, such as anxiety, mania, or hallucinations, and about 10% mentioned these 
same symptoms newly appearing or worsening. Weight gain was mentioned by 22.5% of 
consumers, and increased appetite and cravings (especially sugar and carbohydrate 
cravings) were mentioned by 12.7% of consumers. 
Figure 4.2 and Table 4.18 show the most commonly reported effects for Seroquel 
across 4 websites. The bar chart in Figure 4.2 illustrates greater homogeneity in reported 
effects across websites as compared to the same chart in Figure 4.1 for Lexapro. With p-
values set at 0.002 for multiple comparisons involving the originating websites, 
statistically significant chi-square coefficients were reached for 2 of the 8 effects listed: 
extreme sleepiness and weight gain. Consumers on AskaPatient mentioned these effects 
at a considerably higher rate than the other 3 websites. Consumers on RevolutionHealth 
mentioned symptom improvement more often than consumers on other websites, and 
mentioned new or worsening symptoms the least often. WebMD also had fewer reports 
of new or worsening symptoms compared to the 2 consumer-constructed websites, and 
had the least mentions of all websites of abnormal movements.  
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In Table 4.19, effects listed by at least 3% of consumers are compared across 
consumer- and expert-constructed websites. One of the 18 effects listed showed 
significant values at the p<0.002 level, indicating that there was an association between 
new/worsened symptoms and the classification of the website on which it was reported. 
Significantly more consumers on consumer-constructed websites reported Seroquel 
worsened or induced new symptoms (p =.000), while more consumers on expert-
constructed sites reported it improved their symptoms (p=.008). Similarly, a higher 
percentage of consumers posting on consumer-constructed sites reported the drug made 
them excessively sleepy and tired (p=.009), while those on expert-constructed websites 
reported that it helps with sleep (p=.105). 
In sum, effects on mental or mood symptoms and effects on sleep were reported 
by consumers for both drugs more often than any other types of effects. In general, 
reporting across websites was more heterogeneous for Lexapro than for Seroquel. 
Consumers across each website and for both drugs reported improvements in mental or 
mood symptoms at a higher rate than worsened or induced symptoms. However, the trend 
for both drugs was that consumers on expert-constructed sites reported higher rates of 
symptom improvement (and helpful sleep on Seroquel), but generally lower rates of side 
effects.  
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Table 4.16  
Top 5 Effect Categories Mentioned by Consumers for Seroquel 
Category of effects % of consumers mentioning the effect
Sleep effects 60.6% 
Mental or mood effects 52.9% 
Appetite and weight effects 30.8% 
Musculoskeletal and neurological effects 18.1% 
Other effects 16.0% 
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Table 4.17  
Effects of Seroquel Mentioned by at Least 3% of Consumers  
Drug effect % of consumers mentioning the effect 
(N=480) 
Helps me sleep 35.6% 
Extreme sleepiness / tired 33.1% 
Symptoms reduced / improved 24.8% 
Weight gain 22.5% 
Brain fog / zombie 15.2% 
Increased appetite / cravings 12.7% 
Symptoms new / worsened 10.2% 
Abnormal movements 8.8% 
Emotionally stable / calm / "normal" 7.9% 
Difficult to wake up 6.3% 
Other misc effects 5.0% 
Dizzy / lightheaded / faint 4.8% 
Blood sugar high / diabetes 4.8% 
Dry mouth / sore throat 4.6% 
Dreams vivid / nightmares 4.4% 
Numb / detached / lack of energy or 
interest 4.2% 
Memory loss 3.8% 
Hungover / drunk 3.1% 
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Figure 4.2 Most Popularly Mentioned Seroquel Effects by Consumers across Websites 
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Table 4.18  
Number of Consumers on Each Website Mentioning the Most Popularly Reported Effects 
of Seroquela 
 AskaPatient
N=120 
CrazyMeds
N=120 
RevHealth
N=120 
WebMD 
N=120 
Chi-
square 
p-
value 
Helps me sleep 38 39 50 44 3.298 0.348 
Extreme 
sleepiness/ tired 60 33 39 27 23.276 0.000 
Symptoms 
improved 21 26 42 30 10.76 0.013 
Weight gain 45 17 23 23 21.792 0.000 
Increase appetite/ 
cravings 18 21 9 13 6.366 0.095 
Brain fog/zombie 21 16 19 17 0.953 0.813 
Symptoms new/ 
worsened 19 19 4 7 -- -- 
Abnormal 
movements 17 11 9 5 7.828 0.05 
ap-value set at 0.002 for k=25 comparisons in Tables 4.18 and 4.19 
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Table 4.19  
Seroquel Effects Mentioned by >3% of Consumers According to Website Classification 
Drug effect Consumer-
constructed 
(N=220) 
Expert-
constructed 
(N=220) 
Chi-square p-value 
Helps me sleep 77 94 2.625 0.105 
Extreme sleepiness / 
tired 
93 66 6.856 0.009 
Symptoms reduced / 
improved 
47 72 6.983 0.008 
Weight gain 62 46 3.059 0.08 
Brain fog / zombie 37 36 0.016 0.899 
Increased appetite / 
cravings 
39 22 5.427 0.02 
Symptoms new / 
worsened 
38 11 16.569 0.000 
Abnormal 
movements 28 
14 5.114 0.024 
Emotionally stable / 
calm / "normal" 
25 13 4.115 0.042 
Difficult to wake up 19 11 2.276 0.131 
Other misc effects 13 11 0.175 0.675 
Dizzy / lightheaded / 
faint 
11 12 0.046 0.831 
Blood sugar high / 
diabetes 
13 10 0.411 0.521 
Dry mouth / sore 
15 7 3.049 0.081 
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Drug effect Consumer-
constructed 
(N=220) 
Expert-
constructed 
(N=220) 
Chi-square p-value 
throat 
Dreams vivid / 
nightmares 
16 5 6.026 0.014 
Numb / detached / 
lack of energy or 
interest 
13 7 1.878 0.171 
Memory loss 11 7 0.924 0.337 
Hungover / drunk 10 5 1.720 0.19 
ap-value set at 0.002 for k=25 comparisons in Tables 4.18 and 4.19 
 
Drugs Effects According to Experts 
Lexapro.  
 Table 4.20 lists a count and proportion of the most frequently mentioned effects of 
Lexapro in expert text. For example, abnormal movements were mentioned 1 time on 
RevolutionHealth and mentioned 4 times on WebMD. As a proportion of the total 
frequency of mentions of all effects, abnormal movements made up 2.6% and 3.2% of all 
mentions of effects on RevolutionHealth and WebMD, respectively. In all but two 
instances (agitated/restless and brain fog/zombie), WebMD cited effects more often than 
RevolutionHealth. However for several effects, RevolutionHealth showed a higher 
proportion of the frequency of mentions. For example, WebMD mentioned new or 
worsening symptoms twice as often as RevolutionHealth (8 times versus 4 times). Out of 
all mentions of effects on RevolutionHealth, though, 10.3% were related to new or 
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worsening symptoms, whereas 6.5% of total mentions on WebMD were this effect.  
Figures 4.3 and 4.4 illustrate this difference using the top 6 most frequently mentioned 
effects in expert text as measured by number of mentions (Figure 4.3) and proportion of 
all mentions (Figure 4.4). Four of the top 6 effects were the most frequently mentioned 
regardless of measurement: blood related changes, suicidal thinking/planning, symptoms 
new/worsened, and other misc effects. The remaining 2 effects changed depending on 
whether the measurement was number or proportion of mentions. In both cases, WebMD 
had the highest number of mentions (nausea/vomiting and dizzy/lightheaded/faint), 
whereas RevolutionHealth had the highest proportion of mentions (brain fog/zombie and 
agitated/restless). 
 The most frequently mentioned effect in WebMD fell under the code “other misc 
effects,” which included effects that were sparsely reported across websites, such as 
serotonin syndrome, toothache, kidney failure, and bronchitis. The most frequently 
mentioned effects in RevolutionHealth were agitated/restless, suicidal thinking/planning, 
and symptoms new/worsened, each appearing 4 times in that text. Additionally, 4 of the 
14 effects listed in Table 4.20 were mentioned in one expert text and not the other. In 
only 1 of these instances did RevolutionHealth cite an effect (brain fog/zombie) not 
mentioned on WebMD.  
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Table 4.20  
Most Frequently Mentioned Effects of Lexapro in Expert Text (frequency >3% of total 
mentions of effects on either website) 
 # of times effect is mentioned in text                       
(% of all mentions of effects in text) 
 RevolutionHealth WebMD 
Other misc effects 1 (2.6%) 13 (10.5%) 
Agitated/restless 4 (10.3%) 3 (2.4%) 
Suicidal thinking/ 
planning 
4 (10.3%) 5 (4.0%) 
Symptoms new/ 
worsened 
4 (10.3%) 8 (6.5%) 
Brain fog/zombie 3 (7.7%) 0 (0%) 
Blood related changes 0 (0%) 9 (7.3%) 
Dizzy/lightheaded/ faint 2 (5.1%) 7 (5.6%) 
Extreme sleepiness/tired 2 (5.1%) 4 (3.2%) 
Trouble sleeping/ 
insomnia 
2 (5.1%) 3 (2.4%) 
Nausea/sick 
stomach/vomiting 
1 (2.6%) 6 (4.8%) 
Heartbeat changes 1 (2.6%) 4 (3.2%) 
Abnormal movements 1 (2.6%) 4 (3.2%) 
Fever/chills/infection 0 (0%) 4 (3.2%) 
Other sexual effects 0 (0%) 4 (3.2%) 
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Figure 4.3 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text Measured 
by Number of Mentions  
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Figure 4.4 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text Measured 
by Proportion of All Mentions of Effects  
  
Seroquel. 
 Table 4.21 lists a count and proportion of the most frequently mentioned effects of 
Seroquel in expert text. RevolutionHealth mentioned 11 effects more frequently than 
WebMD, with 5 of these related to mental or mood changes. WebMD mentioned 8 
effects more frequently than RevolutionHealth, all of which were physical effects. 
Figures 4.5 and 4.6 illustrate that the proportion of total mentions of effects remained 
consistent with the number of mentions on each website. For example, RevolutionHealth 
mentioned suicidal thinking/planning and symptoms new/worsened more frequently than 
WebMD as measured both by the number of mentions and proportion of all mentions.  
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 The most frequently mentioned effect in WebMD was dizzy/lightheaded/faint (7 
mentions). In RevolutionHealth, they were brain fog/zombie and symptoms 
new/worsened (5 mentions each). For 3 of the 21 effects listed in Table 4.21, an effect 
was mentioned on one expert website and not the other. Increased energy/euphoria/mania 
and increased appetite/cravings were mentioned 2 times and 3 times, respectively, on 
RevolutionHealth and zero times on WebMD. Other labs and chronic conditions, such as 
pancreatitis and underactive thyroid, were mentioned 4 times on WebMD and not at all 
on RevolutionHealth.    
 For both drugs, it appeared that the expert text on WebMD more frequently mentioned 
physical effects, such as blood-related changes and nausea/vomiting, while 
RevolutionHealth more frequently mentioned mental or mood “side effects,” such as 
brain fog/zombie and agitated/restless. Most of the commonly reported effects in Tables 
4.20 and 4.21 were cited at least once in both texts, however for both drugs there were 
considerable discrepancies between websites in the relative attention (measured by 
number and proportion of mentions) given to effects.  
 
 
 
 
 
 
 
 
121 
 
Table 4.21  
Most Frequently Mentioned Effects of Seroquel in Expert Text (frequency >3% of total 
mentions of effects in either website) 
 # of times effect is mentioned in text                    
(% of all mentions of effects in text)  
 RevolutionHealth WebMD 
Brain fog/zombie 5 (7.6%) 1 (1.0%) 
Symptoms new/worsened 5 (7.6%) 1 (1.0%) 
Dizzy/lightheaded/faint 2 (3.0%) 7 (6.9%) 
Suicidal thinking/ planning 4 (6.1%) 2 (2.0%) 
Weakness 4 (6.1%) 2 (2.0%) 
Abnormal movements 2 (3.0%) 5 (4.9%) 
Vision/eye changes 3 (4.5%) 3 (2.9%) 
Headache increased 3 (4.5%) 2 (2.0%) 
Agitated/restless 3 (4.5%) 1 (1.0%) 
Heaviness/soreness/ 
pain/numbness 
3 (4.5%) 1 (1.0%) 
Urinary changes/ problems 3 (4.5%) 1 (1.0%) 
Increased appetite/ cravings 3 (4.5%) 0 (0%) 
Extreme sleepiness/ tired 2 (3.0%) 4 (3.9%) 
Other misc effects 2 (3.0%) 4 (3.9%) 
Blood sugar high/ diabetes 1 (1.5%) 4 (3.9%) 
Other labs or chronic 
conditions 
0 (0%) 4 (3.9%) 
Fever/chills/infection 2 (3.0%) 3 (2.9%) 
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 # of times effect is mentioned in text                    
(% of all mentions of effects in text)  
 RevolutionHealth WebMD 
Heartbeat changes 2 (3.0%) 3 (2.9%) 
“Sweating like a pig” 2 (3.0%) 2 (2.0%) 
Trouble sleeping/ insomnia 2 (3.0%) 1 (1.0%) 
Energy increased/ 
euphoria/mania 
2 (3.0%) 0 (0%) 
 
Figure 4.5 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text Measured 
by Number of Mentions  
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Figure 4.6 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text Measured 
by Proportion of All Mentioned of Effects  
 
Drug Effects by Experts versus Consumers 
Lexapro. 
 Experts and consumers both mentioned the category mental or mood effects more 
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mentions in the expert text (Figure 4.8). Experts gave the most attention to other misc 
effects, blood related changes, suicidal thinking/planning, and dizzy/lightheaded/faint, 
while consumers mentioned these effects much less frequently.   
As seen in Figure 4.8, experts and consumers did have comparable rates of 
mentions for new or worsening symptoms (7.4% and 6.5% of mentions, respectively) and 
nausea/sick stomach/vomiting (4.3% and 4.1% of mentions, respectively). Table 4.22 
provides a representative selection of excerpts from each website of text coded 
“symptoms new/worsened,” with some overlap of suicidal thinking/planning as, when 
mentioned, the latter effect often co-occured with the former. Experts provided a laundry 
list of new or worsening symptoms for users to beware of. As the excerpts in Table 4.22 
demonstrate, the expert list of symptoms and consumers’ reports of new/worsening 
symptoms appeared to largely overlap. Reports from consumers, however, provided 
situational examples and context for how the effect may be experienced or manifested in 
a single individual.  
 Tables 4.23 and 4.24 compare experts and consumers on frequency of mentions and 
descriptions of weight and appetite effects and sexual effects, respectively. These 
categories were selected to compare and contrast expert and consumer descriptions 
because of their richness of data. Table 4.23 shows that out of all mentions of effects 
within the category weight and appetite effects, experts gave the most attention to loss of 
appetite, while consumers gave the most attention to weight gain. WebMD described 
increased appetite as rare and decreased appetite as infrequent. An almost even number of 
consumers (4.2% and 4.8%, respectively) mentioned each of these effects at least once, 
though decreased appetite was mentioned more frequently as a proportion of all mentions 
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of weight and appetite effects. Additionally, experts described each effect on weight and 
appetite to be less serious or less severe, while consumers demonstrated more clearly 
differentiated perspectives such as “hugest problem of all” and “appalling” in relation to 
weight gain, and “an extra bonus” in relation to weight loss.  
 Table 4.24 summarizes the same information for sexual effects of Lexapro. Most of the 
mentions of sexual effects in expert text were related to other sexual effects, such as the 
nondescript “sexual problems” or priapism (all from WebMD). Consumers gave more 
attention to lost sex drive (42.2% of mentions) and trouble achieving orgasm (37% of 
mentions), and much less attention to other sexual effects (11.9% of mentions). Lost sex 
drive was mentioned by 10.6% of consumers, though WebMD described this effect as 
infrequent and RevolutionHealth did not cite this effect at all. At the same time, trouble 
achieving orgasm was mentioned by slightly fewer consumers (8.5%), but was labeled a 
frequent effect by WebMD. Trouble achieving orgasm and other sexual effects were 
described as less serious or less severe by experts, while lost sex drive was rated as 
severe by WebMD (worded as “decreased interest in sex”). Consumers described all 
sexual effects using terms such as “the absolute worst, “extremely frustrating,” and 
similar. Some consumers made comments like, “I want to quit…so I can have a frigging 
orgasm,” or “can’t perform sexually so you get depressed and anxious.”  
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Figure 4.7 Comparison of Frequency of Mentions of Lexapro Effects between Experts 
and Consumers, by Effect Category 
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Figure 4.8 Comparison of Most Frequently Mentioned Lexapro Effects between Experts 
and Consumers 
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Table 4.22  
Excerpts from Experts and Consumers on Selected Mental/Mood Effects of Lexapro 
Effects: Symptoms new/worsened; Suicidal thinking/planning 
 
WebMD (Expert) “Tell the doctor immediately if you notice worsening 
depression/other psychiatric conditions, unusual behavior changes 
(including possible suicidal thoughts/attempts), or other mental/mood 
changes (including new/worsening anxiety, panic attacks, trouble 
sleeping, irritability, hostile/angry feelings, impulsive actions, severe 
restlessness, very rapid speech)” 
 
“Tell your doctor immediately if any of these unlikely but serious 
side effects occur: unusual or severe mental/mood changes (e.g., 
nervousness, unusual high excitement/energy, rare thoughts of 
suicide)…” 
 
RevHealth 
(Expert) 
“Call your doctor at once if you have any new or worsening 
symptoms such as: mood or behavior changes, anxiety, panic attacks, 
trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, 
aggressive, restless, hyperactive (mentally or physically), more 
depressed, or have thoughts about suicide or hurting yourself”  
 
AskaPatient  “And then the worst crippling panic attacks I have ever had to date” 
(#8) 
 
“I got even more depressed that I EVER WAS, even before taking 
the med” (#33) 
 
“I seemed to become more aggressive and assertive. I would just 
speak my mind whenever I got angry, and had no fear. I seemed to 
become more “mean” and “mad” and I just didn’t like myself” (#41) 
 
CrazyMeds “had some hypomania then extreme agitation then suicidality. The 
agitation was awful, felt like I was going to jump out of my skin – 
and my mind was racing.” (#172) 
 
“2 hours of alternating panic attacks/crying jags” (#130) 
 
RevHealth 
(Consumers) 
“A couple of days later I had my first manic experience which lasted 
about 30 minutes of complete reckless driving, I probably should 
have gotten arrested. And a few minutes later I came down into deep 
depression” (#258) 
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WebMD 
(Consumers) 
“I have been very hostile and irritable on this med and my panic 
attacks have been coming more often and they have been much 
worse! I have no patience with my kids or my fiancé, or basically 
anyone around me.” (#364) 
 
Table 4.23  
Comparison of Experts and Consumers on “Appetite and Weight Effects” of Lexapro 
 % of mentions out of 
all “weight and 
appetite effects” 
Description of effect 
Code Experts Consumers WebMD Rev 
Health 
% of consumers 
mentioning effect; 
description of effect 
Increased 
appetite/ 
cravings 
20% 16.8% “rare”      
& “less 
severe” 
-- 4.2% 
Weight 
gain 
20% 50.3% -- “less 
serious” 
(weight 
changes) 
13.1% 
absolutely 
ravenous;  
out of 
control; 
hugest 
problem of 
all;  
no relief 
even with 
exercise 
Loss of 
appetite 
40% 16.1% “common” 
& “less 
severe” 
-- 4.8% 
Weight 
loss 
20% 16.8% -- “less 
serious” 
(weight 
changes) 
4.8% 
better 
control over 
appetite; 
an extra 
bonus; 
good for 
now; 
hope it 
continues 
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Table 4.24  
Comparison of Experts and Consumers on “Sexual Effects” of Lexapro 
 % of mentions out of 
all “sexual effects” 
Description of effect 
Code Experts Consumers WebMD Rev 
Health 
Consumers 
Lost sex 
drive 
22.2% 42.2% “unlikely 
but serious” 
-- Mentioned 
by 10.6% 
of 
consumers 
Trouble 
achieving 
orgasm 
33.3% 37.0% “common” 
& “less 
severe” 
“less 
serious”
Mentioned 
by 8.5% of 
consumers 
Other 
sexual 
effects      
(i.e., 
“sexual 
problems”) 
44.4% 11.9% “infrequent” 
& “less 
severe” 
-- Mentioned 
by 3.1% of 
consumers 
the absolute 
worst; 
really suck; 
very 
bothersome; 
extremely 
frustrating; 
bad; 
this is crazy 
 
Seroquel. 
  Figure 4.9 compares the frequency of mentions of effects by experts and consumers 
according to effect categories. Experts and consumers both mentioned effects within the 
mental or mood category more frequently than effects in any other category, though the 
rate was considerably higher in the consumer group (39.3% vs. 23.9%). The second 
highest rate of mentions was musculoskeletal/neurological effects by experts, and sleep 
effects by consumers. Rates of mentions were most similar (though not exactly 
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comparable) between the two groups for gastrointestinal/urinary effects, sexual effects, 
skin effects, and head/face effects.   
 Figure 4.10 compares experts and consumers on the most frequently mentioned 
individual effects from both groups. There were large discrepancies for effects related to 
sleep, symptom improvement, and weight gain, with consumers far more frequently 
mentioning these effects. The effect “helps me sleep,” reflecting the use of Seroquel as a 
sleep aid, was not at all mentioned in the expert group. There were less extreme 
discrepancies in the effects most often mentioned by experts, including 
dizzy/lightheaded/faint, vision/eye changes, weakness, and suicidal thinking/planning.  
Experts and consumers had somewhat comparable rates of mentions for three 
effects: brain fog/zombie (3.6% and 5.6% of mentions, respectively), abnormal 
movements (4.2% and 3.5% of mentions), and other miscellaneous effects (3.6% and 
1.7% of mentions). The physical effect, abnormal movements, was also similarly 
described by both groups. Experts listed “jerky muscle movements you cannot control,” 
“involuntary quivering,” and “abnormal movements” among other terms, and consumers 
reported phrases such as “body jerks,” “restless legs,” “twitches,” “tremors,” and 
“involuntary movements.” There were, however, differences between experts and 
consumers in describing the mental/mood effect of brain fog/zombie. Table 4.25 provides 
a representative selection of excerpts coded “brain fog/zombie” from each website. Most 
notably, the expert text stated the effect technically, while the consumer text provided 
examples of the possible impact and consequence of the effect on an individualized level.  
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Tables 4.26 and 4.27 compare experts and consumers on the frequency of 
mentions and descriptions of Seroquel’s sleep effects. Consumers’ attention was divided 
evenly between extreme sleepiness/tired and helps me sleep, as measured both by the 
frequency of mentions out of all sleep effects and the percentage of consumers who 
reported the effect. Experts most frequently mentioned extreme sleepiness, followed by 
trouble sleeping/insomnia, and labeled each as less severe/serious. In contrast to 
WebMD’s description of both of these effects as frequent, approximately 33% of 
consumers mentioned extreme sleepiness while only 2.3% of consumers reported trouble 
sleeping. Additionally, the sample excerpts of selected sleep effects in Table 4.27 show a 
qualitatively different understanding of these effects between experts and consumers. 
While experts cited “drowsiness” and “tiredness” as possible effects of Seroquel, 
consumers reported “coma like sleep,” “extreme sleeping,” and being “unwakable” for 
many hours. This same effect was described by consumers as both helpful and unhelpful 
depending on the context and circumstance of the consumer’s life. 
Figure 4.9 shows that out of all mentions of effects according to category, 8.6% of 
mentions in the expert group fell under the category “lab tests and chronic conditions.” 
This was the least frequently mentioned category of effects by consumers, taking only 
0.5% of consumers’ mentions, and just over 7% of consumers mentioned an effect within 
this category at all. Within this category, Table 4.28 shows that most attention was given 
by experts and consumers to increased blood sugar and diabetes (33% and 50% of 
mentions within the category, respectively). Effects on the liver were not mentioned in 
any expert text, but were reported by a small fraction of consumers (0.8%).  
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Table 4.28 also demonstrates an inconsistency in reporting among expert 
websites. RevolutionHealth only listed 1 of the 6 effects falling under this category, and 
did not attach a description or label to blood sugar high/diabetes. WebMD cited an 
increase in blood sugar as an infrequent effect in one paragraph and as a rare effect in 
another paragraph. On both occasions the effect was labeled severe or potentially severe. 
Other effects listed as infrequent or rare by WebMD were mentioned by relatively few 
consumers, but increased blood sugar/diabetes was mentioned by considerably more 
(4.8% of consumers) and received much greater attention (50% of mentions within this 
category, and 1.7% of mentions within all drug effects).  
For each of the 2 drugs, both experts and consumers gave the most attention to 
mental or mood effects. Consumers most frequently mentioned positive and negative 
changes in mental or mood symptoms, along with sleep and weight effects. Expert text 
more often attended to negative changes in mental or mood symptoms, such as suicide 
and agitation, along with other physical effects, like nausea/vomiting. Expert text tended 
to list possible mental or mood effects in summary form, while consumer text provided 
context and situational examples. There were clear and major differences in how effects 
were described by each group. For example, expert descriptions of “less serious” did not 
match consumer descriptions of “the worst” for certain weight and sexual effects. 
Similarly, expert frequency estimates of “common” and “infrequent” were not 
proportional to the rate of mentions in consumer text, especially for sleep effects of 
Seroquel and sexual effects of Lexapro. However, since the consumer rate of mention 
does not equal frequency of the effect, the latter finding might again only reflect 
consumers’ perceived severity.   
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Figure 4.9 Comparison of Frequency of Mentions of Seroquel Effects between Experts 
and Consumers, by Effect Category 
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Figure 4.10 Comparison of Most Frequently Mentioned Seroquel Effects between 
Experts and Consumers 
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Table 4.25  
Excerpts from Experts and Consumers on “Brain Fog/Zombie” Effect of Seroquel 
Effect: Brain fog/zombie 
 
WebMD (Expert) “Common side effects…. Difficulty speaking…………….Severe” 
 
RevHealth 
(Expert) 
Quetiapine can cause side effects that may impair your thinking or 
reactions” 
 
“Other serious side effects include:… confusion, problems with 
vision, speech, or balance” 
 
AskaPatient  “With this drug I cannot function the next day, I have a foggy mind 
and feel I just cannot move around” (#514) 
 
CrazyMeds “…slow, dumb, exhausted” (#603) 
 
“It just put me in total zombie land, and caused me to fall asleep with 
my eyes open a few times” (#657) 
 
“I could intermittently find myself someplace and have no idea why I 
was there or what I was doing… I have never experienced such a 
profound blankness. I found myself in the walk-in closet, and had to 
deduce why I might be in there… ‘Ok, I am completely dressed, so 
I’m not doing that…’” (#634) 
 
RevHealth 
(Consumers) 
“decreasing mental acuity, decreased gross motor function, excessive 
fine motor tremor, your basic zombie” (#747) 
 
“my mind went all numb and I couldn’t think straight” (#781) 
 
WebMD 
(Consumers) 
“I wake up in the morning feeling sluggish and drugged. On some 
days I have such a hard time shaking the fogginess off that I am 
completely withdrawn” (#905) 
 
“It also makes it hard to communicate as well. If someone asks me 
something after taking it I’m very incoherent” (#941) 
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Table 4.26  
Comparison of Experts and Consumers on “Sleep Effects” of Seroquel 
 % of all mentions of 
“sleep effects” 
Expert description  
Code Experts Consumers WebMD Rev 
Health 
% of consumers 
mentioning the 
effect 
Extreme 
sleepiness/ 
tired 
66.7% 45.1% “common” & 
“less severe” 
“less 
serious” 
33.1% 
Helps me 
sleep 
0% 44.7% -- -- 35.6% 
Trouble 
sleeping/ 
insomnia 
33.3% 2.6% “common” & 
“less severe” 
No 
description 
2.3% 
Difficult to 
wake up 
0% 7.7% -- -- 6.3% 
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Table 4.27  
Excerpts from Experts and Consumers on Selected “Sleep Effects” of Seroquel 
Effects: Helps me sleep; Extreme sleepiness/tired 
 
WebMD (Expert) “Common side effects: drowsiness……………Less Severe” 
 
“tiredness” 
 
RevHealth 
(Expert) 
“The following warnings are available for this medication:…. May 
cause drowsiness” 
 
AskaPatient  “So while it does provide me sleep…it’s the kind of sleep that 
wouldn’t allow me to be woken, even if my house is on fire. I am not 
able to be woken from this coma like sleep for hours. That scares 
me.” (case #515) 
 
“extreme sleeping” (#570) 
 
CrazyMeds “I like what this drug does to me (sleepy bye bye land)” (#613) 
 
“You’ll sleep until next Tuesday. Of course, that could be a good 
thing, depending on how your life is at this moment” (#1084) 
 
RevolutionHealth “Seroquel puts me to sleep. It’s that simple. I take it and within an 
hour I’m out – unwakable – for the next 12 or more hours” (#739) 
 
“helped very, very effectively with sleep: 30 minutes max after 
taking 125-150mg at night, I am out for good” (#808) 
 
“the worst side effect is the sleepiness – I sleep 10-12 hours a day 
and still have periods when I have to nap (or could fall asleep 
standing up)” (#773) 
 
WebMD “It helped me sleep very well, but I was very groggy in the morning” 
(#871) 
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Table 4.28  
Comparison of Experts and Consumers on “Lab Tests and Chronic Conditions” 
Mentioned for Seroquel 
 % of all mentions of 
“lab tests and 
chronic conditions” 
Expert description 
  
Expert 
 
Consumers
 
WebMD 
 
Rev 
Health 
 
% of 
consumers 
mentioning 
the effect 
Blood sugar 
high/diabetes 
33.3% 51.0% “infrequent”/“rare” 
& “severe” (Blood 
sugar);   
“rare” & “severe” 
(Diabetes) 
Not 
described 
4.8% 
Other labs or 
chronic conditions 
26.7% 13.7% “infrequent”/“rare” 
& “less severe”/ 
“severe” 
-- 1.5% 
Blood related 
changes 
13.3% 2.0% “rare” & “severe” -- 0.2% 
Cholesterol high 13.3% 11.8% “infrequent” & 
“less severe” 
-- 0.6% 
Blood pressure 
changes 
13.3% 11.8% “common”/ 
“infrequent” & 
“less 
severe”/“severe” 
-- 1.3% 
Liver 
levels/hepatoxicity/ 
hepatitis 
0% 9.8% -- -- 0.8% 
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Drug Effects by Variables 
Lexapro and gender. 
 Male and female consumers reported similar effects of Lexapro across all drug effect 
categories, except for sexual effects (Table 4.29) where more males (41.6%) than females 
(17.1%) mentioned an effect. Table 4.30 compares consumers who did and did not report 
gender across drug effect categories, and shows a significant difference at the p<0.002 
level (corrected for multiple comparisons) for appetite and weight effects, and mental or 
mood effects. Each category was reported more frequently by consumers who did report 
gender. Table 4.31 further compares each gender to those who did not report gender for 3 
categories of effects. Both appetite and weight effects, and mental or mood effects were 
significantly different only for females (p=0.001 and 0.000, respectively). Sexual effects 
were tested because they approached significance in the previous comparison, and were 
found here to only significantly differ for males (p=0.000).  
Lexapro and age. 
 There were no significant differences in the proportion of consumers in 3 age brackets 
(7-24, 25-44, and 45+) who mentioned an effect of Lexapro according to effect category 
(Table 4.32). Considerably fewer consumers in the 45+ age bracket (56.9%) reported 
mental or mood effects compared to 7-24 year old consumers (75.6%) and 25-44 year old 
consumers (73.3%). Each age group reported appetite and weight effects more frequently 
than those who did not report their age, though the rate was highest for the youngest age 
group (33.3%). Other differences included a slightly higher reporting of sleep effects in 
the youngest age group (51.1%) and middle age group (43.5%), compared to the oldest 
age group (31.9%) and those who did not report their age (29.7%). The middle age group 
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had the highest proportion of consumers reporting musculoskeletal and neurological 
effects (18.3%), compared to the youngest age group (8.9%) and those who did not report 
their age (9.1%). Table 4.33 compares consumers who did and did not report age across 
drug effect categories. Two categories reached statistical significance at the p<0.003 level 
(corrected for multiple comparisons), and in each case more consumers who did provide 
their age reported effects in these categories. 
Lexapro and length of time taken. 
 Table 4.34 compares reported effects of Lexapro in effect categories by the length of 
time the consumer had been taking the drug. To minimize empty and small cells, time 
categories were collapsed into 2 groups: consumers taking the drug for less than 6 
months, and longer than 6 months. Three of the 10 effect categories were significantly 
different between groups, and each was reported more frequently by consumers taking 
Lexapro for less than 6 months. These categories included “side effects” that would be 
expected to resolve over time. Also, it would be unlikely for individuals experiencing 
many of these effects to remain on the drug if the effects persisted for longer than 6 
months. Most of the categories that did not show a significant difference between groups, 
particularly sexual effects, appetite and weight effects, and mental or mood effects, 
would generally be sustained over time and not expected to disappear as part of the initial 
“side effects” of Lexapro.  
 Table 4.35 compares drug effect categories by consumers who did and did not report 
how long they had been taking Lexapro. Three of the categories were significantly 
different between groups at the p<0.003 level. Similar to the gender and age variables, 
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consumers who did provide the length of time taking Lexapro reported these effects at a 
higher rate than those who did not provide that information.  
Table 4.29  
Gender of Consumers who Mentioned an Effect of Lexapro According to Drug Effect 
Categorya 
 Female 
(N=215) 
Male 
(N=77) 
Chi-
square 
p-
value 
Sexual Effects 37 (17.1%) 32 (41.6%) 18.816 0.000 
Appetite and Weight Effects 63 16 2.028 0.154 
Other Effects 34 8 1.324 0.250 
Musculoskeletal and Neurological 
Effects 28 13 0.725 0.395 
Mental or Mood Effects 154 51 0.692 0.405 
Head or Face Effects 30 13 0.406 0.524 
Nose Throat Chest Effects 18 8 0.297 0.586 
Gastrointestinal and Urinary Effects 35 12 0.016 0.899 
Sleep Effects 83 30 0.007 0.934 
ap-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31 
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Table 4.30  
Reporting of Gender and Drug Effect Category for Lexaproa  
  
Gender given 
(N=292) 
Gender not given 
(N=188) 
Chi-
square 
p-
value 
Mental or Mood Effects 205 (70.0%) 91 (48.7%) 21.914 0.000 
Appetite and Weight Effects 79 (27.0%) 28 (15.0%) 9.472 0.002 
Sexual Effects 69 (23.5%) 27 (14.4%) 5.922 0.015 
Sleep Effects 113 59 2.444 0.118 
Musculoskeletal and 
Neurological Effects 41 18 2.02 0.155 
Other Effects 42 34 1.268 0.260 
Skin Effects 25 11 1.156 0.282 
Nose Throat Chest Effects 26 12 0.945 0.331 
Head or Face Effects 43 24 0.322 0.570 
Gastrointestinal and Urinary 
Effects 47 32 0.095 0.758 
ap-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31 
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Table 4.31  
Male and Female Consumers Compared to Those Who Did Not Report Gender on Drug 
Effects for Selected Categories of Lexaproa 
 
Female 
(N=215) 
Gender not given 
(N=188) 
Chi-
square 
p-
value 
Appetite and Weight 
Effects 63 (29.2%) 28 (15.0%) 11.55 0.001 
Mental or Mood Effects 154 (71.3%) 91 (48.7%) 21.541 0.000 
Sexual Effects 37 27 0.543 0.461 
 
Male      
(N=77) 
Gender not given 
(N=188)   
Appetite and Weight 
Effects 16 28 1.324 0.25 
Mental or Mood Effects 51 (66.2%) 91 (48.7%) 6.774 0.009 
Sexual Effects 32 (41.6%) 27 (14.4%) 23.116 0.000 
ap-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31 
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Table 4.32  
Age of Consumers Who Mentioned an Effect of Lexapro According to Drug Effect 
Categorya 
 
7-24 yrs 
(n=45) 
25-44 yrs 
(n=131) 
45+ yrs 
(n=72) 
Chi-
square 
p-
value 
Mental or Mood Effects 34 (75.6%) 96 (73.3%) 41 (56.9%) 6.913 0.032 
Sleep Effects 23 (51.1%) 57 (43.5%) 23 (31.9%) 4.637 0.098 
Head or Face Effects 9 22 7 2.718 0.257 
Musculoskeletal and 
Neurological Effects 4 (8.9%) 24 (18.3%) 10 (13.9%) -- -- 
Other Effects 4 21 14 -- -- 
Sexual Effects 13 32 13 1.982 0.371 
Skin Effects 6 11 5 1.475 0.478 
Appetite and Weight 
Effects 15 (33.3%) 37 (28.2%) 17 (23.6%) 1.328 0.515 
Gastrointestinal and 
Urinary Effects 6 24 10 0.992 0.609 
Nose Throat Chest Effects 5 11 9 0.927 0.629 
ap-values set at 0.003 for k=18 comparisons involving age in Tables 4.32 and 4.33 
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Table 4.33  
Reporting of Age by Drug Effect Category for Lexaproa 
 
Age given 
(n=248) 
Age not given 
(n=232) 
Chi-
square 
p- 
value 
Mental or Mood Effects 171 (69.0%) 125 (53.9%) 11.519 0.001
Appetite and Weight Effects 69 (27.8%) 38 (16.4%) 9.061 0.003
Sleep Effects 103 (41.5%) 69 (29.7%) 7.248 0.007
Musculoskeletal and 
Neurological Effects 38 (15.3%) 21 (9.1%) 4.372 0.037
Sexual Effects 58 38 3.679 0.055
Nose Throat Chest Effects 25 13 3.296 0.069
Skin Effects 22 14 1.39 0.238
Head or Face Effects 38 29 0.795 0.373
Gastrointestinal and Urinary 
Effects 40 39 0.04 0.841
Other Effects 39 37 0.004 0.947
ap-values set at 0.003 for k=18 comparisons involving age in Tables 4.32 and 4.33 
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Table 4.34  
Consumers Taking Lexapro According to Length of Time Taken and Drug Effect 
Categorya 
  
Taken <6 months 
(n=228) 
Taken >6 months 
(n=140) 
Chi-
square 
p-
value 
Musculoskeletal and 
Neurological Effects 45 (19.7%) 9 (6.4%) 12.27 0.000 
Gastrointestinal and Urinary 
Effects 59 (25.9%) 7 (5.0%) 25.686 0.000 
Head or Face Effects 50 (21.9%) 9 (6.4%) 15.482 0.000 
Sleep Effects 107 (46.9%) 45 (32.1%) 7.823 0.005 
Nose Throat Chest Effects 28 (12.3%) 7 (5.0%) 5.343 0.021 
Skin Effects 26 (11.4%) 7 (5.0%) 4.357 0.037 
Sexual Effects 46 35 1.176 0.278 
Appetite and Weight Effects 63 36 0.162 0.687 
Mental or Mood Effects 159 95 0.143 0.705 
Other Effects 37 24 0.052 0.819 
ap-values set at 0.003 for k=18 comparisons involving time taken in Tables 4.34 and 4.35 
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Table 4.35  
Reporting Length of Time Taking Lexapro According to Drug Effect Categorya 
  
Time taken 
given (n=368) 
Time taken not 
given (n=112) 
Chi-
square 
p-
value 
Appetite and Weight Effects 99 (26.9%) 8 (7.1%) 19.353 0.000 
Sleep Effects 152 (41.3%) 20 (17.9%) 20.531 0.000 
Mental or Mood Effects 254 (69.0%) 42 (37.5%) 36.093 0.000 
Musculoskeletal and 
Neurological Effects 54 (14.7%) 5 (4.5%) 8.302 0.004 
Head or Face Effects 59 (16.0%) 8 (7.1%) 5.65 0.017 
Nose Throat Chest Effects 35 3 -- -- 
Skin Effects 33 3 -- -- 
Sexual Effects 81 15 3.986 0.046 
Other Effects 61 15 0.653 0.419 
ap-values set at 0.003 for k=18 comparisons involving time taken in Tables 4.34 and 4.35 
 
Seroquel and gender. 
 Male and female consumers did not differ in reported effects (grouped by category) for 
Seroquel (Table 4.36). Table 4.37 further shows no differences at the p<0.003 level 
between consumers who did give their gender compared to those who did not give that 
information. 
Seroquel and age. 
 Reported effects of Seroquel grouped by category did not differ significantly (p<0.003) 
between the age brackets of 7-24, 25-44, and 45+ years old (Table 4.38) or between 
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consumers who did report their age and those who did not report that information (Table 
4.39). Similar to trends in Lexapro data, the youngest age category mentioned appetite 
and weight effects (40.9%) and sleep effects (72.7%) more often than the other age 
groups and those who did not report age.  
Seroquel and length of time taken. 
 Table 4.40 compares effect categories for Seroquel by the length of time consumers had 
taken the drug (less than and more than 6 months). Significantly more consumers taking 
Seroquel for longer than 6 months mentioned appetite and weight effects (44.7% versus 
27.5%) and lab tests and chronic conditions (13.7% versus 3.0%) at the p<0.003 level. 
Two effect categories were significantly different between consumers who did provide 
the length of time taking Seroquel and those who did not give that information (Table 
4.41). Consumers taking Seroquel for less than or more than 6 months all reported sleep 
effects (62.9% and 69.6%, respectively) at a higher rate than consumers who did not 
provide the time taken (48.7%).   
 In sum, a high number of consumers not reporting the above variables prevented a 
detailed examination of differences in drug effects by gender, age, and time taken. 
Instead, comparisons were made according to broader drug effect categories. The primary 
finding was that the more information consumers provided, the more likely the consumer 
was to report a drug effect. In general, there were fewer differences for Seroquel than for 
Lexapro in reported effects by each of the 3 variables. Men were more likely than women 
to mention sexual effects of Lexapro. There were no differences between the genders for 
effects of Seroquel. The youngest age group tended to more frequently mention sleep and 
weight effects for both drugs. Finally, more consumers reported what appeared to be 
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initial “side effects” of Lexapro, whereas more reported sustained effects lasting longer 
than 6 months (i.e., weight and blood sugar) of Seroquel.  
Table 4.36  
Gender of Consumers Who Mentioned an Effect of Seroquel According to Drug Effect 
Categorya 
  
Female 
(N=207) 
Male 
(N=91) 
Chi-
square 
p-
value 
Musculoskeletal and Neurological 
Effects 51 14 3.173 0.075 
Other Effects 37 10 2.256 0.133 
Head or Face Effects 11 9 2.114 0.146 
Skin Effects 12 2 -- -- 
Sexual Effects 2 (1.0%) 2 (2.2%) 0.724 0.395 
Gastrointestinal and Urinary Effects 14 4 -- -- 
Sleep Effects 132 54 0.528 0.467 
Mental or Mood Effects 111 52 0.316 0.574 
Nose Throat Chest Effects 26 10 0.147 0.701 
Lab Tests and Chronic Conditions 18 9 0.109 0.741 
Appetite and Weight Effects 70 (33.8%) 31 (34.1%) 0.002 0.967 
ap-values set at 0.002 for k=18 comparisons involving gender in Tables 4.36 and 4.37 
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Table 4.37  
Reporting Gender by Drug Effect Category for Seroquela  
  
Gender given 
(N=298) 
Gender not given 
(N=182) 
Chi-
square 
p-
value 
Musculoskeletal and 
Neurological Effects 65 (21.8%) 22 (12.1%) 7.2 0.007 
Lab Tests and Chronic 
Conditions 27 (9.1%) 7 (3.8%) 4.668 0.031 
Skin Effects 14 2 -- -- 
Appetite and Weight Effects 101 47 3.449 0.063 
Gastrointestinal and Urinary 
Effects 18 6 1.791 0.181 
Nose Throat Chest Effects 36 15 1.753 0.185 
Head or Face Effects 20 7 1.747 0.186 
Sleep Effects 186 105 1.056 0.304 
Mental or Mood Effects 163 91 1.001 0.317 
Sexual Effects 4 2 -- -- 
Other Effects 47 30 0.042 0.837 
ap-values set at 0.003 for k=18 comparisons involving gender in Tables 4.36 and 4.37 
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Table 4.38  
Age of Consumers Who Mentioned an Effect of Seroquel According to Drug Effect 
Categorya 
 
7-24 yrs 
(n=44) 
25-44 yrs 
(n=119) 
45-75+ yrs 
(n=82) 
Chi-
square 
p-
value 
Appetite and Weight 
Effects 18 (40.9%) 41 (34.5%) 29 (35.4%) 0.598 0.742 
Gastrointestinal and 
Urinary Effects 2 10 2 -- -- 
Head or Face Effects 6 6 6 3.486 0.175 
Lab Tests and Chronic 
Conditions 5 4 10 -- -- 
Mental or Mood Effects 25 68 42 0.752 0.686 
Musculoskeletal and 
Neurological Effects 9 29 13 2.14 0.343 
Nose Throat Chest Effects 7 (15.9%) 14 (11.8%) 12 (14.6%) 0.617 0.735 
Other Effects 5 21 10 1.626 0.444 
Skin Effects 2 6 4 -- -- 
Sleep Effects 32 (72.7%) 74 (62.2%) 52 (63.4%) 1.621 0.445 
ap-values set at 0.003 for k=16 comparisons involving age in Tables 4.38 and 4.39 
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Table 4.39  
Reporting Age by Drug Effect Category for Seroquela  
 
Age given 
(n=245) 
Age not given 
(n=235) 
Chi-
square 
p- 
value 
Appetite and Weight Effects 88 (35.9%) 60 (25.5%) 6.068 0.014 
Nose Throat Chest Effects 33 (13.5%) 18 (7.7%) 4.264 0.039 
Skin Effects 12 4 -- -- 
Sleep Effects 158 133 3.131 0.077 
Head or Face Effects 18 9 2.795 0.095 
Musculoskeletal and 
Neurological Effects 51 36 2.443 0.118 
Mental or Mood Effects 135 119 0.959 0.327 
Other Effects 36 41 0.675 0.411 
Gastrointestinal and Urinary 
Effects 14 10 0.538 0.463 
Lab Tests and Chronic 
Conditions 19 15 0.343 0.558 
ap-values set at 0.003 for k=16 comparisons involving age in Tables 4.38 and 4.39 
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Table 4.40  
Consumers Taking Seroquel by Length of Time Taken and Drug Effect Categorya 
  
Taken <6 months 
(n=167) 
Taken >6 months 
(n=161) 
Chi-
square 
p-
value 
Lab Tests and Chronic 
Conditions 5 (3.0%) 22 (13.7%) 12.356 0.000 
Appetite and Weight Effects 46 (27.5%) 72 (44.7%) 10.499 0.001 
Musculoskeletal and 
Neurological Effects 40 (24.0%) 28 (17.4%) 2.147 0.143 
Gastrointestinal and Urinary 
Effects 13 7 1.691 0.193 
Sleep Effects 105 (62.9%) 112 (69.6%) 1.639 0.2 
Nose Throat Chest Effects 25 (15.0%) 19 (11.8%) 0.709 0.4 
Other Effects 26 30 0.544 0.461 
Mental or Mood Effects 96 87 0.395 0.53 
Skin Effects 7 9 0.345 0.557 
Head or Face Effects 12 12 0.009 0.926 
Sexual Effects 2 2 -- -- 
ap-values set at 0.003 for k=17 comparisons involving time taken in Tables 4.40 and 4.41 
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Table 4.41  
Reporting Length of Time Taking Seroquel by Drug Effect Categorya 
  
Time taken 
given (n=328) 
Time taken not 
given (n=152) 
Chi-
square 
p-
value 
Appetite and Weight Effects 118 (36.0%) 30 (19.7%) 12.843 0.000 
Sleep Effects 217 (66.2%) 74 (48.7%) 13.286 0.000 
Nose Throat Chest Effects 44 (13.4%) 7 (4.6%) 8.488 0.004 
Musculoskeletal and 
Neurological Effects 68 (20.7%) 19 (12.5%) 4.743 0.029 
Skin Effects 16 0 -- -- 
Head or Face Effects 24 3 -- -- 
Mental or Mood Effects 183 71 3.439 0.064 
Gastrointestinal and Urinary 
Effects 20 4 -- -- 
Lab Tests and Chronic 
Conditions 27 7 2.075 0.15 
Other Effects 56 21 0.818 0.366 
Sexual Effects 4 2 -- -- 
ap-values set at 0.003 for k=17 comparisons involving time taken in Tables 4.40 and 4.41 
 
Themes Mentioned by Consumers 
Overview of theme categories. 
 Themes around drugs and drug use were grouped in the umbrella category “My Drug,” 
which was divided into 7 main categories under which codes fell (see codebook in 
Appendix D). While coding for drug effects was restricted to Lexapro and Seroquel only, 
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use of codes within “My Drug” were open to any general or specific comments about 
drug use. The first category was “Assessing the Overall Experience,” reflecting 
consumers’ weighing of benefits and costs of the drug. Two codes in this category, 
“Lexapro/Seroquel is a miracle/saved my life” and “I hate Lexapro/Seroquel,” were the 
only codes under “My Drug” that solely included comments specific to the drugs under 
study (Table 4.42). The second category was “Dealing with Side Effects/Finding 
Optimum Effectiveness,” reflecting consumers’ attempts and strategies for counteracting 
drugs’ side effects and/or for enhancing drugs’ effectiveness. The next category, “Do I 
Need Meds?” included consumers’ comments about wanting to remain on or quit drug 
treatment for their problems, desires or attempts at alternative non-drug treatments, and 
reflections on how drugs have affected them. The fourth category, “Evidence,” involved 
consumers’ attempts to decipher the exact nature and cause of a particular effect they 
experienced, and also included comments about the lack of research on a use, effect, or 
other aspect of a drug. The “Other Drug Issues” category included various other codes 
involving drug dependence and withdrawal, dosing issues, miscellaneous descriptions of 
symptoms related to a diagnosis, comparisons of brand versus generic drugs, and the 
phenomenon of drug effects weakening or changing over time. The sixth category was 
“Other Drugs and Drug Combinations,” which included comments about effects of drugs 
other than Lexapro and Seroquel, recommendations for or warnings against specific drug 
combinations, and lists of consumers’ current and past drug regimens. The final category 
under “My Drug” was “Theories of Drug Action,” reflecting consumers’ comments about 
how drugs work in their brains or bodies. 
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 In addition to the “My Drug” umbrella category, there were 5 other smaller categories 
called: “My Doctor,” “Finances/The System,” “Family and Friends,” “Pharmaceutical 
Companies/FDA,” and “Support and Advice.” The final codebook included 6 codes 
under “My Doctor,” all of which reflected some type of interaction, conflict, or question 
related to doctors. The “Finances/The System” category included comments related to the 
expense or affordability of drugs, insurance-related issues, involuntary hospitalization 
and forced medication, and other comments about navigating through hospitals and “the 
system.” All comments about family and friends fell under the appropriately named 
category. This included stories about a drug’s effect on a family member or friend, a drug 
effect that a family member or friend observed in the consumer, and situational 
information related to having supportive or unsupportive family and friends. Codes 
falling under the “Pharmaceutical Companies/FDA” category included statements about 
the FDA approval status of a drug or indication, and remarks about the business interests 
of pharmaceutical companies in making and marketing drugs. Finally, comments from 
consumers who were worried about possible drug effects or who were seeking the 
experiences or advice of other users were coded under the “Support and Advice” 
category.   
My drug: Assessing the overall experience. 
 Table 4.42 shows the frequency of consumers within each of the 5 websites who 
mentioned a code in this category. Specific to Lexapro and Seroquel, slightly more 
consumers described these drugs as “a miracle/saved my life” (10.9%) than the opposite, 
“I hate this drug” (8.0%). This ratio remained true across all websites, except for 
AskaPatient where an almost even number of consumers described the drugs both ways.  
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 The remaining codes in this category included comments about any drug experience, 
and so were not specific to Lexapro and Seroquel. Comments were also coded in this 
category only if there was a clear assessment or weighing of benefits and costs of a drug. 
Again, a slightly higher percentage of consumers across all websites described the 
benefits of a drug’s use outweighing its costs (9.4% versus 7.3%). However, the largest 
percentage of consumer comments within this category described drugs’ limited 
helpfulness (15.3%). Neither benefits nor costs necessarily outweighed one another, but 
rather the drug was “just okay,” “not my wonder drug,” or the drug had no discernable 
effect either way.  Finally, “YMMV” or “your mileage may vary” was a popular slogan, 
especially among the consumer discussion forums, and meant that each individual is 
different and may have a different experience or come to a different assessment from the 
one being described. It was often used as a caveat so as not to discourage or overly 
encourage readers about trying a particular drug.  
 Table 4.43 provides a comparison of these codes with websites grouped according to 
their status as expert- or consumer-constructed. Statistical significance was reached for 
only 1 code, “YMMV,” due to its predominance on the 2 consumer discussion forums.  
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Table 4.42  
Frequency of Consumers Within Each Website Who Mentioned a Code Within the 
Category “Assessing the Overall Experience” 
 All 
consumers
(N=1080) 
Ask a 
Patient 
(N=220)
Crazy 
Meds 
(N=220)
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
 
(N=220)
Lexapro/Seroquel is 
a miracle/saved my 
life/I recommend ita 
10.9% 13.3% 6.3% -- 12.5% 11.7% 
I hate 
Lexapro/Seroquel/ 
Stay away from ita 
8.0% 13.8% 2.9% -- 6.3% 9.2% 
All in all, I am 
positive/ Side effects 
tolerableb 
9.4% 8.8% 12.5% 9.2% 11.3% 5.4% 
Not worth it/ Side 
effects too greatb 
7.3% 7.5% 9.2% 6.7% 8.8% 4.2% 
No or limited 
helpfulness/ Not my 
wonder drugb 
15.3% 8.8% 20.0% 19.2% 20.0% 10.4% 
YMMV (Your 
mileage may vary)b 
7.3% 3.3% 14.2% 23.3% 2.1% 1.7% 
aFrequencies include only comments specifically referring to Lexapro or Seroquel; 
excludes comments from IcarusProjet 
bFrequencies include comments referring to any drug; not limited to comments only 
about Lexapro or Seroquel 
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Table 4.43  
Number of Consumers Mentioning Codes under “Assessing the Overall Experience,” 
According to Website Classification 
 Consumer-
constructed 
(N=600) 
Expert-
constructed 
(N=480) 
Chi-
square 
p-
value 
Lexapro/Seroquel is a 
miracle/saved my life/I 
recommend it 
47a 58 1.294 0.255 
I hate Lexapro/Seroquel/ Stay 
away from it 
40a 37 0.127 0.721 
All in all, I am positive/ Side 
effects tolerable 
62b 40 1.247 0.264 
Not worth it/ Side effects too great 48b 31 0.935 0.334 
No or limited helpfulness/ Not my 
wonder drug 
92b 73 0.003 0.955 
YMMV (Your mileage may vary) 70b 9 37.711 0.000 
a“Consumer-constructed” count includes consumers from AskaPatient and CrazyMeds 
(n=480) 
b“Consumer-constructed” count includes consumers from AskaPatient, CrazyMeds, and 
IcarusProject 
 
My drug: Dealing with side effects/finding optimum effectiveness. 
 Table 4.44 lists the frequencies of consumers who mentioned a code within the category 
“Dealing with Side Effects/Finding Optimum Effectiveness.” The top 4 strategies 
mentioned by the most total consumers were: wait to see if the side effect eventually goes 
away on its own (19.2%), stop taking the drug and/or switch to another drug (18.4%), 
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adjust the dosage of the drug (13.7%), and add another drug to counteract the side effect 
or to enhance the effectiveness of the current drug (10.4%).  
 Users of CrazyMeds mentioned each of these strategies more often than users of each of 
the other websites. While over 25% of users on CrazyMeds commented about or 
suggested adding another drug to a regimen, less than half of that percentage on any of 
the other 4 websites made similar comments or suggestions. In a similar pattern, 
CrazyMeds users commented more about mixing caffeine and alcohol with drugs, 
checking and monitoring blood levels, effects of and strategies for diet and exercise, and 
learning to simply accept and live with certain undesirable drug effects.  
 When websites were grouped according to their status as expert- or consumer-
constructed, 4 of the 11 strategies listed in Table 4.45 were statistically significantly 
different between groups (Table 4.45). All 4 were more often mentioned on consumer-
constructed sites than expert-constructed, though the difference for “add another med” 
was largely due to the predominance of that code on CrazyMeds. Users of the 3 
consumer-constructed sites more often commented on changes in diet and exercise to 
counteract side effects or enhance drug effectiveness, and the importance of starting on a 
low dose of a drug and titrating slowly up to the target dose. Few users on AskaPatient 
described “other methods,” so the statistically significant difference between groups is 
due to the more frequent use of this code on CrazyMeds and IcarusProject. Users of these 
discussion forums described such “other” strategies as crushing, cutting and scraping the 
coating of off pills to counteract over-sensitivities to some drugs, using Vaseline and 
other accessories to counteract certain sexual drug effects, and having friends or family 
nearby to talk them through a particularly intense mental or mood drug effect.  
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Table 4.44  
Frequency of Consumers Within Each Website Who Mentioned a Code Within the 
Category “Dealing with Side Effects/Finding Optimum Effectiveness,” Mentioned by at 
Least 3% of Consumers on Any Website 
  
All 
consumers 
(N=1080) 
Ask a 
Patient  
(N=220) 
Crazy 
Meds 
(N=220) 
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
 
(N=220) 
Add another med 10.4% 2.9% 25.4% 9.2% 10.4% 3.3% 
Avoid / Drink 
more 
caffeine/alcohol 
            
1.5% 
1.7% 4.6% 0.0% 0.4% 0.0% 
Changing time of 
day 
6.3% 
4.6% 10.8% 1.7% 8.8% 3.3% 
Check blood levels 1.4% 0.0% 4.2% 2.5% 0.4% 0.4% 
Diet / Food /  
Exercise 
7.6% 
7.9% 14.6% 7.5% 3.3% 4.6% 
Dose adjustment 13.7% 12.5% 20.8% 5.0% 16.7% 9.2% 
Learn to live with 
it 
1.6% 
0.0% 4.2% 1.7% 2.1% 0.0% 
Other methods 4.4% 0.4% 11.7% 6.7% 3.3% 0.8% 
Ride out the storm 
/ Eventually goes 
away / Waiting 19.2% 14.2% 27.1% 18.3% 25.8% 10.0% 
Switch meds / Stop 
med 
            
18.4% 14.6% 29.2% 11.7% 19.6% 13.8% 
Taper SLOWLY / 
Low starting dose 
            
6.8% 7.1% 10.8% 7.5% 5.4% 3.3% 
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Table 4.45  
Codes Under “Dealing with Side Effects/Finding Optimum Effectiveness” that Reached 
Statistical Significance (p<.05) According to Website Classification 
 Consumer-
constructed  
(N=600) 
Expert-
constructed 
(N=480) 
Chi-
square 
p-
value 
Add another med 79 33 11.357 0.001 
Diet / Food /  Exercise 63 19 16.265 0.000 
Other methods 37 10 10.682 0.001 
Taper SLOWLY / Low 
starting dose 52 21 7.793 0.005 
 
My drug: Do I need meds? 
 Table 4.46 shows the frequency of consumers who mentioned a code under the category 
“Do I Need Meds?” and Table 4.47 shows that each code reached statistical significance 
according to website classification (“Making a plan/Just in case…” was not included in 
the significance test because of empty cells). The most popular codes in this category 
were “Trying/tried alternative treatment” (mentioned by 8.0% of all consumers) and 
“Drugs won’t work/I’m done/I don’t need it” (7.4%). The former code included all 
comments about having tried, wanting to try, or recommendations to try a non-drug 
treatment, such as a psychotherapy, cognitive-behavioral therapy, group therapy, holistic 
therapies, and electro-convulsive therapy, among others. The latter code included 
comments from consumers who wanted to quit drug treatment altogether, who 
determined they no longer needed or wanted drug treatment, or who thought drug 
treatment was not working to solve their particular problems.  
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In contrast to the previous category where CrazyMeds dominated, the present 
category was dominated by users of IcarusProject. More users of IcarusProject (25.8%) 
than any other website commented that they wanted to quit or did not need drug 
treatment, however more users of this forum (11.7%) compared to the other sites also 
commented that drug treatment may be part of their long-term solution.  The code 
“Making a plan/Just in case…,” reflecting consumers’ making prevention, emergency, or 
back-up plans, was only brought up in the 2 consumer discussion forums and not on the 
other websites.  
Table 4.46  
Frequency of Consumers Within Each Website Who Mentioned a Code Within the 
Category “Do I Need Meds?” 
  
All 
consumers 
(N=1080) 
Ask a 
Patient  
(N=220) 
Crazy 
Meds 
(N=220) 
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
 
(N=220) 
Drugs won't work 
/ I'm done / I 
don't need it 
7.4% 4.6% 8.8% 25.8% 4.2% 2.9% 
Going back on 
meds / Meds may 
be the solution 3.1% 0.8% 4.2% 11.7% 2.5% 0.4% 
Looking 
back.../Since I 
stopped the 
med... 4.7% 3.3% 6.7% 12.5% 2.5% 2.5% 
Making a plan / 
Just in case... 1.6% 0.0% 3.3% 7.5% 0.0% 0.0% 
Trying/Tried 
alternative tx 8.0% 2.5% 8.8% 35.8% 5.4% 1.3% 
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Table 4.47  
Number of Consumers Mentioning Codes Under “Do I Need Meds?” According to 
Website Classification 
  
Consumer-
constructed  
(N=600) 
Expert-
constructed 
(N=480) 
Chi-
square 
p-
value 
Drugs won't work / I'm done / I 
don't need it 63 17 18.825 0.000 
Going back on meds / Meds 
may be the solution 26 7 7.441 0.006 
Looking back on it.../Since I 
stopped the med... 39 12 9.483 0.002 
Trying/Tried alternative 
treatment 70 16 26.268 0.000 
 
Other “My Drug” categories. 
 Table 4.48 provides the frequency of consumers mentioning a code within the 
remaining 4 categories under “My Drug,” as well as the most popular code within each 
category. Each of the categories and codes listed were dominated by users of the 2 
consumer discussion forums. Table 4.49 shows significance testing for these codes, 
except for “Theories of Drug Action” because of empty cells. Under the category 
“Evidence,” the code “drug or something else?” was mentioned by over 10% of all 
consumers. This code reflected the idea of uncertainty as to the nature or cause of an 
observed drug effect. Most often cited causes of a drug effect were the drug itself, other 
drugs the consumer was taking, lifestyle choices (diet, exercise, etc), a return of their 
mental illness, or a placebo effect. For example, in a review of Seroquel on AskaPatient, 
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a consumer noted, “I do have some memory and concentration problems, but these could 
be related to 25 years with depression and bipolar disorder, or to the other meds I take 
(Wellbutrin 400mg, Depakene 400mg).” A user on CrazyMeds remarked that some 
people find Seroquel helpful for depression, but “Whether it’s the consistent sleep or the 
drug itself I’m not entirely sure, but I suspect it’s a combination of the two.” Again 
referring to Seroquel, a user on IcarusProject commented, “I don’t know if I gained 
weight from it (Seroquel). I am fat to start with, plus I was taking lithium and 
depressed/not exercising.” Other users commented more generally on the dilemma, “it’s 
kinda hard to tell hebee jebees from side effects, or crazyness, or drugs doing what they 
are supposed to do.” Still other users provided a best guess as to the cause of an effect or 
advice, such as “try one med at a time. If you have reactions or side effects after 
beginning two meds at once, you won’t know which to blame.”  
 Under the category “Other Drug Issues” the codes relating to drug dependence/ 
withdrawal, and diagnosis/symptoms were both mentioned by 10.5% of all consumers, 
though very few consumers outside of the 2 discussion forums mentioned the latter. The 
former code included comments about drug discontinuation or withdrawal experiences, 
and advice about how to properly discontinue a drug to avoid adverse effects. Most users 
who offered advice about discontinuation suggested tapering slowly off the drug rather 
than stopping “cold turkey.” For example, users on CrazyMeds advised “taking a very 
low 5mg (of Lexapro) every few days to keep the brain zaps away,” or that “generally 
10% reduction a week is a good rule of thumb.” This code also included the idea of 
becoming “dependent” on the drug by, for example, having to take increasing amounts 
over time to achieve the same effect or having to remain on the drug because of 
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intolerable discontinuation effects. As one user shared, “The first time I tried coming off 
Lexapro (earlier this year), I had anxiety and general pissed off and agitated feeling. So, I 
just went back to my normal dose.” A user on WebMD voiced a common apprehension 
about Seroquel, “It really does work but I am concerned that I will never get off of it and 
develop sleep patterns of my own. I can’t sleep a full night without it.”  
 A full 25% of all consumers commented on or described their current drug cocktail or 
their previous drug history (code: “My drug combo/So many damn meds…”). Most of 
these comments came from the 2 discussion forums as well as a high percentage from 
RevolutionHealth. Table 4.49 shows that this was the only of the above-mentioned codes 
that did not achieve a significant chi-square value between expert- and consumer-
constructed websites. Comments within this code included references to specific drug 
cocktails users have tried or are trying, as well as the general concept of having tried 
many different drugs in the past. A typical recounting of a drug history might resemble 
this comment from a CrazyMeds user, “I have tried other drugs – Zoloft, Wellbutrin, 
Prozac, Cymbalta. I couldn’t tolerate Wellbutrin and Cymbalta. I felt numb emotionally 
on Zoloft. Prozac caused anorgasmia yet did nothing for my depression.” More generally, 
users referred to the idea that they’ve “tried virtually every medication out there,” they’ve 
been on the “med merry-go-round” for a long time, or they’ve “taken so many damn 
meds” that they have difficulty recalling which ones had what effects on them. 
 The final category, “Theories of Drug Action,” was the least mentioned by consumers 
across websites, and was again dominated by users of the 2 discussion forums. This 
category included all descriptions of how or why drugs work in the body and brain, as 
well as references to drugs being “potent” or “selective” in their action on the brain. For 
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example, users of CrazyMeds often attempted to explain differences in drug efficacy or 
the safety of a particular drug combination by referencing drugs’ action in the body: 
“Lots of pdocs (psychiatrists) in my area are giving stims (stimulants) to people that have 
to take AP’s (antipsychotics). In theory, the dopamine actions are occurring in different 
places. There are 5 dopamine pathways...” Similarly, “Celexa hits the serotonergic 
system less hard, which might be a pro concerning side effects.” No consumers on 
WebMD or AskaPatient and few consumers on RevolutionHealth (1.3%) mentioned the 
most common code within this category, and a chi-square test was not completed due to 
these zero frequencies.  
 In sum, all of the above “My Drug” themes were dominated by users of the 2 discussion 
forums. Users of CrazyMeds offered the most strategies for dealing with side effects, 
while users of IcarusProject commented most on the need for drugs and alternative 
treatments. Taken together, the “My Drug” themes showed a rich variety of concerns, 
experiences, and perspectives of consumers. 
 
 
 
 
 
 
 
 
 
169 
 
Table 4.48  
Frequency of Consumer Comments on Drug Theme Categories (in bold text) and the 
Most Frequently Mentioned Code Within that Category (in plain text) 
 All 
consumers
(N=1080) 
Ask a 
patient 
(N=220)
Crazy 
Meds 
(N=220)
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
   
(N=220)
Evidence 15.3% 9.6%  31.3% 29.2% 7.9% 5.4% 
Drug or something 
else? 
10.4% 5.0% 23.3% 20.8% 4.6% 3.3% 
Other Drug Issues 34.1% 20.4% 60.4% 58.3% 28.8% 14.6% 
Dependence / 
Withdrawal 
10.5% 5.4% 18.8% 24.2% 6.3% 4.6% 
Diagnoses / 
Symptoms 
10.5% 0.8% 22.1% 40.0% 3.3% 0.8% 
Other Drugs and 
Drug Combinations 
32.4% 12.5% 51.7% 63.3% 32.9% 17.1% 
My drug combo / So 
many damn meds… 
25.4% 10.8% 35.0% 46.7% 29.2% 15.8% 
Theories of Drug 
Action 
3.9% 0.4% 10.8% 9.2% 1.7% 0% 
Targets/restores brain 
molecules/chemicals/ 
neurotransmitters 
2.3% 0% 7.1% 4.2% 1.3% 0% 
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Table 4.49  
Number of Consumers Mentioning Codes under Other Drug Theme Categories 
According to Website Classification 
  
Consumer-
constructed  
(N=600) 
Expert-
constructed 
(N=480) 
Chi-
square 
p-
value 
EVIDENCE: Drug or something else? 93 19 38.217 0.000
OTHER DRUG ISSUES: 
Dependence/Withdrawal 87 26 23.486 0.000
OTHER DRUG ISSUES: 
Diagnoses/Symptoms 103 10 64.76 0.000
OTHER DRUGS/COMBINATIONS:      
My drug combo/So many damn meds… 166 108 3.76 0.053
 
My doctor. 
 Table 4.50 shows the frequency of consumers who mentioned a code within the 
category “My Doctor,” and Table 4.51 shows significant chi-square tests for each code 
according to website classification as expert- or consumer-constructed. Similar to themes 
under “My Drug,” themes under “My Doctor” were dominated by users of the 2 
discussion forums. The code “talking with doc/doc explained/consult doc” was the most 
popular theme across each website, except for IcarusProject where the most popular 
theme was “I’m taking control/I’m my own best advocate.” The former code included all 
references to having talked with the doctor, needing to consult the doctor, and 
information the doctor explained or decisions the doctor made about drugs or drugs’ 
effects. For example, consumers often relayed some information their doctor explained to 
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them, “My doctor says Lexapro wakes most people up but can have the opposite effect, 
as it started to have with me.” Many consumers noted a doctor-made decision, “I was 
ready to switch to another SSRI…but my doctor decided to add Wellbutrin instead.” This 
code also included suggestions to or advice about talking with the doctor, such as general 
statements “Consult your doctor,” more directive statements “If it’s akathesia, talk to 
your doc about ultram,” or cautions to “talk to your doctor before doing anything” that 
might impact your medication regimen. Finally, consumers generally advised others to be 
open and honest when talking to the doctor about their concerns and needs, “Being 
lifeless, lazy, flat, zombie…is not acceptable. Tell your Doctor that you are NOT willing 
to just exist.”  
 The next code, “doctor won’t listen/we disagree/ I wasn’t informed,” was mentioned by 
over 10% of all consumers, including almost 30% of consumers on IcarusProject. This 
code reflected disagreements and conflicts between the consumer and their doctor, 
remarks about the doctor being wrong about a drug or drug effect, and the idea that the 
doctor did not support, listen to, or properly inform them about medication issues. Some 
consumers described a disagreement with their doctor about the appropriate course of 
action and made a decision to listen or not listen to the doctor’s instructions, “I begged 
the doc to take me off this and he didn’t want to so I took myself off of it.” A consumer 
on RevolutionHealth summarized the experience of the doctor being wrong about what to 
expect from a drug, “Pdoc assured me that it would help me sleep. It made me 
excessively tired but not sleepy. In fact, I slept less which I can’t cope with.” Similarly, 
some consumers complained about being misinformed or poorly informed by their 
doctor, “my pdoc definitely down-played the effects on my memory. I had a rude 
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awakening at just how much I would lose, and for how long. It makes me angry too.” 
Many consumer comments under this code relayed feelings of not being listened to or 
validated by the doctor, “Is there anyone who had/has this experience with such a low 
dose? My Pdoc sometimes looks at me like I am making all this stuff up, I am not. I am 
depressed but not stupid.”  
 The most popular “My Doctor” code among IcarusProject users and mentioned by 
about 9% of all consumers was “I’m taking control/I’m my own best advocate.”  These 
were comments about consumers becoming informed or advocating for themselves to the 
doctor, often by doing their own research on a drug, monitoring their treatment, or 
asserting their treatment-related decisions to their doctor. Many consumers offered 
general advice, such as “definitely do your own research on all things,” or explained their 
understanding of an issue “based on my research.” Some consumers requested specific 
drugs from their doctor or suggested that others do so, “Read about each one 
(medication) and pick one that you think you would like to try, actually pick a few 
because he’s (the doctor) probably going to object to a few of them. Try one and see how 
it works.” Also typical were consumers making treatment-related decisions on their own, 
such as adjusting their dose of a drug, “I also decided last week to try to decrease my 
Seroquel dose and see if I could sleep a little less and have more energy. I didn’t ask my 
doctor.” 
 The final codes under “My Doctor” mentioned by at least 3% of all consumers were 
“trusting the doctor?” and “other doctor-related issues.” About 8% of all consumers, and 
a fifth or more on each of the discussion forums, were hesitant to fully trust their doctor’s 
word. Some consumers were seeking to verify with others some information the doctor 
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had given them, such as “my psychiatrist says Lexapro is the Cadillac of SSRI’s, is this 
really true or just a one person bias?” At other times, consumers would chime in with 
suspicion or caution about a doctor-made decision of another consumer, “The fact that 
she (the doctor) even considered lithium with your history of epilepsy means she’s 
throwing darts.” Finally, a small percentage of consumers (4.3%) made a comment 
related to “the doctor” that did not fit in the above codes, such as advice for finding a new 
doctor or praise for having a supportive doctor.  
 Similar to findings for “My Drug,” the comments for “My Doctor” reflected an array of 
relationships and interactions with, and feelings towards doctors.  
Table 4.50  
Frequency of Consumers within Each Website who Mentioned a Code Within the 
Category “My Doctor,” Mentioned by at Least 3% of All Consumers 
  
All 
consumers 
(N=1080) 
Ask a 
Patient  
(N=220) 
Crazy 
Meds 
(N=220) 
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
 
(N=220) 
Talking with doc 
/ Doc explained /  
16.8% 5.4% 37.5% 28.3% 11.3% 7.1% 
Doctor won't 
listen /  We 
disagree  10.3% 5.4% 13.3% 29.2% 7.1% 5.8% 
I'm taking control 
/ I'm my own 
best advocate 9.0% 2.1% 16.7% 34.2% 2.9% 1.7% 
Trusting the 
doctor ? 8.2% 0.8% 20.0% 22.5% 2.5% 2.5% 
Other doctor-
related issues 4.3% 0.8% 7.9% 16.7% 0.8% 1.3% 
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Table 4.51  
Number of Consumers Mentioning Codes under “My Doctor” According to Website 
Classification 
 Consumer-
constructed  
(N=600) 
Expert-
constructed 
(N=480) 
Chi-
square 
p-
value 
Talking with doc / Doc 
explained / Consult doc 137 44 35.703 0.000 
Doctor won't listen /  We 
disagree / I wasn't informed 80 31 13.668 0.000 
I'm taking control / I'm my own 
best advocate 86 11 47.3 0.000 
Trusting the doctor ? 77 12 37.656 0.000 
Other doctor-related issues 41 5 21.935 0.000 
 
Finances/the system. 
Table 4.52 shows the frequency of consumer comments within the remaining 
theme categories along with their most popular code. Under “Finances/The System,” 
6.5% of all consumers made a comment related to the expense of drugs and insurance-
related issues. This code appeared from consumers on all websites, though only once on 
AskaPatient.  Many of the comments under this code were related to the cost of brand 
name drugs compared to generic drugs, and the involvement of insurance companies in 
trying to reduce costs by forcing consumers to switch to cheaper generics. A typical 
comment related to this was, “I have to switch from Lex to Celexa because of insurance 
BS and I really hope it doesn’t get any worse than it is,” or “The main downfall to 
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Lexapro is it is another drug on the “hit list” of drugs my insurance company hates to pay 
for, so it costs me a fortune every month.” Some consumers found the expense worth it, 
“it costs me $50 for a month’s supply. It’s pricey, but so far, absolutely worth it,” while 
others were simply unable to afford it, “due to loss of insurance and cost of prescription I 
had to stop taking it.” A number of consumers found free samples given to doctors by 
drug companies to be an invaluable supplementary source, “I survive at least half the 
time on samples from pdoc because this stuff is so damn expensive.” 
Family and friends. 
 At least 6% of consumers on each website mentioned their family or friends in their 
drug review or discussion post. The most popular code in this category was “Drug did 
*this* to them/ doing what they did,” which most often included descriptions of drug 
experiences of family members or friends. Consumers shared things like, “my ex 
boyfriend took it (Seroquel) to sleep and slept like the dead,” “a close friend of mine 
developed NMS from Seroquel,” or “I found out over the holidays that both my mother 
and aunt are on Seroquel too and it seems to be really helping them (both BP like me).” 
Often the experiences of family or friends influenced the consumer’s perspective or 
decision on taking the drug, such as in the latter comment where the consumer was 
encouraged to try Seroquel based on the positive experience of her family. Others shared 
the negative experiences of family or friends in order to warn others of possible dangers, 
“My husband was in a study sponsored by Lilly using large doses of Seroquel, 800mg a 
day. Within 6 months he had full blown type 2 diabetes…no blood sugar issues in the 34 
years prior to this. Bad, bad, bad Seroquel!” 
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Pharmaceutical companies/FDA. 
 Under “Pharmaceutical Companies/FDA” the code “it’s a business” included any 
remark about pharmaceutical companies being in the business of selling drugs. No 
consumers on the expert-constructed sites and only 1 consumer on AskaPatient made a 
comment that fell under this code. Many comments centered around the relationship 
between pharmaceutical company representatives and doctors, “my doctor must have 
been getting some great perks from the drug company as he kept trying to push it on me,” 
or “I hate to piss off my regular doc, but I’m afraid she might be basing my treatment on 
what the Lexapro rep with all the samples told her.” Consumers also made references to 
“drug company hype,” “financial reasons NOT to do a study,” “pharmacomafia,” and a 
number of comments about the financial incentives to develop, market, and provide 
samples for brand name drugs versus generic drugs. “Other” pharmaceutical company 
issues, mentioned by 2.5% of all consumers, largely involved miscellaneous comments 
about lawsuits against drug companies, questions concerning “who’s watching” the 
pharmaceutical industry, and views about the “medical model.”  
Support and advice. 
Nearly 15% of all consumers elicited others’ experiences of drugs, or described 
being scared or worried about taking a drug, usually after reading of others’ experiences 
on the Internet. In a review of Lexapro, a consumer on AskaPatient remarked they were 
“rather scared of going off (of Lexapro) after reading about it on this site, but think that’s 
the only solution at this point,” and another user on the site was worried because, “I am 
quite health conscious and read some reviews where people put on a lot of weight.” Many 
consumers were seeking advice from others with first-hand experience, “Has anyone had 
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experience with generic Lex? Anyone switched from the name brand to the generic?” 
Another popular question related to Lexapro was, “Do sexual side effects ever wear off?” 
In general, though, most questions shared some common themes: “Is this normal?” “Has 
anyone else experienced this?” “Do you think this drug has caused/will cause this 
effect?” and “Will this go away?” 
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Table 4.52  
Frequency of Consumer Comments on Other Theme Categories (in bold text) and the 
Most Frequently Mentioned Code Within that Category (in plain text) 
 All 
consumers
(N=1080) 
Ask a 
patient 
(N=220)
Crazy 
Meds 
(N=220)
Icarus 
Project 
(N=120) 
Rev 
Health 
(N=220) 
WebMD
   
(N=220) 
Finances/The 
System 
8.1% 0.8% 14.2% 27.5% 5.0% 2.9% 
Expenses/Insurance 
6.5% 0.4% 11.7% 18.3% 5.0% 2.9% 
Friends and Family 
11.3% 6.7% 12.9% 31.7% 7.9% 7.5% 
Drug did *this* to 
them/ Doing what 
they did 
5.0% 2.1% 7.5% 14.2% 2.9% 2.9% 
Pharmaceutical 
Companies/FDA 
6.1% 0.4% 13.3% 23.3% 1.3% 0.8% 
It’s a business 2.6% 0.4% 6.3% 10.0% 0.0% 0.0% 
Other pharma/ 
regulatory/FDA 
issues 2.5% 0.0% 3.8% 14.2% 0.0% 0.4% 
Support and 
Advice 
16.9% 
6.3% 34.2% 38.3% 8.3% 8.3% 
Seeking experiences 
/ Worried about 
effects 14.5% 4.2% 32.1% 27.5% 7.5% 7.9% 
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Themes by Experts versus Consumers 
Overview of expert themes. 
 Expert text included codes from each of the 6 main thematic categories reviewed above 
for consumers (My Drug, My Doctor, Finances/The System, Family and Friends, 
Pharmaceutical Companies/FDA, and Support and Advice). However, from consumer 
text, there were 61 codes across the 6 categories. Table 4.53 lists the 28 of these 61 codes 
(45.9%) that were mentioned in the expert text. There remained 33 themes mentioned by 
consumers from the 6 categories that did not come up in the expert text. Of the 28 themes 
mentioned, 4 of them came up in all 4 expert cases: talking with doc/doc 
explained/consult doc, dose-related issues, other drug issues, and targets/restores brain 
chemicals. Sixteen of the 28 codes (57%) came up on one expert site and not the other.  
 The 4 above-stated codes mentioned by all expert cases were also the most frequently 
mentioned codes in expert text (there were multiple mentions of each code in a single 
case). The code “talking with doc…” was mentioned in these 4 cases a total of 109 times. 
As a proportion of total mentions of all themes, this meant that 52.7% of all mentions of 
theme codes by experts were related to “talking with doc/doc explained/consult doc.” In 
contrast, a total of 181 consumers mentioned this theme 316 times, so that 5.1% of all 
mentions of theme codes by consumers were related to “talking with doc…” To ensure a 
fair comparison, the same proportion was taken for consumers using total mentions of 
only the 28 themes in expert text (rather than dividing the 316 mentions by total mentions 
of all 61 themes), and 11.2% of all mentions by consumers out of  those 28 themes were 
related to “talking with doc…”   
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Figure 4.11 compares experts and consumers on the proportion of all thematic 
mentions according to the most popular themes of each group (note: “talking with doc…” 
is not included on this table).   The second most popular theme in expert text was issues 
related to dosing, such as what to do in the case of a missed dose or overdose, as well as 
instructions to take the drug as prescribed and with food and water. Next were “Other” 
drug issues, which were largely related to proper storage of the drug, for example, “do 
not refrigerate.” Two of the 4 most popular themes of consumers did not show up in 
expert text: “My drug combo/so many damn meds” and “No/limited helpfulness/not my 
wonder drug.” 
Table 4.53  
Codes From All Theme Categories That Were Mentioned in Expert Text 
  RevolutionHealth (N=2) WebMD (N=2) 
OTHER drug issues 2 2 
Talking with doc / Doc 
explained / Consult doc 2 2 
Targets/Restores brain 
chemicals 2 2 
Dose related issues / advice 2 2 
Dependence / Withdrawal 1 2 
Check blood levels 1 2 
Ride out the storm/ 
Eventually goes 
away/Waiting 1 2 
Other pharma/FDA issues 1 2 
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  RevolutionHealth (N=2) WebMD (N=2) 
YMMV 1 2 
FDA approval status 2  
Family/friend observed an 
effect 2  
Expense / Insurance 2  
Generic/other drug 
equivalence 2  
Dose adjustment 2  
Other methods (to deal with 
side effects) 1 1 
Efficacy/Safety not 
established 1 1 
All in All, I am positive / 
Side effects tolerable  2 
Switch meds / Stop med  2 
Taper SLOWLY / Low 
starting dose  2 
Other doctor-related issues 1  
Don't take this drug/ 
combination 1  
Possible effects / What to 
expect from other drugs 1  
Avoid / Drink more 
caffeine/alcohol 1  
Other general support 1  
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  RevolutionHealth (N=2) WebMD (N=2) 
I'm taking control / I'm my 
own best advocate  1 
Diet / Food /  Exercise  1 
Routine  1 
 
Figure 4.11 Proportion of Mentions of the Most Popular Themes by Experts and 
Consumers, Respectively, Out of Total Mentions of All Themesa 
aThere may be more than 1 mention in a single case. As an example, 274 consumers 
mentioned “My drug combo/so many damn meds” a total of 400 times. The code 
frequency (400) divided by the total number of mentions of all 60 themes equals 6.5%.  
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Assessing the overall experience. 
 Table 4.54 compares consumers and experts on codes within “assessing the overall 
experience.” Just over 15% of consumers made an assessment of the benefits and costs of 
a drug experience and decided that the drug was of limited benefit or that it was “just 
okay.” Another 9.4% of consumers decided that the drug benefits outweighed costs, and 
7.3% decided that costs outweighed benefits. In expert text, only the “benefits outweigh 
costs” code appeared, while the other 2 codes were absent. WebMD mentioned this code 
for each drug under study (see exact statement in Table 4.55), while no codes under this 
category appeared in the expert text of RevolutionHealth. Table 4.55 provides excerpts 
that illustrate each position. 
Table 4.54  
Number of Consumer and Expert Cases that Mention a Code under “Assessing the 
Overall Experience” 
Category: “Assessing Benefits and Costs” Consumers 
N=1080 
N (%) 
Experts 
N=4 
N (%) 
 
All in all, it is worth it (Benefits outweigh costs) 102 (9.4%) 2 (50%) 
Side effects are too great (Costs outweigh benefits) 79 (7.3%) 0 
No or limited helpfulness 165 (15.3%) 0 
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Table 4.55  
Expert and Consumer Descriptions of “Assessing the Overall Experience” 
All in all, it is worth it 
EXPERT: “Remember that your doctor has prescribed this medication to you because he 
or she has judged that the benefit to you is greater than the risk of side effects” (WebMD) 
CONSUMER:  
“I have almost no sex drive…a dry mouth most of the time… (and) have gained some 
weight. But as long as I don’t have to deal with the panic attacks I am ok.” (#445) 
“If you gain weight on this drug, I have found it is very hard to shed it off while still on 
it. But, it is so much better to be bootylicious than suicidal” (#138) 
 
“I wake up and feel a little doped out in the mornings however I can live with that 
considering it’s saved me from the tragedy of no sleep and late night TV!” (#572) 
 
Side effects are too great 
EXPERT: N/A 
CONSUMER:  
“Lexapro did not work for me. I felt distant, with no emotions. No, I wasn’t depressed 
anymore but I’m not sure the side effects were worth it!” (#34) 
“Felt like a new man for 5 months. Best most secure days of my life. I quit – you guessed 
it – NO sex drive, maybe one erection a week and impossible to orgasm.” (#433) 
“Gained 30 pounds in seven months…enough weight gain that I am going off this drug 
even though it works” (#571) 
No or limited helpfulness 
EXPERT: N/A 
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CONSUMER:  
“Helped depression, but caused weight gain, which caused more depression… a vicious 
cycle.” (#11) 
“Lexapro sucked. My doctor prescribed lexapro and it didn’t make me feel any better.” 
(#263) 
“I was prescribed Seroquel, and I do have to say that it did bring me back to a more stable 
state at the time. That state was not exactly anything to write home about, but at least it 
was an improvement over where I was before.” (#650) 
“Not the perfect med but better than others I have tried…less side effects too.” (#920) 
 
Dealing with side effects/finding optimum effectiveness. 
 Figure 4.12 shows the proportion of mentions of the most popular codes of experts and 
consumers within the category “dealing with side effects/finding optimum effectiveness” 
out of total mentions of all codes within that category. Only 1 code, “Add another med,” 
was mentioned by one group (consumers) and not the other (experts). The most 
frequently mentioned code among experts (24% of mentions) was “other methods,” 
which primarily included cautions to stand up slowly to avoid dizziness and to take care 
when driving a vehicle. Consumers who mentioned this code provided similar advice, as 
well as offered additional recommendations, such as allow plenty of time for sleep at 
night, set multiple alarm clocks, and take a shower in the morning to help wake up.  
The most frequently mentioned code among consumers (24% of mentions) was 
“ride out the storm/eventually goes away/waiting,” which also took 12% of all mentions 
within this category in the expert text. Expert text stated that it may take “4 weeks or 
longer” for Lexapro and “several weeks” for Seroquel before feeling the “full benefits” of 
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the drug. Consumers made similar statements, “they take a few weeks to kick in,” or 
“took a few weeks to get used to, excellent results after that!” While expert text 
uniformly listed a 4 or “several” week time frame, there was a wider range of time frames 
cited by consumers, from “it took about 1 week to really kick in,” to “after 18 months, 
my body is well-adjusted to it and it helps a great deal with regulating my mood.” Both of 
the latter statements were from reviews of Lexapro. Unlike expert text which only 
mentioned a time frame for benefits to be felt, consumers also shared information on how 
long it took for “side effects” to go away. Some consumers offered general rules of 
thumb, “initial side effects should go away within a week or two. If they don’t, they’re 
there to stay,” and others shared their personal experience of side effects, “Depressed and 
zoned out bad first couple of weeks. Sexual side effects went away after 2-3 months.”  
While expert text did not comment on the popular consumer code “add another 
med,” consumers infrequently mentioned the popular expert code “check blood levels.” 
Expert text emphasized the importance of regular monitoring of blood sugar levels while 
on Seroquel, and periodic monitoring of other laboratory tests on either drug. Consumers 
offered the same information and encouragement, however, at a lower rate of mention 
compared to the frequencies of other codes in this category.   
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Figure 4.12 Proportion of Mentions of the Most Popular Codes Within the Category 
“Dealing with Side Effects/Finding Optimum Effectiveness” Out of Total Mentions 
Within the Category 
 
My doctor. 
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“talking with the doc…,” always pointing to the doctor as the major source for 
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recommend trying it if your doctor suggests it.” Beyond this, however, consumers 
demonstrated a broader range of relationships with the doctor by frequently commenting 
on how their doctor was wrong, their doctor did not inform them of certain potential 
effects, their doctor didn’t believe them when they shared a particular drug experience, 
and so on as Table 4.57 illustrates.  
Table 4.56  
Consumers and Experts on the “My Doctor” Code: “Talking with Doc/Doc 
Explained/Consult Doc” 
 Consumers Experts 
Sample size 1080 4 
% of cases that mention the code 16.8% (n=181) 100% 
Total number of occurrences of the code 316 109 
% of words coded out of total text 3.8% 18.4% 
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Table 4.57  
Excerpts from Consumers and Experts on “My Doctor” 
Codes: Talking with doc / Doc explained / Consult doc 
Doc was wrong / We disagree / I wasn't informed 
Trusting Doc ? 
Expert text “Tell your doctor about…”; “Tell your doctor if…” 
 
Talk to your doctor before…” 
 
Call your doctor at once if…”; “Tell the doctor immediately if…” 
 
“Do not…without telling your doctor”; “Do not…without first 
talking to your doctor” 
 
“Your doctor will need to check you at regular visits…” 
 
“Consult your doctor or pharmacist for more details”;  
“Contact your doctor for…” 
 
“…unless your doctor instructs you otherwise” 
 
“Discuss the risks and benefits with your doctor” 
 
AskaPatient  “I was told by my Psychiatrist that the only side effects were 
sleepiness and POSSIBLE weight gain. I was not warned of the 
diabetes risk or other side effects” (#494) 
 
“I’m not sure that the tingling that I’m feeling is from Anxiety like 
my psychiatrist says, or as a side effect of the Lexapro. I think it’s 
the lexapro” (#58) 
 
“my doctor must have been getting some great perks from the drug 
company as he kept trying to push it on me despite my repeated 
telling him how awful it was” (#16) 
 
CrazyMeds “I see Dr on the 6th – but he is fast and furious in his visits and I 
would like input from the “experts” as well as him. I do take his 
advise but also like other input” (#217) 
 
“I’ve actually read that weight loss was possible and my doctor 
made it sound like side effects in general are rare and minor. It’s 
pretty confusing.” (#132) 
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 “Only doctors can diagnose and treat an illness. Some doctors tend 
to get pissed off by patients who know too much about medications, 
so tread lightly when and where appropriate.” (#1083) 
 
“Some psychiatrists are really stupid.” (#638) 
 
“All docs I’ve had, from gp to pdoc2, are obsessed with Cymbalta as 
a pain aid. Only pdoc1 listened to me when I told her it didn’t touch 
my pain,… Pdoc2 is totally fixated on Cymbalta for pain. They all 
have the same mantra: ‘It’s been tested for pain and it works.’” 
(#685) 
 
RevolutionHealth “I chose this medication over Paxil because my doctor told me it 
would be faster acting and have less side effects.” (#298) 
 
“I think I might stay on it just long enough to show up in my pdoc’s 
office in this “condition” so that he can see first hand what I’m 
talking about.” (#768) 
 
“I’ve told the doc this and he says it will get better, but it’s been 
about 2 months and I am still completely incoherent in the morning.” 
(#791) 
 
WebMD “It took my new doctor a while to find the right dose for me… It 
took may psychiatrists to finally figure it out. None of them 
completely understood all the past meds I was on and the weight 
gain I experienced on all of them.” (#959) 
 
“…my whole body would jump and twitch… I was scared to drive 
my car fear that I would cause an accident. My doctor tells me that 
its not because of seroquel but I disagree.” (#841) 
 
“…it makes me extremely sleepy so I am not sure why she has 
prescribed this medication twice a day. I’ve spoken to her numerous 
times about this issue because it is affecting me staying awake at my 
job…” (#866) 
 
Icarus “People need to feel empowered with education and choice before 
taking stuff (and don’t necessarily trust the docs to tell you 
everything you need to know).” (#986) 
 
“I finally got some appropriate drugs after the TENTH psychiatrist 
I’ve seen in my life. (patience is key when looking for the right 
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drugs and the right person who actually bothers to keep up on the 
current research and actually bothers to listen to you as an 
individual…)” (#962) 
 
“I argued with my doc because I had no life. All I did was sleep. She 
was more concerned with me being stable, but the side effects were 
so bad.” (#991) 
 
Dose-related issues. 
 “Dose-related issues” made up 11.6% of all mentions of themes in expert text, as Figure 
4.11 shows, compared to 3.2% of all mentions of themes by consumers. Under this code, 
experts provided information on what to do in the case of an overdose, “seek emergency 
medical attention,” or a missed dose, “take it as soon as you remember…(or)…skip the 
missed dose and resume your usual dosing schedule.” Experts further emphasized to take 
only the prescribed dose as instructed by the doctor and to “not start, stop, or change the 
dosage of any medicine before checking with your doctor or pharmacist first.”  
Consumer comments under this code largely involved attempts to ascertain the 
lowest and highest appropriate and/or effective doses, “For Lexapro, 20mg is about the 
ceiling, though some people get doses as high as 40mg…It would be a good idea to stick 
to 10mg until you’re able to evaluate the effectivity of the drug…” A paradoxical dosing 
guideline for Seroquel came up several times, “Seroquel is highly sedating in the lower 
doses (i.e., 25, 50, 100, etc),” while “higher doses can be used for treatment of acute 
mania” including psychosis and bipolar mania, but not for insomnia. Rather than stating a 
general rule, many consumers simply shared with others their personal experience at 
various doses, “seroquel at low dose 50 knocks me out, 100 tired for about an hour, 200 
at bed nothing, that’s just me.” Some consumers spoke of the “right dosage,” or “correct 
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dosage,” noting that there is no single dose that works for everyone or for all problems, 
but that “once you find what it is you will know it.” Other comments that appeared in 
consumer text included the comparability of extended release versions of drugs to regular 
dosing, and the possibility of using a drug PRN, or “as needed,” instead of on a daily 
schedule.  
In sum, expert text included less than half of the themes mentioned by consumers, 
and a majority of these themes were mentioned on only 1 or the other expert site. Expert 
text offered unitary discourses around benefits versus costs of the drug, and the doctor. 
Expert and consumer text shared several similar strategies for dealing with side effects, 
but consumers provided many additional practical strategies not covered in expert text. 
Comments about dosing issues were divergent between groups, with consumers making 
more specific dosing inquiries and suggestions and expert text making general references 
to seeking professional assistance for many dosing issues.  
Usability of Consumer Sites According to “Typical” Web Use 
Lexapro. 
Tables 4.58 and 4.59 compare the most recent 20 posts from AskaPatient, 
CrazyMeds, WebMD, and RevolutionHealth (n=80) to the full dataset of consumer 
reviews for Lexapro (n=480). Table 4.58 compares the groups on the effects most 
mentioned by consumers, and shows considerable comparability for these 9 effects. One 
effect, extreme sleepiness/tired, reached a significant chi-square value (chi-square=4.026, 
df=1, p=0.045), with more consumers reporting this effect in recent posts. Overall for the 
most popularly mentioned effects of Lexapro, the 20 most recent posts from each website 
demonstrated comparable frequencies to the full dataset of consumer reviews.  
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Table 4.59 makes a similar comparison for less frequently mentioned effects of 
Lexapro. There were 5 effects mentioned by greater than 3% of consumers in the full 
dataset, but mentioned by fewer than 3% of consumers in recent posts. All 5 were 
physical effects, such as dizziness, sweating, and weight loss. Internet users relying on 
the first 20 posts on these websites run the risk of missing or underestimating these few 
effects. All other effects mentioned by more than 3% of consumers in the full dataset 
were also mentioned by at least that many in recent posts. 
There were another 5 effects mentioned by few consumers (<3%) in the full 
dataset that were mentioned by more consumers (>3%) in recent posts. Two of these 
were mental or mood effects: suicidal thinking/planning/attempts and crying 
spells/emotional rollercoaster. The full dataset contained 3 cases each of hot flash/heat 
stroke and vision/eye changes, all of which were present in recent posts.  A typical 
Internet user seeing all 3 cases out of 80, rather than out of 480, might over-estimate the 
frequency of these effects. Again, though, all other effects mentioned by less than 3% of 
consumers in the full dataset were also mentioned by that many or fewer in recent posts.  
 
 
 
 
 
 
 Table 4.58  
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Most Frequently Mentioned Effects of the Most Recent 20 Consumer Posts From Each 
Website Compared to All Consumer Posts for Lexapro 
 Recent posts
(N=80) 
Full dataset 
(N=480) 
Symptoms reduced / improved 32.5% 30.4% 
Extreme sleepiness / tireda 32.5% 23.8% 
Symptoms new / worsened 18.8% 15.8% 
Trouble sleeping / insomnia 11.3% 13.3% 
Emotionally stable / calm / "normal" 15.0% 13.1% 
Weight gain 13.8% 13.1% 
Nausea / sick stomach / vomiting 11.3% 12.1% 
Numb / detached / lack of energy or interest 8.8% 11.3% 
Brain fog / zombie 12.5% 10.8% 
aChi-square=4.026, df=1, p=0.045 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.59  
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Less Frequently Mentioned Effects from Recent Posts Compared to the Full Dataset for 
Lexapro 
 Recent 
posts 
(N=80) 
Recent 
posts 
% 
Full 
dataset 
(N=480)
Full 
dataset
% 
Effects mentioned by >3% of consumers in 
full dataset, and <3% of consumers in most 
recent posts 
    
“Sweating like a pig” 2 2.5% 28 7.1% 
Loss of appetite 2 2.5% 21 5.3% 
Weight loss 2 2.5% 21 5.3% 
Dizzy/lightheaded/faint 2 2.5% 20 5.1% 
Other misc effects 1 1.3% 19 4.8% 
Effects mentioned by <3% of consumers in 
full dataset, and >3% of consumers in most 
recent posts 
    
Helps me sleep 5 6.3% 9 2.3% 
Suicidal thinking / planning / attempts 3 3.8% 6 1.5% 
Crying spells / emotional rollercoaster 3 3.8% 4 1.0% 
Hot flashes / heat stroke 3 3.8% 3 0.8% 
Vision / eye changes 3 3.8% 3 0.8% 
 
 
 
 
 
Seroquel. 
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 Tables 4.60 and 4.61 compare the most recent 20 posts from the 4 websites (n=80) to 
the full dataset of consumer reviews for Seroquel (n=480). Table 4.60 makes this 
comparison using the most frequently mentioned effects of Seroquel, and again shows 
good comparability for these 9 effects. One effect, brain fog/zombie, reached statistical 
significance (chi-square=3.958, df=1, p=0.047), with more consumers in recent posts 
reporting this effect.  Otherwise, recent posts and the full dataset appeared to be 
comparable in reported frequencies of the most popular effects of Seroquel.  
 Table 4.61 makes a similar comparison using the less frequently mentioned effects of 
Seroquel. Four effects were mentioned by 3% or more of consumers in the full dataset, 
and by few or no consumers in recent posts. Two were mental or mood effects, and two 
were physical effects. In contrast, the second half of the table lists the 4 effects mentioned 
by few consumers (<3%) in the full dataset and by a greater number (>3%) in recent 
posts. All 4 were physical effects. For the remaining effects of Seroquel, recent posts and 
the full dataset were comparable. 
 
 
 
 
 
 
Table 4.60  
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Most Frequently Mentioned Effects of the Most Recent 20 Consumer Posts From Each 
Website Compared to All Consumer Posts for Seroquel 
 Recent posts
(N=80) 
Full dataset
(N=480) 
Helps me sleep 41.3% 35.6% 
Extreme sleepiness / tired 32.5% 33.1% 
Symptoms reduced / improved 28.8% 24.8% 
Weight gain 20.0% 22.5% 
Brain fog / zombiea 22.5% 15.2% 
Increased appetite / cravings 11.3% 12.7% 
Symptoms new / worsened 11.3% 10.2% 
Abnormal movements 8.8% 8.8% 
Other misc effects 8.8% 5.0% 
aChi-square=3.958, df=1, p=0.047 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.61  
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Less Frequently Mentioned Effects of Recent Posts from Each Website Compared to the 
Full Dataset for Seroquel 
 
 Recent 
posts 
(N=80) 
Recent 
posts 
% 
Full 
dataset 
(N=480)
Full 
dataset
% 
Effects mentioned by >3% of consumers in 
full dataset, and <3% of consumers in most 
recent posts 
    
Dry mouth / sore throat 1 1.3% 21 5.3% 
Dreams vivid / nightmares 1 1.3% 20 5.0% 
Numb / detached / lack of energy or interest 1 1.3% 19 4.8% 
Sweating like a pig 0 0% 11 2.8% 
Effects mentioned by <3% of consumers in 
full dataset, and >3% of consumers in most 
recent posts 
    
Headache increased 3 3.8% 10 2.5% 
Heartbeat changes 4 5.0% 9 2.3% 
Loss of appetite 3 3.8% 5 1.3% 
Breathing problems / shortness of breath 3 3.8% 4 1.0% 
 
Themes. 
 Table 4.62 shows the 25 most frequently mentioned themes in recent posts (n=160) 
compared to the full dataset (n=960) for both drugs combined. For nearly all of the listed 
themes, recent posts showed a higher proportion of consumers mentioning the theme 
compared to the full dataset, though in most of the cases the differences appeared slight.  
Diet/food/exercise under the “dealing with side effects…” category was the only code 
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mentioned by considerably fewer consumers in recent posts. Overall, the number of 
consumers mentioning themes appeared to be comparable between the 2 groups.  
Table 4.62  
Most Frequently Mentioned Themes of Most Recent 20 Posts from Each Website 
Compared to the Full Dataset of Both Drugs  
  
Recent 
posts  
(N=160) 
Recent 
posts  
% 
Full 
dataset  
(N=960)a 
Full 
dataset  
% 
MY DOCTOR     
Doctor won't listen /  we disagree / I 
wasn't informed 
18 11.3% 76 7.9% 
I'm taking control / I'm my own best 
advocate 14 8.8% 56 5.8% 
Talking with doc / doc explained / 
consult doc 27 16.9% 147 15.3% 
Trusting the doctor ? 16 10.0% 62 6.5% 
MY DRUG: Assessing the Overall 
Experience     
A miracle / saved my life / I  
recommend  18 11.3% 105 10.9% 
I hate this drug / stay away from it  15 9.4% 77 8.0% 
All in All, I am positive / side effects 
tolerable 22 13.8% 91 9.5% 
Not worth it / side effects too great 14 8.8% 71 7.4% 
No or limited helpfulness / It's not my 
wonder drug 29 18.1% 142 14.8% 
YMMV 13 8.1% 51 5.3% 
200 
 
  
Recent 
posts  
(N=160) 
Recent 
posts  
% 
Full 
dataset  
(N=960)a 
Full 
dataset  
% 
MY DRUG: Dealing with Side 
Effects/Finding Optimum Effectiveness     
Add another med 19 11.9% 101 10.5% 
Diet / food /  exercise 6 3.8% 72 7.6% 
Dose adjustment 29 18.1% 142 14.8% 
Ride out the storm / eventually goes 
away / waiting 30 18.8% 185 19.3% 
Switch meds / stop med 32 20.0% 185 19.3% 
MY DRUG: remaining sub-categories     
Drugs won't work / I'm done / I don't 
need it 12 7.5% 49 5.1% 
Trying/tried alternative treatment 7 4.4% 43 4.5% 
Drug or something else? 18 11.3% 87 9.1% 
Dependence / withdrawal 14 8.8% 84 8.8% 
Diagnoses / symptoms 15 9.4% 65 6.8% 
Dose related issues  18 11.3% 95 9.9% 
Generic/other drug equivalence 15 9.4% 85 8.9% 
My drug combo / so many damn meds... 39 24.4% 218 22.7% 
Possible effects / what to expect from 
other drugs 17 10.6% 81 8.4% 
SUPPORT AND ADVICE     
Seeking experiences / worried about 
effects 17 10.6% 124 12.9% 
aExcludes postings from IcarusProject. 
201 
 
Preliminary Data Checking 
 Communication with web 2.0 informants. 
Prior to starting the present research, 9 Web 2.0 researchers, bloggers, and 
webmasters were contacted with inquiries as to the state-of-the-art for identifying or 
preventing unauthentic accounts on sites for consumer reviews or discussion. Five 
responses were received, and no one was able to offer a sure method. However, a few 
responses were noteworthy: 
The owner/moderator of a consumer-constructed discussion forum related to 
psychiatric medications described: 
We had someone from Cephalon [a pharmaceutical company] come by.  
The person was easy to spot.  Again I'm fine with it.  It's just like science.  
They have to defend their positions and we have to defend ours… As we 
didn't agree with this person all the time they just stopped showing up… 
As we're good with pattern recognition we can easily spot someone from 
the industry by the language they use.  I no longer have time to read other 
sites, so I don't know if they are popping up elsewhere.  Given that they 
have set up their own sites I seriously doubt if they are going to bother 
with peer-to-peer sites / user generated media / whatever they are calling 
us this month. 
In a follow-up email, the owner elaborated on the type of language an industry 
representative might use: 
Pharm reps write somewhere between high school and college-level, they 
don't use too many technical terms if they can avoid them.  They speak to 
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effects and only mild, temporary side effects.  They will mention off-label 
usage, but everything is one condition at a time.  Drug-drug interactions 
are only for meds someone is currently taking.  They'll defend their meds 
if something hasn't been 100% proven, using studies that were funded by 
their companies or just pulling stuff out of the PI sheets.  Sometimes it's as 
if they copied a paragraph or two from the company's website and pasted 
it into a post. 
The Head of Operations of an expert-constructed health site that integrates expert 
knowledge and consumer participation responded: 
Discussions with marketing personnel at a number of pharmaceutical 
companies (not individual sales reps) suggest a more cautious approach.  
Because many social networking websites with consumer blogs contain 
potentially unreported serious adverse events (SAE), pharma personnel are 
"discouraged" from visiting these websites because if they see an 
unreported SAE, they would be bound to report it to the FDA.  [Our 
website] is working in collaboration with several pharma companies to 
submit a citizens petition (at the request of the FDA) for guidance on 
responsibilities for SAE reporting for on-line communities… For [our 
website], we also screen our patient comments for promotional messages 
and anything with a promotional message is deleted… 
Hope that helps shed a bit of light on "official" FDA guidance, senior 
pharma response, and our activities.  What happens at the rep level, 
however, is tough to monitor.  That said, with 250,000+ individuals 
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enrolled in [our website], its hard to think that "sales representatives going 
against FDA/company policies" can skew the data significantly. 
David and Pinch (2005) found that individuals contributing to product review 
sites may have a number of agendas apart from sharing a genuine experience or expertise. 
In their analysis of 50,000 user reviews of 10,000 books and CDs on amazon.com, they 
found that about 1% of user reviews were plagiarized either verbatim or with variations. 
Plagiarized reviews appeared to promote a certain agenda, carry out personal attacks, and 
boost the user’s reputation in the amazon.com tiered reputation system, among other 
things. They concluded that the great majority of reviews, however, “can probably be 
taken at face value and are authors’ attempts to give their own honest appraisal of the 
product” (p. 23). Both authors were contacted as part of the above inquiry, and neither 
was aware of a program or method to judge the authenticity of user contributions. The 
software program they developed to detect plagiarism on amazon.com is partly available 
open-source, but would not have fit the needs of the present research (and would have 
require considerable re-programming for use on another website).  
Wikiscanner search. 
Wikiscanner was used to search Astra-Zeneca, Eli Lilly, and GlaxoSmithKline for 
Wikipedia edits. Any edited entries related generally or specifically to medications or 
pharmaceutical companies were identified. A detailed listing of search results can be 
found in Appendix H. Briefly, there were 949 edits by persons on Astra Zeneca’s 
network, of which 23 (2.4%) were relevant to medications or drug companies. These 
included 1 or more edits to the following entries: AstraZeneca, Federal Food, Drug, and 
Cosmetic Act, FDA, Good Manufacturing Practice, Omeprazole, Quetiapine, 
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Risperidone, and Thalidomide. In addition to the publicized quetiapine edit mentioned 
above, a sentence about the heavy marketing of omeprazole in the face of generic 
competition was deleted and summaries of several studies in which omeprazole 
outperformed its competitor drug were added. Such edits may be considered controversial 
or salacious as there is a very possible conflict of interest involved. However, there were 
only 3 such edits, equaling 13% of the 23 relevant edits and 0.3% of all 949 edits. 
There were 832 edits returned for Eli Lilly, of which 38 (4.6%) were relevant to 
medications or drug companies. In one edit, 6 contraindications were deleted for 
drotrecogin alfa, including for pregnancy, breast feeding, and use in patients under 18 
years of age. A link for Lilly’s drug Cialis was added to the page for erectile dysfunction. 
The word “deceptive” was deleted in a description of Lilly’s marketing campaign for a 
drug. On the user talk pages for fluoxetine (where users discuss and justify edits to an 
entry), a person from the Eli Lilly network stated, “I have been taking fluoxetine and had 
very little in the way of side effects - just a small amount of nausea at the start. It has 
been very successful in treating my depression so far and I'm feeling good for the first 
time in ages…”   
Finally, a search for GlaxoSmithKline returned 1,148 edits, of which 31 (2.7%) 
were related to medications or the drug industry. Under the entry for “GSK,” someone 
from their network added a section titled “Good Works” and a paragraph describing the 
company’s global leadership in eradicating lymphatic filariasis (elephantiasis). 
Otherwise, Wikipedia edits from these companies appeared innocuous, even when they 
were related to specific medications the company had a financial interest in (see 
Appendix H). Of course, it was also apparent that each company did monitor entries 
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relevant to their respective company or a specific drug they marketed, as a majority of 
relevant edits were done to their own company and drugs.  
In sum, it appears that verifying whether users are authentically representing 
themselves on the Web is an elusive quest. The owner and moderator of one popular 
consumer discussion forum seemed unaffected by possible intrusions of corporate 
representatives, and the Head of Operations of a consumer-centric health site suggested 
such intrusions are discouraged, probably infrequent, and minimally impacting. The 
Wikiscanner search further indicated that anonymous activity of persons on 
pharmaceutical company networks in the highly popular Wikipedia was relatively 
infrequent during 2002-2007.  
Data Checking of the Research Sample 
Recent posts vs. older posts. 
Tables 4.58 and 4.60, discussed in the previous section, show that the most recent 
consumer posts for both drugs are comparable to the full dataset on “symptoms 
improved” and “symptoms new/worsened.” Thus, there did not appear to be an imbalance 
of favorable comments for either drug in the most recent posts.  
Table 4.63 divides all consumer posts from 4 websites (excluded IcarusProject) 
and both drugs by the time period the comment was posted: 2002-2005 and 2006-2009. 
There were significantly fewer comments in the more recent time period for effects 
related to sleep, and gastrointestinal and urinary systems. Table 4.64 lists the frequency 
of consumers who mentioned each code within these 2 categories of effects. Fewer 
consumers in recent posts mentioned constipation, diarrhea/gas, and nausea/vomiting 
under gastrointestinal effects, and excessive sleeping/tired, helps me sleep, and trouble 
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sleeping/insomnia under sleep effects. However, none of these effects individually 
reached statistical significance. There also did not appear to be a patterned bias in 
reporting of sleep effects, as the “positive” effect (helps me sleep) and the remaining 2 
“negative” or “adverse” sleep effects were each reported by fewer consumers in the most 
recent time period.  
If a bias of overly favorable reports of drug effects were present, it may be most 
likely to appear within mental or mood effects. Table 4.64 therefore also compares 
commonly reported effects within this category against the time period of the post. 
Significantly more consumers in the recent time period reported vivid dreams or 
nightmares, and significantly fewer reported an increase in energy, euphoria or mania. 
Both of these effects could be considered “positive” or “negative” depending on 
individual context and the severity of the effect. A nearly equal proportion of consumers 
across time periods mentioned new or worsening symptoms, but significantly fewer 
consumers in the recent period mentioned an improvement in symptoms (25.5% versus 
35.0%, respectively).  
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Table 4.63  
Data Checking by Time Period of Consumers’ Posts and Drug Effect Categories for 
Lexapro and Seroquel Combined 
  
2002-2005 posts 
(N=203) 
2006-2009 posts 
(N=757) 
Chi-
square 
p-
value 
Sleep Effects 115 (56.7%) 348 (46.0%) 7.312 0.007 
Gastrointestinal and Urinary 
Effects 30 (14.8%) 73 (9.6%) 4.407 0.036 
Lab Tests and Chronic 
Conditions 2 37 -- -- 
Other Effects 40 113 2.727 0.099 
Head or Face Effects 26 68 2.652 0.103 
Appetite and Weight Effects 47 208 1.534 0.215 
Mental or Mood Effects 122 428 0.829 0.363 
Nose Throat Chest Effects 16 73 0.591 0.442 
Skin Effects 9 43 0.486 0.486 
Musculoskeletal and 
Neurological Effects 32 114 0.062 0.804 
Sexual Effects 21 81 0.021 0.884 
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Table 4.64  
Data Checking by Time Period of Consumers’ Posts on Selected Code Categories for 
Both Drugs Combined 
 2002-2005 posts 
(N=203) 
2006-2009 posts 
(N=757) 
Chi-
square 
p-
value 
Gastrointestinal and 
Urinary Effects 
    
Constipation 2.0% 0.8% -- -- 
Diarrhea / gas 3.9% 1.8% 3.127 0.077 
Nausea / sick stomach / 
vomiting 9.9% 6.3% 2.999 0.083 
Urinary changes / problems 1.0% 1.5% -- -- 
Sleep Effects     
Difficult to wake up 2.0% 3.8% -- -- 
Extreme sleepiness / tired 33.5% 26.9% 3.381 0.066 
Helps me sleep 20.7% 18.9% 0.333 0.564 
Trouble sleeping / insomnia 9.4% 7.3% 0.987 0.321 
Yawning 1.5% 1.6% -- -- 
Mental or Mood Effects     
Brain fog / zombie 13.3% 12.8% 0.034 0.854 
Dreams vivid / nightmares 2.5% 6.1% 4.155 0.042 
Energy increased / euphoria / 
mania 6.4% 3.3% 4.05 0.044 
Numb / detached / lack of 
energy or interest 7.4% 7.7% 0.017 0.896 
Symptoms new / worsened 12.3% 13.3% 0.148 0.7 
Symptoms reduced / improved 35.0% 25.5% 7.215 0.007 
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Anonymous versus identifiable posts. 
 Table 4.65 shows results of chi-square testing of drug effect categories for consumer 
reviews posted by anonymous and identifiable users. Two categories, “lab tests and 
chronic conditions” and “head or face effects,” reached statistically significant chi-square 
values. For the remaining categories, there was no association between reported drug 
effects and anonymity of the user. Table 4.66 lists the percentage of consumers from each 
group who mentioned a code within the two statistically significant categories of effects. 
More consumers who provided an identifiable user name reported problems with 
increased blood sugar and/or diabetes. More consumers in the anonymous group reported 
increased headache, hearing/taste/smell changes, and jaw clinching/grinding.  
 Again, if a bias of favorable accounts were present, it may be more likely to appear 
within mental or mood effects. There was a non-significant chi-square value for “mental 
or mood effects” as a category, but selected effects within the category were examined 
more closely to ensure a thorough review of the data. Table 4.67 shows the number of 
consumers mentioning the 5 most frequently reported mental or mood effects for Lexapro 
and Seroquel combined. Only 1 effect, emotional stability or calm, reached statistical 
significance (chi-square=4.503, p=0.034), with more consumers who posted 
anonymously reporting this effect. Anonymous users also more frequently mentioned 
new or worsening symptoms (p=0.057), and almost equally to identifiable users 
mentioned improvements in symptoms (32.3% and 27.6%, respectively). Therefore, 
while there was an imbalance of positive comments relating to emotional stability in the 
anonymous group, the imbalance did not continue through to other mental or mood 
effects. 
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Table 4.65  
Data Checking for Anonymity of Users by Drug Effect Categories for Lexapro and 
Seroquel Combined 
  
Anonymous Users 
(N=477) 
Identifiable Users 
(N=243a) 
Chi-
square 
p- 
value 
Lab Tests and Chronic 
Conditions 11 13 4.629 0.031
Head or Face Effects 57 17 4.284 0.038
Mental or Mood Effects 307 140 3.114 0.078
Other Effects 87 32 3.000 0.083
Sleep Effects 258 120 1.429 0.232
Sexual Effects 57 23 1.006 0.316
Gastrointestinal and 
Urinary Effects 59 26 0.431 0.512
Nose Throat Chest Effects 49 23 0.117 0.733
Appetite and Weight 
Effects 134 71 0.100 0.752
Skin Effects 25 13 0.004 0.951
Musculoskeletal and 
Neurological Effects 76 39 0.002 0.968
aExcludes users from CrazyMeds because all users of this forum have an identifiable user 
name.  
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Table 4.66  
Data Checking for Anonymity of Consumers on Statistically Significant Code Categories 
for Both Drugs Combined 
 Anonymous Users  
(N=477) 
Identifiable Users 
(N=243) 
Lab Tests and Chronic 
Conditions 
  
Blood pressure changes 0.6% 0.8% 
Blood sugar high / diabetes 1.0% 4.1% 
Cholesterol high 0.0% 0.4% 
Liver levels / hepatoxicity / 
hepatitis 0.2% 0.8% 
Other labs or chronic conditions 0.6% 0.8% 
Head or Face Effects 
  
Headache / migraines reduced 0.4% 0.0% 
Headache increased 5.9% 3.7% 
Hearing, taste, smell changes 1.3% 0.4% 
Jaw clenching / grinding 4.4% 2.5% 
Vision / eye changes 1.9% 1.6% 
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Table 4.67  
Data Checking for Anonymity of Consumers on Selected “Mental or Mood Effects” for 
Lexapro and Seroquel Combined 
 Anonymous Users 
(N=477) 
N (%) 
Identifiable Users 
(N=243) 
N (%) 
Chi-
square 
p- 
value 
Symptoms improved 154 (32.3%) 67 (27.6%) 1.681 0.195
Emotionally stable / calm  65 (13.6%) 20 (8.2%) 4.503 0.034
Symptoms new / worsened 69 (14.5%) 23 (9.5%) 3.612 0.057
Brain fog / zombie 65 (13.6%) 36 (14.8%) 0.188 0.664
Numb / detached / lack of 
energy or interest 44 (9.2%) 18 (7.4%) 0.675 0.411
 
Scripted comments. 
 Table 4.68 shows results of the search for 14 common key words and phrases found on 
the drug manufacturers’ websites and medication guides. From the sampling frame of 
over 7,000 consumer comments, half of the 14 phrases were found in 1 or more 
comment. For most of the phrases, there was no resemblance between the consumer’s 
comment and information on the manufacturers’ websites or medication guides. For 1 
phrase, a consumer was citing information from the drug’s patient information leaflet. 
One consumer returned for the phrase “safe” stated that he was a pharmacy technician, 
but that he took Seroquel and found it to be “SAFE, EFFECTIVE.” This consumer 
advised, “If you follow the drug guidelines and your doctors recommendations you will 
be fine!” This comment was included in the sampling frame, but was not randomly 
selected for the coding sample.  
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Finally, 1 consumer comment returned for the phrase “takes time” posted an 
extremely positive comment about Lexapro, “I am so glad that I did (try Lexapro)! It 
takes time, so stick with it and you will be so glad you did….Lex has rocked my world in 
the best way. For once in my life I feel like I HAVE a life…For me it has been nothing 
short of a miracle. I praise and thank God, A LOT!” The search phrases  “continue to 
take” and “takes time” came from the following sentence on Lexapro.com: “Remember, 
it is important to continue to take your medicine for as long as your healthcare 
professional advises, even if you start feeling better. Otherwise your symptoms could 
return or worsen. Full recovery takes time.” The above consumer comment, while highly 
favorable, did not duplicate information on Lexapro.com and was kept in the sampling 
frame (though it was not randomly selected for the coding sample).  
 Taking the 3 data checking strategies together, there did not appear to be any consistent 
patterns of bias. There was an imbalance of favorable comments related to emotional 
stability by anonymous users, but this imbalance did not appear for other mental/mood 
effects. Further, there were few differences in reporting according to time period or 
newness of the post. Since this is a preliminary effort at exploring the authenticity issue 
of online consumer reviews, continued vigilance and additional probing is certainly 
necessary. 
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Table 4.68  
Sampling Frame (N=7,114) Search for “Scripted” Comments 
Search terms # of 
returns 
Conclusion about comment(s) 
Effective in the treatment 0  
Can be taken every 0  
Proven effective; proven to 
be an effective 
0  
Significantly improved 2 No resemblance 
Controlled studies; clinical 
studies 
2 Cited information from PI sheet 
Continue to take your 
medicine; continue to take 
20 No resemblance 
Full recovery takes time; 
takes time 
8 Case #4367 was a very positive comment 
Increas* serotonin  2 No resemblance 
Maintain* treatment; prevent 
the depression  
1 No resemblance 
Keep taking your medicine; 
take your medicine 
0  
May take several weeks  0  
Work* well and generally 
safe; safe 
46 In case # 4784, user stated he is a pharmacy 
technician, but that he takes Seroquel 
Symptoms don’t improve 0  
Initial presentation of bipolar; 
precipitat* 
0  
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Chapter 5: Strengths and Limitations 
Research Strategy 
Coding and analysis for this project relied on the researcher-interpreter as 
instrument. Researcher bias, including taken-for-granted assumptions, prior knowledge, 
and personal responses to the data, is a problem for all researchers to handle reflexively 
and transparently. Several strategies were used in this research to minimize the overall 
impact of the researcher’s perspective. First, coding stuck close to the data, especially for 
drug effects where little interpretation was needed. Also, theory construction was not part 
of this research project, which minimized the potential for broad generalizations and 
unfounded conceptual leaps.  
Second, an advantage of using QDA Miner for this project was its ability to track 
every key stroke. The software included a “Command Log” function in which every 
command, code, or change to the data was tracked for ultimate transparency. Memos 
written by the researcher and attached to codes or cases further served to track the 
evolution of ideas and to make note of unusual cases or uncertain coding decisions.  
Finally, a 20% randomly selected sample of the data was coded by 2 independent 
coders and acceptable agreement was reached. While it is in the nature of a grounded 
theory approach for the codebook to continually evolve, for this research many codebook 
revisions were decided through discussion between the 2 coders (after independent 
coding was completed).  
A primary aim of grounded theory coding is to produce categories that fit closely 
with the data (Corbin & Strauss, 2008). The credibility, in terms of the trustworthiness 
and believability, of the present research was enhanced by minimizing interpretation of 
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data, maintaining transparency in the coding process, and including a second independent 
person to test for agreement.   
Authenticity of the Sample 
Due to the inherent anonymity of the Internet coupled with marketing imperatives 
of pharmaceutical companies, it is possible that pharmaceutical company representatives 
may be covertly contributing to consumer-constructed sites, thus compromising the 
integrity of the data as genuine consumer experiences. The credibility of the user-
generated web and the authenticity of individual contributions within specific websites is 
an unresolved and evolving issue. Further, it is difficult to identify possibly unauthentic 
accounts, and there is no precedent for a method to accomplish this task.  Despite their 
lack of credibility in certain quarters, however, user-generated sites are highly trafficked 
and carry utility for their constituents and users.   
Revisions to concepts of truth, credibility, legitimacy, and expertise brought on by 
the Internet are at the heart of discussion and debate among Internet researchers in a 
variety of fields (David, 2007; Keen, 2007; Warnick, 2007). Adding to this discussion, 
the present research sought to investigate the similarities and differences in the drug 
information presented by experts and consumers on various websites. This is to 
distinguish the aim of the research from one that seeks mainly to determine the truth 
value of specific claims. 
The present research included a few strategies to attempt to check the data for 
possible bias. All findings were used to nuance the final conclusions regarding the 
construction of expertise on the Internet. The research compared recent consumer 
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comments to earlier comments, anonymous comments to identifiable ones, and searched 
for “scripted” comments copied from pharmaceutical company material.  
Second, the substantial number of contributions on the consumer-constructed sites 
sampled in this research (minimum 200 contributions) was further intended to reduce the 
overall impact of possible intrusions. Third, preliminary research was conducted by 
contacting Web 2.0 researchers, bloggers, and webmasters, and by performing a 
wikiscanner search of Wikipedia edits.  
It is likely that the issue of authenticity on the web will continue unresolved for 
some time due to the nature of this medium. The information and data resulting from the 
above strategies are not conclusive evidence, but do offer the suggestion that most 
consumer accounts can be accepted at face value as genuine consumer accounts. They 
also suggest the possibility that a small proportion of favorable accounts regarding drugs 
might be posted by drug company representatives posing as consumers. Given the market 
imperatives of drug promotion, the immense financial means of the pharmaceutical 
industry, and the enticing marketing opportunity consumer review sites offer, a skeptical 
watchfulness regarding this issue is prudent.  
The present research sought to contribute to this discussion via the various checks 
on consumer comments completed as part of data analysis. The selection of websites with 
a high number of contributors was a final strategy to ensure rich and varied data. None of 
the above measures, however, can speak to the authenticity of reported consumer 
experiences as actual experiences, and almost no previous research has sought to 
investigate this problem. Until systematic assessments of this kind do occur, it cannot be 
assumed that the data here are genuine consumer experiences; rather they only present 
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themselves to be consumer experiences. They also appear to be regarded by most web 
users as genuine experiences, making an exploration of their content an important, though 
not wholly sufficient initial step for research. This is the chief limitation of the data, and 
must be a top priority for continued research if such data is to be made meaningful and 
useful. 
Generalizability and Applicability 
Applicability refers to findings that provide the insight or understanding that 
allows them to be used in a practical way in policy, practice, or as an addition to a 
knowledge base (Corbin & Strauss, 2008). The findings of the present research were not 
intended to be generalizable in the sense of being representative of a larger population. 
This research was not able to speak to the unknown population of consumer-constructed 
or expert-constructed websites on the Internet, but the findings did result in a deeper 
understanding and insight of the content distributed across the selected sites. The 
sampling of exemplar sites reflecting typologies further increased the applicability of the 
finding, which is discussed in more detail in the Conclusion.  
Units of Analysis 
 Individual consumers were counted as a single case in this study. For the 2 sites with 
discussion forums, all comments from a user across multiple discussion threads were 
collected and put together to count as a single case. Some users may have had 1 entry, 
whereas other users may have posted dozens of comments. It is further likely that the 
heaviest users – in terms of the number of comments they posted – have a stronger 
presence and a different standing within the community compared to those who sparsely 
post. To other community members, the comments of heavy users may hold more weight 
219 
 
or be more authoritative, and may influence others’ comments and the direction of the 
discussion. The present study did not differentiate between these users, so that consumers 
who posted 1 time and those who posted 30 times were given the same weight. The 
analysis, therefore, did not replicate a “typical” reading of this text because it did not 
effectively capture the nuances and particularities of each online community. To partially 
address this limitation, measurements of code frequency (which included multiple 
mentions within a case), rather than case occurrence (which counted each case 1 time 
regardless of the number of times the code appeared), were sometimes used to reflect the 
relative attention given to certain themes/effects by heavy users.  
Statistical Analysis and Comparisons 
 There were a high percentage of consumers who did not report variables of gender, age, 
and length of time taking the drug. These large amounts of missing data and low cell 
frequencies prevented some statistical analyses. To work around this problem, some 
categories were collapsed, such as in the analysis of age group by drug taken where the 2 
oldest and 2 youngest age categories were combined.  
At other times, sparse reporting of individual drug effects, for example sweating 
or rash, necessitated examining them as categories of effects, such as “skin effects.” The 
development of categories for individual effects was based on prior knowledge of body 
systems, as well as the logic and discussion of the two coders. Inter-coder agreement 
indices, however, were based on categories of effects and acceptable agreement was 
reached. Regardless, there is inherently some interpretation involved in grouping items 
together. Whenever statistical tests relied on categories of effects, individual effects 
within that category were further examined to determine where differences, if any, may 
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have resided. Most analyses included some combination of examining effect categories, 
individual effects, and descriptive excerpts from the data. This strategy of looking at the 
data in multiple ways was intended as a checks and balance for bias that may have 
existed at any individual angle. 
 Another difficulty emerged in finding a common metric to compare expert text and 
consumer comments. Simple frequencies of the number of cases from each group or how 
many total times each group mentioned an effect did not provide meaningful comparisons 
because of differences in the quantities (n=4 for experts, n=1080 for consumers) and type 
(informational text versus consumer reviews) of data. An admittedly cumbersome 
common metric was found in taking the proportion of mentions of an effect/theme out of 
all mentions of effects/themes. For example, it was not revealing to state that 100% of 
expert cases mentioned the “talking with the doc…” code and just over 16% of 
consumers mentioned this code. Similarly, because of the large discrepancy in the 
amount of data for each group, it was difficult to interpret what it meant for that code to 
be mentioned 109 times in 4 expert cases and 316 times in 181 consumer cases. 
However, a comparison could be made in the proportion of those frequencies of mentions 
out of all mentions, in this case being 52.7% of all mentions of themes in expert text and 
5.1% in consumer text.  While unwieldy and not intuitive to grasp, this metric offered the 
advantage of estimating the relative attention given by each group to specific effects and 
themes. This metric was complemented by excerpts of text from each group to add depth 
and richness to the comparison. 
Finally, this was an exploratory study intended for hypothesis generation, rather 
than hypothesis testing. There was a lot of data to sort through and a large number of 
221 
 
comparisons were made. In such exploratory studies with many comparisons, it is likely 
that some significant findings will occur in error. In this study, corrections for multiple 
comparisons were made in some cases. However, a more general cautious approach to 
the data was warranted whereby no specific p-value was interpreted too strongly. Rather, 
conclusions were based on the overall pattern of results. Conclusions of the present 
research should further serve as planned hypotheses to test in additional future samples.   
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Chapter 6: Discussion 
Additional Data on Popularly Reported Drug Effects 
 Lexapro. 
 Consumers taking Lexapro mentioned effects related to sleep, weight, and sex more 
often than any other type of effects (excluding mental/mood effects). This finding is 
congruent with other research surveying consumers on “side effects” of antidepressants. 
iGuard.org, an online service that collects drug safety information from their “patient 
community,” randomly surveyed 700 of its members who were taking at least 1 of 5 
antidepressants, including Lexapro (Cascade, Kalali, & Kennedy 2009). The aim was to 
gather “real-world” information about antidepressants’ side effects. Of the 229 
consumers (38%) who reported 1 or more side effects, the most frequently reported 
effects were: problems with sexual functioning (24.5%), sleepiness (23.1%), and weight 
gain (21.4%). A survey of over 3,000 Consumer Reports’ readers being treated for 
depression and anxiety found a 40% incidence of sexual dysfunction and 20% incidence 
of weight gain (“Drugs vs. talk therapy,” 2004). These frequencies are not too different 
from findings in the present research in which 20.2% of Lexapro consumers mentioned 
“sexual effects,” 23.8% excessive sleepiness, and 12.1% weight gain (although “appetite 
and weight effects” were mentioned by 22.5%).  
 Controlled trials have reported widely varying rates of sexual dysfunction with 
antidepressants, sometimes ranging from 20% to 80%. The 20.2% rate of mention for 
sexual effects of Lexapro found in the present study, then, is on the low end of estimates. 
An 8-month double-blind study comparing Lexapro (n=274) to another antidepressant 
and placebo found 48.7% of Lexapro participants reported sexual dysfunction at 8 weeks 
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(Clayton, et al., 2007). This was significantly more than that reported on the other 
antidepressant or placebo (however, the study was funded by the manufacturer of the 
other antidepressant). The rate fell only slightly by the 8-month study ending (43.6%), 
but was no longer significantly different from the other drug.  
 The FDA-approved drug label for Lexapro cites lower rates of sexual dysfunction. Less 
than 2% to up to 7% of clinical trial participants for major depressive disorder and 
anxiety are listed as experiencing decreased libido or impotence. These effects were 
described in WebMD as “infrequent” and “unlikely.” However, within the category of 
sexual effects, lost sex drive was the most frequently mentioned effect by consumers in 
this study (10.6%).  The FDA label further reports that 2% and 6% of participants in 
depression and anxiety trials, respectively, experienced anorgasmia, and 9% and 14%, 
respectively, experienced ejaculation disorder. Trouble achieving orgasm was listed as a 
“common” and “less serious” effect in WebMD, and mentioned by 8.5% of consumers 
taking Lexapro.  Thus, the officially “infrequent” effect of lost sex drive came up more 
frequently in the present sample of websites than what is supposed to be the more 
“common” effect of delayed orgasm.  
The drug label for Lexapro also cites lower rates of sleepiness and weight gain 
compared to consumers in this study and findings from iGuard.org. Somnolence, a term 
than encompasses drowsiness and sedation, has a 6% incidence in depression trials and 
13% incidence in anxiety trials according to the drug label, compared to the over 23% 
rate of mention in both the present and iGuard.org studies.  
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Weight gain is not listed as a side effect on the drug label, rather the following 
statement is present, “Patients treated with Lexapro in controlled trials did not differ from 
placebo-treated patients with regard to clinically important change in body weight” (p. 
13). Following the lead of the drug label, neither weight gain nor weight loss were 
mentioned at all on WebMD, and RevolutionHealth only spoke to “weight changes” as 
“less serious.” WebMD did list increased appetite as a “rare” effect. Again 22.5% of 
consumers in this study mentioned appetite and weight effects of Lexapro, and over a 
fifth of consumers in the iGuard.org survey reported weight gain on antidepressants.  
The primary “side effects” of Lexapro that were reported by consumers in this 
study appear congruent with findings from other consumer surveys. However, the rate of 
sexual effects was on the low end of the varying estimates found in controlled trials. The 
rates of sleep and weight effects were considerably higher than those listed from 
controlled trials on the drug label. Descriptions of effects in the 2 expert texts appeared to 
largely reflect data provided on the FDA-approved drug label.  
Of note, the popularity of an effect among consumer reviews may reflect its 
subjective burden on consumers more than its actual incidence in the drug using 
population or severity in terms of potential health complications. This limits the 
usefulness of comparing frequencies across consumer surveys, controlled trials, and the 
drug label. Caution should be taken not to over-interpret any single finding. Nevertheless, 
such comparisons are a first step to exploring the similarities and differences of these 
sources, and some comparisons, such as the above absence of weight gain on the drug 
label compared to a high rate of mention among consumers, are quite striking.  
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Seroquel. 
For Seroquel, the most commonly reported effects by consumers in this study 
were related to sleep and weight. Over 60% of consumers mentioned sleep effects, and 
over 30% mentioned appetite and weight effects. Antipsychotic induced weight gain is a 
well-known and concerning issue that can often precipitate more serious metabolic 
diseases (Correll, et al., 2009; Goudie, Cooper, & Halford, 2004; Taylor & McAskill, 
2000). On the FDA-approved drug label for Seroquel, there is a confusing discrepancy on 
the incidence of weight gain in controlled trials. A table on page 17 cites that an average 
of 22% of subjects in trials for schizophrenia and bipolar mania, and 8% in trials for bipolar 
depression experienced weight gain greater than 7% of total body weight. However, a table 
on page 28 that lists all adverse effects in trials for schizophrenia and bipolar mania cites a 
5% incidence of weight gain, and 4% incidence in trials for bipolar depression.  WebMD 
cited weight gain on Seroquel as “common” and both expert texts described it as less serious 
or less severe. Over 22% of consumers in this study mentioned weight gain specifically, 
corresponding to the highest estimate provided on the drug label. Consumer descriptions of 
weight gain were not generally congruent with the “less serious” label, as many reported 
feeling extremely burdened by the extra weight and uncontrollable, ravenous appetite, and 
occasionally reported a dangerous amount of rapid weight gain. 
Off-label use of prescription medications is common, and can exceed 50% for many 
psychiatric medications (Radley, Finkelstein, & Stafford 2006). In the present study, over 
one-third of consumers taking Seroquel reported that the drug helped them sleep, and nearly 
the same number reported the drug caused excessive sleepiness. Expert texts included no 
mention of the drug as a sleep-enhancing agent, as it is not a FDA-approved indication, 
226 
 
though this appeared to be a popular use of the drug according to consumer accounts. Studies 
of antipsychotic use in large psychiatric hospitals support this finding and suggest that 
Seroquel is frequently used in practice to induce sleep (Philip, et al., 2008; Stowell, et al., 
2009). An analysis of Veterans Administration data for 2007 showed that over 60% of 
the 279,778 unique patients who received an antipsychotic prescription were using the 
drug for an off-label indication (Leslie, Mohamed, & Rosenheck, 2009). Seroquel had the 
largest proportion of off-label use (42.9%) compared to all other prescribed 
antipsychotics. Off-label uses included PTSD and Anxiety, among other diagnoses, but 
did not include insomnia, as data for the study was based on official diagnoses used for 
prescription reimbursement (use of Seroquel for trouble sleeping is unlikely to show up 
on those records).  
The drug label for Seroquel states, “Somnolence was a commonly reported adverse 
event” occurring in 18% of patients in schizophrenia trials, 16% in bipolar mania trials, and 
57% in bipolar depression trials. Expert text in this study cited “drowsiness” as a “common” 
and less serious or less severe effect. In a departure from the drug label, expert text further 
listed insomnia as another “common” effect of Seroquel. The latter effect was mentioned by 
just over 2% of consumers in this study, indicating that, at least for this sample of consumers, 
sleepiness (whether helpful or not helpful) was a tremendously more “common” drug effect 
than insomnia.  
Reports from consumers in this study seem to reflect real-world use of Seroquel 
as a sleep-aid, among other frequent off-label uses. Appearing to generally reflect data 
from the drug label, information about the drug’s sleep effects on expert text was limited 
to listing “drowsiness” and “insomnia” as “common” side effects. As an aside, the latter 
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effect was barely represented in the present sample of consumers.  The other commonly 
reported effect of Seroquel, weight gain, was listed on the drug label with generally lower 
incidence rates than the rate of mentions found in the current sample of consumers.  
Effect Classification 
 The findings from this study support Moncrieff and Cohen’s (2006) suggestion that the 
labels “side effects” and “therapeutic effects” may be misnomers that cannot be easily 
applied to psychotropic drug effects. One of the more difficult aspects to developing the 
codebook was in classifying drug effects. The initial codebook included categories for 
“side effects,” “beneficial effects,” and effects appearing “neutral.” This became 
impossible to maintain during coding because many of the most commonly reported 
effects were described by consumers as beneficial, or adverse, or both at the same time. 
For example, the sleep effect of Seroquel was often described to be a benefit of the drug 
in the evenings when sleep was needed, and an undesirable effect during the mornings 
when alertness was needed. In listing drug effects, a consumer on AskaPatient recorded 
the dilemma as such, “fatigue (good for sleep though).” Memos written by the researcher 
in December 2009 and February 2010, noted ideas to merge the “helps me sleep” code 
with the “excessive sleeping” code because they so frequently appeared in the data to be 
one-in-the-same effect of sedation (i.e., some consumers found the drug to induce just 
enough sleep, while others found it to induce too much sleep). In the end, the two codes 
were not merged in the hopes of facilitating a more meaningful analysis of sleep effects.   
Also reported, though less often, were the benefits of Lexapro’s “side effects” of 
delayed orgasm and lost sex drive. A minority of consumers were pleased to find they 
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“can last longer” during sexual intercourse, and/or that their previously high sex drive 
was now more “normal.”  
Similar to the sleep effect described above, some mental or mood effects appeared 
to manifest on a spectrum. The codes “emotionally stable/calm/normal” and 
“numb/detached/lack of energy or interest,” for example, shared the basic property of a 
“mellowing” effect that manifested more or less strongly in different individuals. Over 
9% of consumers mentioned that the “calming effect” of Lexapro or Seroquel put them 
on an “even emotional keel” or “levels out emotions” and allowed them to “handle things 
better.” Just over 7% of consumers commented that the drug “made me not care about 
anything,” “desensitizes me,” made them “numb to the world,” “apathetic,” and “felt no 
emotion (happy or sad!).” The mellowing effect was often clearly distinguished as 
desirable or undesirable by the consumer, though some consumers felt ambivalent about 
how to classify it. A consumer reviewing Lexapro on RevolutionHealth remarked that the 
drug produced “such an even keel that it feels strange…I feel like Spock on the old Star 
Trek series – very rational and systematic, not at all emotional.” A user on CrazyMeds 
commenting on the mellowing effect of Lexapro neatly summarized the problem, “I 
rather wonder how a person being treated for anxiety is supposed to decide when ‘not 
being concerned’ is an undesirable side-effect rather than a desired outcome.” 
For the purposes of codebook development, it appeared to be more precise to 
conceptualize that the drugs produced general effects, such as sedation, that some people 
in certain situations found helpful and some people in certain situations found unhelpful 
(Moncrieff & Cohen, 2006). To produce a more accurate representation of consumers’ 
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accounts, the initial codebook categories (i.e., beneficial, side, and neutral effects) were 
dissolved early in the coding process in favor of coding all effects simply as “effects.”    
Variation among Consumers 
 Consumer reviews on WebMD and RevolutionHealth were different from those on 
consumer-constructed sites in important ways. Significantly more consumers on 
consumer-constructed websites reported Seroquel worsened their symptoms (p=.000), 
while more consumers posting reviews on the expert health sites reported it improved 
their symptoms (p=.008). This trend was repeated for Lexapro, but the difference did not 
reach statistical significance at the p<.002 level. In addition to greater reporting of 
symptom improvement, consumers on expert-constructed sites reported generally lower 
rates of “side effects.” For example, consumers for both drugs on RevolutionHealth 
reported the highest rate of symptom improvement compared to the other websites. For 
Lexapro, they reported the lowest rate of weight gain, and for Seroquel, the lowest rate of 
new or worsening symptoms.  
 Consumers on CrazyMeds mentioned drug effects at a generally lower rate than 
consumers on the other 3 websites, but contributed considerably more than the other sites 
to drug themes. This means that between the 2 consumer-constructed sites reporting 
effects for specific drugs, consumers on AskaPatient mentioned drug effects at a much 
higher rate than those on CrazyMeds. AskaPatient also generally reported “side effects” 
at higher rates than any of the other 4 websites. 
 These differences may be explained by actual differences in the types of consumers 
who use these various sites. Many users on CrazyMeds demonstrate an advanced 
knowledge of psychopharmacology and spend more time discussing drug combinations, 
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dosing issues, and the like as opposed to straightforwardly reporting drug effects.  It 
could be reasoned that consumers using AskaPatient may be disconcerted with more 
mainstream health sources due to negative drug experiences, and looking for an 
alternative space to find and share such experiences. The structure of AskaPatient 
supports this hypothesis, as the site specifically solicits information under 2 main fields: 
“comments” and “side effects.” As a logical extension, consumers on WebMD and 
RevolutionHealth may represent the “average,” mainstream drug consumer with an 
“average” drug experience (i.e., some positive, some negative, but mostly hovering 
around a middle point). However, the consistent pattern of imbalance that both favored 
symptom improvement and demonstrated lower rates of side effects on WebMD and 
RevolutionHealth suggests something other than solely contributions from “average” 
consumers. There could be several possible explanations. One, rather than “average” 
consumers, reviews on these sites come from persons with especially positive drug 
experiences. Two, perhaps expert health sites have filtered consumer drug reviews to 
reduce overly negative accounts. Such a practice could reasonably be attributed to 
financial imperatives related to banner advertisements by pharmaceutical companies. 
Three, the “culture” and virtual physical environment of the websites have influenced the 
type of comments that are posted. Visual cues, such as medical advertisements and 
related graphics, may contribute to a “pro-drug” or “pro-medicine” environment that 
attracts those who share a favorable attitude toward drug use and repel those who have a 
negative attitude or are more critical of drug use. Over time, normative themes may 
become established by way of these graphics and the accumulated text contributed by 
consumers. Users of that site may tend to conform to those normative themes rather than 
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post commentary that departs from them. Thus, the structure of the virtual physical and 
social environment of websites may influence certain behavior patterns of site users.   
Regardless, unless the online health searcher who uses consumer reviews actively 
seeks a variety of sources to retrieve those reviews, these differences in consumers’ 
reporting of drug effects across websites could potentially and unknowingly hinder 
informed decision-making.  
It was hoped as part of this research to also examine differences in reported drug 
effects according to consumers’ gender, age, and length of time taking the drug. If 
variation had been found, it would add detail and precision that might increase the value 
of the information as a body of knowledge. Such detail could prove useful for post-
marketing surveillance. At the same time, added variation potentially increases ambiguity 
for individuals making treatment decisions. Most consumers in this sample of online 
reviews did not provide information on the above variables, which prevented a fruitful 
analysis of possible differences in reporting. Future research may find it useful to contact 
consumer reviewers who leave an email address, or use an online survey to gather data 
that would include these variables.  
How do Expert and Consumers Sources Help and Hinder Decision-Making? 
 Drug effects. 
Consumer and expert text reported many of the same drug effects, and differed 
primarily in their descriptions and the attention given to certain effects. First, while 
expert text listed drug effects, consumer text described drug experiences. Language used 
to list effects in expert text tended to be vague (i.e., “drowsiness”) and fixed (i.e., “less 
severe”). The information on expert sites (e.g., the professionally-delivered drug 
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information on expert sites, which does not include the consumer reviews on those sites) 
was homogenized and the diversity of experiences was erased. Expert text successfully 
eliminated ambiguity, making room for more simple and straightforward treatment 
decisions for health seekers. Expert text appeared to follow the lead of the FDA-approved 
drug label in providing the official account of drugs’ effects. Controlled trials, on which 
the drug label and presumably expert text is based, are designed to capture averages and 
report standardized data. It is therefore of little surprise that the language and design of 
expert text reflected that of its information source.  
 The information reported by consumers represented a greater diversity of perspectives, 
and effects were presented in a more specific and relatable manner in terms of providing 
situational examples. For example, what can be learned from consumers is that 
“drowsiness” caused by Seroquel can sometimes translate to “coma-like sleep” or having 
to miss work or school because of the inability to stay awake. For the code “symptoms 
new/worsened,” expert text summarized in list form the adverse mental or mood effects 
reported in FDA black box warnings on the drug labels. These were the most frequently 
mentioned effects in expert text. Consumers reported these same effects, but with many 
examples of how they might manifest in various combinations and to varying degrees 
(see Table 4.22).  
 Next to mental or mood effects, expert text most often mentioned physical “side 
effects” of drugs, such as nausea/vomiting, dizziness, and blood related changes. 
WebMD (though not RevolutionHealth) listed a number of (usually rare) physical effects 
that could only be diagnosed with laboratory tests, and that could cause serious disease 
conditions if left undetected. Only a couple of these effects (i.e., increased blood sugar) 
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were discussed by more than a few consumers. Expertise regarding the human body and 
drugs’ actions on the body may be necessary to ensure patient safety in cases of rare 
adverse effects or those with less obvious manifestation (i.e. that require laboratory tests 
to detect). While consumer accounts offer rich descriptions of many drug effects, less 
discussed effects carry the risk of becoming lost in the volume of data.  
It is difficult in expert text to decipher the relative burden of lists of effects simply 
labeled “less serious” and “serious.” In this study, those labels applied by experts’ did not 
always match up with the perceived importance or severity of effects according to 
consumers. One hypothesis is that expert text may label effects according to their impact 
on the physical body, so that weight gain and sexual dysfunction are generally “less 
severe” effects while a blood clot in the lung is “severe.” Consumers may be more likely 
to label effects according to the impact on their lives as a whole, including the physical 
body, psychological and emotional well-being, and social lives. Weight gain becomes a 
more serious effect judged by its impact on the person’s life, while a possible symptom of 
something more detrimental to the body, such as coughing or trouble breathing, may go 
undetected because it carries less subjective burden on the life of the person experiencing 
it. It is arguable, then, whether consistency in expert and consumer descriptions of the 
“severity” of effects is possible or even desirable. Of course, for many effects, it seems 
reasonable to assess the effect according to its total impact on a life. Expert text might 
increase its relevance to consumers by either better explaining the meaning of its current 
labels or expanding its label system to include effects’ broader impact.   
 A cursory browse (as may be typical for the average Internet user) through consumer 
reviews offers a strong general impression of what the drug may be “like” through 
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concrete, descriptive examples of individuals’ experiences. In such a brief review, 
though, the Internet user would likely miss many less popularly discussed but still 
potentially momentous effects. There is an increased likelihood when relying on 
consumer accounts that persons might miss important information about potential drug 
effects that can only be detected on the basis of laboratory tests. In contrast, for the 
“typical” online health seeker, expert text provides succinct and readable summaries of 
both common and rare, less serious and serious drug effects.  
 Finally, experts and consumers differed in the attention each group gave certain effects. 
Consumers taking both drugs appeared to be most concerned with effects on symptoms, 
sleep, and weight, whereas expert text primarily attended to physical effects. Consumers 
taking Lexapro frequently discussed weight gain, though this effect did not appear at all 
in 1 expert text and only appeared as “weight changes” in the other. About one-third of 
consumers taking Seroquel reported the drug helped them sleep, but there was no 
mention in expert text of the drug’s potential beneficial or desirable impact on sleep. 
Expert text simply listed “drowsiness.”  
In sum, expert and consumer text reported many of the same drug effects, but the 
relative attention given to particular effects was not distributed similarly among the 
groups and descriptions of drug effects were often qualitatively different. Consumers 
frequently discussed effects that were either more obvious or especially burdensome, 
such as weight gain, changes in sleep, and mental or mood changes. Other than 
repetitions of the black box warning from the drugs’ labels, expert text more frequently 
mentioned physical effects, which are more likely to be manifested in less obvious ways 
or carry fewer practical burdens. Consumers offered full and descriptive accounts of drug 
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effects, but the usability of this information is limited by the volume of data that must be 
sorted through. Expert text offered succinct and comprehensive summaries of drug 
effects, but the meaningfulness of this information is limited by the lack of context. In 
answer to the first research question, “Does the accumulated consumer knowledge that 
the Internet allows dissolve the traditional boundary between expert/scientific and 
consumer/lay knowledge?” it seems that both groups have legitimate claims to expertise, 
and both forms of knowledge (that based on the scientific method and that based on 
experience) are beneficial for informed decision-making. The limitations of one are made 
up by the advantages of the other. However, if consumer reports were more organized 
and accessible (their major limitation currently), then the expert accounts found on 
WebMD and RevolutionHealth could arguably be considered superfluous. Similarly, if 
expert accounts increased their relevance by more richly describing the range of drug 
effects, then online consumer reviews may not be such a necessary innovation for the 
thousands of active and potential drug consumers who rely on them. 
Themes. 
 Consumers mentioned more than double the number of themes found in expert text in 
relation to drugs, doctors, family and friends, expense and insurance, pharmaceutical 
companies, and general support and advice. Among the themes overlapping between 
experts and consumers, consumers showed a range and diversity of perspectives, while 
expert text reflected a more uniform discourse. For example, expert text provided lengthy 
lists of possible drug “side effects,” but only 1 statement on 1 of the sites referenced an 
assessment of benefits and costs, and it was clearly in favor of drug use. As part of their 
drug reviews, consumers often made assessments of benefits and costs, and came to 
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favorable, unfavorable, and uncertain decisions. More often than anything, consumers 
came to the conclusion that the drug was for any variety of reasons of limited benefited. 
Consumers also stressed that each person must make their own individual assessment 
(“your mileage may vary”), which is important given the lack of predictability of 
psychotropic drug effects. 
 There was a strikingly uniform discourse in expert text around “the doctor.” Expert text 
was adamant, as measured by the number of times the code appeared in the text as well as 
the percentage of words from the total text that received the code, about telling, calling, 
talking to, consulting with, discussing with, or otherwise making no drug-related decision 
without getting instruction from the doctor.  It was the most frequently mentioned of all 
themes in expert text, and the only theme involving the doctor that was repeated 
continuously throughout each section of expert text. This circular pattern of self-
references whereby whatever the problem, the doctor holds the answer serves to 
strengthen the popularly accepted notion of an esteemed status and specialized 
knowledge of the medical doctor.  
 Consumers appeared to rely on their general practitioner or psychiatrist for their skills 
and technical expertise in medicine, and, with some exceptions, the research found little 
evidence that consumers were trying to exclude their doctor from their care and treatment 
by searching and sharing information online. This conclusion is supported by recent 
focus group research finding that online health seekers felt empowered by instant access 
to information, but were still unwilling to give up face-to-face interactions with their 
doctor (Donnelly, Shaw, & van den Akker 2008). Comments about telling, talking to, 
discussing with, et cetera the doctor were frequent in consumer text. The difference 
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between expert and consumer text was that consumers also demonstrated a range of other 
interactions with and feelings towards the doctor. As discussed in the review of literature, 
previous research has demonstrated insufficiencies in the communicating of drug 
information from doctors to patients/consumers. Those findings are further supported by 
consumer comments in this study.  
Consumer reviews offered the advantage of a diversity of perspectives, as there is 
no single consumer “voice” parallel to the unitary biomedical discourse found on 
mainstream professional health sites. In parallel, expert text seemed to reinforce the 
conventional stereotype of the omniscient doctor and the construction of “medication” as 
an expert domain. 
Theoretical Explanations of Findings 
This research used Foucault’s ideas of power/knowledge and a politics of truth as 
the conceptual framework for analysis. Foucault’s description of knowledge as dispersed, 
often in an incomplete and contradictory manner, appears to be supported by the findings 
of this research. Each consumer (and expert) offered a piece of a larger puzzle by 
highlighting different aspects of the varieties of drug experiences. There was no uniform 
discourse among consumers, but instead multiple, sometimes overlapping and sometimes 
contradictory discourses were present. The extent to which the effects reported by 
consumers were already informed by “expert” information is unknown, and should 
temper the conclusions. However, it appeared that given the opportunity to contribute 
directly to a knowledge field, particularly one involving an “experience good” like 
psychotropic drugs, consumers were able to identify and describe many of the same 
effects reported as part of more scientific methods. If such knowledge is dispersed, as this 
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research suggests, then the question becomes one of understanding how the power 
associated with knowledge becomes linked to one set of truth-making procedures and not 
another. That is, if experts and consumers can both legitimately and meaningfully 
contribute to a body of knowledge utilizing their respective resources (scientific method 
and experience), then differences in status, attention, and influence of that knowledge 
source may relate to power.  
While Foucauldian concepts framed the original research, other theoretical 
explanations of the findings are possible. A more pragmatic framework might 
alternatively argue that the domain of medicine as an expertise is the human body, and 
that the expert text in this research provided a comprehensive and concise accounting of 
drugs’ effects in this regard. Its labels rightly represented the impact of an effect on the 
body.  Expert text also provided information about important effects that would likely go 
unnoticed by those without medical expertise. Thus, medical expertise in the domain of 
psychotropic drugs may be essential and beneficial to those who need it. Further, while 
consumers reported many of the same effects listed in expert text, the presence of bias 
and lack of structure inherent in this data source has limited its usefulness (and therefore 
its use) in the construction of drug knowledge. The scientific method (in its ideal form), 
with its systematic attempts to decipher true effects from noise, may be preferable to an 
unsystematic and (in this case) largely anonymous collection of presumably consumer 
voices.  Still, consumer accounts do appear to add valuable contextual information to the 
understanding of drugs’ effects and their impact on a person’s life. The expert sites in this 
study may have recognized this fact, as evidenced by opportunities provided for 
consumers on the sites to rate and write about their drug experiences.  
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The findings of this study could also be interpreted in terms of evolving tensions 
between expertise and democracy, with the Internet representing an expansion of 
Habermas’ public sphere. Never before has there been the opportunity for public 
participation in constructing official drug knowledge or for potentially identifying drug 
problems. Online patient communities, such as PatientsLikeMe and iGuard, are 
capitalizing on this expansion of consumers’ roles. Consumer comments analyzed in the 
present study did not support fears of some analysts who claim amateur or lay content is 
uninformed, possibly dangerous, and pushes out necessary expertise (Keen, 2007; Siegel, 
2008). On the contrary, consumers reported many of the same effects as listed on expert 
sites, though with sometimes major differences in the evaluation of effects’ significance. 
These differences could not be used to label consumers’ reports as less accurate or of 
lesser quality, but rather may best serve as a supplement to the typically briefer and more 
narrowly focused expert descriptions. Further, some critical theorists argue that the 
Internet is democratizing only inasmuch as marginalized or silenced voices are 
represented (Dahlberg & Siapera, 2007). Expert sites in this study provided opportunities 
for consumers (a traditionally silenced group in clinical drug research) to have “voice,” 
thereby supporting the notion of the Internet as a democratizing space. However, 
important differences were found between consumer accounts on expert-run and 
consumer-run sites, along with considerable imbalances in the number of consumers 
expressing certain themes or topics of concern between sites. As mentioned, these 
differences may reflect consumers’ attempts to maintain congruence with the norms of 
the community (website). They may also suggest that there exist real sub-communities of 
psychotropic drug consumers who have shared experiences and interests related to drug 
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use. Habermas’ public sphere was modified by Hauser who presented the notion of a 
“rhetorical public sphere,” which is “a discursive space in which strangers discuss issues 
they perceive to be of consequence to them and their group” (1999, p. 64). The activity of 
members in a rhetorical public sphere is issue-oriented, then, rather than class-based, 
which may help conceptualize the distinct interests and concerns of consumers across 
websites in this study. The Internet may facilitate the expansion of rhetorical public 
spheres, with the sample of websites in the present study perhaps reflecting this evolution 
in its infancy. As online patient communities continue to grow and additional research 
sheds light on their advantages and disadvantages, it is possible that this new form of a 
public sphere might influence regulatory policy for drugs, including safety surveillance, 
the classification of unpleasant effects as “serious” or other, and the conduct of research.  
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Chapter 7: Conclusion 
Hypotheses for Future Research 
 The grounded theory approach used in this study was intended as an exploratory step 
that would assist in the formulation of hypotheses for more structured future research. 
Several questions emerged. First, the “real” frequencies of sleep, weight, and sexual 
effects of Lexapro need to be further investigated. Considerable discrepancies exist 
between frequencies of mention of these effects in this study, which are supported by 
other consumer surveys, and incidence rates in the published drug label. Does the high 
percentage of consumer reports of these effects reflect an actual greater incidence than 
that captured (or reported) in trials analyzed by the FDA? If these effects are in fact 
occurring at a higher incidence, then how was this missed in large-sized clinical drug 
trials? Alternatively, does the higher percentage found in consumer reports only reflect 
the perceived burden or some other aspect of these effects, but not an actual higher 
frequency of occurrence? A couple of research strategies could examine these questions. 
A large, known (i.e., face-to-face) population of Lexapro consumers could be followed 
for cross-sectional or longitudinal data of drug effects based on structured checklists and 
open-ended response. Controlled trials could incorporate simple targeted measures for 
weight, sleep and sexual effects, rather than continue to rely on “spontaneous” or 
“unsolicited” self-report for such data (a method which tends to underestimate the true 
frequency of events) (Greenhill, et al., 2003; Hughes & Cohen, 2010).  
 For more serious drug effects, data from this study or additional studies of consumer 
reports could be compared to data from the main mechanism through which professionals 
report serious effects they observe in patients, FDA’s MedWatch. The MedWatch system 
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relies on voluntary reports primarily from medical professionals to detect safety issues 
once a drug has been released to the market. A comparison of consumer and professional 
voluntary reports might shed some light on the use of a consumer platform for safety 
surveillance. A number of details should be included in an adverse drug reaction report in 
order for the report to be meaningful, including age, gender, weight, length of time on the 
drug, intensity or severity of the effect, drug history, family history, effect of withdrawal, 
and effect of rechallenge, among other items. Future research could examine how well 
consumers already report these items in online consumer reviews, and make further 
suggestions for how to improve consumer reporting of drug effects. These findings can 
also be compared to the average completeness of MedWatch reports, which are 
specifically designed to elicit this information.  Second, according to findings from this 
study and published research from large hospitals, Seroquel’s primary use and effect is 
related to sleep. This is an off-label use of the drug, and not an “officially” recognized 
primary drug effect (as “drowsiness” is only listed as a “less serious” “side effect”). 
Future research can examine more closely differences between diagnosis and reason for 
use. One hypothesis is that while the official diagnosis or indication (listed for insurance 
reimbursement) may be, for example, bipolar mania, the “reason” for prescribing or using 
Seroquel specifically may be more narrowly related to its desirable effects on sleep. This 
hypothesis runs parallel to Moncrieff and Cohen’s (2009) argument that psychotropic 
drugs have global effects, rather than specific effects on presumed neurobiological 
abnormalities. Consumer review data such as that used in this study could be examined 
for congruence between diagnosis, which was often listed or stated by consumers, and 
reason for use, which was often explained as part of the total review.  
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The present study did not explore differences in drug effects grouped by diagnosis 
or reason for use.  By breaking down frequencies of some “side effects” of Seroquel by 
indication (bipolar mania, schizophrenia, bipolar depression), the drug label implies that 
drugs have specific neurobiological action and that drug effects will differ according to 
the condition being treated. The label sometimes lists considerable differences in 
frequencies of effects among indications, such as a much higher rate of somnolence in 
bipolar depression trials. Of course, it is unknown whether methodological issues may 
have contributed to inflated or deflated estimates in some studies. While not exploring 
diagnosis, the present study did find that drug effects were not easily parceled into the 
categories listed on expert sources and the drug label (i.e., “side effects,” “less serious,” 
etc.). As an alternative explanation to neurobiological specificity, perhaps the global 
effect of sleep is experienced and reported differently by a person presenting with, for 
example, a depressed versus an excitable mood. This hypothesis is supported by classic 
studies of drug use in which 3 factors were found to influence drugs’ effects: 1) drug (the 
pharmacologic action of the drug itself), 2) set (the person’s state of mind, mood, and 
attitude at the time of drug use), and 3) setting (the physical and social setting within 
which the drug use occurs) (Zinberg, 1986). Also, as mentioned in the Literature Review, 
psychotropic drugs’ effects are unpredictable for any 1 person, and may even differ 
within any 1 individual taking the drug at different points in times (Brunton, Lazo, & 
Parker, 2006). To investigate neurobiological specificity versus global drug effects, 
additional studies examining drug effects in healthy, normal volunteers could help 
determine whether primary drug effects, as Moncrieff and Cohen suggest, occur 
regardless of psychiatric diagnosis. Researchers conducting controlled trials of drugs 
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could broaden their scope of inquiry to include a greater range of psychological and 
behavioral effects (rather than a narrow focus on physical effects), as well as variables 
that might influence the drug experience, such as patient expectation, positive or negative 
suggestion by the doctor or researcher, and patients’ personality characteristics.  
Future Research: Authenticity and Credibility 
     A troubling limitation of the online medium in general is the inherently unknown 
authenticity of persons contributing to content.  It is imperative that the investigation of 
authenticity precede the continued development of and reliance on online consumers as a 
legitimate information source. Authenticity is one of a few issues at the center of the 
debate about filtering online searches to retrieve only “trusted” health information 
sources, and is principally directed towards consumer-generated sites (as well as 
“gimmick” advertising sites, such as online pharmacies).  As expert health sites are 
tacitly “trustworthy,” perhaps due to the alignment of their discourse with science and 
medicine, the burden of proof for trustworthiness more often falls on non-expert sources. 
Future research should investigate the authenticity of online consumer drug accounts in a 
way that does not implicitly favor scientific ways of knowing while forcing those 
offering experiential knowledge to prove their worth.  
Currently, the authenticity problem is unresolved and only a few scrutinizing 
attempts have been made in any field of study. For consumer drug reviews, the findings 
from this study could be replicated using additional samples, websites, and drugs, and 
compared to other online consumer samples, expert health information, and drug 
literature.   
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Another important next step is to compare online consumer comments (with 
unknown authenticity) about specific drugs to face-to-face samples of consumers (with 
known authenticity). If feedback from real-world community samples is found to be 
equivalent to online samples, then this may provide a foundation for the continued 
development of online technology to support consumer-generated drug information (see 
next section). Important differences in face-to-face and online samples may provide some 
interesting and useful insights into who really is contributing to “consumer”-generated 
online content.  
Future Research: Usability 
Consumer drug accounts are scattered across the Internet, making the “usability” 
of this information a chief limitation and a top priority for continued research and 
development. First, as there is no “typical” online health search that can be replicated, 
several samples drawn in different ways should be analyzed for representativeness as was 
done in this study with the most recent 20 posts from each website. While AskaPatient 
lists consumer reviews by date, WebMD sorts reviews according to diagnosis then date, 
and RevolutionHealth by diagnosis then “most helpful.” It is likely that a “typical” search 
would include exposure to any number of combinations of reviews based on the 
particular navigation pathways and interests of the user. The preliminary work of the 
present study should be expanded to replicate additional possible searches. 
The present study explored the content of online consumer reports, but a more 
structured examination of specific variables (such as items needed for an adverse drug 
reaction report, listed in the previous section) is necessary to further devise strategies that 
might increase the usability of this information source. One hypothesis stemming from 
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the present research is that many consumers naturally report at least some important 
items within the context of describing their drug experience. This may happen 
sporadically, though, as evidenced by the large amount of missing data in this study for 
gender, age, and length of time on drug. However, the 2 websites that specifically elicited 
that information (WedMD and AskaPatient) had very high rates of completed data. It 
appears then that consumers may be willing to provide additional details if asked for 
them. Existing and developing websites that collect consumer accounts could enhance 
their relevance to safety surveillance and opportunities for more advanced decision-
making by eliciting such information.  
To further increase usability, existing and developing websites could also 
integrate an advanced search function that would allow users to search consumer 
comments for key words, such as “weight” or “tingling,” as well as return thesaurus 
terms associated with those key words, such as “appetite” with “weight” or “zaps” with 
“tingling.” Currently, the websites reviewed in this study sort consumer reviews 
according to date posted, indication, or helpfulness, with no additional options for 
organizing or filtering the hundreds or thousands of comments.   
An additional step would be to develop a “meta” website that integrates the mass 
of dispersed online consumer reviews, and somehow organizes them in a logical and 
useful way. Currently there are patient communities, such as patientslikeme.com and 
iGaurd.org, which attempt to not only collect consumer accounts (like AskaPatient), but 
also to organize and report back in summary form the data from its users. These sites rely 
on the dedication of their users to monitor and report changes in their condition and 
treatment on an ongoing basis. Thus, it may be reasonable to assume that these sites 
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represent a more pro-active and possibly informed group of healthcare consumers, 
compared to those who do not participate in consumer-generated online media and even 
to those whose participation is limited to writing a single drug review on WebMD, for 
example. The present research found important differences among drug consumers who 
posted a review or comment on various websites. To achieve the most balanced and 
representative snapshot of consumer experiences, then, these differences need to be 
accounted for. Individual online patient communities are innovative and useful for many 
reasons, but they are limited in the preceding respect.  
However, there are currently websites for travel (kayak.com) and consumer home 
and electronic goods (consumersearch.com) that pull together information from multiple 
sites and present it in a single organized site. Kayak.com searches travel deals from all 
the major travel sites, such as cheaptickets, travelocity, expedia, and so on, to bring the 
user the best deals without having to visit each site individually. Consumersearch.com 
brings together expert reviews on consumer goods, such as reviews from PC Magazine 
and PC World on a laptop, and lists each full review as well as provides a summary of 
pros and cons based on an assessment of all the reviews. It appears that the technology 
exists to develop the usability of consumer drug reviews, and future research should 
explore the logistics for its application to this domain. Such a “meta” website would 
prove useful for individual drug decision-making, as well as hold potential for active 
post-marketing safety surveillance.  
 
Searching for Health Information on the Internet 
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Currently, search engines such as Google are optimizing health searches to return 
government and other institutional sources at higher rankings, to the exclusion of 
(consumer delivered) sources lacking “quality” seals of approval (Fox, 2010). 
Approximately two-thirds of online health searches start at a general search engine, and 
Google leads the way garnering over 72% of U.S. searches. Thus, search results can 
“make or break” a website in terms of access and attention.  Previously, all searches in 
Google returned websites according to “the ‘democratic’ PageRank algorithm,” which 
favored websites having, for example, a high number of links in and links out, high site 
traffic, ample metadata or key words, and frequent site updating. This somewhat leveled 
the playing field for large and small websites, as the usefulness and relevance of the site 
mattered more than the resources of the site owners.  
Google’s latest initiative, in response to the ongoing debate over health 
information quality on the Internet, is “to guide consumers to safe, trusted health 
websites” (Fox, 2010, para. 3). This has resulted in a new mechanism for ranking 
websites in health searches, whereby the most widely used expert health sites featuring 
quality seals of approval, including WebMD, MayoClinic, and Medline, are highlighted 
at the top of returns (preceded of course by “sponsored links,” or advertisements). This 
search return strategy clearly and openly favors the “big players” with networks of 
human, knowledge, and capital resources.  
However, this research suggests that the “dangerousness” of consumer delivered 
drug information on the Internet may be exaggerated. A cursory review of consumer drug 
reviews, reminiscent of the average web user, reflected drug effects in fair proportion to a 
full representative sample of consumer reviews, which in turn was largely comparable to 
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effects listed on expert health sites. In this study, both expert and consumer information 
sources offered distinct advantages and disadvantages. It does not appear to be true, then, 
that the “best” information is universally to be found on the biggest, most well-resourced, 
expert-run health sites.  
The questionable objectivity and credibility of expert-derived drug information, as 
outlined extensively in the review of literature, warrants a parallel, though rarely 
considered caution when seeking information for making treatment decisions. In fact, it is 
safe to say that the objectivity and credibility of both expert and consumer sources can be 
legitimately questioned, and both sources again have benefits and limitations for 
decision-making. The disparity in labeling sources “trustworthy” and “quality” may 
reflect the power accorded to procedures of science and scientific/medical discourse more 
than actual differences in the trustworthiness or other quality measures of information. 
The promise of the Internet to “democratize” participation in constructing and delivering 
knowledge in a variety of fields is dying in favor of the status quo of the off-line world.  
As the historical advocates for the powerless and silenced, social workers are encouraged 
to promote democratization on the Internet by seeking out consumer delivered health 
sites at least as frequently as other sources during online searches. Practitioners can also 
take the additional time necessary to find and utilize the most useful and relevant sites 
(whatever the information source) rather than simply those that appear at the top of 
search engine returns. These recommendations are not meant to favor consumer over 
expert health sources, but to promote that potential of a level playing field that the 
Internet theoretically allows. Social work practitioners should also support clients who 
show interest in participating in the consumer-generated online realm of healthcare. 
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Until the above investigations concerning authenticity and usability come to pass, 
clinicians and consumers seeking drug information on the Internet may want to be open, 
but cautious when reviewing consumer-generated content. A suitable approach may be to 
read a similar number of reviews from multiple sources, as done in the present research, 
in order to maximize the possibility of exposure to a variety of drug accounts. Anything 
less, such as reading 5 or 10 reviews from a single website, should be avoided, especially 
when the information is being gathered for anything more than simple curiosity. It should 
also be noted that, at least in the current online environment, consumer-generated 
information is complementary to, not in replacement of, a thorough review (certainly by 
social work professionals, if not consumers too) of other drug information sources.  
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APPENDIX A 
Screen Shots of the 5 Selected Websites 
Figure A1. Homepage on AskAPatient.com  
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Figure A2. Lexapro page on AskAPatient.com  
 
Figure A3. Homepage on CrazyMeds.us 
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Figure A4. Lexapro page on CrazyMeds.us 
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Figure A5. Homepage on TheIcarusProject.net 
 
 
Figure A6. Medication page on TheIcarusProject.net 
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Figure A7. Homepage on WebMD.com 
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Figure A8. Lexapro page on WebMD.com 
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Figure A9. Lexapro user ratings/reviews on WebMD.com 
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Figure A10. Homepage on RevolutionHealth.com 
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Figure A11. Lexapro page on RevolutionHealth.com 
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Figure A12. Lexapro user ratings/reviews on RevolutionHealth.com 
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APPENDIX B 
QDA Miner 3.2 Screen Shots of Coded Data 
Figure B1.  
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Figure B2. 
 
 
 
Figure B3. 
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APPENDIX C 
Initial Codebook: September 2009 
 CITATIONS AND LINKS 
o Academic Journal Internet 
 
 DRUG EFFECTS 
o Changes for the Better/Favorite or Best 
Effects 
 Able to live my life 
 The world is good again 
o Changes for the worse/”Worst” side 
effects 
 I feel fat now 
 Sex used to be part of my life 
o Consequences of Side Effects 
 A disease for the rest of my life 
 Can ruin my day 
 Frightened 
 Spun into mania by ADs/ re-
diagnosed manic/bipolar 
 Unable to work/missing work 
 
o Discontinuing / Missed Doses 
 “withdrawals” 
 Depression coming back (Disc) 
 Diarrhea (Disc) 
 Dizziness (Disc) 
 Feel like a druggie needing a fix 
(Disc) 
 Feel sick (Disc) 
 Hallucinations (real and 
frightening) (Disc) 
 Headache (Disc) 
 
o General Beneficial Effects 
 Ability to do things in absence of 
symptoms 
 Absence of specific symptoms 
 Clear thinking/Less negative 
thoughts 
 Comfortable/At ease with 
myself/life 
 Decrease hallucinations 
 Depression lifted/ Smile and laugh 
more 
 Emotionally stable / appropriate 
 Energized 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Irritability (Disc) 
 Making me crazier than before (Disc) 
 Passing out (Disc) 
 Trouble sleeping (Disc) 
 Visual tracers (Disc) 
 Vomiting/nausea (Disc) 
 
 
 
 
 Physically relaxed 
 Pleasant / fun dreams 
 Prevent/decrease mood swings/mania 
 Reduced/eradicated anxiety 
 Reduced anger 
 Relatively normal / feel better 
 Relief from problems/can handle stress 
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 Helps me sleep 
 Improved concentration 
 
 
o General Effects Not Specified 
 Knocked me out 
 
o General Side Effects 
 Agitation/jump out of my skin 
 Bad taste in mouth 
 Carb cravings 
 Constipation 
 Crazy, vivid dreams/nightmares 
 Depressed/feeling down/worsened 
depression 
 Diabetes 
 Difficult to wake up 
 Difficulty 
focusing/Confused/Fuzzy 
 Discomfort 
 Dizzy 
 Dry/sore eyes 
 Dry mouth 
 Dyskinesia 
 Excessive sleeping 
 Feel “high” 
 Feel worthless 
 Flat feelings/no emotions 
 Gassy 
 Groggy/Foggy 
 Hangover feeling 
 Headache 
 Heaviness/soreness/pain/numbness 
in legs 
 High blood pressure 
 Impossible to get aroused 
 Inability to reach orgasm 
 Increase appetite 
 Irregular menstruation 
 Jaw clenching 
 Jitteriness/”spazzy freak” 
 Light headed 
 Loss of appetite 
 Lost sex drive/decreased libido 
 Memory loss 
 
o No Beneficial Effects 
o No Effect On… 
 
 Nasal congestion/snoring 
 Nausea/sick stomach 
 No interest in life 
 No/diminished energy 
 Not sleeping well 
 Overactive thoughts 
 Painful sex 
 Rapid pulse 
 Sensitive/amplified hearing 
 Sexual (nondescript) 
 Shortness of breath/breathing problems 
 Sore breasts 
 Spasms/twitching/tremors 
 Stroke/heart failure in elderly 
 Suicidal thinking 
 Suicide attempts 
 Swollen/tight/cramped 
 Tired 
 Tired, but cannot sleep 
 Trouble/Inability to achieve orgasm 
 Urge to urinate/ wet myself 
 Urinary hesitance 
 Weakness 
 Weight gain 
 Weight loss 
 Worsened / induced mania 
 Worsened anxiety 
 Worsened drug cravings 
 Zombie 
 
 
 
 Panic attacks 
 Sex drive 
 Sleep, at high doses 
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 Anger/irritability/rage/impulse 
control 
 Internal thoughts/reactions 
 My chemical imbalance 
 
o No Initial Benefits 
o No Initial Side Effects 
o No Side Effects 
o Timing 
 Initial effect 
 Newly emerged effect 
 Over time 
 
 FINANCES / THE SYSTEM 
 Jumping through hoops 
 
 FRIENDS AND FAMILY 
 Disconnect between family 
perception and user 
experience 
 Dosing/tapering as they did 
 Drug worked well for them 
 
 MY DIAGNOSIS / REASON FOR USE 
 Anger/Irritability/Impulse 
Control 
 Anti-psychotic 
 Anti-psychotic, at higher doses 
 Anxiety 
 Bipolar 
 Depressed / Depression 
 Fear / Inability to live life 
 For a diagnosis 
 For an effect 
 For sleep 
 I am NOT –blank- 
 
 MY DOCTOR 
o Changing Doctors 
 New docs always change your 
meds 
o Doctor doesn’t believe / listen to me 
o Doctor identified side effect 
o Doctor suggested / Doctor put me on 
 
 I feel out of control / cannot shut 
mind off 
 Insomnia due to… 
 Manic/manic-depression 
 Migraines 
 OCD 
 Schizophrenia / Schizoaffective 
 Situational depression 
 Stressful job 
 Unable to function due to tragedy 
 
o I asked for the drug 
o Report to / Listen to your doctor 
o Seems extreme 
o Talk to doc / How to talk to doc 
o Unsure how much I trust my doctor 
o Verifying Doc’s info / Is my pdoc 
right? 
 
 Increase/decrease/adjust dose 
 Liquid form of drug 
 Lubrication/toys for sex 
 Ride out the storm 
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o Doctor was wrong about effects 
o Doctor wouldn’t help me wean off 
o GP or Pdoc 
o I am not a doctor, but… 
 
 
 
 MY DRUG 
o Contra-indications 
 
o Dealing with Side Effects / Finding 
Optimum Effectiveness 
 Add another med 
 Avoid/cut down on caffeine/ 
alcohol 
 Changing time of day 
 Diet/nutrition 
 Differs by time of day 
 Drink more coffee/caffeine 
 Eat a snack with drug 
 Eventually goes away 
 Exercise/stay physically active 
 
o Drug Action 
 Regulates 
 Targets/restores brain 
molecules/chemicals 
 
o Drug-Drug Interactions 
 Don’t take this combination 
 Possible effects of combo 
 Try this combo 
 
o Evidence of Causality 
 Anecdotal 
 Drug or other drug? 
 Drug or pre-existing condition? 
 Medical tests 
 
o Finding the Right Dose 
 Adjusted/tapered myself 
 Different effects/uses at 
different doses 
 
o Judging Effectiveness 
 Side effect trade-off 
 Switch meds 
 Taper SLOWLY / Low starting dose 
 Vitamins and supplements 
 
 
 
 My usual state / I know my body 
 No family history 
 Stop/restart drug 
 While on med 
 
 Increased dose, no help/harm 
 Take exactly as prescribed 
 OK, but not great 
 YMMV 
 
 Returned to this drug once again 
 So many damn meds for so many 
years 
 This time seems different! / The best 
yet! 
 
 Now I need to work on my… 
 Poop out 
 Worsens other conditions 
 
 No better choices 
 Not sure 
 Side effects are too great 
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 Rating scale 
 
o My Drug Experience 
 A miracle/saved my life 
 I hate this drug 
 It’s not like what people say it 
is 
 
o Search for the Right One 
 Doing my research 
 Going back to another drug 
 It’s starting to kick in 
 Not enough time / too soon to 
tell 
 Other drugs made it worse 
 
o Unsolved or Additional Problems 
 Helped with one, but not the 
other 
 Helps only for a few days 
 More meds for other problems 
 
o Weighing Benefits vs Risks/Side 
Effects 
 All in all, I am positive / Side 
effects tolerable 
 Benefits not enough 
 Feel great, no side effects 
 
 PHARMACEUTICAL COMPANIES 
o Brainwashed doctors 
o FDA approval status 
o It’s a business 
o PI Sheet 
 Three percent my ass! 
o Sex is only a problem for med 
 
 SUPPORT AND ADVICE 
o A good mindset 
o Drug Recommendations 
 Better alternative than benzos 
 Doesn’t help like benzos do 
 Don’t take this drug! 
o Seeking experiences / worried 
about effects 
 Drugs won’t work for you/me 
 Generic equivalence 
 I recommend trying it 
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o What to expect 
o Withdrawal 
 Looking back on it… 
 May cause dependence 
 Wait and see 
 
 
 
 
 
APPENDIX D 
Most Recent Codebook: April 2010 
 CITATIONS AND LINKS 
o Academic Journal / “Research shows…” 
o Government/University 
o Internet 
o PI Sheet 
o Within website 
 
 DRUG EFFECTS 
o Classification of Effects 
 Category of Effect 
 “Side Effect” 
 Best/Fun Effect 
 Less serious/ Less severe  
 Serious/ Severe 
 Worst/ Most Annoying Effect 
 Frequency 
 Frequent 
 Infrequent 
 Rare 
 Timing 
 Initial Effect 
 Newly Emerged/ Over Time 
 
o Contraindications (Only for Lex & Ser) 
 For certain people/age groups 
 With alcohol or illicit drugs 
 With certain foods 
 With other medicines 
 
o Discontinuing / Missed Doses (Only for Lex & Ser) 
 Gastrointestinal disc effects 
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 Neurological disc effects 
 None / No withdrawals 
 Other disc effects 
 Psychiatric/emotional/ behavioral disc effects 
 
o Effects (Only for Lex & Ser) 
 Appetite and Weight Effects 
 Increase appetite/ cravings 
 Loss of appetite 
 Weight gain 
 Weight loss 
 
 
 Gastrointestinal and Urinary Effects 
 Constipation 
 Diarrhea/Gas 
 Menstruation Irregular 
 Nausea/ sick stomach/ vomiting 
 Urinary changes/ problems 
 Head or Face Effects 
 Headache/Migraines Reduced 
 Headache Increased 
 Hearing, taste, smell changes 
 Jaw clenching/grinding 
 Vision/eye changes 
 Lab Tests and Chronic Conditions 
 Blood pressure changes 
 Blood related changes 
 Blood sugar high / Diabetes 
 Cholesterol high 
 Liver levels/Hepatoxicity/Hepatitis 
 Other labs or chronic conditions 
 Mental or Mood Effects 
 Ability to do things in absence of symptoms 
 Agitated / Restless 
 Brain fog / Zombie 
 Crying spells / Emotional rollercoaster 
 Dreams vivid / nightmares 
 Emotionally stable / calm / “normal” 
 Energy increased / Euphoria / Mania 
 Memory loss 
 Numb/ detached / lack of energy or interest 
 Other mental/mood changes 
 Suicidal thinking/planning/attempts 
 Symptoms new/worsened 
 Symptoms reduced/improved 
 Musculoskeletal and Neurological Effects 
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 Abnormal movements 
 Dizzy/Lightheaded/Faint 
 Heaviness/Soreness/Pain/Numbness 
 Neuroleptic Malignant Syndrome 
 Seizure 
 Swollen/Tight/Cramped 
 Weakness 
 Zaps/Tingling 
 Nose, Throat, Chest Effects 
 Breast soreness/lactation 
 Breathing problems/Shortness of breath 
 Chest pain/ heartburn 
 Difficulty swallowing / speaking 
 Dry mouth / sore throat 
 Fever/ Chills / Infection 
 Heart Disease/ Inflammation 
 Heartbeat changes 
 Nasal changes 
 Other Effects 
 Allergic reaction 
 Alleviates side effect from another drug 
 Hot flashes / heat stroke 
 Hungover / Drunk 
 No/Limited side effects 
 Other misc effects 
 Sexual Effects 
 Increased sex drive 
 Lost sex drive/libido 
 Other sexual effects 
 Trouble achieving orgasm 
 Skin Effects 
 Bruising 
 Hair loss/thinning 
 Itching/Rash 
 Stevens-Johnson Syndrome 
 Sweating like a pig 
 Sleep Effects 
 Difficult to wake up 
 Extreme sleepiness / Tired 
 Helps me sleep 
 Trouble sleeping / Insomnia 
 Yawning 
 
 FINANCES / THE SYSTEM 
o Expense / Insurance 
o Jumping through hoops / Hospitals 
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 FRIENDS AND FAMILY 
o Drug did *this* to them / Doing what they did 
o Family/friend observed an effect 
o Other family/friend issues 
 
 MY DIAGNOSIS / REASON FOR USE 
o Anger / Irritability / Impulse Control 
o Anxiety / Panic 
o Bipolar / Mania 
o Change of life 
o Depressed / Depression 
o Eating problems 
o For sleep/insomnia 
o I am –NOT- blank 
o Inability to function/ Stressful life situation 
o Migraines 
o Other reason / diagnosis 
o PTSD 
o Schizophrenia / Psychosis / Anti-Psychotic 
o Skeptical of my diagnosis / Misdiagnosed 
 
 MY DOCTOR 
o Doctor won’t listen / We disagree / I wasn’t informed 
o GP or Pdoc ? 
o I’m taking control / I’m my own best advocate 
o Other doctor-related issues 
o Talking with doc / Doc explained / Consult doc 
o Trusting the doctor? 
 
 MY DRUG 
o Assessing the Overall Experience 
 A miracle / saved my life / I recommend (Lex/Ser only) 
 All in all, I am positive / Side effects tolerable 
 I hate this drug / Stay away from it (Lex/Ser only) 
 No or limited helpfulness / It’s not my wonder drug 
 Not worth it / Side effects too great 
 YMMV 
 
o Dealing with Side Effects / Finding Optimum Effectiveness 
 Add another med 
 Avoid / Drink more caffeine/alcohol 
 Changing time of day 
 Check blood levels 
 Diet / Food / Exercise 
 Differs by time of day 
 Dose adjustment 
 Learn to live with it 
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 Other methods 
 Ride out the storm / Eventually goes away / Waiting 
 Routine 
 Switch meds / Stop med 
 Taper SLOWLY / Low starting dose 
 Vitamins and supplements 
 
o Do I Need Meds 
 Drugs won’t work / I’m done / I don’t need it 
 Going back on meds / Meds may be the solution 
 Looking back on it…/ Since I stopped the med… 
 Making a plan / Just in case… 
 Trying/Tried alternative treatment 
 
o Evidence 
 Anecdotal 
 Drug or Something Else? 
 Efficacy/Safety not established 
 Medical tests 
 My usual state / I know my body 
 Stop/Restart drug 
o Other Drug Issues 
 Dependence / Withdrawal 
 Diagnoses / Symptoms 
 Dose related issues / advice 
 Generic/other drug equivalence 
 OTHER 
 Poop out / Effects changed 
 
o Other Drugs and Drug Combinations 
 Don’t take this drug/combination 
 My drug combo / so many damn meds… 
 Possible effects / What to expect from other drugs 
 Try this drug/combination 
 
o Theories of Drug Action 
 Targets/Restores brain molecules/chemicals/neurotransmitters 
 Unsure about mechanism/Other 
 
 PHARMACEUTICAL COMPANIES / FDA 
o FDA approval status 
o It’s a business 
o Other pharma/regulatory/FDA issues 
o Three percent my ass! 
 
 SUPPORT AND ADVICE 
o Other general support 
o Seeking experiences / worried about effects 
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APPENDIX E 
Most Recent Codebook with Descriptions of Codes 
CITATIONS AND LINKS 
 Academic journal/ “Research shows…”: Cites, quotes summarizes, references, or 
links to an academic or medical journal, or to a published book or text; Also 
references such as “clinical trials show…” or “research shows…” 
 Government/University: Cites, links, quotes, summarizes information from a 
government website or University’s website 
 Internet: Cites, links, quotes, summarizes information from an Internet website that 
is non-academic, non-governmental; Examples may be medicalnewstoday.com or 
Wikipedia.com 
 PI Sheet: Cites, quotes, summarizes, references, or links to drug label or patient 
information sheet that accompanies the drug 
 Within website: Cites, quotes, summarizes, references, or links to information 
within the same website; Examples include a hyperlink on WebMD that links to 
another page on WebMD, or a hyperlink on a CrazyMeds discussion that links to 
another page on CrazyMeds 
DRUG EFFECTS 
 Classification of Effects 
o Category of Effect 
 “Side Effect”: Effects is listed or identified as a “side effect” 
 Best/Fun Effect: Effect is described as the best effect, “my favorite 
effect,” or similar; Effect is described as fun, enjoyable, cool. 
 Less serious/Less severe: Effect is described as less serious, less 
severe, “not too bad,” mild, “just a little,” or similar 
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 Serious/Severe: Effect is described as serious, severe, strong, 
“really bad,” extreme, or similar; Or effect results in an 
emergency room visit 
 Worst/Most annoying effect: Effect is described as the worst effect, 
the worst side effect, “my least favorite effect,” annoying, 
frustrating, or similar 
o Frequency 
 Frequent: Common, typical, or frequent effect 
 Infrequent: Infrequent, not common effect 
 Rare: Uncommon, rare effect 
o Timing 
 Initial Effect: Described as initial or immediate effect(s) of the drug; 
Effect appeared immediately or almost immediately upon taking 
the drug 
 Newly emerged/Over time: Effect is a new effect that began after 
having been on the drug for some time, such as “this drug has 
always worked great, but after 2 years on it I am starting to sleep 
16 hours a day” or “as I continued to take the drug, my anxiety 
levels increased”; Effect is something that built up over time, such 
as “I gained 45 lbs over 9 months of using the drug” 
 Contraindications 
o For certain people/age groups: Drug is contraindicated for or should be 
used with caution for certain age groups (i.e., children, elderly) or certain 
people (i.e., pregnant women, breastfeeding women), or for people who 
have a certain medical history 
o With alcohol or illicit drugs: Avoid alcohol and/or illicit substances while 
taking this medication 
o With certain food: Dangerous interaction may occur if you take this drug 
with a certain food, i.e., grapefruit 
o With other medicines: Drugs may have a dangerous interaction with other 
drugs, such as anticholinergics, dopamine-like drugs, drugs that cause 
drowsiness, etc. 
 Discontinuing/Missed Doses 
o Gastrointestinal disc effects: Gastro-intestinal effects occur or may occur 
when discontinuing/withdrawing from the drug, or upon missing doses(s), 
including diarrhea, nausea, vomiting, etc. 
o Neurological disc effects: Neurological effects occur or may occur upon 
discontinuing or withdrawing from the drug or upon missing dose(s), 
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including spasms, headaches, zaps, movements, insomnia, fainting, 
dizziness, etc. 
o None/No withdrawals: No noticeable effects upon discontinuing 
o Other disc effects: All other effects that occur or may occur upon 
discontinuing or withdrawal of the drug or upon missed dose(s), such as 
“Some conditions may become worse when the drug is suddenly stopped” 
o Psychiatric/emotional/behavioral disc effects: Tapering off the drug or 
discontinuation of the drug may cause or does cause psychiatric, 
emotional, or behavioral effects, including hallucinations, depression, 
irritability, mania, agitation, crying spells, feeling sick/crazy/abnormal, 
etc. 
 Effects 
o Appetite and Weight Effects 
 Increase appetite/cravings: Increased appetite, often experienced as 
a ravenous insatiable appetite, or making multiple trips to the 
refrigerator all through the night, and cravings for carbs and 
sweets; Also includes effect of “sleep eating,” which is eating 
during sleep with no memory of it happening 
 Loss of appetite: Reduced appetite, loss of appetite, no appetite 
 Weight gain: Weight gain of any amount 
 Weight loss: Weight loss of any amount 
o Gastrointestinal and Urinary Effects 
 Constipation 
 Diarrhea/Gas: Diarrhea, gas, and other changes in bowels 
 Menstruation Irregular: Irregular menstruation, including missed 
periods, additional periods, heavy periods, painful periods 
 Nausea/sick stomach/vomiting 
 Urinary changes/problems: Changes or problems with urine, 
including changes in amount of urine, sudden urges to urinate, 
wetting oneself, urinary hesitance 
o Head or Face Effects 
 Headache/Migraines reduced: Reduced frequency or intensity of 
migraines or headaches 
 Headache increased: Headache or migraine is induced, worsened, 
or increased by the drug 
 Hearing, taste, smell changes: Changes in hearing (i.e., sensitive or 
amplified hearing), taste (i.e., bad, unpleasant, or odd taste in 
mouth), or smell 
 Jaw clenching/grinding: Jaw clenching, teeth grinding 
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 Vision/eye changes: Vision or eye change or problems, i.e., dilated 
pupils, odd eye movements, sore eyes, dry eyes, etc 
o Lab Tests and Chronic Conditions 
 Blood pressure changes: Blood pressure high/increased or 
low/decreased 
 Blood related changes: Blood related abnormal findings, including 
decrease in white blood cells, decrease in blood platelets, etc; 
Blood related changes, such as blood thinning, bleeding easily 
from nose, anus, internal organs, etc 
 Blood sugar high/Diabetes: Increased or high blood sugar, at risk of 
diabetes, or diagnosis or diabetes 
 Cholesterol high 
 Liver levels/Hepatoxicity/Hepatitis: Abnormal liver levels, or 
hepatoxicity, or hepatitis, or other changes in liver functioning 
 Other labs or chronic conditions: Other lab test results or 
development of chronic conditions, including pancreatitis, 
prolonged Q-T interval on EKG, thyroid abnormalities, and 
increased triglycerides 
o Mental or Mood Effects 
 Ability to do things in absence of symptoms: Ability to do things 
(i.e. drive, work, go outside) that a person may have previously 
unable to do because of anxious feelings, depression, etc, or better 
performance or functioning at work, school, etc. 
 Agitated/Restless: Agitation, feeling as though they want to jump out 
of their skin, or crawl out of their skin; jitteriness, spazzy, restless, 
can’t sit still, akathisia, etc. 
 Brain fog/Zombie: Cognitive slowing, including problems speaking, 
slurred speech, stuttering, unable to articulate words or thoughts, 
slowed problem-solving abilities; Difficult to focus or concentrate, 
confusion, mind fuzziness, foggy head, cloudy 
 Crying spells/Emotional rollercoaster 
 Dreams vivid/nightmares: Vivid dreams; odd, bizarre, or crazy 
dreams that may include nightmares or may include fun/pleasant 
dreams 
 Emotionally stable/calm/”normal”: Emotions and/or outward 
reactions are stable/steady, and not explosive or out of proportion 
to the situation; Emotions are appropriate to the situation; Can 
handle stress, problems, difficult situations; Feeling calm, relaxed, 
or at ease with life; More comfortable with one’s life; Less 
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despair, less hopeless; Also for comments such as “I felt more 
normal,” “I felt like myself again,” etc 
 Energy increased/Euphoria/Mania: Increased energy, or high 
energy, which could be perceived as desirable or undesirable; 
Giddiness, excessive cheerfulness, “wired,” “talking a mile a 
minute,” euphoria, feeling “high,” feels like taking speed or 
cocaine; Also includes induced or worsened hypomania, mania 
 Memory loss: Memory loss, including sleep-walking type events 
 Numb/Detached/Lack of energy or interest: Feeling of no emotions 
(not happy, not sad, not depressed, not anything_; flat emotion, 
flat feeling of nothingness; Lack of energy, lack of motivation, no 
interest in life, apathy; Feeling numb or detached from emotions, 
from life, from the world; feeling disassociated or unreal 
 Other mental/mood changes: Other mental or mood changes not 
specified by a code in this category 
 Suicidal thinking/planning/attempts: Thoughts of suicide or actively 
planning suicide; suicide attempts, including acts of self-
injury/self-harm 
 Symptoms new/worsened: New, worsened, or increased symptoms, 
including anger, aggression, being “mean,” irritable, anxiety, 
fear, panic, impulsive, depressed, hallucinations, psychosis, 
overactive/bizarre /uncontrollable thoughts or thinking, paranoia 
 Symptoms reduced/improved: Reduction in or alleviation of 
symptoms, including anger, rage, aggression, “meanness,” 
depression (i.e., depression lifted, smiled and laugh more, 
happier), anxiety, fear, panic, hallucinations, mania, clearer 
thoughts, fewer negative thoughts 
o Musculoskeletal and Neurological Effects 
 Abnormal movements: Abnormal movements, including tardive 
dyskinesia, or effects identified as possible or definite dyskinesia, 
Parkinson symptoms, and spasms, twitching, shakes, tremors, 
jerks, restless legs, etc 
 Dizzy/Lightheaded/Faint 
 Heaviness/Soreness/Pain/Numbness: Heaviness, soreness, pain, or 
numbness in legs, feet, arms, hands, or joints 
 Neuroleptic Malignant Syndrome 
 Seizure 
 Swollen/Tight/Cramped: Swollen or tight arms, cramping in 
extremities or muscles 
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 Weakness: Weakness in muscles or extremities 
 Zaps/Tingling 
o Nose, Throat, Chest Effects 
 Breast soreness/lactation: Breasts swollen or sore, or 
lactation/discharge of milk from breasts 
 Breathing problems/Shortness of breath 
 Chest pain/heartburn 
 Difficulty swallowing/speaking 
 Dry mouth/sore throat: Dry mouth or throat; Sore or irritated throat 
 Fever/Chills/Infection: Fever, chills, other flu-like symptoms, or 
signs of infection 
 Heart disease/Inflammation: Heart disease, inflammation of the 
muscle of the heart, or other heart-related conditions  
 Heartbeat changes: Heart throbbing or pounding, and/or rapid 
heartbeat or pulse, palpitations, slowed heartbeat, etc. 
 Nasal changes: Nasal congestion, snoring, nose bleeds, runny nose, 
etc 
o Other Effects 
 Allergic reaction 
 Alleviates side effect from another drug:  Seroquel or Lexapro 
relieves, improves, or alleviates an effect caused by another 
medication the person is taking 
 Hot flashes/heat stroke: Ho flashes, heat stroke, or increased risk of 
heat stroke in hot weather 
 Hungover/Drunk 
 No/Limited side effects: Drug has no side effects, or virtually no 
side effects; Side effects are limited, or person specifically states 
the drug sis not have a certain effect, i.e., “I’ve had not sexual 
side effects” 
 Other Misc Effects: Other misc effects not otherwise categorized 
o Sexual Effects 
 Increased sex drive 
 Lost sex drive/libido: Decrease in sex drive, no interest in sex, loss 
of libido 
 Other sexual effects: Other sexual effects that do no fir the other 
codes, i.e., a nondescript remark about “sexual side effects,” 
painful sex, prolonged erection, or premature ejaculation 
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 Trouble achieving orgasm: Difficult to achieve orgasm, difficult to 
obtain an erection, difficult to achieve lubrication, lack of 
sensation 
o Skin Effects 
 Bruising 
 Hair loss/thinning 
 Itching/Rash 
 Stevens-Johnson Syndrome 
 Sweating like a pig: From increased perspiration to profuse 
sweating 
 
o Sleep Effects 
 Difficult to wake up: Difficult to wake up in the morning, which may 
include comments about sleeping through alarm clocks, unable to 
get out of bed until noon, etc. 
 Extreme sleepiness/Tired: From drowsiness to extreme fatigue, as 
well as excessive sleeping or napping, often referred to as 
“extreme sleeping” or “extreme sleepiness” 
 Helps me sleep: Drug effect is improved sleep; helps person sleep 
better 
 Trouble sleeping/Insomnia: Trouble sleeping, unable to sleep, 
unable to fall asleep, not sleeping soundly, tired but cannot sleep; 
includes worsened insomnia 
 
FINANCES / THE SYSTEM 
 Expense/Insurance: Any comment related to the expense of the drug, i.e., the 
drug is too expensive or unaffordable; the drug is affordable; Any 
comment related to insurance issues, i.e., insurance was cancelled so the 
person can’t afford the drug 
 Jumping through hoops / Hospitals: Description of the obstacles to 
navigating “the system,” i.e., trying to find another doctor, waiting lists 
and referral systems, too many patients and too few doctors, having to find 
a new doc, having to get a new doc because of insurance, etc; Description 
of or feelings about hospital experiences (positive or negative) and issues 
around involuntary hospitalization and forced medications 
 
FRIENDS AND FAMILY 
 Drug did *this* to them / Doing what they did: Comment regarding how a 
drug worked or did not work for a friend or family member, i.e., friend or 
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family member did well on a specific drug and that influenced the User’s 
choice of drug or it influenced their evaluation of their own drug 
experience, i.e., “I think I’m just a quirk because most people I know were 
just fine” on the drug; Any other anecdotal story about a person(s) who 
have had a particular experience with the drug; Following the experience 
of a friend or family member, i.e., “I am tapering off this drug the same 
way my sister did” 
 Family/friend observed an effect: An effect of the drug is pointed out, 
observed, noticed by a family member or friend 
 Other family/friend issues: Any other comment or information related to 
family or friends, such as how their family is supportive or not supportive 
of their treatment decisions, or how they get along with, take care of, or 
fight with their family 
 
MY DIAGNOSIS/REASON FOR USE 
 Anger / Irritability / Impulse Control 
 Anxiety / Panic: Anxiety or Anxiety Disorder, including all anxiety 
disorders in the DSM (generalized anxiety disorder, social anxiety 
disorder, panic disorder, etc) 
 Bipolar / Mania: Bipolar or Bipolar Disorder; Mania, Manic-Depression 
 Change of life: “Change of life” signs; Hot flashes 
 Depressed/Depression 
 Eating problems: Eating-related problems, including anorexia, compulsive 
eating 
 For sleep / Insomnia: Drug is taken to help with sleep or insomnia, 
including insomnia due to another problems (i.e., insomnia due to anxiety) 
 I am –NOT- blank: Reason for use is partly defined by the diagnosis that a 
person DOES NOT have. This may include hesitance by a person to use 
the drug because they do not have a particular diagnosis, i.e., “I was very 
freaked out for the fact that I am NOT bipolar” 
 Inability to function / Stressful life situation: Drug is used for a person who 
feels out of control in their lives, they cannot “shut my mind off” or calm 
down, unable to function due to fear or overactive thoughts; Person is 
under too much stress and cannot handle problems/life; Drug sis used to 
help a stressful life situation, i.e., anxiety due to a stressful job, depression 
due to family problems, a tragedy or after having a child, etc 
 Migraines 
296 
 
 Other reason/diagnosis: Using the medication for a reason or diagnosis not 
listed, i.e., as a preventative, to counteract side effects of another 
medication, to help during withdrawal from another medication, for 
ADHD, fibromyalgia, IBS, etc 
 PTSD 
 Schizophrenia/Psychosis/Anti-Psychotic: Schizophrenia, Schizoaffective, 
Psychotic Disorder, Psychosis, used as an antipsychotic 
 Skeptical of my diagnosis/Misdiagnosed: There is doubt, skepticism, or 
uncertainty around their diagnosis; Person is misdiagnosed, or has been 
misdiagnosed, and perhaps was put on the “wrong” drug because of the 
misdiagnosis, i.e., “I am bipolar, but was misdiagnosed depressed and put 
on Lexapro” 
 
MY DOCTOR 
 Doctor won’t listen / We disagree / I wasn’t informed: Any general 
disagreement of conflict between the patient and doctor, i.e., “My doctor 
thinks this is a miracle pill for long-term management of my symptoms, 
but I am ready to get off this drug;” Doctor is wrong about an effect, i.e., 
“my pdoc said this would help my insomnia, but it made it worse;” Doctor 
discounts, minimizes, or invalidates an effect the user reports, and/or the 
User states that their doctor does not listen to them or believe them about 
some other medication-related issue, i.e., their doctor doesn’t heed their 
caution about using a drug they had a bad experience with in the past; 
Doctor will not help the patient wean off the medication or does not 
support the patient in wanting to switch medications; The person states 
they feel like they were misinformed or not informed well about the drug 
or drug effects. 
 GP or Pdoc ?: Any comment regarding what type of practitioner to use for 
medication-related decisions and prescriptions, i.e., a general practitioner 
versus a psychiatrist versus a neurologist versus a pharmacist, etc 
 I’m taking control/I’m my own best advocate: Person does their own 
research, monitors their own treatment or condition, or makes some 
treatment-related decision on their own, for example by quitting the drug 
on their own, asking their doctor for a specific drug, etc; Comments about 
having to get informed in order to advocate for yourself to the doctor and 
others 
 Other doctor-related issues: Any other comment or issues related to the 
doctor, such as advice about looking for a new doctor, comments about 
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how supportive the doctor is, or other comments that do not fir in the 
other codes 
 Talking with doc / Doc explained / Consult doc: Recommendation to 
consult, discuss with, or report to your doctor, and/or to listen to your 
doctor’s instructions; Advice or information about how to talk to your 
doctor or how to prepare for a doctor’s visit; Include any other doctor-
made decision, i.e., my new pdoc decided to change up all my meds, or 
include anything explained by the doctor, i.e., my doctor explained that my 
jitteriness might be a side effect of the drug 
 Trusting the doctor?: Involves all issues of trust in relation to the doctor; 
User describes how they are unsure if or how much they trust their doctor 
or doctors in general; User describes some information their doctor gave 
them and they want to verify the information with other users; User 
describes the doctor’s decision, recommendation, or lack of attention to a 
problem as seeming unusual, strange, or extreme  
 
MY DRUG 
 Assessing the Overall Experience 
o A miracle / saved my life / I recommend: The drug or a drug effect 
is described as a miracle or as having saved their life; may also 
include language like the drug was wonderful, amazing, the best 
one yet, changed my life, etc; Also code if the drug is 
recommended because the person loved it or had a great 
experience with it 
o All in all, I am positive / Side effects tolerable: Benefits of the drug 
outweigh side effects, risks, and/or costs; There may still be some 
side effects, but, all in all, the user feels positive about the drug; 
Side effects/adverse effects/costs (including financial costs) are 
insignificant and/or tolerable compared to the benefits of the drug 
o I hate this drug/Stay away from it: I hate this drug, do not like this 
drug, would not take this drug again, had a bad experience on this 
drug; Recommendation to stay away from the drug or not to take 
the drug 
o No or limited helpfulness/It’s not my wonder drug: No beneficial 
effects, few or limited beneficial effects; Drug is okay but not 
great; It’s no miracle drug; Any comment regarding only limited 
helpfulness of the drug; The drug only partially helps solve a 
problem, or helps one problem but not other problems, i.e., Helped 
my anxiety, but not my depression; Also includes comments about 
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having to weigh pros and cons of a drug, but without having 
reached a decision in the comment itself (otherwise, it would be 
coded ‘all in all, I am positive’ or ‘side effects too great’). 
Weighing the pros and cons reflects the ‘limited helpfulness’ of the 
drug, i.e., it’s no miracle cure 
o Not worth it / Side effects too great: Costs/side effects/adverse 
effects outweigh any benefits of the drug 
o YMMV: Your Mileage May Vary; User may have a good or bad 
experience on the drug, but notes that other people may have a 
similar or different experience; Any acknowledgement that 
different people may have different experiences 
 
 
 Dealing with side effects/Finding optimum effectiveness: 
o Add another med: Add a drug to Lex or Ser to help relieve or 
balance out certain drug effects, i.e., uses Wellbutrin with Lexapro 
to help their sex drive, or takes Ativan with Lexapro to help them 
sleep 
o  Avoid/Drink more caffeine/alcohol: Avoid or reduce caffeine 
and/or alcohol intake to reduce side effects or adverse effects, or to 
maximize drug effectiveness; Drink more caffeine (like coffee) or 
alcohol to reduce certain effects (like sleepiness) or maximize 
effectiveness 
o Changing time of day: Try different times of day to take the drug, in 
an attempt to increase effectiveness or reduce side effects 
o Check blood levels: Monitor risk of diabetes and development of 
other conditions with regular tests, i.e., check blood sugar levels 
o Diet/Food/Exercise: Monitor diet or nutrition in order to reduce 
certain effects, like weight gain, or maximize effectiveness, 
including drinking lots of water, counting calories, staying away 
from carbohydrates, etc.; Take drug with food or drink, i.e., eat a 
snack with the drug to avoid nausea; Exercise or stay physically 
active to minimize side effects or maximize effectiveness 
o Differs by time of day: Side effects are better or worse depending on 
time of day, i.e., drowsiness in the morning goes away by evening 
o Dose adjustment: Counter, reduce, alleviate certain effects by 
adjusting the dose either up or down (usually down), and/or 
increase or decrease dose to increase effectiveness; Any comment 
that involves adjusting a dose, including splitting or crushing pills 
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o Learn to live with it: Learn to live with, deal with, or just accept the 
drug; Comment about realizing that there is nothing to be done to 
relieve the effect, so the person must simply live with it 
o Other methods: Any other strategy or method not already listed to 
help minimize side effects or maximize effectiveness, including 
stand up slowly to avoid dizziness, avoid heat, use lubrication for 
sex, report effect to a hotline (like poison control, FDA, or pharma 
company hotline), take PRN or as-needed by not every day, liquid 
form of drug, and “side effect trade-off” 
o Ride out the storm / Eventually goes away / Waiting: Remark that 
“side effects” or “adverse effects” are temporary or will 
eventually go away with time; User describes being willing to ride 
out the side effects, assuming they will go away, or user describes 
how they kept with it through the side effects and found that they 
went away; Also, any comment that involves the concept of 
waiting, such as drug effects, particularly benefits, are not 
apparent immediately, but may “kick in” after a period of time of 
waiting; A person stops taking the drug and is waiting to see what 
happens next, for example, if withdrawal symptoms are going to be 
bad or if their depression will come back (a “wait and see” 
concept) 
o Routine: Minimize side effects or maximize benefits by getting into a 
routine, i.e., a bedtime routine or a sleep routine 
o Switch meds/Stop med: Recommendation or decision to switch meds 
and/or stop take the medication because a specific side effects has 
not gone away with time, and/or the drug has stopped working, did 
not work well, or had too many side effects 
o Taper SLOWLY/Low starting dose: Recommend or advise to taper 
up or down very slowly, or to start with a low dose and taper up, 
or to not stop or quit a drug too quickly or “cold turkey”; Also 
code for any comment generally related to how to start, taper, or 
withdraw from a drug appropriately 
o Vitamins and Supplements: Using vitamins, supplements, and/or 
herbs to counteract or help relieve certain effects, i.e., Vitamins 
B5, B6, and magnesium, to help with fatigue 
 Do I Need Meds? 
o Drugs won’t work/I’m done/I don’t need it: Drugs are not the 
answer for a person’s problems; Recommendation to a User that 
drugs may not be the answer to their problem, i.e., “Drugs aren’t 
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going to get you to sleep if your aversion is PTSD based. Only 
some heavy duty therapy is going to get around that;” user has 
had enough and is done with taking medications, i.e., “No more 
antidepressant!”; User wants to get off/to stop taking medications 
for whatever reasons, i.e., doesn’t need them anymore, doesn’t like 
them anymore, etc. 
o Going back on meds/Meds may be the solution: Meds may be a 
long-term or lifetime solution, or the right solution for this person, 
or meds are definitely part of the overall whole situation; Decision 
to go back to taking meds, or a realization that meds are needed 
for them 
o Looking back on it…/Since I stopped the med…: Comment 
regarding what has happened since the person has stopped taking 
the drug, a reflection of the drug experience now that the person is 
no longer on the drug, OR a reflection of the condition or problem 
now that the person is on meds. Some of these comments reflect 
positive changes (i.e., I feel so much better, more like myself now 
that I am off the meds; I never realized how depressed I was until I 
was put on Lexapro), or negative changes (i.e., now I see how 
much I really needed meds to stay stable; this med messed up my 
brain for years after having stopped taking it) 
o Making a plan/Just in case…” Making a back-up plan, a prevention 
plan, a long-term plan, or a “just in case” or emergency plan  
o Trying/Tried alternative treatment: Tried or is trying an alternative 
treatment, such as talk therapy, CBT, DBT, ECT, EMDR, herbal 
remedies, etc in conjunction with or as an alternative to 
medication; Includes comments about medication not being the 
whole answer, but only part of a bigger plan that includes other 
treatment modalities or lifestyle changes for achieving or 
maintaining health 
 Evidence 
o Anecdotal: Description or explanation of an effect or a possible 
effect based on anecdotal evidence, i.e., from their observations, 
from their reading of discussion forums over the years, etc 
o Drug or Something Else?: An effect may come from the drug or from 
another source, including another drug, another condition (i.e., 
headaches from drug or from previous neck injury?), or from 
placebo effect; There is uncertainty as to the source of the effect, 
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or it is explained why an effect comes from the drug versus another 
source 
o Efficacy/Safety not established: The efficacy and/or safety of the 
drug is not established, is uncertain, or unknown, i.e., efficacy of 
this drug has not been established for adolescents; Long-term 
effects are unknown; There is no evidence, a lack of evidence, or 
uncertainty in relation to a specific use/indication or effect, i.e., It 
is unknown if this drug passes into breastmilk 
o Medical tests: Recommendation or description of medical tests 
(blood work, eye exams, for example) to help determine if an effect 
(i.e., fatigue, spasms, blurred vision) has a physical/biological 
basis 
o My usual state / I know my body: Remark that a person (or 
“people” in general) know their own body enough to be able to tell 
if an effect is from a drug, i.e., User describes that usually they are 
one way, and now they are another way (usually their blood 
pressure is low, and now it is high); Also includes family history or 
lack of family history (of diabetes, for example) as evidence that 
the drug caused an effect 
o Stop/Restart drug: Effect goes away once the person stops using the 
drug, and/or the effect stops once the person stops using the drug 
and returns once the user begins taking the drug again 
 Other Drug Issues 
o Dependence/Withdrawal: Any information or advice about 
dependence (i.e., caution that drug may cause dependence; drug 
did cause dependence for User), or withdrawal (i.e., how to 
withdraw or discontinue from the drug safely) 
o Diagnoses/Symptoms: Information, advice, discussion about 
diagnosis or symptom-related issues, i.e., discussion about having 
depression vs bipolar vs drug-induced mania 
o Dose related issues/advice: Any comment related to drug dosage; 
Information about maximum dosage, what dosage is too high, or 
drug overdose; any comment about taking the medicine exactly as 
prescribed, taking it consistently and regularly; Information on 
missed doses, i.e., what to do if a dose is missed; Also code for 
comments about the drug having a different effect and/or being 
used for a different reason at different doses, i.e., Seroquel is sleep 
inducing at low doses, and sleep neutral at high doses 
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o Generic/other drug equivalence: Recommendation or description of 
a generic or other equivalents of the drug; may include dosing 
equivalents, i.e., “10mg celexa = 5mg or less of lexapro”; and/or 
comparison of similar drugs, i.e., contrasting effects of Lexapro 
and another SSRI 
o OTHER: Garbage can code for any segments that do not fit 
elsewhere. Meds and pregnancy; meds and kids; I am new to meds 
so don’t know what I should be feeling; street use or value of the 
drug’ recycling or storage of meds; self-medicating with other 
substances 
o Poop out/Effects changed: Drug stopped working after a period of 
time that it did work, or effects of the drug changed over time, i.e., 
“At first the drug helped keep me calm, but after taking it for a 
while I found myself getting angry and aggressive” 
 Other Drugs and Drug Combinations 
o Don’t take this drug/combination: Recommend or advise to avoid a 
specific drug or combination; User identifies combination of drugs 
they used and states it  was a poor combination or made things 
worse, didn’t work for them, etc 
o My drug combo/so many damn meds: Remark or description 
regarding a person’s current drug combo, drug history, the 
various drugs and combinations of drugs the person has tried over 
the years, and past bad drug experiences; Note, if it is a 
recommendation or caution, please use other codes; General idea 
that they’ve tried everything, i.e., “I’ve taken every antidepressant 
(or whatever) on the market,” tried other drugs that made their 
problems even worse, tried other drugs that had too many side 
effects, tried other drugs that were not effective; If a specific 
comparison of a previous drug and the current drug, then code 
under ‘other drug equivalence’ 
o Possible effects/ What to expect from other drug: Description of 
possible effects to look out for or what a person can expect when 
taking a drug or combination of drugs, i.e., lowered seizure 
threshold from taking combo of antidepressant and multiple 
anticonvulsants, or “Lamictal is often activating, Abilify is…”; 
Code for effects or possible effects of any drug(s) other than 
lexapro or seroquel 
o Try this drug/combination: List or identification of a drug or a 
combination of drugs that was or may be helpful for a person 
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 Theories of Drug Action 
o Targets/restores brain molecules/chemicals/neurotransmitters: Drugs 
works by targeting or restoring chemicals in the brain; Includes 
comments about the drug being “potent,” “selective,” “targeting 
receptors,” etc 
o Unsure about mechanism/Other: Not sure or not clear about the 
mechanism of action of the drug/how the drug “works;” Or any 
other theory of how the drug may work or have its effects, i.e., 
whether weight gain is caused by metabolic slowdown, stimulation 
of appetite, both, or something else; Other general references to 
“imbalance,” “chemical imbalance,” “messing with brain 
chemicals,” etc. 
 
PHARMACEUTICAL COMPANIES / FDA 
 FDA approval status: Lists or clarifies FDA approval status for a drug and/or 
indication, including whether uses are approved or off-label/ unapproved 
 It’s a business: Remark that pharmaceutical companies are in the business of 
selling drugs; May include a description of a pharmaceutical company gimmick 
or way of doing business to maximize profits, i.e., launching a new drug when 
another one is about to go off patent; May includes doctors’ role in prescribing 
medicines as a business. Or pharma’s role in attempting to influence how doctors 
prescribe drugs\ 
 Other pharma/regulatory/FDA issues: Any other comment or information related to 
the pharmaceutical industry, regulatory industry or process, or other similar 
issues 
 Three percent my ass!: Drug information from pharmaceutical manufacturers or 
on the drug label is limited, narrow in scope, is missing a particular effect, or 
somehow inaccurately estimates the scope of frequency of a drug effect, i.e., 
“according to pharma sexual side effects are only a problem for me” 
 
SUPPORT AND ADVICE 
 Other general support: Any comment giving general support or advice. 
Recommendation to keep a good/positive mindset when taking a drug. Comment 
that a person feels validated about their own experience after reading similar 
experiences of others on the website. Comment about the importance, helpfulness, 
strength of the “community” of online users 
 Seeking experiences/worried about effects: User is wondering if others have 
experienced anything similar to what they have experience, and/or User is 
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seeking others’ experiences with a drug, which may be specific (“does this sdrug 
trigger hypomania?) or general (“what should I expect to happen when I take this 
drug?”); User describes feeling worried or scared about taking the drug, usually 
after having read about experiences of others on the websites, i.e., after reading 
about weight gain or other side effects 
 
 
 
 
 
 
APPENDIX F 
Complete Log of Memo-Writing 
Date Case Memo Code Consumer Comment 
10/23/2009  Case 
#27 
We initially had two codes on 
this segment: Side effects too 
great and I hate this drug. I think 
I'll make a general coding rule to 
use the All in all, I'm positive 
code and Side effects too great 
code if they can be applied 
BEFORE the more general A 
miracle code and I hate this drug 
code. I want to avoid applying 2 
similar codes to the same 
segment, and would prefer to 
use the more specific code if it 
fits before a more general code.  
Not worth it 
/ Side 
effects too 
great 
This lexapro works too much like a 
neuroleptic..i  hate feeling out of 
control, detached...  I would rather be 
depressed than totally anihilated !!! 
10/24/2009  Case 
#45 
About being mis-informed or 
uninformed about possible drug 
effects?? Keep an eye to see if 
this comes up more... 
 
12/1/09 update: This came up a 
couple times in the agreement 
sample. I added this as a 
dimension of Doctor was wrong -
- which is now "Doctor was 
wrong / We disagree / I wasn't 
informed" 
Doctor won't 
listen /  We 
disagree / I 
wasn't 
informed 
Nobody warns you about the apathy 
when you start this drug, had I known 
that I would no longer care about the 
people and things I love, I would have 
never started taking this drug. 
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Date Case Memo Code Consumer Comment 
10/26/2009  Case 
#65 
Emotionally stable/calm/ normal 
and Brain fog/Zombie (and/or 
Lack of interest code)  may be 
two sides of the same coin. It's a 
mellowing effect that for some 
people is just the "right amount" 
of mellowing to the point of 
feeling "normal" or able to 
handle stressful situations, and 
for other people is "too much" 
mellowing to the point of 
becoming a zombie or spacey 
(or to the point of apathy). 
Emotionally 
stable / 
calm / 
"normal" 
Noticed being very mellow the day 
after the 1st dose. The second day I 
seemed a litte more myself, but at no 
point felt "zombieish". 
10/26/2009  Case 
#77 
I am wondering how best to 
characterize consumers' 
categorization of effects. Right 
now I have Best Effect and 
Worst Effect, but am not sure 
how representative that is. It's 
not as straight forward as 
experts' categorization of 
"severe" "serious" "less serious" 
etc. This particular case seems 
to be an example of an aspect of 
the drug that is cool or good, 
maybe not the Best Effect, but 
SOMETHING nonetheless.  
No / Limited 
Side Effects 
Plus, you can have a few drinks on 
them with no ill effects!  SIDE 
EFFECTS. Not many, 
10/27/2009  Case 
#125 
I think I'll really want to do some 
analysis on this code to reflect 
all the dimensions of doctor told 
me to do this, I'm afraid to ask 
my doctor or mention this to my 
doctor (as in the present 
example), how should I bring 
this up to my doctor, etc. This 
seems like a rich category. 
Talking with 
doc / Doc 
explained / 
Consult doc 
My question is: I'm seeing my doctor 
next week and am planning to tell her 
how well things are working out. Do I 
mention these side effects? I'm afraid 
she may want to switch me to another 
med. While it's only been three weeks 
- I really think the Celexa is working. 
10/27/2009  Case 
#129 
Coded as "other methods" 
because this person is agreeing 
with the previous post, which 
said: "I'm betting that the AD 
makes you hypomanic/manic, 
and you reach for a cig to calm 
you down." 
Other 
methods 
You hit the nail on the head.  Come to 
think of it, it explains what happened 
before and what is happening now. 
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Date Case Memo Code Consumer Comment 
10/27/2009  Case 
#133 
Unsure if "stupid" and "dopey" 
are more similar to feeling "high" 
or feeling confused/fuzzy/foggy, 
or something else. Come back 
to this... 
 
Update: For now I will combine 
Zombie and Dopey and 
determine later if that's 
appropriate 
 
Update 12/7/09: I combined all 
of these together into Cogntive 
Slowing / Foggy/ Dopey 
Brain fog / 
Zombie 
Lexapro And Dopey Feeling Posted 
by: Ginger Sun 28 September 2008 
18:11:19 GMT +0000  I got a little 
stupid on Lexapro, and it did 
eventually go away. 
10/27/2009  Case 
#133 
Person must just accept the side 
effect, deal with it, live with it, 
etc. 
Learn to live 
with it 
I am afraid the weight is here to stay 
until I get off the Lex. I am going to try 
a little harder in my exercise, but I'm 
not a hard-core workout nut like I was 
in college, so I will probably end up 
just maintaining where I am. 
10/28/2009  Case 
#143 
This whole thread is about 
people sharing their weight gain 
stories on Lexapro. 
Weight gain I guess I missed the part where 
Lexapro causes weight gain I've been 
steadily gaining weight the past four 
years, but  have only been on Lexapro 
for about a year or so, maybe a year 
and a half. 
10/28/2009  Case 
#147 
Coded "Drug or Something 
Else?" because previous poster 
was suggesting the hair loss 
was due to previous stress, 
rather than the drug that the 
person had only been on for 4 
weeks. The current post is 
agreeing that that may be the 
case. 
Drug or 
Something 
Else? 
May was my standout month for 
extreme stress this year. Oh and 
February. And all summer. No wonder 
my hair is thin! 
10/29/2009  Case 
#173 
Perhaps  create a code about 
other people - family, friends, 
doctor, etc - observing an effect 
the drug is having on the 
consumer. 
 
12/1/09 Update: I collapsed 
some of the family codes into 
one general "Other family/friend 
issues" which inclues the 
dimension above. 
Family/frien
d observed 
an effect 
My partner has noticed that I seem 
somewhat spaced out and forgetful 
(minor things like car keys, turning on 
dishwasher, not hearing what 
someone is saying to me for a 
moment, etc). 
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Date Case Memo Code Consumer Comment 
10/29/2009  Case 
#185 
This comment in response to a 
poster asking about what to 
expect by taking her full dose of 
Lexapro once a day rather than 
split twice a day. Specifically 
asking if there is a risk of mania. 
Dose 
related 
issues / 
advice 
From Twice A Day To Once A Day 
Posted by: Anna Thu 4 December 
2008 14:28:33 GMT +0000  Anything's 
possible when you are disturbing the 
homeostasis... But honestly, I don't 
think the risk is like, huge. Unless it 
really hits your neurotransmitters like a 
ton of bricks or something... 
11/10/2009  Case 
#96 
I'm trying to distinguish "So 
many damn meds" and "Other 
drug equivalence." I am moving 
comments like this one in which 
there is a specific comparison of 
or reference to a previous drug 
and the current drug. More 
general comments, like "I've 
tried lots of meds..." will remain 
under "so many damn meds." 
Generic/oth
er drug 
equivalence 
I've been on lexapro for 3 years and 
has been the only medication that has 
really worked. I tried taking Zoloft and 
it made my depression worse. 
11/10/2009  Case 
#239 
Should this be coded as "Don't 
take this combo" or as a 
Contraindication? Maybe I need 
to merge the two codes... 
 
12/1/09 Update: This seems like 
a clear contraindication now that 
I read it again. But will need to 
clearly distinguish or merge 
these. 
With other 
medicines 
By the way, if you start on SSRI 
treatment, you should stop the 5HTP 
since it may lead to 5HT-syndrome - 
especially with Lexapro. 
11/16/2009  Case 
#123 
Not sure whether to code No 
beneficial effects or Ok, but not 
great. I don't want 2 codes with 
similar meaning for the same 
segment. 
 
12/1/09 Update: This same 
question had come up a few 
times in the agreement coding. I 
merged No beneficial effects into 
Ok, but not great, as well as 
pulled out the Limited 
Helpfulness cases from Poop 
Out and merged them into Ok, 
but not great. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
And I did not find that it was working 
all that well to begin with, 
11/27/2009  Case 
#163 
This comment is a response to 
the previous post: "Lexapro left 
me with my libido intact, but I 
could not orgasm." 
Trouble 
achieving 
orgasm 
That totally happened to me, too!  It 
freaked me out and then I 
remembered... Oh, this is a side-effect. 
It was weird. 
308 
 
Date Case Memo Code Consumer Comment 
11/28/2009  Case 
#185 
Not sure whether to code 
Dependence/Withdrawal, or 
Taper SLOWLY. Again, do not 
need 2 codes with similar 
meanings on 1 segment. 
Dependenc
e / 
Withdrawal 
since you are cross-tapering from one 
ssri to another, there shouldn't be a 
problem in going relatively quickly. The 
slower taper that is recommended with 
ssris is more about if you are coming 
off completely, to avoid withdrawal 
effects. 
12/1/2009  Case 
#115 
We decided to use these codes  
for consumer comments about 
effects being "nothing intense," 
"mild," "insignificant" and other 
words like "less severe" or 
"severe" 
Less 
serious / 
Less severe 
SIDE EFFECTS. Nothing intense, but   
I have noticed that I'm always hungry 
12/4/2009  Case 
#60 
This would fit under the code I 
originally had under Support and 
Advice: Feeling validated. This 
refers to a person feeling like 
their experience is validated 
after reading about others' 
experiences online. 
Other 
general 
support 
I spend most of my spare time in bed 
sleeping - I'm barely participating in 
life. I seriously thought I had chronic 
fatigue syndrome, but after reading 
about other people's experiences, now 
I suspect it's the Lexapro. 
12/4/2009  Case 
#86 
Sometimes the experience of 
the drug is defined by what 
effects are ABSENT. 
No / Limited 
Side Effects 
Never had any tiredness or spaciness 
on it. I also did not experience serious 
sexual side effects. 
12/4/2009  Case 
#124 
I'm wondering if I will need a 
code like "Clinical trials show...". 
Or if I should just put this under 
the citation code? 
 
12/13/09 Update: I've decided to 
add this to the Citation code 
"Academic Journal / Research 
shows..." 
Academic 
Journal / 
"Research 
shows..." 
He said that there are clinical trials that 
show that 80% of those who will 
respond to it at all will show some 
change in the first 2 weeks 
12/8/2009  Case 
#130 
In reference to worsened anxiety 
upon starting Lexapro 
Symptoms 
new / 
worsened 
I just wanted to add that I was in the 
same boat and I couldn't take ONE 
day! You're awfully brave. 
12/8/2009  Case 
#133 
This would fall into a code like: 
"Accepting / Dealing with *it*" as 
a method of dealing with (or not 
being able to deal with?) side 
effects. Rather the person is 
having to learn to just live with it. 
Learn to live 
with it 
Well, I have stayed in the vicinity of an 
overall gain of 8-10 pounds. I did buy 
some new pants. What else are you 
going to do? I looked stupid in the 
pants I had. I know I'll fit into them 
when I get off this medication in 
another 6 months, but I am just sort of 
accepting it right now and dealing with 
it. 
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Date Case Memo Code Consumer Comment 
12/8/2009  Case 
#149 
Another comment about 
"accepting" or "dealing 
with/learning to live with" side 
effects. 
Learn to live 
with it 
I'm only on here venting about how I 
am stressed and concerned about 
weight gain, not saying I have quit yet. 
I need some time to accept the side 
effects. 
12/8/2009  Case 
#156 
I see this idea come up at times: 
I don't plan on ever stopping this 
drug / I will take this for a 
lifetime, etc. I have been coding 
these under "A miracle" and 
possibly under "OTHER" at 
times 
A miracle / 
saved my 
life / I  
recommend 
(Lex/Ser 
only) 
I feel much less insane now, and don't 
plan to stop taking it any time soon, I 
haven't felt this serene in a long time. 
12/9/2009  Case 
#134 
I highlighted this in addition to 
Dependence/Withdrawal 
because of the comment 
referring to "Looking back on the 
drug experience..." now they can 
see that their creativity had been 
zapped. 
 
12/13/09 Update: Decided to 
add a code called "Looking back 
on it.../Since I stopped the 
med..." because this concept 
continues to come up. 
Looking 
back on 
it.../Since I 
stopped the 
med... 
I was having dinner and we had the 
ketchup out, and Heinz has some 
dumb commercial contest going on, 
and I came up with a totally cool 
commercial idea!! I wouldn't have been 
able to think something like that up 
when I was on the meds. But, at the 
same time, I didn't notice that my 
creativity was zapped while I was on 
the meds. 
12/9/2009  Case 
#472 
Added Best/Fun Effect code 
here because I wanted to mark 
her comment "a benefit I had not 
anticipated", and that comment 
does not really fit anywhere else. 
Best / Fun 
Effect 
A benefit I had not anticipated was 
while taking Lexapro I no longer had 
sleep paralysis. 
12/9/2009  Case 
#472 
She says it HELPED her hot 
flashes, so I will have to break 
the improves from the worsens 
hot flashes during analysis. 
Hot flashes / 
heat stroke 
I also think it helped my hot flashes 
12/9/2009  Case 
#533 
I did not code this My Drug 
Combo (as I anticipate Kristina 
will) because I thought Drug Or 
Something Else? is more 
specifically what this comment 
refers to. 
Drug or 
Something 
Else? 
hard time getting up in the morning  . I 
am also on bp meds and klonopin 
which all cause drowsiness. 
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Date Case Memo Code Consumer Comment 
12/9/2009  Case 
#554 
Ok, I am seeing that Taper 
Slowly and 
Dependence/Withdrawal are not 
defined enough to clearly 
differentiate them. I will have to 
somehow merge them or 
differentiate them (after we finish 
agreement coding) 
Taper 
SLOWLY / 
Low Starting 
Dose 
I will start tapering off of it after being 
on it for a year. Take 200mg at 
bedtime, now taking 100mg for a 
month or two and going from there! 
12/10/2009  Case 
#573 
After agreement coding, I think I 
should merge Helps Me Sleep 
with Tired/Excessive Sleeping - 
and rename this new code 
simply "Increased Sleep / 
Sleepiness". As it stands now, 
comments like this would be 
difficult to classify as either 
"Helps me" or "Excessive" 
Extreme 
sleepiness / 
Tired 
I did sleep for 14 hours straight 
12/10/2009  Case 
#591 
Not sure if this belongs here, or 
a code under Muscoloskeletal 
and Neurological Effects 
Brain fog / 
Zombie 
slurred speech, problems with walking 
correctly/balance. 
12/10/2009  Case 
#613 
This would have fallen within 
Side Effect Trade-Off, however I 
deleted that code prior to this 
last round of agreement coding 
because I had not seen it come 
up often. 
Other 
methods 
Now at 500mg the difficulty falling 
asleep has returned  and  I'm  back to 
waking up sweaty  with bad dreams 
more often.  But my daytime sedation 
has gone down. 
12/10/2009  Case 
#613 
This is in response to a concern 
about taking a 300mg dose - i.e., 
whether that is too high, whether 
they should start with something 
lower, etc? 
Dose 
related 
issues / 
advice 
Not just for the sake of being contrary, 
I think the 'listen to your body' 
approach can be appropriate in some 
cases. NOTE: I am NOT saying it's ok 
in ALL, or even MOST cases, just 
SOME... especially with a med like 
slurroquel where there's a huge dosing 
range. 
12/10/2009  Case 
#613 
I code these sorts of comments 
with 'Waiting' because I interpret 
this as the person is hoping 
(read: waiting) to see what 
happens next, i.e., whether the 
weight will come off. 
Ride out the 
storm / 
Eventually 
goes away / 
Waiting 
I'm HOPING to experience rapid 
weight loss as I taper down the 
slurroquel. 
12/10/2009  Case 
#613 
In response to a suggestion for 
getting the "Anxiety and Phobia 
Workbook" 
Trying/Tried 
alternative 
treatment 
I opted for Silver's suggestion of 
Master your Panic, etc. Pretended that 
I was ordering them for a client to 
actually get me to get the books in the 
house. Now would be a great time to 
take them out! 
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12/11/2009  Case 
#650 
Nice example for illustrating how 
the absence of an effect can be 
as defining as the presence of 
an effect. 
No / Limited 
Side Effects 
I haven't gained any weight on it, 
although that's more a matter of 
avoiding a bad thing than saying a 
good thing. 
12/11/2009  Case 
#675 
This comment is in response to 
a person asking if there is an 
online Canadian pharmacy they 
can get generic Seroquel? 
Generic/oth
er drug 
equivalence 
Unfortunately we can't answer that 
question. paypal are dicks about that 
sort of thing, not that it's explicit in their 
TOS or anything.  Generic quetiapine 
is available in other countries and  if 
you read 
http://www.crazymeds.us/InternetPhar
macists.shtml you can find out on your 
own. 
12/11/2009  Case 
#675 
Not sure if I want to put these 
comments about monitoring 
blood levels for diabetes under 
Dealing with Side Effects, or 
under Medical Tests - Evidence 
of Causality. It is a medical test, 
but not having to do with 
causality, but rather having to do 
with Dealing with Side Effects. 
Learn to live 
with it 
What's This About Seroquel And 
Diabetes? Posted by: Jerod Poore Thu 
14 August 2008 12:33:47 GMT +0000 
There's like this blood test you can get 
from a doctor. Just being on Seroquel 
with a family history of diabetes is 
enough to warrant it.  Viola! Question 
answered. Get one every six months 
and you're set. 
12/11/2009  Case 
#675 
Quote is from female with 
menstruation irregularities. 
Menstruatio
n Irregular 
SEE QUOTE.    It's damn rare, 
12/11/2009  Case 
#675 
Would code as "Learning to live 
with it..." 
Learn to live 
with it 
There's not much you can do about it. 
It usually gets worse the longer you 
take Seroquel. 
12/11/2009  Case 
#675 
Talking about sensitivity to heat, 
getting overheated, and terrible 
sweats. 
Hot flashes / 
heat stroke 
Am I The Only One Who Had This 
Side Effect? Posted by: Jerod Poore 
Mon 31 March 2008 14:07:04 GMT 
+0000  Hardly. And t he reason jook 
didn't spot it is because  AstraZenca 
decided to use doctorese to describe 
it.    Asthenia. Fatigue, malaise, night 
sweats, hot flashes, and a mimicking 
of arthritis.   Up to 10% of people who 
take Seroquel reported this during the 
clinical trials! 
12/11/2009  Case 
#747 
Code "Learning to live with it..." Learn to live 
with it 
I've learned to live with this but I hope 
no one else has to 
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12/11/2009  Case 
#772 
I should note that comments like 
this have been coded under "so 
many damn meds" and NOT 
also under "limited or no 
helpfulness." More specific 
instances of a med not working 
have been coded under the 
latter. General references to 
"none of the meds I've tried have 
worked" or "I've tried 4 other 
SSRI's and none of them worked 
until I was prescribed Lexapro," 
etc are coded under "so many 
damn meds" 
My drug 
combo / so 
many damn 
meds... 
I had tried everything and it didn't work 
(ambien, anything herbal, ativan) and 
seroquel works! 
12/12/2009  Case 
#974 
I interpret the "they" in this 
comment as referring to doctors. 
Other 
doctor-
related 
issues 
being on my meds- which they finally 
got right after 12 years- allowed me to 
accomplish things that I never would 
have thought I was able to do. 
12/13/2009  Case 
#1003 
Here again the dilemma of 
having to choose between 
mental and physical health 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
my gut is telling me to get off zyprexa 
too, but i don't really know what my 
alternatives are, and i do want to be 
stabilized. it's a tough situation. 
12/13/2009  Case 
#1014 
Sleep eating Increase 
appetite / 
cravings 
I would eat in my sleep and even if I 
was awake, I literally could not feel full, 
no matter how much I ate. 
12/17/2009  Case 
#245 
I highlighted because of the term 
"adverse reactions" to describe 
the effects. We've been coding 
for "side effects", but not for 
other terms that people may 
use. Not sure if I need to return 
to this and code them all under 
"side effects" (to be sorted out 
during analysis), add additional 
terms for coding, or just ignore it 
completely. 
"Side Effect" I guess I'm having too many adverse 
reactions.    Let's see.....nausea,   
migraine ,  upset stomach,   trembling ,  
heart palpitations ,  dizzy ,  completely 
lost appetite (can't eat at all) . 
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12/17/2009  Case 
#254 
This person is definitely 
weighing benefits vs costs, but 
does not come to a decision. I 
coded it as Side Effects Too 
Great because she answers "no" 
to her question about would she 
have gone on Lexapro if she 
knew about the weight gain. 
Not worth it 
/ Side 
effects too 
great 
great for panic attacks . bad for weight  
Thanks to Lexapro, I no longer have 
anxiety attacks. they are still there, but 
they don't come full blast. .   However 
and this is a big HOWEVER,   I have 
gained 35lbs on this med. I can't lose it 
no matter what... Had I known about 
this side effect would have gone on 
Lexapro ? No.. . even though my life is 
back...  it's hard now because I am in a 
size 16 and I am normally a size 10.. . 
But which is better.. being anxiety free 
and overweight? or skinny and panic 
ridden? it's a hard question 
12/30/2009  Case 
#276 
Relieved 
withdrawal/discontinuation 
symptoms caused by another 
drug. 
Alleviates 
side effect 
from 
another 
drug 
Three days after stopping Zoloft I had 
severe and constant dizziness, 
increased blood pressure and heart 
rate  - so my DR thought I should try 
going on something different as I 
wasn't coping well going cold turkey. 
Within an hour of starting Lexapro the 
dizziness disappeared, my heart rate 
dropped over 24 hours and I felt ok 
again. 
12/30/2009  Case 
#278 
Relieved side effects caused by 
another drug. 
Alleviates 
side effect 
from 
another 
drug 
I tried lexapro to reduce the side 
effects of effexor and hopefully have a 
better mood elevation.  It did solve the 
sexual side effects 
12/30/2009  Case 
#280 
Serotonin syndrome - I also 
coded these effects individually. 
Other Misc 
Effects 
After almost 5 weeks at a dose of 
10mg  I started to experience 
symptoms of what seemed like, to me, 
serotonin syndrome - agitation and 
anxiety ;  general tremor and tremor in 
the jaw ;  confusion ;  headache ;  
sweating  etc. -  so  dropped my dose 
down to 5mg and these effects 
disappeared pretty quickly . 
12/30/2009  Case 
#283 
Relieves side effects caused by 
other drugs 
Alleviates 
side effect 
from 
another 
drug 
Have been on Lexapro two weeks, 
best of Paxil, (gained weight/lost all 
sex drive), Effexor, (severe headaches 
and no sex drive), Wellbutrin, (gave 
me a seizure second night), and now 
Lexapro.  So far better; sex drive 
returning 
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12/30/2009  Case 
#289 
I am merging Flat feelings with 
Feeling detached or unreal 
because I think the emotional 
numbness described here is a 
central defining feature of each. 
Feeling detached from their 
emotions, from their lives, from 
the world.  
Numb / 
Detached / 
Lack of 
energy or 
interest 
mainly consisted of a "detached" 
feeling or what I would describe as 
emotional numbness . 
12/30/2009  Case 
#296 
Not really weight gain, but 
"difficult to lose weight" - not 
sure if I need an additional code 
for this or just note it during 
analysis. 
Weight gain Lexapro seems to make it more 
difficult to take weight off than before 
12/30/2009  Case 
#300 
Code: "Learn to live with it" Learn to live 
with it 
I am able to squeeze in two sessions 
of gym a week. I make a huge will-
power effort to control my apetite.  But 
I have also accepted that I am not 
going to be back to my weight of three 
years ago before Lexapro. And, 
frankly, I am not adding Wellbutrin for 
weight loss. It makes me jittery. 
12/30/2009  Case 
#309 
Should I combine Flat feelings 
codes and Feeling detached or 
unreal code? Are they kind of 
similar? 
Numb / 
Detached / 
Lack of 
energy or 
interest 
there is a feeling of being "detached" 
from things that would normally 
produce extreme sadness. 
12/30/2009  Case 
#319 
I don't have a code for shooting 
pain / electrical zaps / brain zaps 
Zaps / 
Tingling 
have some  shooting pain in my head 
that comes and goes. 
12/31/2009  Case 
#1081 
I am noticing here a difference in 
language use: these mental and 
mood changes are called 
"symptoms" whereas effects 
called "side effects" are more 
often physical effects (with only 
a few mental/mood changes, 
including agitation, restlessness, 
and nervousness). To me, it 
implies that worsening 
mood/mental changes may be 
part of the original problem 
rather than or more so than an 
effect of the drug. 
Talking with 
doc / Doc 
explained / 
Consult doc 
Call your doctor at once if you have 
any new or worsening symptoms such 
as: 
1/1/2010  Case 
#333 
Code: "Learned to live with it / 
Learned to accept it" 
Learn to live 
with it 
I have gained a bit of weight, but I dont 
care. I am still pretty small just not 
obsessed with being a size 0 anymore. 
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1/1/2010  Case 
#348 
Yes, this definitely illustrates 
how Flat Feelings are the other 
side of the Emotionally Stable 
coin! 
Numb / 
Detached / 
Lack of 
energy or 
interest 
In a way, the medication has me on 
such an even keel that it feels strange. 
My reaction to things that would 
normally upset me (and perhaps 
should upset me) have been very 
restrained. Pardon the simile, but I feel 
like Spock on the old Star Trek series -
- very rationale and systematic, not at 
all emotional. My therapist thought I 
would not like being on Lexapro for 
this very reason, but I guess it is 
helping me work out issues at work in 
a more productive way, and helping 
me plan for a future career that is less 
stress-inducing. 
1/1/2010  Case 
#349 
Code: "Learn to live with it" Learn to live 
with it 
I do have a slight ringing in my ears-- 
that I think is from the Lexapro -- but Ill 
deal with that --  anything is better than 
the panic and anxiety I had before. 
1/1/2010  Case 
#382 
I've come across a couple 
comments about taking Lexapro 
during pregnancy, including this 
one that Lex was a safer choice 
than another med. There was 
another comment within Lexapro 
about a woman who did stay on 
Lex during pregnancy and 
breastfeeding and all turned out 
well. Obviously, these would not 
be contraindications, but what 
should I code them as? 
Generic/oth
er drug 
equivalence 
Is not as effective as Paxil. Switched 
from Paxil thinking Lexapro was safer 
since I want to get pregnant. 
1/2/2010  Case 
#162 
Code: Electrical tingling / shocks Zaps / 
Tingling 
there has been this strange sensation 
which I'm finding difficult to deal with. 
It's in my arms mostly and feels like 
there's a layer under my skin of 
electrical pluses  and when waking at 
3 and 4 in the morning (still), I have 
the desire to cut the skin and peel it 
off, or cut the skin in a spiral round and 
round the arm.  It does go away 
towards the end of the day (on most 
days, but not today)  and sometimes 
it's around my head as well. 
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1/2/2010  Case 
#272 
I've been coming across this 
idea of "I'm new to drugs / this is 
only my 1st (or 2nd) drug so I 
don't know what I should be 
feeling or I have nothing to 
compare this experience to" 
OTHER I'm happy with the drug, but it was only 
my second drug. 
1/21/2010  Case 
#172 
Unsure how to categorize 
"activating" as an effect. 
 
Mar 2010 update: Coding this as 
Energized / Euphoric because 
activating is generally meant to 
reflect a manic-type reaction. 
Energy 
increased / 
Euphoria / 
Mania 
Lexapro (on its own) was activating for 
me.  My impression from lurking this 
board for some time is that it is 
activating for some others also. 
1/24/2010  Case 
#194 
Code as "Side Effect Trade-Off" Other 
methods 
Dear me. Someone who'd pick thin 
over sexual function. Think about that 
for a minute. One is an appearance 
issue. (You didn't say fit. You said thin. 
Difference.) The other one is a basic 
human drive and arguably integral to 
primary bond relationships. It's like 
Fernando from SNL all over again. It's 
better to look good than to feel good. 
1/24/2010  Case 
#194 
Code as "Learning to deal with 
it/ live with it" 
Learn to live 
with it 
I don't, personally, feel it's "fair" that 
the medication that seems to be the 
most effective for me is also the one 
that's nibbling at my kidneys. I'm 
taking it because it's preferable to the 
alternative. (I'm also far past the belief 
that the world is fair, though, so maybe 
a certain amount of cynicism helps 
here.) 
1/24/2010  Case 
#195 
This comment relates to the 
general idea of weighing pros 
and cons, which is why I coded it 
here (taking from "there are no 
absolutes here") rather than All 
in All or Side Effects Too Great. 
Neither of the latter exactly fit. 
YMMV Not taking antidepressants carries its 
own set of very real risks, up to and 
including death of mom and child. 
There are no absolutes here. 
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1/24/2010  Case 
#196 
This is about mixing lexapro and 
alcohol, but it's just the opposite 
of a contraindication. He is 
saying it's probably okay to mix 
them and there should be no 
interactions. I don't believe I 
have a code that this would fall 
under. 
OTHER Because so many people drink, 
especially depressed people, that the 
drug companies do shitloads of tests 
mixing the two.   There is no 
interaction, no change in the effects of 
either drug, no nothing. Of course 
doctors should tell people not to drink, 
but  a beer or two every now and then 
has yet to affect anyone I've observed 
or who has written about taking an 
SSRI. 
1/24/2010  Case 
#204 
I've coded this for a couple 
comments relating to the effects 
of the drug being different from 
when the person took it at a 
previous point in time. 
Poop Out / 
Effects 
Changed 
It does seem like a strange 
paradoxical reaction...perhaps your 
nervous system is in a more sensitzed 
state this time? 
1/24/2010  Case 
#207 
Another more general comment 
about weighing pros and cons. 
Even more specifically here, the 
relativeness of effects as 
desireable or undersireable. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
I am not concerned, probably because 
it hasn't gone on long enough to really 
move from unpleasant but interesting 
to outright irritating, but I rather wonder 
how a person being treated for anxiety 
is supposed to decide when not being 
concerned is an undesirable side-
effect rather than a desired outcome. 
1/24/2010  Case 
#212 
Learn to live with it/ deal with it Learn to live 
with it 
Once I had the crown replaced I just 
got used to that side effect as the 
combo worked so well for my moods 
for several years. I was on 300 mg 
Wellbutrin and started at 10 mg 
Lexapro and later raised to 20 mg. I 
still have all my teeth and no long-term 
damage that I'm aware of. 
1/24/2010  Case 
#232 
Learn to live with; Also again this 
idea of an effect as beneficial or 
not is relative 
Learn to live 
with it 
this is the one that still strikes me.  It's 
one I can live with and may even be a 
beneficial effect depending on how 
you think about it. 
1/25/2010  Case 
#233 
A response to another user 
stating that they expend more 
calories than they take in, so 
why do they continue to gain 
weight? It goes against the laws 
of science (according to this 
user). The coded comment says 
it would work that way but these 
chemicals get in the way. 
Unsure 
about 
mechansim 
/ Other 
Lexapro User And Weight Gain Posted 
by: Cyeic Sun 16 December 2007 
5:35:35 GMT +0000 It would be 
thermodynamics, and a simple case of 
weighing energy intake against energy 
expenditure, if those pesky genes and 
neurochemicals didn't get involved. 
Look up "leptin" and associated 
molecules. 
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1/26/2010  Case 
#620 
Relieves an adverse effect 
caused by another drug. 
Alleviates 
side effect 
from 
another 
drug 
Now I have switched to Seroquel as I 
have thinning bones from amenorrhea  
and within a month my prolactin levels 
have dropped from 3000 to 57 and my 
periods have returned. 
1/26/2010  Case 
#623 
Maybe broaden the code "Going 
back on meds" to also include 
comments similar to "meds are 
the solution for me" 
Going back 
on meds / 
Meds may 
be the 
solution 
Truth is, I function pretty well without 
any of my meds, I just feel better with 
them. I always need something for 
sleep so while I'm taking something for 
sleep I might as well take something 
for everything else that ails me lol. 
1/26/2010  Case 
#624 
"Tweaking" Other 
methods 
Things are really not all too bad right 
now when you look at how bad they 
have been in the past! I just think 
maybe my meds need to be tweaked a 
bit... 
1/26/2010  Case 
#632 
Use it PRN instead of daily Other 
methods 
I had tried it once before back in 
March and didn't like it because I was 
taking it every night and made me into 
a zombie during the day , but now I 
take it only when feeling agitated at 
night and once the zombification 
wears off I feel a lot better. 
1/26/2010  Case 
#633 
"Side effect trade-off" Other 
methods 
when i take it on and off, i dont sleep 
enough, so im totally exhausted 
physically, then i take it and crash, 
sleep too much. 
1/26/2010  Case 
#633 
Though this comment is 
referring to how to tweak a med 
combo, rather than just a 
statement of what the combo is. 
I've come across several general 
statements about med combos 
or cocktails needing to be 
tweaked... 
My drug 
combo / so 
many damn 
meds... 
was just reading other post in the 
treatments for bipolar section... and 
read up on the topamax sheet - if that 
is a sleepy kind of drug, maybe that + 
lamictal would be good and i wouldnt 
need the seroquel as often. plus, it 
would keep the headaches (which i 
think are more like cluster than 
migraine) more in check. 
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1/27/2010  Case 
#638 
Kind of similar to "Side Effect 
Trade-Off", but not sure if that's 
the best code here 
Other 
methods 
After 4 years on seroquel I have been 
having quite a bit of trouble getting my 
sleep routine back into shape. The 
thing is, the new medication that I am 
on also has the initial side effect of 
insomnia. I have been on that for 7 or 
8 weeks now. I'm cool when it comes 
to getting to sleep but I almost always 
wake up at 3am and sometimes can't 
get back to sleep until about 6am or 
so. 
1/27/2010  Case 
#641 
This is a general comment about 
having to weigh side effects and 
benefits 
YMMV Sometimes I adjust to the side effects, 
other times the side effects win out. 
1/27/2010  Case 
#641 
"Waiting" to see if the effects will 
last... 
Ride out the 
storm / 
Eventually 
goes away / 
Waiting 
If you are at a point where it feels good 
then pat yourself on the back and say 
a prayer that it lasts. Sometimes there 
is no rhyme or reason for the change. 
1/27/2010  Case 
#647 
This is in response to a user 
stating the seroquel they've 
been on for 2 years is "bombing 
out." The present comment is 
advising that they plan what they 
could do next. 
Poop Out / 
Effects 
Changed 
Q's Bombing Out? Posted by: seaview 
Fri 2 January 2009 15:48:42 GMT 
+0000 Yes. It may not hit, but better 
plan what your next moves will be if it 
does. 
1/27/2010  Case 
#647 
Is the drug "bombing out" or is it 
life stresses getting to me? (this 
is the question the previous user 
poses) 
Drug or 
Something 
Else? 
SEE QUOTE. Possibly. Possibly not. 
(I'm dead helpful sometimes, me.) But 
you know you've had a "fair bit to deal 
with" recently, and you've moved, and 
it's the time of year for festilities that 
unbalance all of us in some way. All 
adds to the mix. 
1/27/2010  Case 
#647 
This refers to having or making 
plans for ongoing well-being 
and/or stability. Kind of reminds 
me of users talking about 
needing to tweak their cocktails, 
or trying to think ahead or plan 
ahead for what they anticipate 
may be about to happen. 
Making a 
plan / Just 
in case... 
It's good that all your support eggs 
aren't in one basket. That's a clumsy 
way to put it, sorry - I guess I mean 
that it's good that you have a GP and 
meds and people acting as carers and 
some maintenance / crisis plans. 
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1/27/2010  Case 
#647 
Learn to live with it/deal with it Learn to live 
with it 
a need to eat masses of carbohydrate. 
Far more than my body could 
genuinely need for day-to-day 
functioning. I could easily add another 
10 pounds in a week or so.   I don't like 
this side-effect, but I don't think too 
much about it. 
1/27/2010  Case 
#649 
Compare data to code here - 
maybe needs to go in Making a 
plan/Just in case.... I think that's 
where I've put other comments 
about keeping around 
emergency meds 
Making a 
plan / Just 
in case... 
Plus, a lot of people don't really like 
using AAP's as long term, 
maintenance therapy, but see them as 
best used only as short term, 
emergency meds. 
1/27/2010  Case 
#659 
Again, Making A Back-Up Plan 
or Strategy 
Making a 
plan / Just 
in case... 
No, haven't tried Topa, but it is my 
back up plan if I get the rash from 
lamictal.  See if he'll give it to you, 
because it seems like any weight-gain 
med may trigger an e/d episode. 
1/27/2010  Case 
#666 
The comments by this user 
seem suspicious to me - like this 
info is just copied from a PI 
sheet or some other source, and 
a couple spelling/grammar 
errors are thrown in to make it 
appear authentic. Don't know... 
Symptoms 
reduced / 
improved 
it works at low doses as it is the most 
sedating of the anti-pyyscotics  so will 
calm your anxiety and help to stabilise 
your depression if your prone to 
cycling. 
1/27/2010  Case 
#679 
Having a back-up plan or 
strategy 
Making a 
plan / Just 
in case... 
It's good that you have a plan and it 
sounds like you have good 
professionals too. 
1/27/2010  Case 
#682 
Other methods to make it okay 
to have a few drinks while on 
seroquel 
Other 
methods 
Alcohol Effects/ Libido On Seroquel 
Posted by: therapeuticbrigg84 Sun 14 
December 2008 22:13:15 GMT +0000 
I guess you're right in that it takes 
staying out late out of the equation, but 
I don't think that one night a week of 
staying out late is bad on this drug. as 
I would end up taking it at a later time 
maybe at 1am or 2am instead of my 
regular 12 am drop- basically cuz I'm 
pretty much a nightowl anyways. 
1/28/2010  Case 
#686 
Change to blood sugar / glucose 
changes 
Blood sugar 
high / 
Diabetes 
And jooks right about the glocose 
levels. Mine shot down when I woke 
up from a seroquel saturated slumber. 
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1/28/2010  Case 
#715 
Relieves adverse effect caused 
by another drug 
Alleviates 
side effect 
from 
another 
drug 
im currently suffering from lamictal 
induced psychosis that wont go away 
with zyprexa, clozapine (getting worse)  
and bit better on seroquel and abilify 
1/28/2010  Case 
#717 
Previous user stated that their 
doctor said 75mg of Seroquel 
will not make them gain weight, 
and was asking the forum if this 
was true... 
Trusting the 
doctor ? 
So maybe, maybe not.  Seroquel is 
definately one of the AAP associated 
with weight gain , so perhapse your 
doctor was trying to reasure you, or.... 
1/28/2010  Case 
#717 
General comment about the 
user having to weigh benefits 
and side effects 
YMMV Yes, seroquel has side effects, but all 
medications do, you're not guarenteed 
to get them  - it seems you've been on 
the medication for 5 years without 
problems. 
1/31/2010  Case 
#532 
I see this a lot - the "trade-off" - 
this concept *could* fall under 
the 'Limited Benefit' code. 
Extreme 
sleepiness / 
Tired 
Secondly, it makes me way too 
sleepy... after an hour after I take the 
medication I'm usually unable to move 
about without tripping and falling. On 
the flipside, without it I can't sleep, and 
if I do sleep, it's like a 2 hour nap. Not 
fun. 
1/31/2010  Case 
#538 
I coded this as "limited benefit/ok 
but not great" because this user 
is weighing the benefits and 
costs, but has not yet reached a 
conclusion - other than the fact 
that the drug isn't 'perfect' 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
have been on 400mgs a day for a 
month.dont know yet if  the 
benifits(less anxious,less easily 
upset,moodswings lessen )is worth  
the side effects. 
1/31/2010  Case 
#546 
Not sure whether to code this 
here or under "I'm done / I want 
off". I put it here because there 
is some element of weighing the 
benefits and costs of the drug 
here (as it DOES help them 
sleep, but it may not be worth 
the other effects). 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
Seems to help alittle but  really want to 
get off this stuff - only thing is - it does 
help me sleep. 
2/1/2010  Case 
#557 
Another one where they know 
they have to weigh pros and 
cons, but did not reach a 
conclusion within this review. I 
put it here because it's an 
acknowledgement of "limited 
benefit" - in that the drug 
partially solves their problem, 
but causes other problems. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
So I ask myself: fat and happy or thin 
and crazy? Hmmmmmm...  I have 
gained 30lbs since 12/06 and I know 
that cannot ALL be my fault!  It's kinda 
bad when you have to choose 
between your mental and physical 
health. It is a tough choice to make. 
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2/1/2010  Case 
#563 
weight gain isn't a "real" side 
effect because it's just a given 
effect for any antipsychotic 
"Side Effect" Long term use has not had any real 
side effects except for the traditional 
weight gain with an anti-psychotic. 
2/1/2010  Case 
#568 
I see this over and over again - 
being tired or fatigued, but also 
liking this same effect for it's 
help in sleeping. The same 
effect is both good and bad 
depending on what the user 
needs at a certain time or in a 
certain context. I need to be sure 
to read through all the sleep 
codes, and may need to merge 
the "helps sleep" with the "tired" 
code - as they are really the 
same effect, just a different 
interpretation given. 
Extreme 
sleepiness / 
Tired 
Fatigue (good for sleep though) 
2/1/2010  Case 
#570 
This is almost another code for 
sleeping: "extreme sleeping". It 
doesn't quite fit within "helps me 
sleep" and it's not "excessive 
sleeping", but users most often 
describe it as "extreme" sleeping 
Extreme 
sleepiness / 
Tired 
This pill feels very strong as it truly 
knocks me out after taking at night. I 
wonder if I could wake if the house 
was on fire?!?  SIDE EFFECTS 
extreme sleeping within half hour at 
night taking 300mg. 
2/1/2010  Case 
#584 
I am coding any instance that a 
person has, may have, or is 
warning others of the risk of 
diabetes. I decided to code this 
way because I code 'expert' 
sites based on warnings of side 
effects, i.e., WebMD lists a 
bunch of side effects and I code 
them as side effects. I thought it 
was only fair to treat consumer 
sites the same way, so even if it 
is not a personally experienced 
effect, but something that they 
list as a possible effect, I am 
coding it as an effect. 
Blood sugar 
high / 
Diabetes 
I have heard there is a risk for 
diabetes with seroquel and blood tests 
should be required periodically 
2/1/2010  Case 
#590 
Limited benefit because of the 
"trade-off" 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
Why does there always have to be a 
trade-off with medications? You either 
do well physically without, but suffer 
mentally - or you take the meds, feel 
well menatally, but pudge out! If these 
med-researchers ever figure out the 
metabolism/weight gain/endocrine 
problems, they would hit the jack-pot!!! 
GET IT RIGHT DOCS. 
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2/1/2010  Case 
#768 
For so many people, the same 
effect is both good and bad at 
the same time. 
Numb / 
Detached / 
Lack of 
energy or 
interest 
I was taking a lower dosage of 
Seroquel for over a year before and 
complained about the 'doziness.' I 
didn't really care about day-to-day stuff 
like mounting bills and housework, etc. 
On the other hand, I didn't get anxiety 
attacks either. 
2/2/2010  Case 
#803 
I'm taking this as an effect of the 
drug - this user was able to cut 
down on alcohol use as a result 
of the seroquel working so well. 
Other Misc 
Effects 
I have cut back on my alcohol use to a 
much more acceptable level 
2/2/2010  Case 
#810 
I coded this segment twice - as 
'helps me sleep' and 'other'. The 
'Other' is because it relieves an 
adverse effect of another drug 
Alleviates 
side effect 
from 
another 
drug 
Seroquel has enabled me to take my 
antidepressants, which cause 
insomnia. 
2/2/2010  Case 
#811 
Learn to live with it/deal with it Learn to live 
with it 
I hope to find a cure for the eating 
thing...if not, I'll just have to be heavy 
2/2/2010  Case 
#823 
Relieves adverse effect of 
another drug 
Alleviates 
side effect 
from 
another 
drug 
It always beats my insomnia,  which is 
caused by my Bipolar and other the 
medications that I'm on. 
2/2/2010  Case 
#826 
helps with IBS Other Misc 
Effects 
It helps w/hypomanic,  sleep , IBS 
2/2/2010  Case 
#862 
This is a combo of appetite and 
memory loss or sleep-walking - 
"sleep eating". Good term to use 
as a code or as a term to 
describe users' experience. 
 
General Note, two terms 
invented by users: 
sleep eating and 
extreme sleeping 
Increase 
appetite / 
cravings 
Thanks to the person who mentioned 
the sleep eating! I began doing that 
suddenly and did not know it was the 
Seroquel 
2/2/2010  Case 
#870 
with sleep walking Memory 
loss 
Taking 600mg every night. Sometime 
during the night I went into my 
livingroom and somehow wrecked my 
whole apt.! I woke up on the rug and 
realized what I had done. 
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2/2/2010  Case 
#872 
Another case of weighing pros 
and cons without reaching a real 
conclusion, other than the drug 
fixes some problems and causes 
many others. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
He is closely monitored, but even with 
that he is now experiencing health 
problems that are a direct result of this 
med.  His triglicerides are off the chart 
,  blood-pressure is too low ,  sugar 
high , and  occasional chest pains . 
Since we have been through most of 
the available meds for his dissorders, 
and he is relative stabile,it has been 
decided that taking him off of the meds 
will cause him to crash.  I am in the 
process of working with the doctors, 
med and pcp, to decide what to do 
before... I'm not sure what could 
happen to him, but I was told his 
situation is dangerous.  I know it isn't 
fair that there are not better meds out 
there, or ones that the side affects 
wouldn't kill you, so what is a mother 
to do? Either way it seems to me that 
my son is the looser; breakdown- 
suicide attempts or diabetes, heart 
disease, or stroke. What would you 
do????? 
2/3/2010  Case 
#1002 
I am coding books as 'academic' 
though I may need to go back 
and pull these out into their own 
category 
Academic 
Journal / 
"Research 
shows..." 
have you ever read---The Looney Bin 
Trip? By Kate Millet...good read, from 
a very intellectual woman who didn't 
like her lithium....but I am not anti-
lithium, 
2/3/2010  Case 
#1055 
User is stating that they want to 
go from taking their 
antipsychotic everyday as 
maintenance treatment to an as-
needed/PRN basis. 
Dose 
related 
issues / 
advice 
let me taper off the risperidone and let 
me try something else to stabilize my 
mood, and just have the anti-psychotic 
as a safety net. 
2/3/2010  Case 
#1055 
Link to an MSN article about 
risperidone being on the list of 
the top 10 most dangerous 
drugs 
Internet Wow, thanks dionysian. Definitely 
helps. I emailed that link to the 
psychiatrist too. 
2/6/2010  Case 
#977 
Learn to live with it / deal with it Learn to live 
with it 
He said he would be willing to work 
with me on changing meds...but 
recommended that I just deal with the 
tremor , unless it gets worse. 
2/8/2010  Case 
#986 
General comment about 
weighing benefits vs negative 
effects 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
Perhaps list the effects of the medicine 
you are taking. If the effects do not line 
up with your goal or the negative 
effects outweigh the positive then this 
is a very good case for change. 
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2/8/2010  Case 
#986 
PBS show on tv. I coded it here 
because I also coded 'books' 
here, and may separate them 
out into 1 category later 
Academic 
Journal / 
"Research 
shows..." 
PBS Frontline, Tuesday Jan8 The 
Medicated Child Posted by: Inel  just 
saw it...   it was very anti-climactic for 
me. a little too soft-core. 
2/8/2010  Case 
#991 
In this 'Other' category, I've 
come across several times this  
idea of "I wish, I wish, I wish..." 
OTHER Would'nt it be nice to be happy and 
normal without having to swallow all of 
this damn rat poison??!!! 
2/8/2010  Case 
#1013 
Wants to quit meds, but stays on 
them because of fear of what 
might happen without them.... Is 
that coded here, or as a 
Dependence issue? 
Drugs won't 
work / I'm 
done / I 
don't need it 
Wow i know exatly what you're talking 
about. I haven't even been able to 
make it to trying to go down on my 
meds but i think about it all the time. 
I'm just so afraid of my symptoms 
returning. without meds, mine are 
quite strong and this scares the 
daylights out of me. 
2/9/2010  Case 
#1036 
Not really 'drugs won't work,' but 
a comment about the limited and 
appropriate use of drugs... 
Drugs won't 
work / I'm 
done / I 
don't need it 
People who are in severe psychotic 
states or in states of self-injuring or 
injuring others, or who are totally 
unable to function often need to be 
medicated. But the medication should 
be short-term, at as low a dosage as 
possible, with polypharmacy avoided 
(no more than two drugs together), 
and the  patients should be titrated off 
properly as soon as they are given the 
proper modalities to support healing at 
the root level of the condition, which 
can be orthomolecular, energetic, 
psychotherapeutic, probably several 
things in combination--in a caring 
environment that embraces nature.  
However, our society is not set up in 
such a way as to permit this. 
2/9/2010  Case 
#1040 
"Side effect trade-off" Other 
methods 
My doc added zonegran to the 
zyprexa to try and mediate the weight 
gain.  Makes me very sleepy though. 
2/10/2010  Case 
#1085 
"Warnings" - not "side effects" - 
but I had no where else to code 
this term 
"Side Effect" What warnings do you have for 
Seroquel (Quetiapine)? The following 
warnings are available for this 
medication:  May impair driving.    Do 
not drink alcohol.    Obtain advice for 
OTCs.    May cause drowsiness.    
Check with your doctor before 
becoming pregnant. 
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2/10/2010  Case 
#1086 
"used with or without other 
medications" 
OTHER This medication is used with or without 
other medications to treat certain 
mental/mood conditions 
2/11/2010  Case 
#1083 
I coded this here because of the 
last 2 sentences.... which 
comment on the lack of 
transparency in both published 
articles and the PI sheet. Jarod 
here is trying to piece these 
incomplete bits of info together 
Three 
percent my 
ass! 
I could find a study 
http://www.ncbi.nlm.nih.gov/entrez/que
ry.fcgi?cmd=Retrieve&db=PubMed&lis
t_uids=14744167&dopt=Abstractindica
ting that Lexapro (escitalopram 
oxalate) is good to prevent relapses of 
major depressive disorder when 
compared to a placebo.    Close to 
75% of the people taking Lexapro 
(escitalopram oxalate) after 4-6 
months were still not depressed, vs. 
60% taking the wonder drug Placebo.    
Unfortunately we don't get to see how 
their MADRS scores were.  I suspect 
this was the fourth trial mentioned in 
the PI sheet. 
2/11/2010  Case 
#1083 
Relieved an adverse effect of 
another drug 
Alleviates 
side effect 
from 
another 
drug 
I've found one reference to a single 
case 
studyhttp://www.ncbi.nlm.nih.gov/entre
z/query.fcgi?cmd=Retrieve&db=PubM
ed&list_uids=14660288&dopt=Abstrac
t  where someone overcame the 
sexual side effects of 
Prozachttp://www.crazymeds.us/proza
c.html (fluoxetine hydrochloride) by 
switching to Lexapro (escitalopram 
oxalate). 
2/12/2010  Case 
#1084 
Agitation Other 
reason / 
diagnosis 
If you're agitated, jumping out of your 
skin  and you just can't sleep, then  
Seroquel (quetiapine fumarate) might 
be just what you're looking for . 
2/12/2010  Case 
#1084 
I need to look at the "zmobie" 
codes, which I have put all under 
"cognitive slowing, spacey, 
dopey". Jarod equates zombie 
with "flat feelings, lack of 
interest". Perhaps I need to 
merge these codes?? 
Numb / 
Detached / 
Lack of 
energy or 
interest 
not giving a damn about anything 
(a.k.a. the zombification effect). 
2/12/2010  Case 
#1084 
Learn to live with it/deal with it Learn to live 
with it 
Except for the excessive sleepiness, 
which could hang around for as long 
as you take this med. 
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3/10/2010  Case 
#1058 
Finding a doc Other 
doctor-
related 
issues 
Re. docs, ask any docs (of any type) 
that you trust to give you names of any 
pdocs (psychiatrists) they've heard 
particularly good stuff about (and/or 
deal with bipolar a lot). 
3/10/2010  Case 
#1058 
Finding a doc Other 
doctor-
related 
issues 
Last change I had to make, I asked my 
primary care doc, therapist, old doc 
(she was going to work for the VA), my 
husband's doc at the VA, our couples' 
therapist at the VA . . . I heard the 
same name from a couple of people I 
really respected, tried that doc & am 
really pleased with him. Of course, if I 
hadn't been, it'd have been back out 
there again. You have to have 
someone you feel is competent & does 
care (within the very limited time they 
can give) 
3/10/2010  Case 
#1065 
Med hoarding / disposing Making a 
plan / Just 
in case... 
I absolutely horde medication. 
Prescriptions, over the counter meds, 
herbs, vitamins, supplements, 
tinctures, teas, expired, variously 
acquired, frequently useful, but some 
of which I can't even remember what 
they do or how i came to posses them. 
And all with this vague concept that I 
might need them either for myself or 
others, or, on bad days, because i 
might at some point decide to 
consume all of everything and see 
what happens.  but mostly i just can't 
seem to make myself get rid of these 
things. 
3/10/2010  Case 
#1069 
Afraid of stopping or changing 
meds 
Looking 
back on 
it.../Since I 
stopped the 
med... 
afraid to go off meds because of what 
I've described elsewhere as the illness 
I felt all the time once off them. As for 
the headaches, I don't have them 
anymore, but I don't know what would 
happen if I tried anything new out.  As 
I've said elsewhere, Zyprexa has 
sometimes been a weight gainer for 
me, although there are other reasons 
why I've put on weight in the past 
year...but I can't let go of it because of 
the year I lost of my life to all sorts of 
other meds. And that started with evil 
deathforce Seroquel. 
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3/10/2010  Case 
#1070 
I am not sure where I am putting 
these comments that 
recommend someone get 
regular tests for something: 
either "medical tests" (but it's 
really not Evidence of Causality) 
or "I'm taking control" (because 
they are monitoring drug effects) 
or something else? 
Check blood 
levels 
Also, if you take Seroquel, it's good to 
have a fasting blood sugar check 
every few months (a fingerstick at 
least 2 hours after eating or drinking 
anything except water.) 
3/10/2010  Case 
#1073 
meds and pregnancy OTHER i'm on lithium and zyprexa. my doctor's 
recommendation was to stay on both 
throughout the pregnancy, and i'm 
going to  (i tried to get off the lithium 
but it was a disaster). 
3/11/2010  Case 
#135 
Comment about having to weigh 
benefits and costs - though not 
making a decision about them. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
If you do gain weight (which isn't 
guaranteed in the first place), I think 
it's important to consider how much 
weight you actually gain vs. how well 
the antidepressant is helping your 
mood. It may still be worth it. 
3/11/2010  Case 
#135 
Brain zaps on Lexapro (while on 
a stable dose) 
Zaps / 
Tingling 
I've been on 20 mg Lexapro for a year 
and a half at this point, perhaps 
longer. I've also been on 200 mg of 
generic Wellbutrin (100 mg taken twice 
a day) for the better part of the year.   
The zaps aren't comparable to the 
ones I experienced during Effexor 
withdrawal, but they're nonetheless 
annoying.  (I assume they have more 
to do with Lexapro than with 
Wellbutrin.) I've been having them for 
3 days at this point, but I haven't been 
missed a dose of my meds. (OK, I did 
forget to take my stupid statin last 
night, but that shouldn't be related, 
right?) 
3/11/2010  Case 
#135 
Comment about having to make 
an assessment, but no decision 
made... 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
At the end of the trial period, you'll be 
able to decide whether the benefits are 
worth whatever side effects you might 
develop.  (There are some lucky 
people who don't experience any side 
effects to speak of.) 
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3/11/2010  Case 
#135 
Learn to live with it Learn to live 
with it 
Do Sexual Side Effects Ever Wear 
Off? Posted by: Artemisia Mon 10 
December 2007 15:52:53 GMT +0000 
I'm one of those "zero, zilch, nada, 
nothing, never" cases. Nothing works 
even when I'm not on any meds... 
3/11/2010  Case 
#964 
Not so much the 'doctor' but the 
'system' is wrong 
Doctor won't 
listen /  We 
disagree / I 
wasn't 
informed 
The whole system needs to change. I 
think if only I was taught to live with 
specific symptoms. Like I have a fast 
brain. No doubt about it- it's just fast. 
They (medical community) wanted to 
slow it down and I downed pills for it. 
But I couldn't deal with a slower brain- 
that made me more crazy. But no one 
saw that. If only I were taught how to 
handle it going fast- taught how to 
organize my fast thoughts. I had to 
learn that stuff the hard way. I self-
taught myself to handle my speech so 
its understandable not fast and 
jumping around topics. I may be 
thinking that fast but I've learned how 
to have appropriate conversations. 
3/11/2010  Case 
#964 
Thinking of going back on meds Going back 
on meds / 
Meds may 
be the 
solution 
At times I wonder about going back on 
Ritalin but only because my 
organizational skills are nil. I can't 
organize for the life of me and it 
shows- my desk is always a mess as 
is my whole therapy area where I treat 
the kids. It is a constant struggle for 
me to keep it all together. 
3/11/2010  Case 
#964 
Related to "the system" - but not 
jumping through hoops. I coded 
this here because if this user 
was complaining about "the 
hospital" or "the system" I would 
code it here. I may need to re-
label this code to reflect any 
comments related to 'the 
system,' then. 
Jumping 
through 
hoops / 
Hospitals 
hospitals didn't destroy my life- I still 
went to college full time, I still held a 
full time job (though it had flexible 
hours to allow me the time off 
sometimes)...I still had a very full life, 
just with tiny interludes to get my head 
straight.   And to this day even though 
I am shifting away from a pure medical 
model, if I went nuts for some 
reason...I still know that a hospital can 
give me reprieve's. 
3/11/2010  Case 
#964 
Thinking of going back on a 
med; prevention 
Making a 
plan / Just 
in case... 
So this post is about PREVENTION 
and not INTERVENTION. I want to 
head off any bad things now before 
anything happens and I think going 
back on a mood stabilizer may help. 
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3/12/2010  Case 
#135 
Helped IBS Other Misc 
Effects 
I've been tentatively diagnosed with 
IBS a couple of years ago (I was on 
Effexor XR then). I've been oscillating 
between constipation and diarrhea. 
Switching to Lexapro actually made 
my intestinal adventures less bad for a 
while, but then they returned. They're 
still not as bad as they were on Effexor 
XR, though. 
3/14/2010  Case 
#1045 
I think I've been coding any 
"hospital experience" here just to 
have them all in the same place.  
Jumping 
through 
hoops / 
Hospitals 
i remember having one of those 
experiences getting locked up (in beth 
israel medical center on 17th and 1st) 
and i was totally freaking out having a 
panic attack thinking i was dying and 
the psych doctor in his glasses and 
white coat said that he could give a pill 
that would help me and i told him to 
fuck off, but then a couple hours later 
at the request of some friends i gave in 
and took it (it was xanax) and a couple 
minutes later i felt totally fine. it was 
pretty unnerving and quite a relief at 
the same time. 
3/14/2010  Case 
#1066 
I have come to put all comments 
related to therapies other than 
drugs here - so this now 
includes positive comments 
about other therapies, negative 
comments/ disadvantages / 
problems with other therapies, 
and suggestions for other 
therapies to seek out. 
Trying/Tried 
alternative 
treatment 
I want out. I don't want to do it 
anymore. I'm sick of the heart-to-heart 
chats, the raw disclosure, the drama 
therapy, the art therapy, the group 
therapy. I want to be left alone, but you 
say that and they gently suggest you 
write an "action plan" to schedule 
"don't hurt self" into your unmonitored 
evening.  No one is close enough to 
help, and those who are close are held 
at arm's length because the idea of 
being misunderstood by people I care 
about so much is too painful to 
contemplate experiencing.  I think the 
only treatment is self acceptance. 
Getting there, however, is not always 
achieved.  What becomes of those 
who fail? 
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3/14/2010  Case 
#1066 
Making the decision to go back 
on meds 
Going back 
on meds / 
Meds may 
be the 
solution 
For years I thought I could maintain on 
my own, but when it became 
impossible to do my boring desk job, it 
was clear I needed help, and therapy 
once a week isn't enough.   I have an 
appointment soon, thank goodness. I 
want to get this ball rolling. I only see 
my moods getting more violent as time 
goes on. Maybe after I get some 
stability, I'll be better able to attend to 
the alternative methods that I don't 
have the concentration to be diligent 
about now.  I quit Paxil cold 
turkey...I'm sure I can quit again when 
the time comes. 
3/30/2010  Case 
#675 
In response to a person who has 
missed 2 days of Seroquel and 
is suddenly very itchy all over. 
Jerod proposes the itchiness is 
caused by what he explains 
here... 
Alleviates 
side effect 
from 
another 
drug 
You've increased the Lamictal since 
you've been on Seroquel, right? 
Seroquel's antihistamine qualities have 
probably been suppressing Lamictal's 
itchy side effect. Or Wellbutrin's. In any 
event it took care of a side effect from 
one or more of them. 
4/2/2010  Case 
#612 
"Sedating" is difficult to code 
because it's a neutral term. 
Extreme 
sleepiness / 
Tired 
Seroquel is sedating. There's no way 
around that. 
4/4/2010  Case 
#612 
Not sure the best place to code 
this. Kind of saying that the drug 
didn't work for them, but may 
work for you (hence, YMMV). 
But it is an interesting example 
of Drugs Only Have Effects that 
Some Will Find Helpful and 
Other Will Not. 
YMMV Lexapro. I hated the stuff, but the 
reason I hated the stuff is the same 
reason I'm going to suggest it. It 
makes you not care as much. (At least 
that's what it did for me.) 
4/4/2010  Case 
#1064 
Commenting on cognitive 
decline over time on meds. 
Another example of weighing 
benefits and costs, but without 
explicitly stating which 
outweighs which - it's simply a 
difficult trade-off. 
No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
When I read what I wrote even 10 
years ago, I know I was smarter then. 
But I also know I would not be alive 
now had it not been for the drugs. 
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4/4/2010  Case 
#1064 
Again, the trade-off. No or 
limited 
helpfulness 
/ It's not my 
wonder drug 
While I'm grateful that I am no longer 
as mad as I was, I know that I have 
lost an edge. While it was dangerous 
and painful at times, this edge gave 
me the ability to use my madness as a 
tool, a weapon and a shield in the on-
going struggles for Truth, Justice, Etc.  
I am not as effective as an activist. 
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APPENDIX G 
Resolutions to Inter-Coder Disagreements (Decision is in bold) 
Case Code 1st coder 2nd coder 
 Case #101 Evidence of Causality (Any comment) No Yes 
 Case #101 Gastrointestinal and Urinary No Yes 
 Case #101 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #101 Other Drug Issues (Any comment) Yes No 
 Case #101 Other Effects Yes No 
 Case #105 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #108 Friends and Family (Any comment) No Yes 
 Case #109 Evidence of Causality (Any comment) No Yes 
 Case #109 Gastrointestinal and Urinary Yes No 
 Case #109 Head or Face Yes No 
 Case #109 Sexual changes Yes No 
 Case #112 My Doctor (Any comment) No Yes 
 Case #112 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #112 Other Drug Issues (Any comment) Yes No 
 Case #123 Classification of Effects (Overlap with an Effect) No Yes 
 Case #123 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #123 Other Drug Issues (Any comment) Yes No 
 Case #123 Other Effects No Yes 
 Case #13 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #13 Other Effects Yes No 
 Case #13 Theories of Drug Action (Any comment) No Yes 
 Case #134 Classification of Effects (Overlap with an Effect) No Yes 
 Case #134 Evidence of Causality (Any comment) No Yes 
 Case #134 My Doctor (Any comment) No Yes 
 Case #134 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #134 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #138 Classification of Effects (Overlap with an Effect) No Yes 
 Case #138 Evidence of Causality (Any comment) Yes No 
 Case #138 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #138 Theories of Drug Action (Any comment) No Yes 
 Case #139 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #139 Other Drug Issues (Any comment) No Yes 
 Case #139 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #139 Other Effects Yes No 
 Case #139 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #151 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #151 Pharmaceutical Companies / FDA No Yes 
 Case #160 Classification of Effects (Overlap with an Effect) No Yes 
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 Case #160 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #163 Classification of Effects (Overlap with an Effect) Yes No 
 Case #163 Other Effects Yes No 
 Case #164 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #169 Classification of Effects (Overlap with an Effect) No Yes 
 Case #169 Evidence of Causality (Any comment) Yes No 
 Case #169 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #169 My Doctor (Any comment) Yes No 
 Case #169 Other Drug Issues (Any comment) No Yes 
 Case #174 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #174 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #174 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #176 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #176 Other Drug Issues (Any comment) No Yes 
 Case #178 Classification of Effects (Overlap with an Effect) No Yes 
 Case #178 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #179 Classification of Effects (Overlap with an Effect) Yes No 
 Case #179 Evidence of Causality (Any comment) No Yes 
 Case #179 Friends and Family (Any comment) No Yes 
 Case #179 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #179 My Doctor (Any comment) No Yes 
 Case #180 Friends and Family (Any comment) No Yes 
 Case #180 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #180 Other Drug Issues (Any comment) No Yes 
 Case #184 Classification of Effects (Overlap with an Effect) No Yes 
 Case #184 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #185 Classification of Effects (Overlap with an Effect) No Yes 
 Case #185 Contraindications (Only for Lex & Ser) Yes No 
 Case #185 Theories of Drug Action (Any comment) No Yes 
 Case #187 Classification of Effects (Overlap with an Effect) No Yes 
 Case #187 My Doctor (Any comment) No Yes 
 Case #187 Theories of Drug Action (Any comment) No Yes 
 Case #191 Evidence of Causality (Any comment) No Yes 
 Case #191 Muscoloskeletal and Neurological No Yes 
 Case #191 Other Effects No Yes 
 Case #191 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #197 Support and Advice (Any comment) No Yes 
 Case #215 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #215 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #215 Other Drug Issues (Any comment) No Yes 
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 Case #216 Classification of Effects (Overlap with an Effect) No Yes 
 Case #218 Other Drug Issues (Any comment) No Yes 
 Case #218 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #22 Classification of Effects (Overlap with an Effect) No Yes 
 Case #22 Gastrointestinal and Urinary Yes No 
 Case #239 Classification of Effects (Overlap with an Effect) No Yes 
 Case #239 Evidence of Causality (Any comment) Yes No 
 Case #239 Mental or mood changes No Yes 
 Case #239 My Doctor (Any comment) No Yes 
 Case #243 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #243 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #243 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #243 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #244 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #244 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #244 Other Effects No Yes 
 Case #244 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #252 Classification of Effects (Overlap with an Effect) No Yes 
 Case #252 Mental or mood changes Yes No 
 Case #253 Classification of Effects (Overlap with an Effect) No Yes 
 Case #253 Mental or mood changes Yes No 
 Case #253 Support and Advice (Any comment) No Yes 
 Case #253 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #256 My Doctor (Any comment) No Yes 
 Case #256 Other Drug Issues (Any comment) No Yes 
 Case #259 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #259 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #259 Other Effects No Yes 
 Case #27 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #270 Mental or mood changes Yes No 
 Case #270 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #270 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #270 Other Drug Issues (Any comment) No Yes 
 Case #270 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #271 Classification of Effects (Overlap with an Effect) No Yes 
 Case #271 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #271 Other Drug Issues (Any comment) No Yes 
 Case #277 Gastrointestinal and Urinary Yes No 
 Case #277 Other Effects No Yes 
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Case Code 1st coder 2nd coder 
 Case #279 Classification of Effects (Overlap with an Effect) Yes No 
 Case #279 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #288 Classification of Effects (Overlap with an Effect) No Yes 
 Case #288 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #288 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #288 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #292 Classification of Effects (Overlap with an Effect) No Yes 
 Case #292 Evidence of Causality (Any comment) Yes No 
 Case #292 My Doctor (Any comment) No Yes 
 Case #292 Other Drug Issues (Any comment) No Yes 
 Case #293 Friends and Family (Any comment) No Yes 
 Case #293 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #293 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #297 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #299 Classification of Effects (Overlap with an Effect) No Yes 
 Case #299 Support and Advice (Any comment) No Yes 
 Case #303 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #303 Other Drug Issues (Any comment) Yes No 
 Case #303 Other Effects No Yes 
 Case #307 Other Effects No Yes 
 Case #308 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #313 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #313 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #313 Other Effects No Yes 
 Case #315 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #315 Other Drug Issues (Any comment) Yes No 
 Case #315 Other Effects Yes No 
 Case #334 Classification of Effects (Overlap with an Effect) No Yes 
 Case #34 Muscoloskeletal and Neurological No Yes 
 Case #34 Other Drug Issues (Any comment) No Yes 
 Case #34 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #34 Support and Advice (Any comment) No Yes 
 Case #342 Classification of Effects (Overlap with an Effect) No Yes 
 Case #346 Sleep changes Yes No 
 Case #346 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #352 Classification of Effects (Overlap with an Effect) No Yes 
 Case #352 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #352 Other Effects No Yes 
 Case #352 Support and Advice (Any comment) No Yes 
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Case Code 1st coder 2nd coder 
 Case #357 Classification of Effects (Overlap with an Effect) No Yes 
 Case #357 Mental or mood changes Yes No 
 Case #357 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #357 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #357 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #362 Classification of Effects (Overlap with an Effect) No Yes 
 Case #362 My Doctor (Any comment) No Yes 
 Case #362 Other Drug Issues (Any comment) Yes No 
 Case #363 Classification of Effects (Overlap with an Effect) No Yes 
 Case #363 Head or Face Yes No 
 Case #363 Other Drug Issues (Any comment) No Yes 
 Case #363 Other Effects No Yes 
 Case #363 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #364 Classification of Effects (Overlap with an Effect) No Yes 
 Case #364 Friends and Family (Any comment) No Yes 
 Case #364 Other Drug Issues (Any comment) No Yes 
 Case #373 Friends and Family (Any comment) No Yes 
 Case #374 Classification of Effects (Overlap with an Effect) No Yes 
 Case #374 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #374 Other Effects No Yes 
 Case #377 My Doctor (Any comment) No Yes 
 Case #385 Finances / The System (Any comment) Yes No 
 Case #385 Theories of Drug Action (Any comment) No Yes 
 Case #388 Classification of Effects (Overlap with an Effect) No Yes 
 Case #390 Classification of Effects (Overlap with an Effect) No Yes 
 Case #393 Evidence of Causality (Any comment) No Yes 
 Case #393 Other Effects No Yes 
 Case #393 Sleep changes Yes No 
 Case #393 Support and Advice (Any comment) No Yes 
 Case #394 Classification of Effects (Overlap with an Effect) No Yes 
 Case #396 Friends and Family (Any comment) No Yes 
 Case #396 Other Effects Yes No 
 Case #397 Other Drug Issues (Any comment) Yes No 
 Case #397 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #400 My Doctor (Any comment) No Yes 
 Case #400 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #400 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
No Yes 
 Case #401 Classification of Effects (Overlap with an Effect) No Yes 
 Case #401 My Drug Experience (Only for Lex & Ser) No Yes 
 Case #401 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
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Case Code 1st coder 2nd coder 
 Case #413 Other Effects No Yes 
 Case #413 Sexual changes Yes No 
 Case #415 Classification of Effects (Overlap with an Effect) No Yes 
 Case #416 Classification of Effects (Overlap with an Effect) No Yes 
 Case #416 My Doctor (Any comment) No Yes 
 Case #43 Other Drug Issues (Any comment) No Yes 
 Case #43 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #43 Other Effects Yes No 
 Case #436 Classification of Effects (Overlap with an Effect) No Yes 
 Case #445 Classification of Effects (Overlap with an Effect) No Yes 
 Case #447 Friends and Family (Any comment) No Yes 
 Case #59 Other Drug Issues (Any comment) Yes No 
 Case #6 Evidence of Causality (Any comment) No Yes 
 Case #7 Other Drug Issues (Any comment) No Yes 
 Case #7 Support and Advice (Any comment) No Yes 
 Case #80 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #80 My Doctor (Any comment) No Yes 
 Case #80 Nose Throat Chest No Yes 
 Case #80 Skin No Yes 
 Case #80 Sleep changes No Yes 
 Case #83 Muscoloskeletal and Neurological Yes No 
 Case #83 Other Effects No Yes 
 Case #87 My Doctor (Any comment) No Yes 
 Case #87 Other Drugs and Drug Combinations (Any comment) Yes No 
 Case #88 Evidence of Causality (Any comment) No Yes 
 Case #89 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #91 Other Drug Issues (Any comment) No Yes 
 Case #91 Weighing Benefits vs Side Effects/Cost (Any 
comment) 
Yes No 
 Case #99 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #99 My Drug Experience (Only for Lex & Ser) Yes No 
 Case #99 Support and Advice (Any comment) No Yes 
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Part II of Inter-Coder Agreement Resolutions 
Case Code 1st coder 2nd coder 
 Case #1001 Evidence of Causality (Any comment) Yes No 
 Case #1001 Other Drug Issues (Any comment) No Yes 
 Case #1002 Citations and Links (Any comment) Yes No 
 Case #1002 Evidence of Causality (Any comment) No Yes 
 Case #1002 Support and Advice (Any comment) No Yes 
 Case #1003 Assessing the Overall Experience Yes No 
 Case #1003 Evidence of Causality (Any comment) No Yes 
 Case #1005 Evidence of Causality (Any comment) Yes No 
 Case #1005 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #1005 Pharmaceutical Companies / FDA Yes No 
 Case #1014 Citations and Links (Any comment) No Yes 
 Case #1014 Evidence of Causality (Any comment) No Yes 
 Case #1020 Assessing the Overall Experience Yes No 
 Case #1020 Evidence of Causality (Any comment) No Yes 
 Case #1020 Friends and Family (Any comment) No Yes 
 Case #1020 Support and Advice (Any comment) No Yes 
 Case #1021 Other Drug Issues (Any comment) Yes No 
 Case #1021 Support and Advice (Any comment) No Yes 
 Case #1028 Citations and Links (Any comment) No Yes 
 Case #1028 Contraindications (Only for Lex & Ser) Yes No 
 Case #1028 Pharmaceutical Companies / FDA Yes No 
 Case #1028 Support and Advice (Any comment) No Yes 
 Case #1031 Support and Advice (Any comment) No Yes 
 Case #1037 Assessing the Overall Experience Yes No 
 Case #1037 Evidence of Causality (Any comment) No Yes 
 Case #1037 Theories of Drug Action (Any comment) No Yes 
 Case #1043 Classification of Effects (Overlap with an Effect) No Yes 
 Case #1047 My Doctor (Any comment) No Yes 
 Case #1056 Citations and Links (Any comment) No Yes 
 Case #1056 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #1056 Friends and Family (Any comment) Yes No 
 Case #1056 Other Drug Issues (Any comment) Yes No 
 Case #1060 Citations and Links (Any comment) No Yes 
 Case #1060 Evidence of Causality (Any comment) No Yes 
 Case #1060 My Doctor (Any comment) Yes No 
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Case Code 1st coder 2nd coder 
 Case #1060 Support and Advice (Any comment) No Yes 
 Case #1072 Other Drug Issues (Any comment) Yes No 
 Case #1072 Support and Advice (Any comment) No Yes 
 Case #1079 Muscoloskeletal and Neurological No Yes 
 Case #1079 Other Drug Issues (Any comment) No Yes 
 Case #1079 Other Effects No Yes 
 Case #1079 Support and Advice (Any comment) No Yes 
 Case #456 Friends and Family (Any comment) No Yes 
 Case #456 Other Effects Yes No 
 Case #470 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #470 Other Effects Yes No 
 Case #472 Classification of Effects (Overlap with an Effect) Yes No 
 Case #472 Friends and Family (Any comment) No Yes 
 Case #472 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #472 Other Drug Issues (Any comment) No Yes 
 Case #487 Support and Advice (Any comment) No Yes 
 Case #511 Assessing the Overall Experience Yes No 
 Case #511 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #511 Mental or mood changes Yes No 
 Case #511 Nose Throat Chest No Yes 
 Case #516 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #516 Other Drug Issues (Any comment) No Yes 
 Case #519 Other Drug Issues (Any comment) No Yes 
 Case #533 My Doctor (Any comment) No Yes 
 Case #533 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #537 Assessing the Overall Experience No Yes 
 Case #537 Discontinuing / Missed Doses (Only for Lex & Ser) No Yes 
 Case #537 Muscoloskeletal and Neurological Yes No 
 Case #537 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #537 Other Effects No Yes 
 Case #545 Head or Face Yes No 
 Case #545 Other Effects No Yes 
 Case #547 Assessing the Overall Experience Yes No 
 Case #547 Evidence of Causality (Any comment) No Yes 
 Case #547 Other Drug Issues (Any comment) Yes No 
 Case #548 Other Effects Yes No 
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Case Code 1st coder 2nd coder 
 Case #548 Skin No Yes 
 Case #554 Other Drug Issues (Any comment) No Yes 
 Case #555 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #555 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #560 Mental or mood changes No Yes 
 Case #560 Other Drug Issues (Any comment) Yes No 
 Case #560 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #565 Classification of Effects (Overlap with an Effect) No Yes 
 Case #565 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #567 Other Drug Issues (Any comment) Yes No 
 Case #573 Mental or mood changes Yes No 
 Case #573 Muscoloskeletal and Neurological No Yes 
 Case #581 Assessing the Overall Experience No Yes 
 Case #586 Appetite and Weight No Yes 
 Case #586 Other Effects Yes No 
 Case #591 Friends and Family (Any comment) No Yes 
 Case #591 Muscoloskeletal and Neurological No Yes 
 Case #591 Support and Advice (Any comment) No Yes 
 Case #599 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #599 Other Effects No Yes 
 Case #599 Support and Advice (Any comment) No Yes 
 Case #604 Assessing the Overall Experience Yes No 
 Case #604 Other Effects No Yes 
 Case #613 Citations and Links (Any comment) No Yes 
 Case #613 Pharmaceutical Companies / FDA Yes No 
 Case #613 Skin Yes No 
 Case #617 Appetite and Weight Yes No 
 Case #617 Citations and Links (Any comment) Yes No 
 Case #617 Classification of Effects (Overlap with an Effect) Yes No 
 Case #617 Head or Face Yes No 
 Case #617 Other Drug Issues (Any comment) Yes No 
 Case #617 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #617 Skin Yes No 
 Case #617 Sleep changes Yes No 
 Case #621 Evidence of Causality (Any comment) No Yes 
 Case #621 Other Effects No Yes 
342 
 
Case Code 1st coder 2nd coder 
 Case #626 Assessing the Overall Experience Yes No 
 Case #626 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #626 Support and Advice (Any comment) No Yes 
 Case #629 Appetite and Weight No Yes 
 Case #629 Evidence of Causality (Any comment) No Yes 
 Case #629 My Doctor (Any comment) No Yes 
 Case #629 Other Drug Issues (Any comment) No Yes 
 Case #642 Assessing the Overall Experience Yes No 
 Case #642 Discontinuing / Missed Doses (Only for Lex & Ser) Yes No 
 Case #642 Evidence of Causality (Any comment) Yes No 
 Case #642 Mental or mood changes No Yes 
 Case #642 Other Effects No Yes 
 Case #642 Support and Advice (Any comment) No Yes 
 Case #643 Sleep changes No Yes 
 Case #646 Evidence of Causality (Any comment) Yes No 
 Case #646 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #646 Pharmaceutical Companies / FDA Yes No 
 Case #646 Support and Advice (Any comment) No Yes 
 Case #650 Classification of Effects (Overlap with an Effect) No Yes 
 Case #650 Discontinuing / Missed Doses (Only for Lex & Ser) Yes No 
 Case #650 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #650 Other Effects Yes No 
 Case #654 Head or Face Yes No 
 Case #654 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #654 Support and Advice (Any comment) No Yes 
 Case #655 Assessing the Overall Experience Yes No 
 Case #655 Classification of Effects (Overlap with an Effect) No Yes 
 Case #655 Discontinuing / Missed Doses (Only for Lex & Ser) Yes No 
 Case #655 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #675 Appetite and Weight No Yes 
 Case #675 Assessing the Overall Experience Yes No 
 Case #675 Classification of Effects (Overlap with an Effect) Yes No 
 Case #675 Mental or mood changes Yes No 
 Case #675 Muscoloskeletal and Neurological No Yes 
 Case #675 Support and Advice (Any comment) No Yes 
 Case #681 Classification of Effects (Overlap with an Effect) No Yes 
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Case Code 1st coder 2nd coder 
 Case #681 Mental or mood changes No Yes 
 Case #683 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #683 My Doctor (Any comment) No Yes 
 Case #683 Other Drug Issues (Any comment) Yes No 
 Case #687 Assessing the Overall Experience Yes No 
 Case #687 Evidence of Causality (Any comment) No Yes 
 Case #687 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #695 Classification of Effects (Overlap with an Effect) Yes No 
 Case #695 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #696 Contraindications (Only for Lex & Ser) No Yes 
 Case #701 Appetite and Weight No Yes 
 Case #701 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #701 Sleep changes No Yes 
 Case #704 Other Drug Issues (Any comment) Yes No 
 Case #704 Support and Advice (Any comment) No Yes 
 Case #716 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #716 Pharmaceutical Companies / FDA Yes No 
 Case #718 Evidence of Causality (Any comment) No Yes 
 Case #719 Evidence of Causality (Any comment) Yes No 
 Case #719 Friends and Family (Any comment) Yes No 
 Case #719 Other Effects No Yes 
 Case #720 Assessing the Overall Experience Yes No 
 Case #720 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #720 My Doctor (Any comment) No Yes 
 Case #723 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #723 Other Drug Issues (Any comment) No Yes 
 Case #725 Mental or mood changes Yes No 
 Case #725 Other Effects No Yes 
 Case #747 Assessing the Overall Experience No Yes 
 Case #747 Classification of Effects (Overlap with an Effect) Yes No 
 Case #747 Discontinuing / Missed Doses (Only for Lex & Ser) No Yes 
 Case #747 Muscoloskeletal and Neurological No Yes 
 Case #747 Other Drug Issues (Any comment) Yes No 
 Case #752 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
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Case Code 1st coder 2nd coder 
 Case #761 Friends and Family (Any comment) No Yes 
 Case #761 My Diagnosis / Reason for Use (Only for Lex & Ser) No Yes 
 Case #761 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #772 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #772 My Doctor (Any comment) No Yes 
 Case #772 Other Drug Issues (Any comment) Yes No 
 Case #773 Other Effects Yes No 
 Case #777 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #777 Head or Face No Yes 
 Case #777 Nose Throat Chest No Yes 
 Case #777 Other Drug Issues (Any comment) No Yes 
 Case #779 Appetite and Weight No Yes 
 Case #779 Discontinuing / Missed Doses (Only for Lex & Ser) No Yes 
 Case #779 Evidence of Causality (Any comment) Yes No 
 Case #779 Friends and Family (Any comment) No Yes 
 Case #779 My Doctor (Any comment) No Yes 
 Case #779 Other Drug Issues (Any comment) Yes No 
 Case #780 Classification of Effects (Overlap with an Effect) No Yes 
 Case #780 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #784 Assessing the Overall Experience Yes No 
 Case #784 My Doctor (Any comment) No Yes 
 Case #784 Other Drug Issues (Any comment) No Yes 
 Case #786 Assessing the Overall Experience No Yes 
 Case #786 Friends and Family (Any comment) No Yes 
 Case #786 My Doctor (Any comment) No Yes 
 Case #786 Support and Advice (Any comment) Yes No 
 Case #799 Evidence of Causality (Any comment) No Yes 
 Case #799 My Doctor (Any comment) No Yes 
 Case #799 Other Effects Yes No 
 Case #812 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #814 Mental or mood changes No Yes 
 Case #828 Other Drug Issues (Any comment) No Yes 
 Case #832 Classification of Effects (Overlap with an Effect) No Yes 
 Case #832 Discontinuing / Missed Doses (Only for Lex & Ser) No Yes 
 Case #832 My Diagnosis / Reason for Use (Only for Lex & Ser) Yes No 
 Case #832 Other Drug Issues (Any comment) Yes No 
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Case Code 1st coder 2nd coder 
 Case #832 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #832 Other Effects Yes No 
 Case #854 Assessing the Overall Experience No Yes 
 Case #854 Classification of Effects (Overlap with an Effect) Yes No 
 Case #854 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #854 Discontinuing / Missed Doses (Only for Lex & Ser) No Yes 
 Case #854 Lab Tests Yes No 
 Case #855 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
No Yes 
 Case #855 Friends and Family (Any comment) No Yes 
 Case #855 Head or Face No Yes 
 Case #855 Other Effects No Yes 
 Case #855 Sleep changes Yes No 
 Case #866 Classification of Effects (Overlap with an Effect) No Yes 
 Case #866 Evidence of Causality (Any comment) No Yes 
 Case #866 Support and Advice (Any comment) No Yes 
 Case #880 Classification of Effects (Overlap with an Effect) No Yes 
 Case #880 Mental or mood changes Yes No 
 Case #880 My Doctor (Any comment) Yes No 
 Case #880 Nose Throat Chest No Yes 
 Case #888 Mental or mood changes Yes No 
 Case #888 My Doctor (Any comment) No Yes 
 Case #895 Appetite and Weight No Yes 
 Case #895 Other Effects Yes No 
 Case #898 Classification of Effects (Overlap with an Effect) No Yes 
 Case #906 Mental or mood changes No Yes 
 Case #906 Sleep changes No Yes 
 Case #921 Assessing the Overall Experience No Yes 
 Case #938 Classification of Effects (Overlap with an Effect) Yes No 
 Case #967 Friends and Family (Any comment) No Yes 
 Case #974 Assessing the Overall Experience Yes No 
 Case #974 My Doctor (Any comment) Yes No 
 Case #974 Other Drugs and Drug Combinations (Any comment) No Yes 
 Case #974 Support and Advice (Any comment) No Yes 
 Case #975 Finances / The System (Any comment) No Yes 
 Case #992 Appetite and Weight No Yes 
 Case #992 Assessing the Overall Experience Yes No 
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Case Code 1st coder 2nd coder 
 Case #992 Classification of Effects (Overlap with an Effect) No Yes 
 Case #992 Dealing with side effects / Finding optimum 
effectiveness (Any comment) 
Yes No 
 Case #992 Theories of Drug Action (Any comment) Yes No 
 Case #997 Classification of Effects (Overlap with an Effect) No Yes 
 Case #997 Evidence of Causality (Any comment) Yes No 
 Case #997 Other Drug Issues (Any comment) No Yes 
 Case #997 Pharmaceutical Companies / FDA Yes No 
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APPENDIX H 
WikiScanner Search Results for Pharmaceutical Company Edits from 2002-2007 
Astra Zeneca: Total edits: 949  
Edits related to medications or pharmaceutical companies: 23 (2.4%) 
Wikipedia entries edited and a description of edits made 
 “Astra Zeneca”: 6 edits 
o Updated name of CEO, Vice President position title, web address, and similar 
 “Fed Food, Drug, and Cosmetic Act”: 3 edits 
o Added and edited statements about the history of the Act 
 “FDA”: 1 edit 
o Added entry to searchable category “pharmacology” 
 “Good Manufacturing Practice”: 4 edits 
o Added and deleted sections about enforcement and purpose of guidelines 
 “Omeprazole”: 1 edit 
o Deleted sentence: “Faced with the loss of patent protection and competition from generic 
manufacturers, AstraZeneca developed, launched, and heavily marketed [[esomeprazole]] 
(Nexium), a single [[enantiomer]] form of omeprazole” 
o Added summaries of several studies where Nexium outperforms Prilosec 
 “Quetiapine”: 6 edits 
o Edited 2 mistakes about dosages; edited language regarding approved 
indications 
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o Deleted sentence and reference for: “a known risk that teenagers taking the drug 
‘may be more likely to think about harming or killing themselves or to plan or try to do so’” 
 “Risperidone”: 1 edit 
o Deleted sentence: “Risperidone is now the most commonly prescribed [[antipsychotic]] 
medication in the [[United States]]”  
 Note: Risperidone is made by Janssen 
 “Thalidomide”: 1 edit 
o Changed quotations around a phrase to parentheses 
 
Eli Lilly: Total edits: 832  
    Edits related to medications or pharmaceutical companies: 38 (4.6%) 
Wikipedia entries edited and a description of edits made 
 “Dimethoxy-4-iodoamphetamine”: 1 edit 
o Described used of DOI in research 
 “Cocaine”: 1 edit 
o Deleted word “potent” before “SSRI” regarding Venlafaxine as a treatment 
for cocaine addiction 
 “Drotrecogin alfa”: 4 edits 
o Deleted word “deceptive” before “marketing campaign” regarding Lilly’s 
promotion of drug; Changed indication to state that a second opinion is not 
necessary 
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o Added sentence, “PROWESS was terminated early for a statistically significant positive 
efficacy signal - unethical to continue trial - as this would have meant exposing severe sepsis 
patients to possibly receiving placebo.” 
o Deleted 6 contraindications, including for pregnancy, breast feeding, and 
patients under age 18 
 “Eli Lilly and Company”: 13 edits 
o Corrected revenue figures from $12.6 billion to $13.9b 
o Added names of drugs to a list of Lilly’s products; minor edits to title of 
former president Bush who was a board member  
 “Erectile Dysfunction”: 2 edits 
o Added link to the Cialis home page 
 “G D Searle and Company”: 1 edit 
o Deleted statement that former CEO Donald Rumsfeld “could be the most 
prominent [[douchebag]] in the U.S.” 
 “Insulin/ Insulin analog”: 6 edits 
o Edited mode of production; corrected spelling of “lilly” and “lispro” (a drug) 
 “Lilly Research Laboratories”: 1 edit 
o Created page for above entry; added 1 introductory sentence 
 “Novo Nordisk”: 1 edit 
o Deleted “the first” regarding NovoLog being “the first rapid acting insulin 
analogue” 
 “Olanzapine”: 1 edit 
o Corrected registered name of drug 
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 “Pemetrexed”: 1 edit 
o Added that drug is “clinically developed by Indianapolis based drug maker, Eli Lilly & 
Company” 
 “Pfizer”:  2 edits 
o Grammatical clean-up 
 “Potassium bromide”: 3 edits 
o Added information about use for seizures in dogs 
 Talk:Fluoxetine: 1 contribution 
o Added paragraph: “I have been taking fluoxetine and had very little in the way of side 
effects - just a small amount of nausea at the start. It has been very successful in treating my 
depression so far and I'm feeling good for the first time in ages. I just wanted to add this as 
I'm sure there are others who it has helped and as mentioned above they don't tend to speak 
out. I think that an explanation in part of why there is such a broad range of reactions to drugs 
like these is the limited understanding of the basis of the disease. In my opinion what we 
know as depression could have many causes each presenting with similar symptoms 
explaining why some treatments only work for some individuals.” 
 
GlaxoSmithKline: Total edits: 1,148  
         Edits related to medications or pharmaceutical companies: 31 (2.7%) 
Wikipedia entries edited and a description of edits made 
 “Celecoxib”: 2 edits 
o Corrected grammar 
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 “Fluticasone”: 4 edits 
o Edited grammar and links  
 “GlaxoSmithKline”: 15 edits 
o Added paragraph that starts: “For many years now GSK has been a leading 
contributor to a multinational govenment and industry alliance to rid the world of 
lymphatic filariasis (elephantiasis)….” and added new subheading called “Good 
Works” 
o Minor edits to headquarters and locations; updated revenues (an increase) 
and number of employees (an increase); added links to GSK site for 
corporate governance, global locations and merger history 
 “Lamotrigine”: 2 edits 
o Added and then deleted link to generic drug manufacturer 
 “Lapatinib”: 1 edit 
o Corrected name of drug 
 “Motilin”: 1 edit 
o Elaborated on description of the hormone 
 “Neuropathy”: 1 edit 
o Added word “central” to nervous system disorder 
 “Resistin”: 3 edits 
o Minor edits to existing references for clinical studies 
 Talk:GlaxoSmithKline: 1 edit 
o Added statement that GSK still makes Ribena 
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 Talk:Reverse transcriptase inhibitor: 1 edit 
o Created talk page with: “Understanding RTI provide a novel platform for 
the developing of anti-HIV medication. This is one area that 
GlaxoSmithKline needs to be commended.” 
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